<SEC-DOCUMENT>0001829126-23-007422.txt : 20231114
<SEC-HEADER>0001829126-23-007422.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114161542
ACCESSION NUMBER:		0001829126-23-007422
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		231406469

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>titanpharma_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ttnp="http://titanpharm.com/20230930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_ttnp_titanpharm.com_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230101_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000910267 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCentralIndexKey">0000910267</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsAndNotesReceivableNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" id="xdx2ixbrl0058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:NotePayableToRelatedParty" contextRef="AsOf2022-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-07-012023-09-30_us-gaap_LicenseAndServiceMember" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0290" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0306" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0328" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:ShareBasedPaymentArrangementMilestonePayment" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:ProceedsFromEquityOfferings" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSubordinatedShortTermDebt" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfSubordinatedShortTermDebt" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:InventoryTransferredWithSaleOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:PropertyAndEquipmentNetTransferredWithSaleOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:NotesReceivableReceivedInConnectionWithSaleOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:AccountsPayableRelatedToSaleOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:OtherAccruedLiabilitiesTransferredWithSaleOfAssets" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0739" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0761" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0769" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0786" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0790" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_custom_ConvertibleNotesMember" id="xdx2ixbrl0794" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_custom_ConvertibleNotesMember" id="xdx2ixbrl0798" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" id="xdx2ixbrl0892" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ttnp-20230930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_DavidLazarAndActivistInvestingLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ttnp:DavidLazarAndActivistInvestingLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-15_custom_RubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_ProNeuraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:ProNeuraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_N2015OmnibusEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:N2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredFiveYearAndSixMonthWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31_custom_HauPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31_custom_HauPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_HauPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:LazarPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_LazarPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:LazarPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_CashNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:CashNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:MDMWorldwideSolutionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000753" toRefs="Footnote000774"></ix:relationship>
  <ix:relationship fromRefs="Fact000755" toRefs="Footnote000774"></ix:relationship>
  <ix:relationship fromRefs="Fact000757" toRefs="Footnote000774"></ix:relationship>
  <ix:relationship fromRefs="Fact000759" toRefs="Footnote000775"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0761" toRefs="Footnote000775"></ix:relationship>
  <ix:relationship fromRefs="Fact000763" toRefs="Footnote000775"></ix:relationship>
  <ix:relationship fromRefs="Fact000765" toRefs="Footnote000775"></ix:relationship>
  <ix:relationship fromRefs="Fact000767" toRefs="Footnote000776"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0769" toRefs="Footnote000776"></ix:relationship>
  <ix:relationship fromRefs="Fact000771" toRefs="Footnote000776"></ix:relationship>
  <ix:relationship fromRefs="Fact000773" toRefs="Footnote000776"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
      D.C. 20549</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
      <span id="xdx_905_edei--DocumentType_c20230101__20230930_zu07uj9ZuPS5"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentQuarterlyReport_c20230101__20230930_zeJ2ECZ7F8td"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
      <b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
      the quarterly period ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20230101__20230930_zVe2WgmylK03"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2023</ix:nonNumeric></span>.</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentTransitionReport_c20230101__20230930_z1kHKtnJVJHl"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
      <b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
      the transition period from __________ to __________</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
      File Number <span id="xdx_90E_edei--EntityFileNumber_c20230101__20230930_znHNRz4UY2xb"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityFileNumber">001-13341</ix:nonNumeric></span></b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20230101__20230930_zhsIlndtNRpj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityRegistrantName">Titan Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
      name of registrant as specified in its charter)</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20230101__20230930_zOjs4E1iFjlk"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20230101__20230930_zkAE6pPuQds3"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">94-3171940</ix:nonNumeric></span></b></span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
            or other jurisdiction of<br />incorporation or organization)</b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
            Employer<br />Identification No.)</b></span></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20230101__20230930_zVZQ3m6qylvj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine1">400 Oyster Point Blvd.</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20230101__20230930_z0txYglI7Lqa"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine2">Suite 505</ix:nonNumeric></span>,<br /><span id="xdx_903_edei--EntityAddressCityOrTown_c20230101__20230930_zE5lYS6gIFD3"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressCityOrTown">South San Francisco</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20230101__20230930_z1r1iCbrdk4k"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20230930_zyglyCbmHMT3"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressPostalZipCode">94080</ix:nonNumeric></span></b></span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
            of principal executive offices)</b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
            Code)</b></span></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_90C_edei--CityAreaCode_c20230101__20230930_zVgZ7dxcpNm1"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CityAreaCode">650</ix:nonNumeric></span>)
<span id="xdx_907_edei--LocalPhoneNumber_c20230101__20230930_z6TgnrhbtIA"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:LocalPhoneNumber">244-4990</ix:nonNumeric></span></b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
      telephone number, including area code)</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      by check mark whether the registrant (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities
      Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
      and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_903_edei--EntityCurrentReportingStatus_c20230101__20230930_zSxhzgn8fvO7"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
      to Rule&#160;405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
      the registrant was required to submit such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20230101__20230930_zcRlJ49iRRO6"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
      company, or an emerging growth company.</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; width: 21%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
            accelerated filer</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; width: 36%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; width: 25%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
            filer</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; width: 18%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20230101__20230930_zllMg0wVMC0f"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
            reporting company</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20230101__20230930_zRSbwd3xxwWk"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
            growth company</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20230101__20230930_zxjpqcrCphW9"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
      an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#9744;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#9744;&#160;&#160;&#160;<span id="xdx_908_edei--EntityShellCompany_c20230101__20230930_zgDWaPmJY6A8"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
      registered pursuant to Section&#160;12(b) of the Act:</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
            of each class</b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
            Symbol(s)</b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
            of each exchange on which registered</b></span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20230101__20230930_zJkyzwQ5LKsk"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:Security12bTitle">Common
            Stock, par value $0.001</ix:nonNumeric></span></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20230101__20230930_ziziCcLOkrQj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:TradingSymbol">TTNP</ix:nonNumeric></span></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20230101__20230930_z6DMJtSmbhr9"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
            Capital Market</span></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #FFFFFF; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; background-color: #FFFFFF; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #FFFFFF; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
            at November&#160;10, 2023</b></span></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: center; vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
            Stock, par value $0.001</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; background-color: #CCEEFF; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; background-color: #CCEEFF; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20231110_zrHbJY1Q48ha" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-11-10" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></span></span></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Titan
      Pharmaceuticals, Inc.</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
      to Form 10-Q</b></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: left; vertical-align: top"><b><span style="text-decoration: underline"><a href="#a_001">Part I. Financial Information</a></span></b></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top; width: 9%">&#160;</td>
    <td style="text-align: left; vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 80%">&#160;</td>
    <td style="text-align: left; vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; width: 9%">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_002">Item 1.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_002">Financial Statements (unaudited)</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_003">Condensed Balance Sheets as of September&#160;30, 2023 and December&#160;31, 2022</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_004">Condensed Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_005">Condensed Statements of Stockholders&#8217; Equity (Deficit) for the three and nine months ended September&#160;30, 2023 and 2022</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_006">Condensed Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_007">Notes to Condensed Financial Statements</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">5</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_008">Item 2.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">15</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_009">Item 3.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_009">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">20</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_010">Item 4.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_010">Controls and Procedures</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">20</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: left; vertical-align: top"><b><span style="text-decoration: underline"><a href="#a_011">Part II. Other Information</a></span></b></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_012">Item 1.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_012">Legal Proceedings</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_013">Item 1A.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_013">Risk Factors</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_014">Item 2.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_014">Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">23</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_015">Item 5.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_015">Other Information</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">23</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; vertical-align: top"><span style="text-decoration: underline"><a href="#a_016">Item 6.</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="text-decoration: underline"><a href="#a_016">Exhibits</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">24</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><b><a href="#a_017">SIGNATURES</a></b></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">25</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_001"></span><b>Part I. Financial Information</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_002"></span><b>Item 1. Financial Statements</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_003"></span><b>TITAN PHARMACEUTICALS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONDENSED BALANCE SHEETS</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands, except share and per share data)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_30D_111_pn3n3_zAqEYRU7Xls2" summary="xdx: Statement - CONDENSED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230930_zSumuh5eoY93" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20221231_zDwpWfWjVBz7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Note 1)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zizXXiiiqPSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zQZ8wtIw20Kb" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzx66_za5ItwpWcQb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCash_i02I_maCzx66_zfGh6H8vA774" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_i02I_maCzx66_zZ6PsdclDp13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsAndNotesReceivableNet_i02I_maCzx66_zt6EZ7GlW0Y7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsAndNotesReceivableNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryNet_i02I_maCzx66_zXV56o0DBRge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzx66_zZ1VF52C1G0a" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzx66_zTJE8csAtm88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Discontinued operations - current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrent_i02TI_mtCzx66_maCzBXz_z37FDj56PIM3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzBXz_zsATyQYZiive" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i01I_maCzBXz_zoNTGI2STtrl" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0073">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzBXz_z6ZtJSQ22nEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_i01TI_mtCzBXz_z2lTbtng95Xk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,999</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zMOplU3oXKg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_i02I_maCzng3_zzoiGcsXn55d" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NotePayableToRelatedParty_i02I_maCzng3_zBewaHoWFN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Note payable to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ttnp:NotePayableToRelatedParty" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maCzng3_zRWLcyzGUbF7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,488</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzng3_ziqoO62aXyJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liability, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredGrantRevenue_i02I_maCzng3_zrH1DHuZj5gf" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred grant revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ttnp:DeferredGrantRevenue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ttnp:DeferredGrantRevenue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pn3n3_maCzng3_z4bHTp2Sdz25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Discontinued operations &#8211; current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i02TI_mtCzng3_maCzXVe_zbhKYrF2E6Jl" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,630</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzXVe_z2vAqfptmvJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease liability, noncurrent</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Liabilities_i01TI_mtCzXVe_maCzHNR_zrQJdWV3DmYd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingenciesDisclosureAbstract_i01B_zq7TiPZHo1me" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitments and contingencies (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maCzPEN_z3hta3nvSMbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, at amounts paid-in, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230930_pdd" title="Preferred stock, par value (in dollar per share)"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20221231_pdd" title="Preferred stock, par value (in dollar per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_c20230930_pdd" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20221231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_c20230930_pdd" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_c20230930_pdd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,000</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at September&#160;30, 2023 and <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20221231_z5QduYtuk6U4"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_zWxve4NZFtua"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December&#160;31, 2022.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0122">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i02I_maCzPEN_zNYJVEio9T17" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, at amounts paid-in, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20230930_pdd" title="Common stock, par value (in dollars per share)"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_c20230930_pdd" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_c20230930_pdd" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_c20230930_pdd" title="Common stock, shares outstanding"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20221231_pdd" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i02I_maCzPEN_zJ7I8EGJTKF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,609</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzPEN_zD7lbbMBOee2" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">389,860</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">386,261</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_mtCzPEN_maCzHNR_zg0214n5YBWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,363</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzHNR_ztBWQphUnZE6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,999</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Notes to Condensed Financial Statements</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_004"></span><b>TITAN PHARMACEUTICALS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONDENSED STATEMENTS OF OPERATIONS</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands, except per share amount)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_30E_113_pn3n3_zcEFoFjbev0e" summary="xdx: Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701__20230930_zhYZxOgduK3g" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220701__20220930_zwetkeKEnqe1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230101__20230930_zY8stxW9LAZf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20220930_zY2CU4bDNJY3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-left: 0.125in; padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended<br /> September&#160;30,</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended<br /> September&#160;30,</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenuesAbstract_iB_z70bLvHwFGAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Revenues:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">License revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" title="Total revenues" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" title="Total revenues" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-07-012022-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" title="Total revenues" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" title="Total revenues" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Grant revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-07-012023-09-30_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-07-012022-09-30_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-09-30_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-09-30_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">427</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_maCzkK1_zHklRu4xCe75" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CostsAndExpensesAbstract_iB_zrbGtv9jJA06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzjYF_zEaILVDAghFc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzjYF_z8MEjJgBjgP" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,641</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,806</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,745</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostsAndExpenses_i01T_mtCzjYF_msCzkK1_zZSr7hRN7f81" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_mtCzkK1_maCz5xT_zxanHzitLRmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,061</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,346</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,624</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zTZKRpj86FK8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeExpenseNonoperatingNet_i01_maCzHnN_zVwRClpD2OO4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GainsLossesOnSalesOfAssets_i01_maCzHnN_zRnJiQ9Aflo" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on asset sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherNonoperatingIncomeExpense_i01_maCzHnN_zRp0OwI2EwFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_mtCzHnN_maCz5xT_zKBVQXTXERLi" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtCz5xT_zD5WAKOv4sY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">338</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,638</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,599</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zEyYa6ipCpK9" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zYzNJyW5Irii" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zVqxT86wTY3f" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_z2Vv839351sf" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zYj1N48E1FP9" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_z0nWvCrckbQ1" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.24</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_zhyIzF0a4kz5" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zB1FD9QsXymb" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.59</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20230930_zOVf8jJ3Vej9" title="Weighted average shares used in computing basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20230930_zCJ7AvhZB9Ig" title="Weighted average shares used in computing diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220701__20220930_zbChAfoWUd" title="Weighted average shares used in computing basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220701__20220930_znyMVMnnXGF4" title="Weighted average shares used in computing diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,629</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230101__20230930_zkFRuKlF0Mp9" title="Weighted average shares used in computing basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230101__20230930_zu0ES5phiR18" title="Weighted average shares used in computing diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20220101__20220930_zlY7BrOi2Gfa" title="Weighted average shares used in computing basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20220101__20220930_zSzwjUBls9b4" title="Weighted average shares used in computing diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,031</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Notes to Condensed Financial Statements</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_005"></span><b>TITAN PHARMACEUTICALS, INC.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONDENSED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY (DEFICIT)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_pn3n3_z864OuTBgSBb" summary="xdx: Statement - CONDENSED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zM1gjPf0cUG2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zBKPU8uQNEYd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zE1tKmbexHr4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zlTgMJz8ur5j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_zWs7nyaqws6k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Preferred Stock</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Additional<br /> Paid-In</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Total<br /> Stockholders&#8217;<br /> Equity</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Deficit)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_43F_c20230101__20230331_eus-gaap--StockholdersEquity_iS_z16FDlppSShg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 30%; vertical-align: top">Balances at December&#160;31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pn3n3_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwmY8feWx9b" title="Beginning balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pn3n3_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMp6NJTSrrr3" title="Beginning balance, shares" style="color: rgb(204,238,255); width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span>&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="color: rgb(204,238,255); width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span>&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,609</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">386,261</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: White; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: White; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span>&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_437_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zy1PXD1VUF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balances at March&#160;31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pn3n3_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjKhf2dctvh7" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pn3n3_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMlxHaHYdL4f" title="Beginning balance, shares" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span>&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,609</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">387,936</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_z1sFVIRcdUw3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,586</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,586</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCjUY2zMcnW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: rgb(204,238,255); text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span>&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zRha1UTAHqzc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balances at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNaCS0yCZKsj" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1GNEKoaPtOk" title="Beginning balance, shares" style="color: White; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span>&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">389,522</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,034</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zvuSGleCB2x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfPreferredStockNet_zJtAixvTpiu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Issuance of preferred stock, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">950</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ttnp:IssuanceOfPreferredStockNet" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ttnp:IssuanceOfPreferredStockNet" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,093</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ttnp:IssuanceOfPreferredStockNet" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,094</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zFOsgs8SiVNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balances at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOeOH9CXyJE7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFgstB3UbfVe" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">950</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">389,860</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,133</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z1HSNLvpLeC5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zNZG4o9qkgpd">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zr0AJMJLZxki" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zWAA8L1oexbd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_zrc6gs4tcWYh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Additional<br />Paid-In</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Total<br />Stockholders&#8217;<br />Equity</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Deficit)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zXoeuDyI3Q0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Balances at December&#160;31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgM7bNM1DGa6" title="Beginning balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,914</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="color: rgb(204,238,255); width: 1%">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">376,055</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zFNgj367V9fg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td style="color: White">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,540</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--ProfitLoss_zTlAtZDSn9aa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of common stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEjDe5ixcu4d" title="Issuance of common stock, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueOther_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_z07wKtaiDwHc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of common stock upon exercises of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_iP3us-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeQbIRphlxel" title="Issuance of common stock upon exercises of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zF7M6jgiOAnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zQA29WJVOwgc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zMc9fZHmAQX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balances at March&#160;31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pn3n3_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcaEz2Ah9Hmi" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255)">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">386,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">378,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_zJRyS8pvUYk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="text-align: left">&#160;</td><td style="color: White">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,462</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,462</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueOther_zHXBKLtR7fP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of common stock upon exercises of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_pn3n3_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhnx4bQwrCu3" title="Issuance of common stock upon exercises of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zMK7ocCSdqE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zdnfYNuPVALf" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balances at June&#160;30, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5HMI4D6g9he" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="color: White">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">386,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">381,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_ztOTHZb0ckp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255)">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,638</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,638</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zTxCNXlQrVF5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zivnwEElbwbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220701__20220930_eus-gaap--StockholdersEquity_iE_zp5BUrUJT609" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balances at September&#160;30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTfnthbnqsm3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: White; padding-bottom: 2.5pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">383,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_006"></span><b>TITAN PHARMACEUTICALS, INC.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONDENSED STATEMENTS OF CASH FLOWS</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in thousands)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_30B_112_pn3n3_zXSyZnmqg8Gh" summary="xdx: Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20230930_zZi75CXr99S6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20220101__20220930_zDEFALvqleMh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended<br /> September&#160;30,</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z6j4cVyYAiDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01N_di_msCzghx_zNOv3C73vHpb" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,599</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,640</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zii9RF3B85Ad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GainsLossesOnSalesOfAssets_i02N_di_msCzghx_zbrQJ06PpuR4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on sale of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzghx_zbm3Euy2U1Mk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ShareBasedPaymentArrangementMilestonePayment_i02_maCzghx_z0vPXUkdQtxf" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based milestone payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ttnp:ShareBasedPaymentArrangementMilestonePayment" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maCzghx_z0FHGFzv2Nwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherOperatingIncomeExpenseNet_i02N_di_msCzghx_zm7QrMSMbRP8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zUoagiYIy924" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCzghx_zDthoxnsThA1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">63</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msCzghx_zHuJHlEtrMYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzghx_zuPGDZMWBdh5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzghx_zbLPjioOkCul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">374</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInDeferredRevenue_i03_maCzghx_zIwq2v110vTg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Deferred grant revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maCzghx_z28UqO7Iqqe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">152</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzghx_maCzUig_zmA92HvinIX6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,846</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,604</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zdwZ7h3ZdqZ2" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzBdr_zDJvkwj5makj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Proceeds from sale of assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_maCzUig_mtNCPBUzBdr_zlnD1BTuGQUj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net cash provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zCPDUnnIfnXl" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromEquityOfferings_i01_maCzK2N_zFJjw2E6Bji2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ttnp:ProceedsFromEquityOfferings" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_maCzK2N_zFWccEtZl3Nj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from issuance of preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromSubordinatedShortTermDebt_i01_maCzK2N_zBm7H0GWM9Fj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from short-term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSubordinatedShortTermDebt" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromWarrantExercises_i01_maCzK2N_zAi9uSrroP1l" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from the exercises of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfSubordinatedShortTermDebt_i01N_di_msCzK2N_zUJLqnaqyNC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Payments on short-term loans</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfSubordinatedShortTermDebt" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzK2N_maCzUig_zyptlPjt76ik" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,594</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,984</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzUig_zAQ6n7vZSJr8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,620</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zrRWmkBmhwVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,332</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z5XWtkopkmW3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash, cash equivalents and restricted cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,109</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,712</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zKEYcb73Ruog" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i01_zEm6KddY8y4f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InventoryTransferredWithSaleOfAssets_i01_zlBk0Bit1VL5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inventory transferred with sale of assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ttnp:InventoryTransferredWithSaleOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PropertyAndEquipmentNetTransferredWithSaleOfAssets_i01_zeTEqzmIJGf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net, transferred with sale of assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ttnp:PropertyAndEquipmentNetTransferredWithSaleOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NotesReceivableReceivedInConnectionWithSaleOfAssets_i01_zBfdEM5Ab9Bd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Notes receivable received in connection with sale of assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ttnp:NotesReceivableReceivedInConnectionWithSaleOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccountsPayableRelatedToSaleOfAssets_i01_zhVnemz4tuvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable related to sale of assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ttnp:AccountsPayableRelatedToSaleOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OtherAccruedLiabilitiesTransferredWithSaleOfAssets_i01_z4X6r7QddM69" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other accrued liabilities transferred with sale of assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ttnp:OtherAccruedLiabilitiesTransferredWithSaleOfAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table provides a reconciliation of cash, cash equivalents and restricted
         cash reported within the condensed balance sheets that sum to the total of the same
         such amounts shown in the condensed statements of cash flows (in thousands):</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zVc9NE1lxjob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCash_iE_z2Qr3SgrQMMg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CashAndCashEquivalentsAndRestrictedCashEquivalents_iE_zP0ZwhzIkUjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,109</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,712</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See Notes to Condensed Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>



<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_007"></span><b>TITAN PHARMACEUTICALS,
INC.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(unaudited)</b></p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmozvx6vuxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_82C_zq2jLnIHhEzk">Organization and Summary of Significant Accounting Policies</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="ttnp:CompanyPolicyPolicyTextBlock"><p id="xdx_846_ecustom--CompanyPolicyPolicyTextBlock_zLeoMA4DSHe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_z2qHsneFQdha">The Company</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a pharmaceutical company developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura<sup>&#xae;</sup>, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our first product based on the ProNeura technology was Probuphine<sup>&#xae;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that had either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an
         approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DavidLazarAndActivistInvestingLlcMember_pdd" title="Ownership interest by Activist"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-07-31_custom_DavidLazarAndActivistInvestingLlcMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction>%</span> ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#8220;Board&#8221;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220801__20220815__srt--CounterpartyNameAxis__custom--RubinMember_zXKXT3GFaOZ4" title="Severance payments"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2022-08-012022-08-15_custom_RubinMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million, of which,
         approximately $<span id="xdx_906_eus-gaap--SeveranceCosts1_pn3p0_c20230101__20230930_znHbsUs4svt5" title="Severance payments"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">247,000</ix:nonFraction></span> have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, (the &#8220;Closing Date&#8221;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#8220;ProNeura Assets&#8221;). In July&#160;2023, <span id="xdx_900_ecustom--AssetSaleDescriptions_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember_zz06Sh1xbTUk" title="Asset sale description"><ix:nonNumeric contextRef="From2023-09-012023-09-30_custom_ProNeuraMember" name="ttnp:AssetSaleDescriptions">we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;)
         with Fedson, Inc., a Delaware corporation (&#8220;Fedson&#8221;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.</ix:nonNumeric></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div id="xdx_238_zCgRjr5Nx392" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zHPJJEwm0sIe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zMUOUwmlzXlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6XMrSt2FfDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zHWyrJfCfZ7d">Basis of Presentation</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited condensed financial statements have been prepared in accordance
         with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial
         information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information
         and footnotes required by GAAP for complete financial statement presentation. In the
         opinion of management, all adjustments (consisting of normal recurring adjustments)
         considered necessary for a fair presentation have been included. Operating results
         for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending
         December&#160;31, 2023, or any future interim periods.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The balance sheet as of December&#160;31, 2022 is derived from the audited financial statements at that date but does not
         include all the information and footnotes required by GAAP for complete financial
         statements. These unaudited condensed financial statements should be read in conjunction
         with the audited financial statements and footnotes thereto included in the Titan
         Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been prepared assuming we will
         continue as a going concern.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30,
      2023, we had cash and cash equivalents of approximately $8.1
      million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zTuW97m8TUH4" title="Cash and cash equivalents" style="display: none"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,096</ix:nonFraction></span>, which we believe, will be sufficient to fund our planned operations through December of 2024. We continue to explore
      several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DiscontinuedOperationsPolicyTextBlock"><p id="xdx_84C_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zbUao7Y1bYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zxqn8GlLGTCl">Discontinued Operations</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind
         down our commercialization activities, and to pursue a plan that will enable us to
         focus on our current, early-stage ProNeura-based product development programs.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been recast for all periods presented
         to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization
         activities as discontinued operations (see Note 7). The accompanying condensed financial
         statements are generally presented in conformity with our historical format. We believe
         this format provides comparability with the previously filed financial statements.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="ttnp:GoingConcernAssessmentPolicyTextBlock"><p id="xdx_840_ecustom--GoingConcernAssessmentPolicyTextBlock_z9YJr1ioPbGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zKHFBuOW8eZe">Going Concern Assessment</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We assess going concern uncertainty in our financial statements to determine if we
         have sufficient cash on hand and working capital, including available borrowings on
         loans, to operate for a period of at least one year from the date the financial statements
         are issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting
         Standard Update ASU No. 2014-15. As part of this assessment, based on conditions that
         are known and reasonably knowable to us, we will consider various scenarios, forecasts,
         projections, estimates and will make certain key assumptions, including the timing
         and nature of projected cash expenditures or programs, and our ability to delay or
         curtail expenditures or programs, if necessary, among other factors. Based on this
         assessment, as necessary or applicable, we make certain assumptions around implementing
         curtailments or delays in the nature and timing of programs and expenditures to the
         extent we deem probable those implementations can be achieved and we have the proper
         authority to execute them within the look-forward period in accordance with ASU No.
         2014-15.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based upon the above assessment, we concluded that, at the date of filing the condensed
         financial statements in this Quarterly Report on Form 10-Q for the nine months ended September&#160;30, 2023, we have sufficient cash to fund our operations for the next 12 months without additional
         funds. Additionally, we have suffered recurring losses from operations and have an accumulated
         deficit that raises substantial doubt about our ability to continue as a going concern beyond the next 12 months. We continue to explore several financing and strategic alternatives; however, there can be no assurance
         that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zgv8mh8HLin5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zyq8yLFBBmEl">Use of Estimates</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with accounting principles generally
         accepted in the U.S. requires management to make estimates and assumptions that affect
         the amounts reported in the financial statements and accompanying notes. Actual results
         could differ from those estimates.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_23B_zlFWgz30hhz9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_z4rv2BbaY5Na" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zvwSfDNdxM4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zVBXZzICS3m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zqhwr1AVKcd5">Inventories</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Inventories are recorded at the lower of cost or net realizable value. Cost is based
         on the first in, first out method. We regularly review inventory quantities on hand
         and write down to its net realizable value any inventory that we believe to be impaired.
         The determination of net realizable value requires judgment including consideration
         of many factors, such as estimates of future product demand, product net selling prices,
         current and future market conditions and potential product obsolescence, among others.
         The components of inventories are as follows:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_z2bAMFYUdLl3" style="display: none">Schedule of components of inventories</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br />2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" title="Raw materials and supplies" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" title="Finished goods" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" title="Total inventories" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      </ix:nonNumeric><p id="xdx_8A5_zTj1jCMRBNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Approximately $<span id="xdx_90C_eus-gaap--InventoryNet_iI_pn3p0_c20221231_zYeYqrXpeO8a" title="Raw materials and supplies and finished goods inventory"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">106,000</ix:nonFraction></span> of raw materials and supplies and finished goods inventory
         at December&#160;31, 2022 were sold to Fedson under the Asset Purchase Agreement in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z91HH0nf1qB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zoO0xQFY0eZc">Revenue Recognition</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We generate revenue principally from collaborative research and development arrangements,
         sales or licenses of technology and government grants. Consideration received for
         revenue arrangements with multiple components is allocated among the separate performance
         obligations based upon their relative estimated standalone selling price.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In determining the appropriate amount of revenue to be recognized as we fulfill our
         obligations under our agreements, we perform the following steps for our revenue recognition:
         (i) identify contracts with customers; (ii) identify performance obligations; (iii)
         determine the transaction price; (iv) allocate the transaction price to the performance
         obligations; and (v) recognize of revenue when (or as) we satisfy each performance
         obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Grant Revenue</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department
         of Health and Human Services, or HHS, the Bill&amp; Melinda Gates Foundation, and other
         government-sponsored organizations for research and development related activities
         that provide for payments for reimbursed costs, which may include overhead and general
         and administrative costs. We recognize revenue from these contracts as we perform
         services under these arrangements when the funding is committed. Associated expenses
         are recognized when incurred as research and development expenses. Revenues and related
         expenses are presented gross in the condensed statements of operations.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Performance Obligations</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A performance obligation is a promise in a contract to transfer a distinct good or
         service to the customer. Our performance obligations include commercialization license
         rights, development services and services associated with the regulatory approval
         process.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have optional additional items in contracts, which are accounted for as separate
         contracts when the customer elects such options. Arrangements that include a promise
         for future commercial product supply and optional research and development services
         at the customer&#8217;s discretion are generally considered as options. We assess if these options provide
         a material right to the customer and, if so, such material rights are accounted for
         as separate performance obligations. If we are entitled to additional payments when
         the customer exercises these options, any additional payments are recorded in revenue
         when the customer obtains control of the goods or services.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_238_zzeVVMGFoa92" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zumuX2V6jPN3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_z4C2ewNqfjb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Transaction Price</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have both fixed and variable considerations. Non-refundable upfront payments are
         considered fixed, while milestone payments are identified as variable consideration
         when determining the transaction price. Funding of research and development activities
         is considered variable until such costs are reimbursed at which point, they are considered
         fixed. We allocate the total transaction price to each performance obligation based
         on the relative estimated standalone selling prices of the promised goods or services
         for each performance obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At the inception of each arrangement that includes milestone payments, we evaluate
         whether the milestones are considered probable of being achieved and estimate the
         amount to be included in the transaction price using the most likely amount method.
         If it is probable that a significant revenue reversal would not occur, the value of
         the associated milestone is included in the transaction price. Milestone payments
         that are not within our control, such as approvals from regulators, are not considered
         probable of being achieved until those approvals are received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For arrangements that include sales-based royalties or earn-out payments, including
         milestone payments based on the level of sales, and the license or purchase agreement
         is deemed to be the predominant item to which the royalties or earn-out payments relate,
         we recognize revenue at the later of (a) when the related sales occur, or (b) when
         the performance obligation to which some or all of the royalty or earn-out payment
         has been allocated has been satisfied (or partially satisfied).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Allocation of Consideration</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As part of the accounting for these arrangements, we must develop assumptions that
         require judgment to determine the stand-alone selling price of each performance obligation
         identified in the contract. Estimated selling prices for license rights are calculated
         using the residual approach. For all other performance obligations, we use a cost-plus
         margin approach.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Timing of Recognition</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Significant management judgment is required to determine the level of effort required
         under an arrangement and the period over which we expect to complete our performance
         obligations under an arrangement. We estimate the performance period or measure of
         progress at the inception of the arrangement and re-evaluate it each reporting period.
         This re-evaluation may shorten or lengthen the period over which revenue is recognized.
         Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot
         reasonably estimate when our performance obligations either are completed or become
         inconsequential, then revenue recognition is deferred until we can reasonably make
         such estimates. Revenue is then recognized over the remaining estimated period of
         performance using the cumulative catch-up method. Revenue is recognized for licenses
         or sales of functional intellectual property at the point in time the customer can
         use and benefit from the license. For performance obligations that are services, revenue
         is recognized over time proportionate to the costs that we have incurred to perform
         the services using the cost-to-cost input method.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Contract Assets and Liabilities</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the activity related to our accounts receivable for the
         nine months ended September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8BA_zJunFJq2kcSf" style="display: none">Schedule of activity related to our accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,<br />2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Balance at January&#160;1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" title="Beginning Balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ttnp:ContractWithCustomerAssetAdditions" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Deductions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" title="Deductions" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ttnp:ContractWithCustomerAssetDeductions" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Balance at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      </ix:nonNumeric><p id="xdx_8A3_z52B391iNeVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_235_zEFB90jypx9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zv80EP2C0mY" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zrRKtrFbq91l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyCqZguNny61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zKu78sT64TXg">Research and Development Costs and Related Accrual</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Research and development expenses include internal and external costs. Internal costs
         include salaries and employment related expenses, facility costs, administrative expenses
         and allocations of corporate costs. External expenses consist of costs associated
         with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research
         studies, product registration, and investigator sponsored trials. Significant judgments
         and estimates must be made and used in determining the accrued balance in any accounting
         period. Actual results could differ from those estimates under different assumptions.
         Revisions are charged to expense in the period in which the facts that give rise to
         the revision become known.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zw10ww79lmq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_z99MMQQsVv4h">Leases</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We determine whether the arrangement is or contains a lease at inception. Operating
         lease right-of-use assets and lease liabilities are recognized at the present value
         of the future lease payments at commencement date. The interest rate implicit in lease
         contracts is typically not readily determinable, and therefore, we utilize our incremental
         borrowing rate, which is the rate incurred to borrow on a collateralized basis over
         a similar term an amount equal to the lease payments in a similar economic environment.
         Certain adjustments to the right-of-use asset may be required for items such as initial
         direct costs paid or incentives received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Lease expense is recognized over the expected term on a straight-line basis. Operating
         leases are recognized on our condensed balance sheets as right-of-use assets, operating
         lease liabilities current and operating lease liabilities non-current.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the minimum lease payments of our operating lease:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none">Schedule of minimum operating lease payments</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total minimum lease payments (base rent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      </ix:nonNumeric><p id="xdx_8AB_zXRT6AQ0IWud" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFedDUfImZA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_z0bHIQxCJrj1">Recent Accounting Pronouncements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In June&#160;2016, the
      FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses, which requires
      an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience,
      current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking
      information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January&#160;1,
      2023. The adoption of Topic 326 did not have a material impact on our condensed financial statements and disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Accounting Standards Not Yet Adopted</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates
         certain models that require separate accounting for embedded conversion features,
         in certain cases. Additionally, among other changes, the guidance eliminates certain
         of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for
         all convertible instruments in the diluted earnings per share calculation and include
         the effect of share settlement for instruments that may be settled in cash or shares,
         except for certain liability-classified share-based payment awards. This guidance
         is effective beginning after December&#160;15, 2023 and must be applied using either a modified or full retrospective approach.
         Early adoption is permitted. We are currently evaluating the impact this guidance
         will have on our condensed financial statements and related disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_23A_zRKJjnFFDou" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zqE26McVBoLh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z6DkvhwdDSid" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcmC12GHullh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4UdCV7EIj1e">Fair Value Measurements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Financial instruments, including receivables, accounts payable and accrued liabilities
         are carried at cost, and their fair values are approximated due to the short-term
         nature of these instruments. Our investments in money market funds are classified
         within Level 1 of the fair value hierarchy.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At December&#160;31, 2022, the fair value of our investments in money market funds was approximately
         $<span id="xdx_90C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zj4aCXB5y65h" title="Fair value of investments"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million which is included within our cash and cash equivalents in our condensed
         balance sheets. We had no investments in money market funds at September&#160;30, 2023.</p>
      </ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzed4J049NR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_82F_z7c9Vn5tng6k">Stock Plans</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes option activity:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z5nnMVw8iJNd" summary="xdx: Disclosure - Stock Plans (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8B7_zYZvduR0ThPc" style="display: none">Schedule of our option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options<br />(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br />Exercise Price<br /> per share</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br />Remaining Option<br />Term (in years)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate
    Intrinsic<br />Value<br />(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at December&#160;31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930_z6Ie8JtpGro2" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">927</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zHUg2qVZL16" title="Weighted average exercise price, outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zdA3szvYYdP3" title="Weighted average remaining contractual term, outstanding (years)"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.34</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20230930_zdQX1r9aVlH8" title="Aggregate Intrinsic Value, option outstanding at beginning" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pn3n3_c20230101__20230930_zTSRuRX48Csl" title="Option granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zUOnt5Zelxo" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AggregateIntrinsicValueOptionGranted_pn3n3_c20230101__20230930_z1iAYIBSGpp8" title="Aggregate Intrinsic Value, Option granted" style="text-align: right"><ix:nonFraction name="ttnp:AggregateIntrinsicValueOptionGranted" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20230930_zzI37ciDhaPl" title="Option forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">91</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zKwlQRNwRNoi" title="Weighted average exercise price, forfeited or expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Outstanding at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930_zPCkxjJ3EP04" title="Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z0NTlHP4Ypn8" title="Weighted average exercise price, outstanding at outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zKK5vz2MwD5k" title="Weighted average remaining contractual term, outstanding (years)"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.84</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20230930_zvC4ApkWn388" title="Aggregate Intrinsic Value, option outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Exercisable at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930_z6ssVuKi8KR9" title="Option exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zkAGJxJf3Iw7" title="Weighted average exercise price per share, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zBUFEZv4KYP4" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">8.84</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20230930_zNf2jzD0sHmd" title="Aggregate Intrinsic Value, Option exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      </ix:nonNumeric><p id="xdx_8AD_zCCEZ8lu8xPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During August and September&#160;2022, our Board granted <span id="xdx_900_ecustom--PurchaseCommonStock_pid_c20220801__20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zvhRumcIyoy5" title="Purchase common stock"><ix:nonFraction name="ttnp:PurchaseCommonStock" contextRef="From2022-08-012022-08-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> options to purchase common stock at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zGXjRaO8k0Hf" title="Purchase price, per value"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.52</ix:nonFraction></span> per share
         and <span id="xdx_909_ecustom--PurchaseCommonStock_pid_c20220901__20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zqginXpCouv8" title="Purchase common stock"><ix:nonFraction name="ttnp:PurchaseCommonStock" contextRef="From2022-09-012022-09-30_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></span> options to purchase common stock at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zGo7bdyUZ0tk" title="Purchase price, per value"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-30_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></span> per share which are subject
         to shareholder approval of an amendment to increase the number of shares reserved
         for issuance under our 2015 Plan. The options vest monthly over a 12-month period
         from the grant dates. The shares underlying these options were approved by our stockholders
         on June&#160;29, 2023 and have been included in the table above as of September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In July&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan, an aggregate of <span id="xdx_90A_ecustom--NumberOfCommonStockVested_pid_c20230701__20230731__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_z9ZDvy3uFPZf" title="NUmber of common stock vested"><ix:nonFraction name="ttnp:NumberOfCommonStockVested" contextRef="From2023-07-012023-07-31_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></span> shares of fully vested unrestricted common
         stock to seven members of the Board of Directors and one member of the management team. As a result,
         we recognized non-cash stock compensation of approximately $<span id="xdx_90B_ecustom--NoncashStockCompensation_pn3n3_dm_c20230701__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zpXIcWTZlXx8" title="Non-cash stock compensation"><ix:nonFraction name="ttnp:NoncashStockCompensation" contextRef="From2023-07-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million during the three months ending September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes the stock-based compensation expense recorded for awards
         under our stock option plans (in thousands):</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zr9U5dxd6CCi" summary="xdx: Disclosure - Stock Plans (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B4_zud6aGf22ZHk" style="display: none">Schedule of the stock-based compensation expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">553</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">359</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">859</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">523</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">965</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">967</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      </ix:nonNumeric><p id="xdx_8A7_zRYi7s2xUi71" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_235_zI3TMi5OLMn8" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_z6dfJljDhaCd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_znZ938MUZjn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We use the Black-Scholes-Merton option-pricing model with the following assumptions
         to estimate the fair value of our stock options:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zscu0XQscKq1" summary="xdx: Disclosure - Stock Plans (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B7_zaoc03bvrYFc" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230701__20230930_zpa7NInYESP" title="Weighted-average risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.08</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220701__20220930_zUQ3j6gyW6m7" title="Weighted-average risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230930_zFe2O8PODCsa" title="Weighted-average risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.06</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20220930_zctL4QeGORuh" title="Weighted-average risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.91</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected dividend payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230701__20230930_pn3n3" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220701__20220930_pn3n3" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230101__20230930_pn3n3" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pn3n3_c20220101__20220930_zPfLS6KjNQB" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected holding period (years)<sup>1</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_fMQ_____zoEf2M7s073c" title="Expected holding period (years)"><ix:nonNumeric contextRef="From2023-07-012023-09-30" format="ixt-sec:duryear" id="Fact000753" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_fMQ_____zm48SGG4Nhi9" title="Expected holding period (years)"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" id="Fact000755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_fMQ_____zZhsBAFFtto7" title="Expected holding period (years)"><ix:nonNumeric contextRef="From2022-01-012022-09-30" format="ixt-sec:duryear" id="Fact000757" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average volatility factor<sup>2</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230701__20230930_fMg_____zpkQ7EmMkD1e" title="Weighted-average volatility factor"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-07-012023-09-30" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.14</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220701__20220930_fMg_____zwsR6B0vI6Qj" title="Weighted-average volatility factor"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230101__20230930_fMg_____zS0oWeOz8tH7" title="Weighted-average volatility factor"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-01-01to2023-09-30" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.10</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20220930_fMg_____zWSFhnUKHTaj" title="Weighted-average volatility factor"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-09-30" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.16</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Estimated forfeiture rates for options granted<sup>3</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230701__20230930_fMw_____zmt8b1hERogc" title="Estimated forfeiture rates for options granted"><ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2023-07-012023-09-30" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220701__20220930_fMw_____zCBW9FUa2Ni1" title="Estimated forfeiture rates for options granted"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230101__20230930_fMw_____zCO0v0ntbPbl" title="Estimated forfeiture rates for options granted"><ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2023-01-01to2023-09-30" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20220930_fMw_____zTs9Swxouyke" title="Estimated forfeiture rates for options granted"><ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2022-01-012022-09-30" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F08_z5kvmQbmxKp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">(1)</td>
            <td id="xdx_F17_zN4SDFeVBgXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"><ix:footnote id="Footnote000774" xml:lang="en-US">Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.</ix:footnote></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F01_zDZIppNRIJS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(2)</td>
            <td id="xdx_F1A_zHJEgIxAIpcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"><ix:footnote id="Footnote000775" xml:lang="en-US">Weighted average volatility is based on the historical volatility of our common stock.</ix:footnote></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F04_zHzkEMlpoTCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(3)</td>
            <td id="xdx_F10_zeMqbuVEBVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"><ix:footnote id="Footnote000776" xml:lang="en-US">Estimated forfeiture rates are based on historical data.</ix:footnote></td>
         </tr>
      </table>
      </ix:nonNumeric><p id="xdx_8A4_zGLiZvG85yR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30, 2023, there was <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_do_c20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zX2JBv3aVJCa" title="Total unrecognized compensation expense related to non-vested stock option"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></span> unrecognized compensation expense related to non-vested stock options.</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_z6JKFjf7Geml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_825_zEc1WsT7mNPf">Net Loss Per Share</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The table below presents common shares underlying stock options and warrants that
         are excluded from the calculation of the weighted average number of common shares
         outstanding used for the calculation of diluted net loss per common share. These are
         excluded from the calculation due to their anti-dilutive effect:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zr6dK2aGu7pg" summary="xdx: Disclosure - Net Loss Per Share (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B8_zwGI0Egyn9Of" style="display: none">Schedule of antidilutive securities excluded from computation of net loss per common share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zT53y0SdXeVj" title="Amount of weighted-average anti-dilutive common shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,767</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBQMbdURpx6h" title="Amount of weighted-average anti-dilutive common shares" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrS28VUi2jaf" title="Amount of weighted-average anti-dilutive common shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z3xFARqviuT2" title="Amount of weighted-average anti-dilutive common shares" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z8uVfaOtoRY6" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zRQKKL1gap42" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zesGqAUUrgt8" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zpD8zvIfSrud" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhr832iv8Qgd" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfSlWR0bMLa" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5mc1mkceIO" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzsb9L2C0tVd" title="Amount of weighted-average anti-dilutive common shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zhqIUwEB4Ey" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,818</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znoxPeF2W8ml" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,933</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpQUgLVuR4Va" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,678</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWgOtDosQEz8" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,586</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zY5pk2y1O8vf" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,950</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zGIVQrWCfKV5" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,865</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_zgGZudZuej71" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,358</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_zt5hwIGHU76c" title="Amount of weighted-average anti-dilutive common shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="ttnp:AssetPurchaseAgreementTextBlock"><p id="xdx_80B_ecustom--AssetPurchaseAgreementTextBlock_zE64lpeKcwo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_825_z7Oe00vghNUl">JT Pharmaceuticals Asset Purchase Agreement</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals,
         Inc., or JT Pharma, to acquire JT Pharma&#8217;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with
         our ProNeura long-term, continuous drug delivery technology, for the treatment of
         chronic pruritus and other medical conditions. Under the terms of the JT Agreement,
         JT Pharma received a $<span id="xdx_901_ecustom--FutureMilestonePayments_pn3p0_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zfcPJZzbvD0b" title="Closing payment"><ix:nonFraction name="ttnp:FutureMilestonePayments" contextRef="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">15,000</ix:nonFraction></span> closing payment and is entitled to receive future milestone
         payments, payable in cash or in stock, based on the achievement of certain developmental
         and regulatory milestones, and single-digit percentage earn-out payments on net sales
         of the product if successfully developed and approved for commercialization. In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $<span id="xdx_90C_ecustom--MilestonePayments_pn3p0_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zvtvmV3AKL3g" title="Milestone Payments"><ix:nonFraction name="ttnp:MilestonePayments" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">100,000</ix:nonFraction></span> and issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zut7iQy2Xe28" title="Issuance of common stock, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,021</ix:nonFraction></span>
         shares of our common stock to JT Pharma. The related expense was included in research
         and development expenses in our condensed statements of operations.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_233_z4q8k6EkGO63" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zYRqN2HjJBx4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zo6G9s8X9cQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_82E_z0ONGqpE1A89">Commitments and Contingencies</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Lease Commitments</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We lease our office facility under an operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $<span id="xdx_907_ecustom--OperatingLeasesRentExpenses_c20230701__20230930_pn3p0" title="Rent expense"><ix:nonFraction name="ttnp:OperatingLeasesRentExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">32,000</ix:nonFraction></span> and $<span id="xdx_901_ecustom--OperatingLeasesRentExpenses_c20230101__20230930_pn3p0" title="Rent expense"><ix:nonFraction name="ttnp:OperatingLeasesRentExpenses" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">96,000</ix:nonFraction></span> for the three and nine months ended September&#160;30, 2023, respectively.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Proceedings</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A legal proceeding has been initiated by a former employee alleging wrongful termination,
         retaliation, infliction of emotional distress, negligent supervision, hiring and retention
         and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted
         utilizing an outside investigator and concluded that such allegations were not substantiated.
         Fedson, as further consideration for the Asset Purchase Agreement, has agreed to assume
         all liabilities related to this pending employment claim (See Note 8. Asset Sale).</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyiSJUdjzlYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_824_zDADuDoPjQZf">Stockholders&#8217; Equity</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our common stock outstanding as of September&#160;30, 2023 and December&#160;31, 2022 was <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_zSmejc0FF3Df" title="Common stock shares, outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zu98KW71MEO4" title="Common stock shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></ix:nonFraction></span></span> shares.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Annual Meeting of Stockholders</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In June&#160;2023, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan
         to increase the number of authorized shares to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--N2015OmnibusEquityIncentivePlanMember_zfDyL7C2eMpd" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-09-30_custom_N2015OmnibusEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>September&#160;2023 Preferred Stock</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with
         The Sire Group Ltd. (&#8220;Sire Group&#8221; or the &#8220;Investor&#8221;), pursuant to which we agreed
         to issue <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20230930_zsJqRX54Xa9k" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,000</ix:nonFraction></span> shares of Series AA Convertible Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930_zZje7QVEvyma" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
         per share (the &#8220;Series AA Preferred Stock&#8221;) to the Investor at a price of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230930_zY1dfd7GBdXb" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per
         share, for an aggregate purchase price of $<span id="xdx_904_ecustom--PurchasePrice_pn3n3_dm_c20230101__20230930_zseXorHTJzti" title="Purchase price"><ix:nonFraction name="ttnp:PurchasePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.5</ix:nonFraction></span> million (the &#8220;Private Placement&#8221;). The purchase price consisted of (i) $5.0 million in cash
         at closing and (ii) $4.5 million in the form of a promissory note from Sire Group
         which was paid off in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each share of Series AA Preferred Stock will be convertible, at the holder&#8217;s option at any time, into shares of our common stock at a conversion rate equal to the quotient of (i) the stated value of
         such share divided by (ii) the initial conversion price of $0.466, subject to specified
         adjustments as set forth in the Certificate of Designations. The Series AA Preferred
         Stock contains limitations that prevent the Investor from acquiring the lower of either
         (i) the maximum percentage of common stock permissible under the rules and regulations
         of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) without first obtaining shareholder approval or (ii) 19.99% of our outstanding common
         stock.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holder of the Series AA Preferred Stock is entitled to receive dividends on shares
         of the Series AA Preferred Stock equal (on an as-if-converted-to-common-stock basis)
         to and in the same form as dividends actually paid on shares of the common stock.
         No other dividends will be paid on shares of the Series AA Preferred Stock. Any shares
         of Series AA Preferred Stock may, at the option of the holder, be converted at any
         time into that number of shares of common stock at the conversion price set forth
         above. Without approval of holders of a majority of the outstanding Series AA Preferred
         Stock, we may not (a) alter or adversely change the powers, preferences or rights
         given to the Series AA Preferred Stock, (b) amend its certificate of incorporation
         or other charter documents in any manner that adversely affects any rights of the
         holders of the Series AA Preferred Stock, (c) increase the number of authorized shares
         of the Series AA Preferred Stock, (d) enter into or consummate any Fundamental Transaction
         (as defined in the Certificate of Designations), or (e) enter into any agreement with
         respect to any of the foregoing. In the event of any liquidation, dissolution or winding
         up, the holder of the Series AA Preferred Stock will be entitled to receive out of
         the assets, whether capital or surplus, the same amount that a holder of common stock
         would receive if the Series AA Preferred Stock were fully converted to common stock,
         which amounts shall be paid <i>pari passu</i> with all holders of common stock.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23E_zZWg22ilNbD2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_z1nhMs44cHXl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zTtv4GqxW8da" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>February&#160;2022 Offerings</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In February&#160;2022, we completed a registered direct offering with an accredited investor pursuant
         to which we issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zHLC9jI8xC3f" title="Issuance of common stock, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></span> shares of our common stock and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zcyIRoPxayWi" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,274,242</ix:nonFraction></span>
         pre-funded warrants to purchase shares of our common stock, with an exercise price
         of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zIfLyefPZ8rl" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. In a concurrent private placement, we sold unregistered pre-funded
         warrants to purchase an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zpU7djWdqoH4" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,289,796</ix:nonFraction></span> shares of common stock with an exercise
         price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z4A56AkdgVZf" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share and issued unregistered five year and six month warrants
         to purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zPV8UXWjLDhf" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,664,038</ix:nonFraction></span> shares of common stock with an exercise price
         of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zbO5HGRD1uk8" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span>. The net cash proceeds from these offerings were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zB0FEOBrdNe6" title="Proceeds from sale of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million
         after deduction of underwriting fees and other offering expenses.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Warrant Exercises</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In March&#160;2022, we received approximately $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zIzA1MnKDUcj" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-03-012022-03-31_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span> from the exercise of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9X29bKolA87" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">974,242</ix:nonFraction></span> pre-funded warrants
         issued in the February&#160;2022 registered direct offering.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>JT Pharma Milestone</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $<span id="xdx_906_ecustom--MilestonePayment_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zGTbrA1eDmP4" title="Milestone payment"><ix:nonFraction name="ttnp:MilestonePayment" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span> and issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zG6NAJ567Hw7" title="Issuance of common stock, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,021</ix:nonFraction></span>
         shares of our common stock to JT Pharma.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Restricted Shares</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2021, we agreed to issue <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zBB2V1qVHb24" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of our common stock pursuant to a restricted
         stock agreement with Maxim Partners, LLC in connection with the entry into an amendment
         to our existing advisory agreement. The shares vested monthly over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zrc4LFyglzYj" title="Vesting period"><ix:nonNumeric contextRef="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span> months. We recorded
         approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zz8DTeAwAhF3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zdfvPeCO6zV1" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,000</ix:nonFraction></span> of stock-based compensation expense during the three
         and nine months ended September&#160;30, 2022, respectively.</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zykkeYiQ52s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_822_zBdiKt5KvhZi">Discontinued Operations</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents information related to assets and liabilities reported
         as discontinued operations in our condensed balance sheets:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zteT5bqhh3T9" summary="xdx: Disclosure - Discontinued Operations (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;<span id="xdx_8BF_z1WwZLuzypm" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230930_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20221231_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pn3n3_maAODGIzGqL_z4M9TA2Moit" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzGqL_zEcaCDBqtcob" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzGqL_zY8IKu8PXB2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIzKdM_zNTLskm0GqLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzKdM_zCMMFjC6G4Pe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="ttnp:AssetsHeldForSaleTextBlock"><p id="xdx_800_ecustom--AssetsHeldForSaleTextBlock_zyJ19nGPjIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_826_zlpEru4H2yn4">Asset Sale</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we closed on the sale of certain ProNeura Assets. In July&#160;2023, <span id="xdx_906_ecustom--AssetSaleDescription_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember" title="Asset sale description"><ix:nonNumeric contextRef="From2023-09-012023-09-30_custom_ProNeuraMember" name="ttnp:AssetSaleDescription">we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.</ix:nonNumeric></span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_239_zUYWf021Zdbc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_ziL1BCLMhUbd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zc5EW5TUCla9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_829_zeMJPa9Sc5Y4">Related Party Transactions</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the nine months ended September&#160;30, 2023, we made payments related to legal fees of approximately $<span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zNu5n9Yes3Ik" title="Payment of legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span> to a law firm operated by one of our Board members.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2023, we received $<span id="xdx_90D_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zm3JGMJPDUF6" title="Proceeds from promissory note"><ix:nonFraction name="ttnp:ProceedsFromPromissoryNote" contextRef="From2023-08-012023-08-31_custom_HauPromissoryNoteMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500,000</ix:nonFraction></span> in funding in exchange for the issuance of a convertible
         promissory note for that principal amount to Choong Choon Hau, a major stockholder
         (the &#8220;Hau Promissory Note&#8221;). Pursuant to the Hau Promissory Note, the principal amount
         will accrue interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember" title="Interest accrued rate"><ix:nonNumeric contextRef="From2023-08-012023-08-31_custom_HauPromissoryNoteMember" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">10% per annum</ix:nonNumeric></span> and will be payable monthly. All principal
         and accrued interest shall be due and payable on January&#160;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our common stock at a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zugrgQc4gGF4" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-08-31_custom_HauPromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5712</ix:nonFraction></span> per share from time to time following the issuance date and ending on the maturity
         date. We incurred interest expense of approximately $<span id="xdx_90E_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zfnyBhUqCEM3" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30_custom_HauPromissoryNoteMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,500</ix:nonFraction></span> during the three months ended September&#160;30, 2023 on this promissory note. The Hau Promissory note is included in Notes Payable to Related Party in the condensed
         balance sheet at September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In July&#160;2023, we received $<span id="xdx_905_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zWojagLkkzB3" title="Proceeds from promissory note"><ix:nonFraction name="ttnp:ProceedsFromPromissoryNote" contextRef="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250,000</ix:nonFraction></span> in funding in exchange for the issuance of an unsecured
         promissory note for that principal amount to David E. Lazar, our Chief Executive Officer
         and chairman of our Board of Directors (the &#8220;Lazar Promissory Note&#8221;). Pursuant to
         the Lazar Promissory Note, the principal amount accrued interest at a rate of the
         <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember" title="Interest accrued rate"><ix:nonNumeric contextRef="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">Prime Rate + 2.00% per annum</ix:nonNumeric></span>, and all principal and accrued interest would have been
         due and payable on the earlier of January&#160;1, 2024 or such time as we receive debt or equity financing or proceeds in excess of
         $500,000 from the aforementioned transaction with Fedson. The promissory note was paid off in September&#160;2023. We incurred interest expense of approximately $<span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zYtyjqRoWyS4" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30_custom_LazarPromissoryNoteMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,718</ix:nonFraction></span> during the three months ended September&#160;30, 2023 on this promissory note.</p>
      </ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zsT4RXxL1O74" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_82D_z9UUaOOH2vJd">Subsequent Events</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have evaluated events that have occurred after September&#160;30, 2023 and through the date that our condensed financial statements are issued.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan (the &#8220;2015 Plan&#8221;) an aggregate of <span id="xdx_90E_ecustom--UnrestrictedCommonStockVested_pid_c20230901__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zfxZD9ileSfl" title="Unrestricted common stock vested"><ix:nonFraction name="ttnp:UnrestrictedCommonStockVested" contextRef="From2023-09-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">113,750</ix:nonFraction></span> shares of fully vested unrestricted common stock to six members
         of the Board of Directors and one member of the management team. The Board conditioned the grant on the filing of a Form S-8 registration statement
         to register the common shares authorized for issuance under the 2015 Plan, which occurred
         on October&#160;25, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2023, Fedson exercised the provision for a second extension of the maturity date of
         the Cash Note in exchange for a cash payment of $<span id="xdx_907_ecustom--CashPayment_pn3n3_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--CashNoteMember_z69qdWTGVslf" title="Cash payment"><ix:nonFraction name="ttnp:CashPayment" contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_CashNoteMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></span>. The Cash Note is currently due and payable on December&#160;1, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2023, we agreed to issue <span id="xdx_90F_ecustom--CommonStockIssuedForSettlementAgreement_pid_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--MDMWorldwideSolutionsMember_zZKSuMqzoEX4" title="Common stock issued for settlement agreement"><ix:nonFraction name="ttnp:CommonStockIssuedForSettlementAgreement" contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of our common stock pursuant to a settlement agreement with MDM Worldwide Solutions, Inc. The shares vested immediately. </p>
      </ix:nonNumeric><p id="xdx_814_zyckWH2Zqfhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_008"></span><b>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This Quarterly Report on Form 10-Q or in the documents incorporated by reference herein may contain &#8220;forward-looking
         statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933 (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) that involve substantial
         risks and uncertainties. We have attempted to identify forward-looking statements
         by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
         &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; or &#8220;will&#8221;
         or the negative of these terms or other comparable terminology. Although we do not
         make forward looking statements unless we believe we have a reasonable basis for doing
         so, we cannot guarantee their accuracy. Forward-looking statements included or incorporated
         by reference in this report or our other filings with the Securities and Exchange
         Commission, or the SEC, include, but are not necessarily limited to, those relating
         to uncertainties relating to:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Our ability to complete one or more strategic transactions that will maximize our
               assets or otherwise provide value to stockholders;</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">our ability to raise capital when needed;</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">difficulties or delays in the product development and regulatory process; and</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">protection for our patents and other intellectual property or trade secrets.</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Forward-looking statements should not be read as a guarantee of future performance
         or results and will not necessarily be accurate indications of the times at, or by
         which, that performance or those results will be achieved. Forward-looking statements
         are based on information available at the time they are made and/or management&#8217;s good faith belief as of that time with respect to future events, and are subject
         to risks and uncertainties, including the risks outlined under &#8220;Risk Factors&#8221; or elsewhere
         in this report, that could cause actual performance or results to differ materially
         from what is expressed in or suggested by the forward-looking statements.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Forward-looking statements speak only as of the date they are made. You should not
         put undue reliance on any forward-looking statements. We assume no obligation to update
         forward-looking statements to reflect actual results, changes in assumptions or changes
         in other factors affecting forward-looking information, except to the extent required
         by applicable securities laws. If we do update one or more forward-looking statements,
         no inference should be drawn that we will make additional updates with respect to
         those or other forward-looking statements. We caution you not to give undue weight
         to such projections, assumptions and estimates.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;Titan,&#8221; and &#8220;our company&#8221; refer to Titan Pharmaceuticals,
         Inc. unless the context otherwise requires.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Probuphine<sup>&#xae; </sup>and ProNeura<sup>&#xae;</sup> are trademarks of Fedson, Inc. This Quarterly Report on Form 10-Q also includes trade names and trademarks of companies other than Titan.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a pharmaceutical company developing therapeutics utilizing the proprietary
         long-term drug delivery platform, ProNeura<sup>&#xae;</sup>, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our first product based on the ProNeura technology was Probuphine<sup>&#xae;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that had
         either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an
         approximately 25% ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#8220;Board&#8221;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $0.4 million, of which,
         approximately $247,000 have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, (the &#8220;Closing Date&#8221;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#8220;ProNeura Assets&#8221;). In July&#160;2023, we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;)
         with Fedson, Inc., a Delaware corporation (&#8220;Fedson&#8221;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone
         payments of up to $50 million on future net sales of the products and certain royalties
         on future net sales of the products. As further consideration, Fedson assumed all
         liabilities related to a pending employment claim against us. On the Closing Date,
         Fedson delivered a written guaranty by a principal of Fedson of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note
         to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; margin-left: 0.25in"><b>ProNeura Continuous Drug Delivery Platform</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant
         made from a mixture of EVA and a given drug substance. The resulting product is a
         solid matrix that is placed subdermally, normally in the inside part of the upper
         arm in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. The drug substance
         is released continuously through the process of dissolution-controlled diffusion.
         This results in a continuous, steady rate of release generally similar to intravenous
         administration. We believe that such long-term, near linear release characteristics
         are desirable as they avoid the fluctuating peak and trough drug levels seen with
         oral dosing that often poses treatment problems in a range of diseases.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The ProNeura platform was developed to address the need for a simple, practical method
         to achieve continuous long-term drug delivery, and, depending on the characteristics
         of the compound to be delivered, can potentially provide treatment on an outpatient
         basis over extended periods of up to 12 months. We believe that the benefits of this
         technology have been demonstrated by the clinical results seen to date with Probuphine,
         and, in addition, that the development and regulatory process have been affirmed by
         the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA,
         and Health Canada approvals of this product. We have further demonstrated the feasibility
         of the ProNeura platform with small molecules, hormones, and bio-active peptides.
         The delivery system works with both hydrophobic and hydrophilic molecules. We have
         also shown the flexibility of the platform by experimenting with the release characteristics
         of the EVA implants, layering the implants with varying concentrations of drug, and
         generating implants of different sizes and porosity to achieve a desired delivery
         profile.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 0; margin-right: 0; margin-bottom: 0; margin-left: 0.25in"><b>Development Programs</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We currently have the following development program for which development activities
         have been substantially curtailed while we are exploring several financing and strategic
         alternatives.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><i>TP-2021 </i>- A subdermal ProNeura implant containing TP-2021, our kappa opioid agonist peptide,
               for the potential delivery of therapeutic concentrations of TP-2021 in human subjects
               with pruritus for up to six months or longer following a single in-office procedure.
               We will need to conduct Investigational New Drug, or IND, enabling non-clinical safety
               and pharmacology studies in preparation for regulatory approval to enter human clinical
               studies.</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We operate in only one business segment, the development of pharmaceutical products.
         We make available free of charge through our website, www.titanpharm.com, our periodic
         reports as soon as reasonably practicable after we electronically file such material
         with, or furnish it to, the SEC.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">See Note 1 to the accompanying unaudited condensed financial statements included in
         Part 1, Item 1 of this Quarterly Report on Form 10-Q for information on recent accounting pronouncements.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Results of Operations for the Three and Nine months ended September&#160;30, 2023 and September&#160;30, 2022</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Revenues</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="22" style="font-style: italic; text-align: center">(In thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Revenues:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">License revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(4</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(8</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Grant revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">91</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(87</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">183</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">427</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(244</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.375in">Total revenues</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(91</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">436</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(252</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>




      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The decrease in total revenues for the three and nine months ended September&#160;30, 2023 was primarily due to decreased activities related to the NIDA grant for the development
         of a Nalmefene implant and the Gates Foundation grant.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Operating Expenses</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="22" style="text-align: center"><i>(In thousands)</i></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 34%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">424</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(508</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,426</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(1,889</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,641</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,806</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,745</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(641</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 2.5pt">Total operating expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,065</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(673</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,530</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The decrease in research and development costs for the three and nine months ended September&#160;30, 2023 was primarily associated with reduced activities related to non-clinical studies
         required for the IND submission as part of our NIDA grant for the development of a
         Nalmefene implant, decreases in expenses related to initial non-clinical proof of
         concept studies related to our TP-2021 implant program and decreases in research and
         development personnel-related costs and other expenses following our December&#160;2022 reduction in our workforce. Other research and development expenses include internal
         operating costs such as research and development personnel-related expenses, non-clinical
         and clinical product development related travel expenses, and allocation of facility
         and corporate costs. As a result of the risks and uncertainties inherently associated
         with pharmaceutical research and development activities described elsewhere in this
         document, we are unable to estimate the specific timing and future costs of our clinical
         development programs or the timing of material cash inflows, if any, from our product
         candidates. However, we anticipate that our research and development expenses will
         increase as we continue our current or any future ProNeura development programs to
         the extent these costs are not supported through grants or partners.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The decrease in general and administrative expenses for the three months ended September&#160;30, 2023 was primarily related to decreases in legal and professional fees and other expenses.
         This was partially offset by increases in employee-related expenses and non-cash stock-based compensation. The decrease in general and administrative expenses for the nine months ended September&#160;30, 2023 was primarily related to decreases in employee-related expenses, legal and professional fees, and other expenses. This was
         partially offset by increases in non-cash stock-based compensation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Other Income (Expense), Net</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="22" style="text-align: center"><i>(In thousands)</i></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 34%; text-align: left">Interest income (expense), net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(11</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">21</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(32</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(8</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Gain on asset disposition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(42</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Other income (expense), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,747</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,763</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The increase in other income (expense), net for the three and nine months ended September&#160;30, 2023 was primarily due to the gain related to the sale of the ProNeura Assets to Fedson and decreases in tax related expenses. This was partially offset by increases in interest expense.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Net Loss and Net Loss per Share</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our net loss from operations for the three-month period ended September&#160;30, 2023 was approximately $0.3 million, or approximately $0.02 per share, compared to our net loss from operations of approximately $2.6 million, or approximately $0.18 per share, for the comparable period in 2022. Our
         net loss from operations for the nine-month period ended September&#160;30, 2023 was approximately $3.6 million, or approximately $0.24 per share, compared to our net loss from operations of approximately $7.6 million, or approximately $0.59 per share, for the comparable period in 2022.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity and Capital Resources</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have funded our operations since inception primarily through the sale of our securities
         and the issuance of debt, as well as with proceeds from warrant and option exercises,
         corporate licensing and collaborative agreements, and government and private sponsored research grants. At September&#160;30, 2023, we had a working capital of approximately $8.0 million compared to working capital of approximately $1.0 million at December&#160;31, 2022.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we entered into a Purchase Agreement with Sire Group, pursuant to which we agreed
         to issue 950,000 shares of Series AA Preferred Stock at a price of $10.00 per share,
         for an aggregate purchase price of $9.5 million. The purchase price consisted of (i)
         $5.0 million in cash at closing and (ii) $4.5 million in the form of a promissory
         note from Sire Group which was paid in September&#160;2023. The net cash proceeds from this transaction were approximately $9.1 million.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we closed on the sale of certain ProNeura Assets. In July&#160;2023, we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note
         to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2023, we received $500,000 in funding in exchange for the issuance of the Hau Promissory
         Note. Pursuant to the Hau Promissory Note, the principal amount will accrue interest
         at a rate of 10% per annum and will be payable monthly. All principal and accrued
         interest shall be due and payable on January&#160;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be converted into our common
         stock at a conversion price of $0.5712 per share from time to time following the issuance date and ending on the maturity
         date.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In February&#160;2022, we completed a registered direct offering with an accredited investor pursuant
         to which we issued an aggregate of 1,100,000 shares of our common stock and 2,274,242
         pre-funded warrants to purchase shares of our common stock, with an exercise price
         of $0.001 per share. In a concurrent private placement, we sold unregistered pre-funded
         warrants to purchase an aggregate of 1,289,796 shares of common stock with an exercise
         price of $0.001 per share and issued unregistered five year and six month warrants
         to purchase an aggregate of 4,664,038 shares of common stock with an exercise price
         of $1.14. The net cash proceeds from these offerings were approximately $5.0 million
         after deduction of underwriting fees and other offering expenses.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30, 2023, we had cash and cash equivalents of approximately $8.1 million, which we believe will be sufficient to fund our planned operations through December of 2024. We are exploring several financing and strategic alternatives; however, there can
         be no assurance that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Sources and Uses of Cash</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br />September&#160;30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center"><i>(In thousands)</i></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 78%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(4,846</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(6,604</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,594</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,984</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,620</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Net cash used in operating activities for the nine months ended September&#160;30, 2023 consisted primarily of our net loss of approximately $3.6 million, approximately $1.7 million of gains related to the sale of assets and approximately $0.6 million related to net changes in operating assets and liabilities. This was partially
         offset by approximately $1.1 million of non-cash charges related to stock-based compensation and depreciation and amortization. Net cash used in operating activities for the nine months ended September&#160;30, 2022 consisted primarily of our net loss of approximately $7.6 million and approximately $0.2 million related to net changes in operating assets and liabilities, partially offset
         by approximately $1.2 million of non-cash charges primarily related to stock-based compensation and depreciation
         and amortization.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Net cash provided by investing activities for the nine months ended September&#160;30, 2023 related to net proceeds from the sale of assets and liabilities to Fedson.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Net cash provided by financing activities for the nine months ended September&#160;30, 2023 consisted of approximately $9.1 million of net cash proceeds from the issuance of preferred stock and approximately $0.8 million of proceeds from short-term debt. This was partially offset by approximately $0.3 million related to payments on short-term
         notes payable. Net cash provided by financing activities for the nine months ended September&#160;30, 2022 consisted primarily of net cash proceeds from the February&#160;2022 offering.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_009"></span><b>Item 3. Quantitative and Qualitative Disclosures About Market Risk</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our market risk disclosures set forth in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 have not materially changed.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_010"></span><b>Item 4. Controls and Procedures</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disclosure Controls and Procedures</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our Chief Executive Officer, being our principal executive and financial officer,
         has evaluated the effectiveness of our disclosure controls and procedures as defined
         in Rules&#160;13a-15(e) and 15d-15(e) of the Exchange Act as of September&#160;30, 2023, the end of the period covered by this report, and has concluded that our disclosure
         controls and procedures were effective to ensure that the information required to
         be disclosed by us in reports we file or submit under the Exchange Act is recorded,
         processed, summarized and reported within the time periods specified in the rules
         and forms of the SEC, and that such information is accumulated and communicated to
         our principal executive and principal financial officer as appropriate to allow timely
         decisions regarding required disclosure.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control Over Financial Reporting</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">There were no changes in our internal control over financial reporting (as defined
         in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) during the nine months ended September&#160;30, 2023 that materially affected, or were reasonably likely to materially affect, our internal
         controls over financial reporting.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_011"></span><b>PART II</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_012"></span><b>Item 1. Legal Proceedings</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A legal proceeding has been initiated by a former employee alleging wrongful termination,
         retaliation, infliction of emotional distress, negligent supervision, hiring and retention
         and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted
         utilizing an outside investigator and concluded that such allegations were not substantiated.
         Fedson, as further consideration for the Asset Purchase Agreement, has agreed to assume
         all liabilities related to this pending employment claim.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_013"></span><b>Item 1A. Risk Factors</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition to the other information set forth in this report, you should carefully
         consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our 2022 10-K, which could materially affect our business, financial
         condition or future results. The risks described in our 2022 10-K are not the only
         risks facing our company. Except as noted below, the risks and uncertainties described
         in &#8220;Item 1A &#8211; Risk Factors&#8221; have not materially changed. Additional risks and uncertainties
         not currently known to us or that we currently deem to be immaterial also may materially
         adversely affect our business, financial condition and/or operating results.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b>We have incurred net losses in almost every year since our inception, which losses
         will continue for the foreseeable future and raise substantial doubt about our ability
         to continue as a going concern</b>.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have incurred net losses in almost every year since our inception. Our financial
         statements have been prepared assuming that we will continue as a going concern. For
         the years ended December&#160;31, 2022 and 2021 and for the nine months ended September&#160;30, 2023, we had net losses of approximately $10.2 million, $8.8 million and $3.6 million, respectively, and had net cash used in operating activities of approximately
         $8.2 million, $7.9 million and $4.8 million, respectively. These net losses and negative cash flows have had, and will
         continue to have, an adverse effect on our stockholders&#8217; equity and working capital, which have declined in the past year. As described elsewhere
         in this report, as of September&#160;30, 2023 we had cash and cash equivalents of approximately $8.1 million. We expect to continue to incur net losses and negative operating cash flow
         for the foreseeable future as we focus on exploring strategic alternatives to enhance
         stockholder value and development of our ProNeura based products. The amount of future
         net losses will depend, in part, on the rate of future growth of our expenses and
         our ability to obtain government or third-party funding for our development programs.
         Our history of losses raises substantial doubt about our ability to continue as a
         going concern.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b>If we cannot continue to satisfy the Nasdaq Capital Market continued listing standards
         and other Nasdaq rules, our common stock could be delisted, which would harm our business,
         the trading price of our common stock, our ability to raise additional capital and
         the liquidity of the market for our common stock.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our Common Stock is currently listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;). The
         listing standards of Nasdaq require that a company maintain stockholders&#8217; equity of at least $2.5 million (the &#8220;Equity Rule&#8221;) and a minimum bid price subject to specific requirements of $1.00 per share. There
         is no assurance that we will be able to maintain compliance with the minimum closing
         price requirement or the minimum stockholders&#8217; equity requirement. Should we fail to comply with the minimum listing standards applicable
         to issuers listed on Nasdaq, our common stock may be delisted from Nasdaq. If our
         common stock is delisted, it could reduce the price of our common stock and the levels
         of liquidity available to our stockholders.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April&#160;5, 2023, we received a notice from Nasdaq notifying us that the Company&#8217;s stockholders&#8217; equity as reported in our Annual Report on Form 10-K for the period ended December&#160;31, 2022 (&#8220;2022 10-K&#8221;), did not satisfy the continued listing requirement under Nasdaq
         Listing Rule&#160;5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company&#8217;s stockholders&#8217; equity be at least $2,500,000. In our 2022 10-K, we reported stockholders&#8217; equity of $1,363,000, and, as a result, we did not satisfy Nasdaq Marketplace Rule&#160;5550(b)(1) as of December&#160;31, 2022. We submitted a compliance plan within 45 days of the date of the notification
         and, on June&#160;5, 2023, we received a letter from the Listing Qualifications Department of Nasdaq
         notifying us that we had been granted an additional 180-day period, or until October&#160;2, 2023, to regain compliance with Nasdaq Listing Rule&#160;5550(b)(1).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In March&#160;2023, we received a letter from the Listing Qualifications staff of The Nasdaq Stock
         Market, or Nasdaq, notifying us that we were no longer in compliance with the minimum
         bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing
         Rule&#160;5550(a)(2) requires listed companies to maintain a minimum bid price of $1.00 per share.
         The letter noted that the bid price of our common stock was below $1.00 for the 30-day
         period ending March&#160;15, 2023. The notification letter had no immediate effect on our listing on the Nasdaq
         Capital Market. In accordance with Listing Rule&#160;5810(c)(3), Nasdaq provided us with 180 days, or until September&#160;12, 2023, to regain compliance with the minimum bid price requirement by having a closing
         bid price of at least $1.00 per share for a minimum of 10 consecutive business days.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On September&#160;13, 2023, we received a determination letter (the &#8220;Determination Letter&#8221;) from the
         Staff stating that we had not regained compliance with Listing Rule&#160;5550(a)(2) and were not eligible for a second 180 day period to regain compliance. Unless the Company
         requested an appeal of this determination, the trading of the Company&#8217;s common stock would be suspended at the opening of business on September&#160;22, 2023, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), which would remove the Company&#8217;s securities from listing and registration on The Nasdaq Stock Market.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition, the Staff indicated in the Determination Letter that, pursuant to Listing
         Rule&#160;5810(d)(2), this deficiency served as an additional and separate basis for delisting, and as such, the Company should
         address its non-compliance with the Equity Rule before a Hearings Panel (the &#8220;Panel&#8221;)
         if it appeals the Staff&#8217;s determination.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We appealed Nasdaq&#8217;s determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing
         Rule&#160;5800 Series to stay the suspension of our securities and the filing of the Form 25-NSE pending the Panel&#8217;s decision. At a Panel hearing on November&#160;2, 2023, we presented our plan to regain compliance with both the minimum bid price
         requirement and the Equity Rule. With respect to the minimum bid price requirement,
         we presented a plan to effect a reverse stock split in early 2024. On November&#160;7, 2023, the Panel granted our request for continued listing subject demonstrating compliance with the minimum bid price requirement by February&#160;1, 2024.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If our common stock is delisted from Nasdaq, our common stock would likely then trade
         only in the over-the-counter market. If our common stock were to trade on the over-the-counter
         market, selling our common stock could be more difficult because smaller quantities
         of shares would likely be bought and sold, transactions could be delayed, and we could
         face significant material adverse consequences, including: a limited availability
         of market quotations for our securities; reduced liquidity with respect to our securities;
         a determination that our shares are a &#8220;penny stock,&#8221; which will require brokers trading
         in our securities to adhere to more stringent rules, possibly resulting in a reduced
         level of trading activity in the secondary trading market for our securities; a reduced
         amount of news and analyst coverage for our company; and a decreased ability to issue
         additional securities or obtain additional financing in the future. These factors
         could result in lower prices and larger spreads in the bid and ask prices for our
         common stock and would substantially impair our ability to raise additional funds
         and could result in a loss of institutional investor interest and fewer development
         opportunities for us.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In addition to the foregoing, if our common stock is delisted from Nasdaq and it trades
         on the over-the-counter market, the application of the &#8220;penny stock&#8221; rules could adversely
         affect the market price of our common stock and increase the transaction costs to
         sell those shares. The Securities and Exchange Commission, or SEC, has adopted regulations
         which generally define a &#8220;penny stock&#8221; as an equity security that has a market price
         of less than $5.00 per share, subject to specific exemptions. If our common stock
         is delisted from Nasdaq and it trades on the over-the-counter market at a price of
         less than $5.00 per share, our common stock would be considered a penny stock. The
         SEC&#8217;s penny stock rules require a broker-dealer, before a transaction in a penny stock
         not otherwise exempt from the rules, to deliver a standardized risk disclosure document
         that provides information about penny stocks and the risks in the penny stock market.
         The broker-dealer must also provide the customer with current bid and offer quotations
         for the penny stock, the compensation of the broker-dealer and the salesperson in
         the transaction, and monthly account statements showing the market value of each penny
         stock held in the customer&#8217;s account. In addition, the penny stock rules generally require that before a transaction
         in a penny stock occurs, the broker-dealer must make a special written determination
         that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s agreement to the transaction. If applicable in the future, these rules may restrict
         the ability of brokers-dealers to sell our common stock and may affect the ability
         of investors to sell their shares, until our common stock no longer is considered
         a penny stock.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_014"></span><b>Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Not required to be furnished.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_015"></span><b>Item 5. Other Information.</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In July&#160;2023, we received $250,000 in funding in exchange for the issuance of an unsecured
         promissory note for that principal amount to David E. Lazar, our Chief Executive Officer
         and chairman of our Board of Directors (the &#8220;Lazar Promissory Note&#8221;). Pursuant to
         the Lazar Promissory Note, the principal amount accrued interest at a rate of the Prime Rate + 2.00% per annum, and all principal and accrued
         interest were due and payable on the earlier of January&#160;1, 2024 or such time as we receive debt or equity financing or proceeds in excess of
         $500,000 from the aforementioned transaction with Fedson. The loan was paid off in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2023, we received $500,000 in funding in exchange for the issuance of a convertible
         promissory note for that principal amount to Choong Choon Hau (the &#8220;Hau Promissory
         Note&#8221;). Pursuant to the Hau Promissory Note, the principal amount accrues interest at a rate of 10% per annum and is payable monthly. All principal and accrued interest is due and payable on January&#160;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our common stock at a conversion price of $0.5712 per share from time to time following the issuance date and ending on the maturity
         date.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_016"></span><b>Item 6. Exhibits</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><b>(b)</b></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><b>Exhibits</b></td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: left"><b>No</b></td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 90%; text-align: left"><b>Description</b></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">4.1</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912623006161/titanpharma_ex4-1.htm">Certificate of Designations, Preferences and Rights of Series AA Convertible Preferred Stock.<sup>(1)</sup></a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.1</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912623005752/titanpharma_ex10-1.htm">Amendment and Extension Agreement between Titan Pharmaceuticals, Inc. and Fedson, Inc., dated as of August&#160;25, 2023.<sup>(2)</sup></a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.2</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912623006161/titanpharma_ex10-1.htm">Form of Securities Purchase Agreement, dated as of September&#160;13, 2023, by and among the Company and The Sire Group Ltd.<sup>(1)</sup></a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.3</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912623006161/titanpharma_ex10-2.htm">Form of Registration Rights Agreement, dated as of September&#160;13, 2023, by and among the Company and The Sire Group Ltd.<sup>(1)</sup></a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.4</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="titanpharma_ex10-4.htm">Convertible Promissory Note between Titan Pharmaceuticals, Inc. and Choong Choon Hau*</a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">31.1</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="titanpharma_ex31-1.htm">Certification of the Principal Executive and Financial Officer pursuant to Rule&#160;13(a)-14(a) of the Securities Exchange Act of 1934*</a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">32.1</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="titanpharma_ex32-1.htm">Certification of the Principal Executive and Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002*</a></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.INS</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Instance Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.SCH</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Taxonomy Extension Schema Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.CAL</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Taxonomy Extension calculation Linkbase Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.DEF</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Taxonomy Extension Definition Linkbase Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.LAB</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Taxonomy Extension Label Linkbase Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">101.PRE</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">XBRL
            Taxonomy Extension Presentation Linkbase Document</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">104</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Cover
            Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in">(1)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; vertical-align: bottom">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated September&#160;18, 2023.</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(2)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; vertical-align: bottom">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated August&#160;30, 2023.</td>
         </tr>
      </table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_017"></span><b>SIGNATURES</b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
         has duly caused this report to be signed on its behalf by the undersigned thereunto
         duly authorized.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>TITAN PHARMACEUTICALS, INC.</b></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: middle">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: middle">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: middle">&#160;</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Dated: November&#160;14, 2023</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">By:</td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">/s/ David Lazar</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Name: </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>David Lazar</b></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Title:</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>Chief Executive Officer</b></td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><b>(Principal Executive Officer)</b></td>
         </tr>
      </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>



<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; text-align: left; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page -->

   </body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>titanpharma_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR OTHER APPLICABLE
EXEMPTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR
FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount: US$500,000</B></FONT></B></FONT></TD>
                                                                                                                                                                              <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue
Date: August 8, 2023</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONVERTIBLE
PROMISSORY NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
VALUE RECEIVED</B>, <B>TITAN PHARMACEUTICALS INC.,</B> a public listed Delaware corporation (hereinafter called the &ldquo;Borrower&rdquo;)
(Trading Symbol: TTNP), hereby promises to pay to the order of Choong Choon Hau, or his registered assigns (the &ldquo;Holder&rdquo;)
the sum of US$500,000 (the &ldquo;Principal&rdquo;) together with interest (the &ldquo;Interest&rdquo;) on the Principal balance hereof
in the amount of ten percent (10%) (the &ldquo;Interest Rate&rdquo;) per calendar year from the date hereof (the &ldquo;Issue Date&rdquo;).
Interest shall be payable on a monthly basis beginning on the date that is one month following the Issue Date. All Principal and accrued
but unpaid Interest owing hereunder, along with any and all other amounts, shall be due and owing on January, 2024, unless extended as
provided herein or accelerated in accordance with the terms hereof (the &ldquo;Maturity Date&rdquo;). This Note may be prepaid in whole
or in part as set forth herein. Any amount of Principal or Interest on this Note which is not paid when due shall bear interest at the
rate of the lesser of (i) eighteen percent (18%) per annum and (ii) the maximum amount permitted under law from the due date thereof
until the same is paid (the &ldquo;Default Interest&rdquo;). Default Interest shall commence accruing upon an Event of Default and shall
be computed on the basis of a 360-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted
into common stock, $0.001 par value per share, of the Borrower (the &ldquo;Common Stock&rdquo;) in accordance with the terms hereof)
shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter
give to the Borrower by written notice made in accordance with the provisions of this Note. Whenever any amount expressed to be due by
the terms of this Note is due on any day which is not a business day, the same shall instead be due on the next succeeding day which
is a business day and, in the case of any interest payment date which is not the date on which this Note is paid in full, the extension
of the due date thereof shall not be taken into account for purposes of determining the amount of interest due on such date. As used
in this Note, the term &ldquo;business day&rdquo; shall mean any day other than a Saturday, Sunday or a day on which commercial banks
in the city of New York, New York are authorized or required by law or executive order to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive
rights or other similar rights of shareholders of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms shall also apply to this Note:</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
I. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONVERSION RIGHTS UPON EVENT OF DEFAULT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Conversion Right</U>. The Holder shall have the right, from time to time following the Issue Date and ending on the Maturity Date
(the &ldquo;Conversion Period&rdquo;), and subject to receipt of any required corporate body and/or listing exchange approvals, to convert
all or any part of the outstanding and unpaid principal, interest, penalties, and all other amounts under this Note into fully paid and
non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities
of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the Conversion Price (as defined below) determined
as provided herein (a &ldquo;Conversion&rdquo;). The number of shares of Common Stock to be issued upon each conversion of this Note
shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date
specified in the notice of conversion, in the form attached hereto as Exhibit A (the &ldquo;Notice of Conversion&rdquo;), delivered to
the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or
e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 11:59 p.m., New York, New
York time on such conversion date (the &ldquo;Conversion Date&rdquo;). The term &ldquo;Conversion Amount&rdquo; means, with respect to
any conversion of this Note, the sum of (1) the Principal to be converted in such conversion <U>plus</U> (2) at the Holder&rsquo;s option,
accrued and unpaid Interest, if any, on such Principal at the interest rates provided in this Note to the Conversion Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<U>Conversion Price</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Calculation of Conversion Price</U>. Subject to the adjustments described herein, the conversion price (as adjusted, the &ldquo;Conversion
Price&rdquo;) shall equal the Trading Price on the Trading Day immediately prior to the Issue Date. To the extent the Conversion Price
of the Borrower&rsquo;s Common Stock closes below the par value per share, the Borrower will take all steps necessary to solicit the
consent of the stockholders to reduce the par value to the lowest value possible under applicable law. The Borrower agrees to honor all
conversions submitted pending this adjustment. If the shares of the Borrower&rsquo;s Common Stock have not been delivered within three
(3) business days to the Borrower or Borrower&rsquo;s transfer agent, the Notice of Conversion may be rescinded. <FONT STYLE="background-color: white">&ldquo;Trading
Price&rdquo; shall mean the daily dollar volume-weighted average sale price for the Common Stock on the Trading Market on any particular
Trading Day during the period beginning at 9:30 a.m.,&nbsp;<U>New York</U>&nbsp;City Time (or such other time as the Trading Market publicly
announces is the official open of trading), and ending at 4:00 p.m.,&nbsp;<U>New York</U>&nbsp;City Time (or such other time as the Trading
Market publicly announces is the official close of trading), as reported by Bloomberg through its &ldquo;Volume at Price&rdquo;, or,
if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing
bid price and the lowest closing ask price of any of the market makers for such security as reported in the Trading Market. If the Trading
Price cannot be calculated for such security on such date on any of the foregoing bases, the Trading Price of such security on such date
shall be the fair market value as mutually determined by the Borrower and the Holder. All such determinations of Trading Price shall
be appropriately and equitably adjusted in accordance with the provisions set forth herein for any stock dividend, stock split, stock
combination or other similar transaction occurring during any period used to determine the Trading Price. </FONT>&ldquo;Trading Day&rdquo;
shall mean any day on which the Common Stock is tradable for any period on the Trading Market. &ldquo;Trading Market&rdquo; shall mean
the Nasdaq Capital Market or on any other principal securities exchange or other securities market on which the Common Stock is then
being traded. The Borrower shall be responsible for the fees of its transfer agent and all DTC fees associated with any such issuance.
The Holder shall be entitled to deduct $500.00 from the conversion amount in each Notice of Conversion to cover Holder&rsquo;s deposit
fees associated with each Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>RESERVED</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Pro Rata Conversion; Disputes</U>. In the event of a dispute as to the number of shares of Common Stock issuable to the Holder in
connection with a conversion of this Note, the Borrower shall issue to the Holder the number of shares of Common Stock not in dispute
and resolve such dispute in accordance with Section 4.13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<FONT STYLE="background-color: white">If at any time the Conversion Price as determined hereunder for any conversion would be less than
the par value of the Common Stock, then the Conversion Price hereunder shall equal such par value for such conversion and the Conversion
Amount for such conversion shall be increased to include Additional Principal, where &ldquo;Additional Principal&rdquo; means such additional
amount to be added to the Conversion Amount to the extent necessary to cause the number of conversion shares issuable upon such conversion
to equal the same number of conversion shares as would have been issued had the Conversion Price not been subject to the minimum price
set forth in this Section 1.2(d).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
<U>Beneficial Ownership Limitation</U>. The Borrower shall not effect any exercise of this Note, and the Holder shall not have the right
to exercise any portion of this Note to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the
Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock
issuable upon exercise of this Note with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Note beneficially owned by the
Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of
any other securities of the Borrower (including, without limitation, any other securities of the Borrower which would entitle the holder
thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, shares of Common Stock (&ldquo;Common Stock Equivalents&rdquo;)) subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as
set forth in the preceding sentence, for purposes of this Section 1.3, beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Borrower
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section
1.3 applies, the determination of whether this Note is exercisable (in relation to other securities owned by the Holder together with
any Affiliates and Attribution Parties) and of which portion of this Note is exercisable shall be in the sole discretion of the Holder,
and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Note is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Note is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Borrower shall have no obligation to verify
or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section
1.3, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Borrower&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)
a more recent public announcement by the Borrower or (C) a more recent written notice by the Borrower or the Transfer Agent setting forth
the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Borrower shall within two
Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Borrower, including this Note, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding
shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall mean, as of any date, the maximum
percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Note that can be issued to the Holder without requiring a vote of the shareholders of the Borrower
under the rules and regulations of the Trading Market on which the Common Stock trades on such date and applicable securities laws. The
Holder, upon notice to the Borrower, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 1.3. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to
the Borrower. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 1.3 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4
<U>RESERVED</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5 <U>Authorized
Shares</U>. The Borrower covenants that during the period while any outstanding balance is owing hereunder or any conversion of the
Note is available, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from
preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note (the &ldquo;Reserved
Amount&rdquo;). The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and
non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would
change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the
Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common
Stock authorized and reserved, free from preemptive rights, for conversion of this Note. The Borrower: (i) acknowledges that it has
irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and
(ii)&nbsp;agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the
duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with
the terms and conditions of this Note. Notwithstanding the foregoing, in no event shall the Reserved Amount be lower than the
initial Reserved Amount, regardless of any prior conversions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at any time the Borrower does not maintain or replenish the Reserved Amount as required hereunder within three (3) business days of the
request of the Holder, the principal amount of the Note shall increase by Five Thousand and No/100 United States Dollars ($5,000) (under
Holder&rsquo;s and Borrower&rsquo;s expectation that any Principal t increase will tack back to the Issue Date) per occurrence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6
<U>Method of Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Mechanics of Conversion</U>. Subject to Section 1.1, this Note may be converted by the Holder in whole or in part at any time from
time to time during the Conversion Period, by (A)&nbsp;submitting to the Borrower or Borrower&rsquo;s transfer agent a Notice of Conversion
(by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 11:59 p.m., New York, New
York time) and (B)&nbsp;subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Surrender of Note Upon Conversion</U>. Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in
accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire
unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the Principal amount
so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower,
so as not to require physical surrender of this Note upon each such conversion. In the event of any dispute or discrepancy, such records
of the Borrower shall, <I>prima facie,</I> be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing,
if any portion of this Note is converted as aforesaid, the Holder may not transfer this Note unless the Holder first physically surrenders
this Note to the Borrower, whereupon the Borrower will forthwith issue and deliver upon the order of the Holder a new Note of like tenor,
registered as the Holder (upon payment by the Holder of any applicable transfer taxes) may request, representing in the aggregate the
remaining unpaid principal amount of this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that,
by reason of the provisions of this paragraph, following conversion of a portion of this Note, the unpaid and unconverted Principal amount
of this Note represented by this Note may be less than the amount stated on the face hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Payment of Taxes</U>. The Borrower shall not be required to pay any tax which may be payable in respect of any transfer involved in
the issue and delivery of shares of Common Stock or other securities or property on conversion of this Note in a name other than that
of the Holder (or in street name), and the Borrower shall not be required to issue or deliver any such shares or other securities or
property unless and until the person or persons (other than the Holder or the custodian in whose street name such shares are to be held
for the Holder&rsquo;s account) requesting the issuance thereof shall have paid to the Borrower the amount of any such tax or shall have
established to the satisfaction of the Borrower that such tax has been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Delivery of Common Stock Upon Conversion</U>. Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or
other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section
1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder copies of Transfer Agent
book entry records for the Common Stock issuable upon such conversion within five (5) business days after such receipt (the &ldquo;Deadline&rdquo;)
(and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Obligation of Borrower to Deliver Common Stock</U>. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed
to be the holder of record of the Common Stock issuable upon such conversion, the outstanding Principal amount and the amount of accrued
and unpaid Interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations under
this Article I, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to
receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have
given a Notice of Conversion as provided herein, the Borrower&rsquo;s obligation to issue and deliver the Common Stock shall be absolute
and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to
any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the
enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination,
or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might
otherwise limit such obligation of the Borrower to the Holder in connection with such conversion. The Conversion Date specified in the
Notice of Conversion shall be the Conversion Date so long as the Notice of Conversion is received by the Borrower before 11:59 p.m.,
New York, New York time, on such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Delivery of Common Stock by Electronic Transfer</U>. In lieu of delivering transfer agent book entry records representing the Common
Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (&ldquo;DTC&rdquo;) Fast Automated
Securities Transfer (&ldquo;FAST&rdquo;) program, upon request of the Holder and its compliance with the provisions contained in Section
1.1 and in this Section 1.4, the Borrower shall use its commercially reasonable best efforts to cause its transfer agent to electronically
transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder&rsquo;s Prime Broker with DTC through
its Deposit Withdrawal At Custodian (&ldquo;DWAC&rdquo;) system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>DTC Eligibility and Market Loss</U>. If the Borrower fails to maintain its status as &ldquo;DTC Eligible&rdquo; for any reason, the
Principal amount of the Note shall increase by Five Thousand and No/100 United States Dollars ($5,000) (and any Principal amount increase
will tack back to the Issue Date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Failure to Deliver Common Stock Prior to Delivery Deadline</U>. Without in any way limiting the Holder&rsquo;s right to pursue other
remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion
of this Note is not delivered by the Deadline (other than a failure due to the circumstances described in Section 1.3 above, which failure
shall be governed by such Section) the Borrower shall pay to the Holder $1,000 per day in cash, for each day beyond the Deadline that
the Borrower fails to deliver such Common Stock until the Borrower issues and delivers a certificate to the Holder or credit the Holder&rsquo;s
balance account for the number of shares of Common Stock to which the Holder is entitled upon such Holder&rsquo;s conversion of any Conversion
Amount (under Holder&rsquo;s and Borrower&rsquo;s expectation that any damages will tack back to the Issue Date). Such cash amount shall
be paid to Holder by the fifth (5<SUP>th</SUP>) day of the month following the month in which it has accrued or, at the option of the
Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added
to the Principal amount of this Note, in which event Interest shall accrue thereon in accordance with the terms of this Note and such
additional Principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that
the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, or interference with
such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision
contained in this Section 1.4(h) are justified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Rescindment of a Notice of Conversion</U>. If (i) the Borrower fails to respond to Holder within one (1) business day from the
Conversion Date confirming the details of Notice of Conversion, (ii) the Borrower fails to provide any of the shares of the Borrower&rsquo;s
Common Stock requested in the Notice of Conversion within three (3) business days from the date of receipt of the Note of Conversion,
(iii) the Holder is unable to procure a legal opinion required to have the shares of the Borrower&rsquo;s Common Stock issued unrestricted
and/or deposited to sell for any reason related to the Borrower&rsquo;s standing, (iv) the Holder is unable to deposit the shares of
the Borrower&rsquo;s Common Stock requested in the Notice of Conversion for any reason related to the Borrower&rsquo;s standing, (v)
at any time after a missed Deadline, at the Holder&rsquo;s sole discretion, or (vi) if Trading Market imposes any trading restriction
on the Common Stock on the day of or any day after the Conversion Date, the Holder maintains the option and sole discretion to rescind
the Notice of Conversion (&ldquo;Rescindment&rdquo;) with a &ldquo;Notice of Rescindment.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7
<U>Concerning the Shares</U>. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Borrower or its transfer agent shall
have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel
in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption
from such registration or (iii)&nbsp;such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) (&ldquo;Rule
144&rdquo;) or other applicable exemption or (iv) such shares are transferred to an &ldquo;affiliate&rdquo; (as defined in Rule 144)
of the Holder who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an &ldquo;accredited
investor&rdquo; (as defined in Rule 501(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;)). Subject to
the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note have been
registered under the Act or otherwise may be sold pursuant to Rule 144 or other applicable exemption without any restriction as to the
number of securities as of a particular date that can then be immediately sold, each certificate for shares of Common Stock issuable
upon conversion of this Note that has not been so included in an effective registration statement or that has not been sold pursuant
to an effective registration statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following
form, as appropriate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR OTHER APPLICABLE
EXEMPTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR
FINANCING ARRANGEMENT SECURED BY THE SECURITIES. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE
WITH THE SECURITIES ACT.&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legend set forth above shall be removed and the Borrower shall issue to the Holder a new certificate therefore free of any transfer legend
if (i) the Borrower or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary for opinions
of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock may be made without registration
under the Act, which opinion shall be reasonably accepted by the Borrower so that the sale or transfer is effected or (ii) in the case
of the Common Stock issuable upon conversion of this Note, such security is registered for sale by the Holder under an effective registration
statement filed under the Act or otherwise may be sold pursuant to Rule 144 or other applicable exemption without any restriction as
to the number of securities as of a particular date that can then be immediately sold. In the event that the Borrower does not accept
the opinion of counsel provided by the Holder with respect to the transfer of Securities pursuant to an exemption from registration,
such as Rule 144 or Regulation S, at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8
<U>Effect of Certain Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Effect of Merger, Consolidation, Etc</U>. At the option of the Holder, the sale, conveyance or disposition of all or substantially
all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more
than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower
with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall either: (i) be deemed to be an
Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation
of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III) or (ii) be treated pursuant
to Section 1.6(b) hereof. &ldquo;Person&rdquo; shall mean any individual, corporation, limited liability company, partnership, association,
trust or other entity or organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Adjustment Due to Merger, Consolidation, Etc</U>. If, at any time when this Note is issued and outstanding and prior to conversion
thereof, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a
result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class
or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all
of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note
shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein
and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the
Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction
(without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect
to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions
for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable,
as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof. The Borrower
shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives fifteen (15) days prior written of the record
date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation,
exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be
entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument
the obligations of this Section 1.6(b). The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers
or share exchanges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Adjustment Due to Distribution</U>. If the Borrower shall declare or make any distribution of its assets (or rights to acquire its
assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend
or distribution to the Borrower&rsquo;s shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary
(i.e., a spin-off)) (a &ldquo;Distribution&rdquo;), then the Holder of this Note shall be entitled, upon any conversion of this Note
after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would
have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder
of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Adjustment Due to Dilutive Issuance</U>. If, at any time when this Note is are issued and outstanding, the Borrower issues or sells,
or in accordance with this Section 1.6(d) hereof is deemed to have issued or sold any shares of Common Stock for a consideration per
share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith) less than
the Conversion Price in effect on the date of such issuance (or deemed issuance) of such shares of Common Stock (a &ldquo;Dilutive Issuance&rdquo;),
then immediately upon the Dilutive Issuance, the Conversion Price will be reduced to the amount of the consideration per share received
by the Borrower in such Dilutive Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower shall be deemed to have issued or sold shares of Common Stock if the Borrower in any manner issues or grants any warrants, rights
or options (not including employee stock option plans), whether or not immediately exercisable, to subscribe for or to purchase Common
Stock or other securities convertible into or exchangeable for Common Stock (&ldquo;Convertible Securities&rdquo;) (such warrants, rights
and options to purchase Common Stock or Convertible Securities are hereinafter referred to as &ldquo;Options&rdquo;) and the price per
share for which Common Stock is issuable upon the exercise of such Options is less than the Conversion Price then in effect, then the
Conversion Price shall be equal to such price per share. For purposes of the preceding sentence, the &ldquo;price per share for which
Common Stock is issuable upon the exercise of such Options&rdquo; is determined by dividing (i) the total amount, if any, received or
receivable by the Borrower as consideration for the issuance or granting of all such Options, plus the minimum aggregate amount of additional
consideration, if any, payable to the Borrower upon the exercise of all such Options, plus, in the case of Convertible Securities issuable
upon the exercise of such Options, the minimum aggregate amount of additional consideration payable upon the conversion or exchange thereof
at the time such Convertible Securities first become convertible or exchangeable, by (ii) the maximum total number of shares of Common
Stock issuable upon the exercise of all such Options (assuming full conversion of Convertible Securities, if applicable). No further
adjustment to the Conversion Price will be made upon the actual issuance of such Common Stock upon the exercise of such Options or upon
the conversion or exchange of Convertible Securities issuable upon exercise of such Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Borrower shall be deemed to have issued or sold shares of Common Stock if the Borrower in any manner issues or sells any Convertible
Securities, whether or not immediately convertible, and the price per share for which Common Stock is issuable upon such conversion or
exchange is less than the Conversion Price then in effect, then the Conversion Price shall be equal to such price per share. For the
purposes of the preceding sentence, the &ldquo;price per share for which Common Stock is issuable upon such conversion or exchange&rdquo;
is determined by dividing (i) the total amount, if any, received or receivable by the Borrower as consideration for the issuance or sale
of all such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any, payable to the Borrower upon
the conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable, by (ii) the maximum
total number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities. No further adjustment
to the Conversion Price will be made upon the actual issuance of such Common Stock upon conversion or exchange of such Convertible Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Purchase Rights</U>. If, at any time when this Note is are issued and outstanding, the Borrower issues any convertible securities
or rights to purchase stock, warrants, securities or other property (the &ldquo;Purchase Rights&rdquo;) pro rata to the record holders
of any class of Common Stock, then the Holder of this Note will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which such Holder could have acquired if such Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Note (without regard to any limitations on conversion contained herein) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights or, if no such record is taken, the date as of which
the record holders of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Notice of Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price as a result of the events
described in this Section 1.6, the Borrower, at its expense, shall promptly compute such adjustment or readjustment and prepare and furnish
to the Holder a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. The Borrower shall, upon the written request at any time of the Holder, furnish to such Holder a like certificate
setting forth (i) such adjustment or readjustment, (ii) the Conversion Price at the time in effect and (iii) the number of shares of
Common Stock and the amount, if any, of other securities or property which at the time would be received upon conversion of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9
<U>Status as Shareholder</U>. Upon submission of a Notice of Conversion by a Holder, (i) the shares covered thereby shall be deemed converted
into shares of Common Stock and (ii) the Holder&rsquo;s rights as a Holder of such converted portion of this Note shall cease and terminate,
excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available
at law or in equity to such Holder because of a failure by the Borrower to comply with the terms of this Note. Notwithstanding the foregoing,
if a Holder has not received certificates for all shares of Common Stock prior to the tenth (10th) business day after the expiration
of the Deadline with respect to a conversion of any portion of this Note for any reason, then (unless the Holder otherwise elects to
retain its status as a holder of Common Stock by so notifying the Borrower) the Holder shall regain the rights of a Holder of this Note
with respect to such unconverted portions of this Note and the Borrower shall, as soon as practicable, return such unconverted Note to
the Holder or, if the Note has not been surrendered, adjust its records to reflect that such portion of this Note has not been converted.
In all cases, the Holder shall retain all of its rights and remedies (including, without limitation, (i) the right to receive Conversion
Default Payments pursuant to Section 1.3 to the extent required thereby for such Conversion Default and any subsequent Conversion Default
and (ii) the right to have the Conversion Price with respect to subsequent conversions determined in accordance with Section 1.3) for
the Borrower&rsquo;s failure to convert this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10
<U>Prepayment</U>. The Borrower may at any time pay or prepay all or any portion of the amounts outstanding hereunder by making a payment
to the Holder of an amount in cash equal to the sum of: (w) the then outstanding Principal amount of this Note <U>plus</U> (x)&nbsp;accrued
and unpaid Interest on the unpaid principal amount of this Note <U>plus</U> (y) Default Interest, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
II. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN COVENANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Distributions on Capital Stock</U>. So long as the Borrower shall have any obligation under this Note, the Borrower shall not without
the Holder&rsquo;s written consent (a) pay, declare or set apart for such payment, any dividend or other distribution (whether in cash,
property or other securities) on shares of capital stock other than dividends on shares of Common Stock solely in the form of additional
shares of Common Stock or (b) directly or indirectly or through any subsidiary make any other payment or distribution in respect of its
capital stock except for distributions pursuant to any shareholders&rsquo; rights plan which are approved by a majority of the Borrower&rsquo;s
disinterested directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Restriction on Stock Repurchases</U>. So long as the Borrower shall have any obligation under this Note, the Borrower shall not without
the Holder&rsquo;s written consent redeem, repurchase or otherwise acquire (whether for cash or in exchange for property or other securities
or otherwise) in any one transaction or series of related transactions any shares of capital stock of the Borrower or any warrants, rights
or options to purchase or acquire any such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Borrowings</U>. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder&rsquo;s
written consent, create, incur, assume guarantee, endorse, contingently agree to purchase or otherwise become liable upon the obligation
of any person, firm, partnership, joint venture or corporation, except by the endorsement of negotiable instruments for deposit or collection,
or suffer to exist any liability for borrowed money, except (a) borrowings in existence or committed on the Issue Date and of which the
Borrower has informed Holder in writing prior to the date hereof, (b) indebtedness to trade creditors financial institutions or other
lenders incurred in the ordinary course of business, (c) borrowings, the proceeds of which shall be used to repay this Note, and (d)
borrowings which are expressly subordinated to this Note. The Borrower shall use the proceeds from any borrowings or financings, other
than those proceeds received pursuant to exceptions (a), (b) or (d) above, following the date hereof to repay this Note and the Borrower&rsquo;s
failure to comply with this covenant shall constitute an Event of Default hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Sale of Assets</U>. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder&rsquo;s
written consent, which consent shall not be unreasonably withheld, sell, lease or otherwise dispose of any significant portion of its
assets outside the ordinary course of business. Any consent to the disposition of any assets shall be conditioned on a specified use
of the proceeds towards the repayment of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
<U>Advances and Loans</U>. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder&rsquo;s
written consent, lend money, give credit or make advances to any person, firm, joint venture or corporation, including, without limitation,
officers, directors, employees, subsidiaries and affiliates of the Borrower, except loans, credits or advances (a) in existence or committed
on the Issue Date hereof and which the Borrower has informed Holder in writing prior to the date hereof, (b) made in the ordinary course
of business or (c) not in excess of $50,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
<U>Section 3(a)(9) or 3(a)(10) Transaction</U>. So long as this Note is outstanding, the Borrower shall not enter into any transaction
or arrangement structured in accordance with, based upon, or related or pursuant to, in whole or in part, either Section 3(a)(9) of the
Securities Act (a &ldquo;3(a)(9) Transaction&rdquo;) or Section 3(a)(10) of the Securities Act (a &ldquo;3(a)(10) Transaction&rdquo;).
In the event that the Borrower does enter into, or makes any issuance of Common Stock related to a 3(a)(9) Transaction or a 3(a)(10)
Transaction while this Note is outstanding, a liquidated damages charge of 25% of the outstanding Principal balance of this Note, but
not less than Fifteen Thousand Dollars $15,000, will be assessed and will become immediately due and payable to the Holder at its election
in the form of cash payment or addition to the balance of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
<U>Preservation of Existence, etc</U>. The Borrower shall maintain and preserve, and cause each of its Subsidiaries to maintain and preserve,
its existence, rights and privileges, and become or remain, and cause each of its Subsidiaries (other than dormant Subsidiaries that
have no or minimum assets) to become or remain, duly qualified and in good standing in each jurisdiction in which the character of the
properties owned or leased by it or in which the transaction of its business makes such qualification necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
<U>Non-circumvention</U>. The Borrower hereby covenants and agrees that the Borrower will not, by amendment of its Certificate or Articles
of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Note, and will at all times in good faith carry out all the provisions of this Note and take all action as may be required to
protect the rights of the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
III. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVENTS OF DEFAULT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the following events of default (each, an &ldquo;Event of Default&rdquo;) shall occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Failure to Pay Principal or Interest</U>. The Borrower fails to pay the principal hereof or interest thereon when due on this Note,
whether at maturity, upon acceleration or otherwise and such failure continues for a period of three (3) business days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Conversion and the Shares</U>. The Borrower (i) fails to issue shares of Common Stock to the Holder (or announces or threatens in
writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance
with the terms of this Note, (ii) fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated
form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when
required by this Note, (iii) directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring
(or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion
of or otherwise pursuant to this Note as and when required by this Note, (iv) fails to remove (or directs its transfer agent not to remove
or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions
in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to
this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor
the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat
not to honor its obligations shall not be rescinded in writing) for three (3)) business days after the Holder shall have delivered a
Notice of Conversion, (v) fails to remain current in its obligations to its transfer agent, (vi) causes a conversion of this Note to
be delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent, (vii) fails to repay Holder, within two
(2) business days of a demand from the Holder, any amount of funds advanced by Holder to Borrower&rsquo;s transfer agent in order to
process a conversion, and (viii) fails to reserve sufficient amount of shares of Common Stock to satisfy the Reserved Amount at all times,
(ix) subject to Holder not being subject to any affiliate resale restrictions under Rule 144, fails to provide a Rule 144 opinion letter
from the Borrower&rsquo;s legal counsel to the Holder, covering the Holder&rsquo;s resale into the public market of the respective conversion
shares under this Note, within two (2) business days of the Holder&rsquo;s submission of a Notice of Conversion to the Borrower (provided
that the Holder must request the opinion from the Borrower at the time that Holder submits the respective Notice of Conversion, provide
its own legal opinion as may be required pursuant to the restrictive legend, and the date of the respective Notice of Conversion must
be on or after the date which is six (6) months after the date that the Holder funded the Principal under this Note), and/or (x) an exemption
under Rule 144 is unavailable for the Holder&rsquo;s deposit into Holder&rsquo;s brokerage account and resale into the public market
of any of the conversion shares under this Note at any time after the date which is six (6) months after the date that the Holder funded
the Principal under this Note (other than as a result of Holder&rsquo;s status as an affiliate of the Borrower, or of having acquired
the Note from an affiliate of the Borrower, and thus subjecting the Holder to affiliate resale restrictions under Rule 144).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>Breach of Covenants</U>. The Borrower breaches any material covenant or other material term or condition contained in this Note and
any collateral documents and such breach continues for a period of five (5) business days after written notice thereof to the Borrower
from the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<U>Breach of Representations and Warranties</U>. Any representation or warranty of the Borrower made herein or in any agreement, statement
or certificate given in writing pursuant hereto or in connection herewith, shall be false or misleading in any material respect when
made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect
to this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
<U>Receiver or Trustee</U>. The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors or commence
proceedings for its dissolution, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part
of its property or business, or such a receiver or trustee shall otherwise be appointed for the Borrower or for a substantial part of
its property or business without its consent and shall not be discharged within fifteen (15) days after such appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
<U>Judgments</U>. Any money judgment, writ or similar process shall be entered or filed against the Borrower or any subsidiary of the
Borrower or any of its property or other assets for more than $50,000, and shall remain unvacated, unbonded or unstayed for a period
of ten (10) days unless otherwise consented to by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
<U>Bankruptcy</U>. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary,
for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary
of the Borrower, or the Borrower admits in writing its inability to pay its debts generally as they mature, or have filed against it
an involuntary petition for bankruptcy relief, all under federal or state laws as applicable or the Borrower admits in writing its inability
to pay its debts generally as they mature, or have filed against it an involuntary petition for bankruptcy relief, all under international,
federal or state laws as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<U>Delisting of Common Stock</U>. The Borrower shall fail to maintain the listing of the Common Stock on at least one of the Nasdaq Capital
Market, Nasdaq Small Cap Market, New York Stock Exchange, NYSE MKT, or an equivalent replacement exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9
<U>Failure to Comply with the Exchange Act</U>. The Borrower shall fail to comply with the reporting requirements of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) (including but not limited to becoming delinquent in its filings); and/or the
Borrower shall cease to be subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10
<U>Liquidation</U>. Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11
<U>Cessation of Operations</U>. Any admission by Borrower that it is otherwise generally unable to pay its debts as such debts become
due, provided, however, that any disclosure of the Borrower&rsquo;s ability to continue as a &ldquo;going concern&rdquo; shall not be
an admission that the Borrower cannot pay its debts as they become due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12
<U>RESERVED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13
<U>Financial Statement Restatement</U>. The restatement of any financial statements filed by the Borrower with the SEC for any date
or period from two years prior to the Issue Date of this Note and until this Note is no longer outstanding, if the result of such restatement
would, by comparison to the unrestated financial statement, have constituted a material adverse effect on the rights of the Holder with
respect to this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14
[Reserved]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15
[Reserved]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16
<U>Replacement of Transfer Agent</U>. In the event that the Borrower proposes to replace its
transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed irrevocable transfer
agent Instructions in a form acceptable to the Holder signed by the successor transfer agent to Borrower and the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17 <U>Cessation
of Trading</U>. Any cessation of trading of the Common Stock on at least one of the Nasdaq Capital Market, Nasdaq Small Cap Market, New
York Stock Exchange, NYSE MKT, or an equivalent replacement exchange, and such cessation of trading shall continue for a period of five
consecutive (5) Trading Days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18 <U>Cross-Default</U>.
Notwithstanding anything to the contrary contained in this Note or the other documents executed in connection herewith (the &ldquo;Transaction
Documents&rdquo;), a breach of or the occurrence of an Event of Default under any of the other Transaction Documents or under loans,
credits or advances (a) in existence or committed on the date hereof and which the Borrower has informed Holder in writing prior to the
date hereof; (b) made in the ordinary course of business; or (c) otherwise permitted under this Note, which in any instance is continuing
after the expiration of applicable notice, grace or cure periods shall, at the option of the Holder, be considered an Event of Default
under this Note and the other Transaction Documents. In such event, the Holder shall be entitled (but in no event required) to apply
all rights and remedies of the Holder under the terms of this Note and the other Transaction Documents by reason of a breach, default
or Event of Default having occurred under this Note or any other Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19   <U>Bid
Price</U>. The Borrower shall lose the &ldquo;bid&rdquo;&nbsp;price for its Common Stock ($0.0001 on the &ldquo;Ask&rdquo; with zero
market makers on the &ldquo;Bid&rdquo; per Level 2) and/or a market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.20
[Reserved]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.21   <U>Inside
Information</U>. Any attempt by the Borrower or its officers, directors, and/or affiliates to transmit, convey, disclose, or any actual
transmittal, conveyance, or disclosure by the Borrower or its officers, directors, and/or affiliates of, material non-public information
concerning the Borrower, to the Holder or its successors and assigns, which is not immediately cured by Borrower&rsquo;s filing of a
Form 8-K pursuant to Regulation FD on that same date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.22 <U>Unavailability
of Rule 144</U>. If, at any time on or after the date which is six (6) months after the Issue Date, and subject to the Holder
submitting its own &ldquo;144 legal opinion letter&rdquo; as may be required hereinunder, the Holder is unable to (i) obtain a
standard &ldquo;144 legal opinion letter&rdquo; from an attorney reasonably acceptable to the Holder, the Holder&rsquo;s brokerage
firm (and respective clearing firm), and the Borrower&rsquo;s transfer agent in order to facilitate the Holder&rsquo;s conversion of
any portion of the Note into free trading shares of the Borrower&rsquo;s Common Stock pursuant to Rule 144, and (ii) thereupon
deposit such shares into the Holder&rsquo;s brokerage account (in each case, other than as a result of Holder&rsquo;s status as an
affiliate of the Borrower, or of having acquired the Note from an affiliate of the Borrower, and thus subjecting the Holder to
affiliate resale restrictions under Rule 144).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.23   <U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.24 <U>Failure
to Hold Meetings of Shareholders</U>. If the Borrower shall fail hold meetings of shareholders as required under its governing documents,
the rules and regulations of the Trading Market on which the Common Stock trades or applicable law, and such failure is not cured within
the timeframe allowed by the Borrower&rsquo;s listing exchange.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UPON
THE OCCURRENCE OF ANY EVENT OF DEFAULT SPECIFIED IN SECTION 3 OF THIS NOTE, THE NOTE SHALL BECOME IMMEDIATELY AND AUTOMATICALLY DUE AND
PAYABLE WITHOUT DEMAND, PRESENTMENT, OR NOTICE AND THE BORROWER SHALL PAY TO THE HOLDER, IN FULL SATISFACTION OF ITS OBLIGATIONS HEREUNDER,
AN AMOUNT EQUAL TO: (A) IN THE EVENT OF AN OCCURRENCE OF ANY EVENT OF DEFAULT SPECIFIED IN OF SECTION 3.2, 3.9, 3.10, 3.16, 3.17, 3.19,
&nbsp;&nbsp;&nbsp;&nbsp;, 3.22, OR 3.24, <FONT STYLE="text-transform: uppercase">the then outstanding principal amount of this Note <U>plus</U> (x) accrued and
unpaid interest on the unpaid principal amount of this Note to the date of payment (the &ldquo;Mandatory Prepayment Date&rdquo;) <U>plus
</U>(y) Default Interest, if any, on the amounts referred to in clauses (w) and/or (x) <U>plus</U> (z) any amounts owed to the Holder
pursuant to Sections 1.3 and 1.4(g) hereof, MULTIPLIED BY One and One Half (2); OR (B) </FONT>IN THE EVENT OF THE OCCURRENCE OF ANY EVENT
OF DEFAULT SPECIFIED IN ANY OTHER SECTION, <FONT STYLE="text-transform: uppercase">the then outstanding principal amount of this Note
<U>plus</U> (x) accrued and unpaid interest on the unpaid principal amount of this Note to the Mandatory Prepayment Date, <U>plus</U>
(y) Default Interest, if any, on the amounts referred to in clauses (w) and/or (x) <U>plus</U> (z) any amounts owed to the Holder pursuant
to Sections 1.3 and 1.4(g) hereof (the then outstanding principal amount of this Note to the date of payment <U>plus</U> the amounts
referred to in clauses (x), (y) and (z) shall collectively be known as the &ldquo;Default Sum&rdquo;)</FONT> or (ii) at the option of
the Holder, the &ldquo;parity value&rdquo; of the Default Sum to be prepaid, where parity value means (a) the highest number of shares
of Common Stock issuable upon conversion of or otherwise pursuant to such Default Sum in accordance with Article I, treating the Trading
Day immediately preceding the Mandatory Prepayment Date as the &ldquo;Conversion Date&rdquo; for purposes of determining the lowest applicable
Conversion Price, unless the Default Event arises as a result of a breach in respect of a specific Conversion Date in which case such
Conversion Date shall be the Conversion Date), <U>multiplied by</U> (b) the highest trading price for the Common Stock during the period
beginning on the date of first occurrence of the Event of Default and ending one day prior to the Mandatory Prepayment Date (the &ldquo;Default
Amount&rdquo;) and all other amounts payable hereunder shall immediately become due and payable, all without demand, presentment or notice,
all of which hereby are expressly waived, together with all costs, including, without limitation, legal fees and expenses, of collection,
and the Holder shall be entitled to exercise all other rights and remedies available at law or in equity. Further, if a breach of Sections
3.9, 3.10 and/or 3.19 occurs or is continuing after the six (6) month anniversary of this Note, then the principal amount of the Note
shall increase by Fifteen Thousand and No/100 United States Dollars ($15,000) (under Holder&rsquo;s and Borrower&rsquo;s expectation
that any principal amount increase will tack back to the Issue Date) and the Holder shall be entitled to use the lowest trading price
during the delinquency period as a base price for the conversion, subject to adjustment as provided in this Note. For example, if the
lowest trading price during the delinquency period is $0.50 per share and the conversion discount is 50%, then the Holder may elect to
convert future conversions at $0.25 per share. If this Note is not paid at Maturity Date, then the outstanding principal due under this
Note shall increase by Fifteen Thousand and No/100 United States Dollars ($15,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holder shall have the right at any time after an Event of Default occurs under this Note to require the Borrower, to immediately issue,
in lieu of the Default Amount and/or Default Sum, the number of shares of Common Stock of the Borrower equal to the Default Amount and/or
Default Sum divided by the Conversion Price then in effect, pursuant to the terms of this Note (including but not limited to any beneficial
ownership limitations contained herein). This requirement by the Borrower shall automatically apply upon the occurrence of an Event of
Default without the need for any party to give any notice or take any other action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging an
attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Borrower for its attorneys&rsquo; fees and
other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging an
attorney, the Holder shall be entitled to use the lowest trading price during the delinquency period as a base price for the conversion
subject to a discount of sixty percent (60%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article
IV. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Failure or Indulgence Not Waiver</U>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Notices</U>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be
in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, electronic mail, or facsimile, addressed as set forth below or to such other address as such party shall
have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be
deemed effective (a) upon hand delivery or delivery by electronic mail or facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such
notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal
business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier
service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses
for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Borrower, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan
Pharmaceuticals Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">400
Oyster Point Blvd., Suite 505</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
San Francisco, CA 94080</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
David Lazar, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
david@activistinvestingllc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choong
Choon Hau</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerald
Heights 23 Lrg Terubong Ria 2, Paya Terubong</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11060
Pulau Pinang </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. Choong Choon Hau</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
choonhauchoong389@gmail.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Amendments</U>. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the
Holder. The term &ldquo;Note&rdquo; and all reference thereto, as used throughout this instrument, shall mean this instrument as originally
executed, or if later amended or supplemented, then as so amended or supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Assignability</U>. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit
of the Holder and its successors and assigns. N Notwithstanding anything herein to the contrary, neither the Borrower nor the Holder
may transfer or assign this Note, whether in whole or in part, nor may they transfer or assign any of their respective rights or obligations
hereunder, without the prior written consent of the other party hereto. The Holder and any assignee, by acceptance of this Note, acknowledge
and agree that following conversion of a portion of this Note, the unpaid and unconverted Principal amount of this Note represented by
this Note may be less than the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Cost of Collection</U>. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof reasonable costs
of collection, including reasonable attorneys&rsquo; fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Governing Law</U>. This Note shall be governed by and construed in accordance with the laws of the State of New York without regard
to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by
this Note shall be brought only in the state courts located in the State of New York or federal courts located in the City of New York,
State of New York. The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon <I>forum non conveniens</I>. <B>THE BORROWER
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY</B>. The prevailing party shall be entitled
to recover from the other party its reasonable attorney&rsquo;s fees and costs. In the event that any provision of this Note or any other
agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or
rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability
of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being
served in any suit, action or proceeding in connection with this Agreement or any other Transaction Document by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Certain Amounts</U>. Whenever pursuant to this Note the Borrower is required to pay an amount in excess of the outstanding Principal
amount (or the portion thereof required to be paid at that time) plus accrued and unpaid Interest plus Default Interest on such Interest,
the Borrower and the Holder agree that the actual damages to the Holder from the receipt of cash payment on this Note may be difficult
to determine and the amount to be so paid by the Borrower represents stipulated damages and not a penalty and is intended to compensate
the Holder in part for loss of the opportunity to convert this Note and to earn a return from the sale of shares of Common Stock acquired
upon conversion of this Note at a price in excess of the price paid for such shares pursuant to this Note. The Borrower and the Holder
hereby agree that such amount of stipulated damages is not plainly disproportionate to the possible loss to the Holder from the receipt
of a cash payment without the opportunity to convert this Note into shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>RESERVED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Usury</U>. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing
usury, the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest
permitted under applicable law. The Borrower covenants (to the extent that it may lawfully do so) that it will not seek to claim or take
advantage of any law that would prohibit or forgive the Borrower from paying all or a portion of the principal or interest on this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Remedies</U>. The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder,
by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at
law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the
Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in
equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach
of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without
any bond or other security being required. No provision of this Note shall alter or impair the obligation of the Borrower, which is absolute
and unconditional, to pay the principal of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Severability</U>. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or rule of
law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity
or enforceability of any other provision hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Dispute Resolution</U>. In the case of a dispute as to the determination of the Conversion Price, Conversion Amount, any prepayment
amount or Default Amount, Default Sum, Closing or Maturity Date, the closing bid price, or fair market value (as the case may be) or
the arithmetic calculation of the Conversion Price or the applicable prepayment amount(s) (as the case may be), the Borrower or the Holder
shall submit the disputed determinations or arithmetic calculations via facsimile (i) within two (2) Business Days after receipt of the
applicable notice giving rise to such dispute to the Borrower or the Holder or (ii) if no notice gave rise to such dispute, at any time
after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Borrower are unable to agree upon such
determination or calculation within two (2) Business Days of such disputed determination or arithmetic calculation (as the case may be)
being submitted to the Borrower or the Holder, then the Borrower shall, within two (2) Business Days, submit via facsimile (a) the disputed
determination of the Conversion Price, the closing bid price, the or fair market value (as the case may be) to an independent, reputable
investment bank selected by the Borrower and approved by the Holder or (b) the disputed arithmetic calculation of the Conversion Price,
Conversion Amount, any prepayment amount or Default Amount, Default Sum to an independent, outside accountant selected by the Holder
that is reasonably acceptable to the Borrower. The Borrower shall cause at its expense the investment bank or the accountant to perform
the determinations or calculations and notify the Borrower and the Holder of the results no later than ten (10) Business Days from the
time it receives such disputed determinations or calculations. Such investment bank&rsquo;s or accountant&rsquo;s determination or calculation
shall be binding upon all parties absent demonstrable error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TITAN PHARMACEUTICALS INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Lazar</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Lazar</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">EXHIBIT
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">NOTICE
OF CONVERSION </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects to convert $_________________principal amount of the Note (defined below) together with $________________ of
accrued and unpaid interest thereto, totaling $_____________ into that <FONT STYLE="background-color: white">number of shares of Common
Stock to be issued pursuant to the conversion of the Note</FONT> (&ldquo;Common Stock&rdquo;) as set forth below, of Titan Pharmaceuticals
Inc., a Delaware corporation (the &ldquo;Borrower&rdquo;), according to the conditions of the convertible note of the Borrower dated
as of August 8, 2023 (the &ldquo;Note&rdquo;), as of the date written below. No fee will be charged to the Holder for any conversion,
except for transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Box
Checked as to applicable instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Borrower shall electronically
transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through
its Deposit Withdrawal At Custodian system (&ldquo;DWAC Transfer&rdquo;).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of DTC Prime Broker:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account Number:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder&rsquo;s calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[ADDRESS]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>









<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Conversion: </FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable Conversion Price: </FONT></TD>
    <TD></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">$</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Number of Shares of Common Stock to be Issued <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to Conversion of the Note:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Amount of Principal
    Balance Due remaining <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Note after this
    conversion: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued and unpaid interest remaining: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[HOLDER]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME]</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[TITLE]</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[DATE]</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 20; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>









</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>titanpharma_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Lazar, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Quarterly Report on Form&nbsp;10-Q of Titan Pharmaceuticals, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant is made known to me by others within those entities, particularly during
    the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November&nbsp;14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: #0F0F0F 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer and Principal Financial Officer) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>titanpharma_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION&nbsp;1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION&nbsp;906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this quarterly report on Form&nbsp;10-Q of Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) for the period ended
September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned
officer of the Company hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, that to the best of his knowledge:</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November&nbsp;14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: #0F0F0F 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer and Principal Financial Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ttnp-20230930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Qpo7xRiXgOn8uPaXcsSa2GSbP9xpJ7eZkhtGl4fZmqjyYn8fhuVShA9X8m4dIH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ttnp="http://titanpharm.com/20230930" elementFormDefault="qualified" targetNamespace="http://titanpharm.com/20230930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://titanpharm.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" id="CondensedStatementsOfStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
          <link:definition>00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>00000007 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlans" id="StockPlans">
          <link:definition>00000008 - Disclosure - Stock Plans</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>00000009 - Disclosure - Net Loss Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" id="JtPharmaceuticalsAssetPurchaseAgreement">
          <link:definition>00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000012 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
          <link:definition>00000013 - Disclosure - Discontinued Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/AssetSale" id="AssetSale">
          <link:definition>00000014 - Disclosure - Asset Sale</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000015 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000016 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlansTables" id="StockPlansTables">
          <link:definition>00000019 - Disclosure - Stock Plans (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
          <link:definition>00000020 - Disclosure - Net Loss Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
          <link:definition>00000021 - Disclosure - Discontinued Operations (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
          <link:definition>00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1">
          <link:definition>00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
          <link:definition>00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails" id="StockPlansDetails">
          <link:definition>00000026 - Disclosure - Stock Plans (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails1" id="StockPlansDetails1">
          <link:definition>00000027 - Disclosure - Stock Plans (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails2" id="StockPlansDetails2">
          <link:definition>00000028 - Disclosure - Stock Plans (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" id="StockPlansDetailsNarrative">
          <link:definition>00000029 - Disclosure - Stock Plans (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
          <link:definition>00000030 - Disclosure - Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" id="JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative">
          <link:definition>00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000032 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000033 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" id="DiscontinuedOperationsDetails">
          <link:definition>00000034 - Disclosure - Discontinued Operations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/AssetSaleDetailsNarrative" id="AssetSaleDetailsNarrative">
          <link:definition>00000035 - Disclosure - Asset Sale (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000036 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000037 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ttnp_DavidLazarAndActivistInvestingLlcMember" name="DavidLazarAndActivistInvestingLlcMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_RubinMember" name="RubinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ProNeuraMember" name="ProNeuraMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_Plan2015Member" name="Plan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" name="FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_JtPharmaceuticalsMember" name="JtPharmaceuticalsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_N2015OmnibusEquityIncentivePlanMember" name="N2015OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_February2022OfferingsMember" name="February2022OfferingsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_UnregisteredPrefundedWarrantsMember" name="UnregisteredPrefundedWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" name="UnregisteredFiveYearAndSixMonthWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" name="RestrictedStockAgreementWithMaximGroupLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_U.s.CommercializationActivitiesMember" name="U.s.CommercializationActivitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_HauPromissoryNoteMember" name="HauPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_LazarPromissoryNoteMember" name="LazarPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CashNoteMember" name="CashNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_MDMWorldwideSolutionsMember" name="MDMWorldwideSolutionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NotePayableToRelatedParty" name="NotePayableToRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DeferredGrantRevenue" name="DeferredGrantRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_IssuanceOfPreferredStockNet" name="IssuanceOfPreferredStockNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ShareBasedPaymentArrangementMilestonePayment" name="ShareBasedPaymentArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ProceedsFromEquityOfferings" name="ProceedsFromEquityOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_InventoryTransferredWithSaleOfAssets" name="InventoryTransferredWithSaleOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets" name="PropertyAndEquipmentNetTransferredWithSaleOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets" name="NotesReceivableReceivedInConnectionWithSaleOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AccountsPayableRelatedToSaleOfAssets" name="AccountsPayableRelatedToSaleOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets" name="OtherAccruedLiabilitiesTransferredWithSaleOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" name="CashAndCashEquivalentsAndRestrictedCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" name="DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AssetPurchaseAgreementTextBlock" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DisclosureAssetSaleAbstract" name="DisclosureAssetSaleAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AssetsHeldForSaleTextBlock" name="AssetsHeldForSaleTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CompanyPolicyPolicyTextBlock" name="CompanyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_GoingConcernAssessmentPolicyTextBlock" name="GoingConcernAssessmentPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ContractWithCustomerAssetAdditions" name="ContractWithCustomerAssetAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ContractWithCustomerAssetDeductions" name="ContractWithCustomerAssetDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AssetSaleDescriptions" name="AssetSaleDescriptions" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AggregateIntrinsicValueOptionGranted" name="AggregateIntrinsicValueOptionGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" name="EstimatedForfeitureRatesForOptionsGrantedToManagement" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PurchaseCommonStock" name="PurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NumberOfCommonStockVested" name="NumberOfCommonStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NoncashStockCompensation" name="NoncashStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_FutureMilestonePayments" name="FutureMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_MilestonePayments" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OperatingLeasesRentExpenses" name="OperatingLeasesRentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AssetSaleDescription" name="AssetSaleDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ProceedsFromPromissoryNote" name="ProceedsFromPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_UnrestrictedCommonStockVested" name="UnrestrictedCommonStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CashPayment" name="CashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CommonStockIssuedForSettlementAgreement" name="CommonStockIssuedForSettlementAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ttnp-20230930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheets" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20230930.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShare" xlink:href="ttnp-20230930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20230930.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSale" xlink:href="ttnp-20230930.xsd#AssetSale" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20230930.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareTables" xlink:href="ttnp-20230930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20230930.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20230930.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20230930.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareDetails" xlink:href="ttnp-20230930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:href="ttnp-20230930.xsd#AssetSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:href="ttnp-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="loc_us-gaapAccountsAndNotesReceivableNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsAndNotesReceivableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NotePayableToRelatedParty" xlink:label="loc_ttnpNotePayableToRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ttnpNotePayableToRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DeferredGrantRevenue" xlink:label="loc_ttnpDeferredGrantRevenue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ttnpDeferredGrantRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="loc_ttnpShareBasedPaymentArrangementMilestonePayment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ttnpShareBasedPaymentArrangementMilestonePayment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="loc_ttnpProceedsFromEquityOfferings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ttnpProceedsFromEquityOfferings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="loc_us-gaapProceedsFromSubordinatedShortTermDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromSubordinatedShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfSubordinatedShortTermDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfSubordinatedShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000008 - Disclosure - Stock Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShare" xlink:title="00000009 - Disclosure - Net Loss Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000013 - Disclosure - Discontinued Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSale" xlink:title="00000014 - Disclosure - Asset Sale" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000019 - Disclosure - Stock Plans (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareTables" xlink:title="00000020 - Disclosure - Net Loss Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000021 - Disclosure - Discontinued Operations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000026 - Disclosure - Stock Plans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000027 - Disclosure - Stock Plans (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000028 - Disclosure - Stock Plans (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000029 - Disclosure - Stock Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareDetails" xlink:title="00000030 - Disclosure - Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000033 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000034 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:title="00000035 - Disclosure - Asset Sale (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000037 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ttnp-20230930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheets" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20230930.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShare" xlink:href="ttnp-20230930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20230930.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSale" xlink:href="ttnp-20230930.xsd#AssetSale" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20230930.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareTables" xlink:href="ttnp-20230930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20230930.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20230930.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20230930.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareDetails" xlink:href="ttnp-20230930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:href="ttnp-20230930.xsd#AssetSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:href="ttnp-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaapGrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapGrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesAbstract_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_130" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_130" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_130" xlink:to="loc_us-gaapCostsAndExpenses_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_130" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapNonoperatingIncomeExpense_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_IssuanceOfPreferredStockNet" xlink:label="loc_ttnpIssuanceOfPreferredStockNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpIssuanceOfPreferredStockNet_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000008 - Disclosure - Stock Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShare" xlink:title="00000009 - Disclosure - Net Loss Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000013 - Disclosure - Discontinued Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSale" xlink:title="00000014 - Disclosure - Asset Sale" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000019 - Disclosure - Stock Plans (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareTables" xlink:title="00000020 - Disclosure - Net Loss Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000021 - Disclosure - Discontinued Operations (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DavidLazarAndActivistInvestingLlcMember" xlink:label="loc_ttnpDavidLazarAndActivistInvestingLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ttnpDavidLazarAndActivistInvestingLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RubinMember" xlink:label="loc_ttnpRubinMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpRubinMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProNeuraMember" xlink:label="loc_ttnpProNeuraMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpProNeuraMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSeveranceCosts1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescriptions" xlink:label="loc_ttnpAssetSaleDescriptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpAssetSaleDescriptions_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000026 - Disclosure - Stock Plans (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000027 - Disclosure - Stock Plans (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000028 - Disclosure - Stock Plans (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000029 - Disclosure - Stock Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_Plan2015Member" xlink:label="loc_ttnpPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchaseCommonStock" xlink:label="loc_ttnpPurchaseCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpPurchaseCommonStock_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NumberOfCommonStockVested" xlink:label="loc_ttnpNumberOfCommonStockVested_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpNumberOfCommonStockVested_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NoncashStockCompensation" xlink:label="loc_ttnpNoncashStockCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpNoncashStockCompensation_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareDetails" xlink:title="00000030 - Disclosure - Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ConvertibleNotesMember" xlink:label="loc_ttnpConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ttnpConvertibleNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FutureMilestonePayments" xlink:label="loc_ttnpFutureMilestonePayments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpFutureMilestonePayments_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayments" xlink:label="loc_ttnpMilestonePayments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpMilestonePayments_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000033 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_N2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpN2015OmnibusEquityIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpN2015OmnibusEquityIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_February2022OfferingsMember" xlink:label="loc_ttnpFebruary2022OfferingsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpFebruary2022OfferingsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PreFundedWarrantsMember" xlink:label="loc_ttnpPreFundedWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpPreFundedWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="loc_ttnpUnregisteredPrefundedWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredPrefundedWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchasePrice" xlink:label="loc_ttnpPurchasePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpPurchasePrice_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayment" xlink:label="loc_ttnpMilestonePayment_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpMilestonePayment_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_160" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000034 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="loc_ttnpU.s.CommercializationActivitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="loc_ttnpU.s.CommercializationActivitiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:title="00000035 - Disclosure - Asset Sale (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProNeuraMember" xlink:label="loc_ttnpProNeuraMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpProNeuraMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescription" xlink:label="loc_ttnpAssetSaleDescription_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ttnpAssetSaleDescription_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_HauPromissoryNoteMember" xlink:label="loc_ttnpHauPromissoryNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpHauPromissoryNoteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_LazarPromissoryNoteMember" xlink:label="loc_ttnpLazarPromissoryNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpLazarPromissoryNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLegalFees_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromPromissoryNote" xlink:label="loc_ttnpProceedsFromPromissoryNote_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ttnpProceedsFromPromissoryNote_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000037 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashNoteMember" xlink:label="loc_ttnpCashNoteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpCashNoteMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MDMWorldwideSolutionsMember" xlink:label="loc_ttnpMDMWorldwideSolutionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpMDMWorldwideSolutionsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnrestrictedCommonStockVested" xlink:label="loc_ttnpUnrestrictedCommonStockVested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpUnrestrictedCommonStockVested_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashPayment" xlink:label="loc_ttnpCashPayment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpCashPayment_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CommonStockIssuedForSettlementAgreement" xlink:label="loc_ttnpCommonStockIssuedForSettlementAgreement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpCommonStockIssuedForSettlementAgreement_40" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ttnp-20230930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DavidLazarAndActivistInvestingLlcMember" xlink:label="ttnp_DavidLazarAndActivistInvestingLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DavidLazarAndActivistInvestingLlcMember" xlink:to="ttnp_DavidLazarAndActivistInvestingLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DavidLazarAndActivistInvestingLlcMember_lbl" xml:lang="en-US">David Lazar and Activist Investing LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RubinMember" xlink:label="ttnp_RubinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RubinMember" xlink:to="ttnp_RubinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RubinMember_lbl" xml:lang="en-US">Rubin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProNeuraMember" xlink:label="ttnp_ProNeuraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ProNeuraMember" xlink:to="ttnp_ProNeuraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ProNeuraMember_lbl" xml:lang="en-US">Pro Neura [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_Plan2015Member" xlink:label="ttnp_Plan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_Plan2015Member" xlink:to="ttnp_Plan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_Plan2015Member_lbl" xml:lang="en-US">Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:label="ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:to="ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ConvertibleNotesMember" xlink:label="ttnp_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ConvertibleNotesMember" xlink:to="ttnp_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="ttnp_JtPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JtPharmaceuticalsMember" xlink:to="ttnp_JtPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_JtPharmaceuticalsMember_lbl" xml:lang="en-US">JT Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_N2015OmnibusEquityIncentivePlanMember" xlink:label="ttnp_N2015OmnibusEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_N2015OmnibusEquityIncentivePlanMember" xlink:to="ttnp_N2015OmnibusEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_N2015OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2015 Omnibus Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_February2022OfferingsMember" xlink:label="ttnp_February2022OfferingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_February2022OfferingsMember" xlink:to="ttnp_February2022OfferingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_February2022OfferingsMember_lbl" xml:lang="en-US">February 2022 Offerings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PreFundedWarrantsMember" xlink:label="ttnp_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PreFundedWarrantsMember" xlink:to="ttnp_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredPrefundedWarrantsMember" xlink:to="ttnp_UnregisteredPrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember_lbl" xml:lang="en-US">Unregistered prefunded warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:to="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_lbl" xml:lang="en-US">Unregistered five year and six month warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:to="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_lbl" xml:lang="en-US">Restricted stock agreement with Maxim Group, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="ttnp_U.s.CommercializationActivitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_U.s.CommercializationActivitiesMember" xlink:to="ttnp_U.s.CommercializationActivitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_U.s.CommercializationActivitiesMember_lbl" xml:lang="en-US">U.s. Commercialization Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_HauPromissoryNoteMember" xlink:label="ttnp_HauPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_HauPromissoryNoteMember" xlink:to="ttnp_HauPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_HauPromissoryNoteMember_lbl" xml:lang="en-US">Hau Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_LazarPromissoryNoteMember" xlink:label="ttnp_LazarPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_LazarPromissoryNoteMember" xlink:to="ttnp_LazarPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_LazarPromissoryNoteMember_lbl" xml:lang="en-US">Lazar Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashNoteMember" xlink:label="ttnp_CashNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashNoteMember" xlink:to="ttnp_CashNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CashNoteMember_lbl" xml:lang="en-US">Cash Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MDMWorldwideSolutionsMember" xlink:label="ttnp_MDMWorldwideSolutionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MDMWorldwideSolutionsMember" xlink:to="ttnp_MDMWorldwideSolutionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MDMWorldwideSolutionsMember_lbl" xml:lang="en-US">M D M Worldwide Solutions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="us-gaap_AccountsAndNotesReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNotesReceivableNet" xlink:to="us-gaap_AccountsAndNotesReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNotesReceivableNet_lbl" xml:lang="en-US">Notes receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Discontinued operations - current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NotePayableToRelatedParty" xlink:label="ttnp_NotePayableToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NotePayableToRelatedParty" xlink:to="ttnp_NotePayableToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NotePayableToRelatedParty_lbl" xml:lang="en-US">Note payable to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DeferredGrantRevenue" xlink:label="ttnp_DeferredGrantRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DeferredGrantRevenue" xlink:to="ttnp_DeferredGrantRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DeferredGrantRevenue_lbl" xml:lang="en-US">Deferred grant revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Discontinued operations &#8211; current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, at amounts paid-in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at September&#160;30, 2023 and no shares issued and outstanding at December&#160;31, 2022.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollar per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xml:lang="en-US">Gain on asset sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares used in computing basic net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used in computing diluted net loss per common share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon exercises of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon exercises of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Amortization of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_IssuanceOfPreferredStockNet" xlink:label="ttnp_IssuanceOfPreferredStockNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_IssuanceOfPreferredStockNet" xlink:to="ttnp_IssuanceOfPreferredStockNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_IssuanceOfPreferredStockNet_lbl" xml:lang="en-US">Issuance of preferred stock, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_2_lbl" xml:lang="en-US">Gain on sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="ttnp_ShareBasedPaymentArrangementMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:to="ttnp_ShareBasedPaymentArrangementMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ShareBasedPaymentArrangementMilestonePayment_lbl" xml:lang="en-US">Stock-based milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred grant revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="ttnp_ProceedsFromEquityOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ProceedsFromEquityOfferings" xlink:to="ttnp_ProceedsFromEquityOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ProceedsFromEquityOfferings_lbl" xml:lang="en-US">Net proceeds from equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Net proceeds from issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="us-gaap_ProceedsFromSubordinatedShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:to="us-gaap_ProceedsFromSubordinatedShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSubordinatedShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from the exercises of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl" xml:lang="en-US">Payments on short-term loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_InventoryTransferredWithSaleOfAssets" xlink:label="ttnp_InventoryTransferredWithSaleOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_InventoryTransferredWithSaleOfAssets" xlink:to="ttnp_InventoryTransferredWithSaleOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_InventoryTransferredWithSaleOfAssets_lbl" xml:lang="en-US">Inventory transferred with sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets" xlink:label="ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets" xlink:to="ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets_lbl" xml:lang="en-US">Property and equipment, net, transferred with sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets" xlink:label="ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets" xlink:to="ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets_lbl" xml:lang="en-US">Notes receivable received in connection with sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AccountsPayableRelatedToSaleOfAssets" xlink:label="ttnp_AccountsPayableRelatedToSaleOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AccountsPayableRelatedToSaleOfAssets" xlink:to="ttnp_AccountsPayableRelatedToSaleOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AccountsPayableRelatedToSaleOfAssets_lbl" xml:lang="en-US">Accounts payable related to sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets" xlink:label="ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets" xlink:to="ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets_lbl" xml:lang="en-US">Other accrued liabilities transferred with sale of assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:to="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract_lbl" xml:lang="en-US">Jt Pharmaceuticals Asset Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetPurchaseAgreementTextBlock" xlink:label="ttnp_AssetPurchaseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetPurchaseAgreementTextBlock" xlink:to="ttnp_AssetPurchaseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AssetPurchaseAgreementTextBlock_lbl" xml:lang="en-US">JT Pharmaceuticals Asset Purchase Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureAssetSaleAbstract" xlink:label="ttnp_DisclosureAssetSaleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisclosureAssetSaleAbstract" xlink:to="ttnp_DisclosureAssetSaleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DisclosureAssetSaleAbstract_lbl" xml:lang="en-US">Asset Sale</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetsHeldForSaleTextBlock" xlink:label="ttnp_AssetsHeldForSaleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetsHeldForSaleTextBlock" xlink:to="ttnp_AssetsHeldForSaleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ttnp_AssetsHeldForSaleTextBlock_lbl" xml:lang="en-US">Asset Sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="ttnp_CompanyPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CompanyPolicyPolicyTextBlock" xlink:to="ttnp_CompanyPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US">The Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:label="ttnp_GoingConcernAssessmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:to="ttnp_GoingConcernAssessmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_GoingConcernAssessmentPolicyTextBlock_lbl" xml:lang="en-US">Going Concern Assessment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs and Related Accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of components of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of activity related to our accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of our option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of the stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions to estimate the fair value of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_lbl" xml:lang="en-US">Raw materials and supplies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="us-gaap_ContractWithCustomerAssetGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetGross_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="ttnp_ContractWithCustomerAssetAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetAdditions" xlink:to="ttnp_ContractWithCustomerAssetAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="ttnp_ContractWithCustomerAssetDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetDeductions" xlink:to="ttnp_ContractWithCustomerAssetDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ContractWithCustomerAssetDeductions_lbl" xml:lang="en-US">Deductions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetGross_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments (base rent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership interest by Activist</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance payments</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescriptions" xlink:label="ttnp_AssetSaleDescriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetSaleDescriptions" xlink:to="ttnp_AssetSaleDescriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AssetSaleDescriptions_lbl" xml:lang="en-US">Asset sale description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_3_lbl" xml:lang="en-US">Raw materials and supplies and finished goods inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, option outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AggregateIntrinsicValueOptionGranted" xlink:label="ttnp_AggregateIntrinsicValueOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AggregateIntrinsicValueOptionGranted" xlink:to="ttnp_AggregateIntrinsicValueOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AggregateIntrinsicValueOptionGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Option forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, option outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Weighted-average risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividend payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected holding period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility factor</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:to="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_lbl" xml:lang="en-US">Estimated forfeiture rates for options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchaseCommonStock" xlink:label="ttnp_PurchaseCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PurchaseCommonStock" xlink:to="ttnp_PurchaseCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PurchaseCommonStock_lbl" xml:lang="en-US">Purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price, per value</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NumberOfCommonStockVested" xlink:label="ttnp_NumberOfCommonStockVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NumberOfCommonStockVested" xlink:to="ttnp_NumberOfCommonStockVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NumberOfCommonStockVested_lbl" xml:lang="en-US">NUmber of common stock vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NoncashStockCompensation" xlink:label="ttnp_NoncashStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NoncashStockCompensation" xlink:to="ttnp_NoncashStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NoncashStockCompensation_lbl" xml:lang="en-US">Non-cash stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation expense related to non-vested stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Amount of weighted-average anti-dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FutureMilestonePayments" xlink:label="ttnp_FutureMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_FutureMilestonePayments" xlink:to="ttnp_FutureMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_FutureMilestonePayments_lbl" xml:lang="en-US">Closing payment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayments" xlink:label="ttnp_MilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayments" xlink:to="ttnp_MilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MilestonePayments_lbl" xml:lang="en-US">Milestone Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_OperatingLeasesRentExpenses" xlink:label="ttnp_OperatingLeasesRentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLeasesRentExpenses" xlink:to="ttnp_OperatingLeasesRentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OperatingLeasesRentExpenses_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares agreed to issue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchasePrice" xlink:label="ttnp_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PurchasePrice" xlink:to="ttnp_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayment" xlink:label="ttnp_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayment" xlink:to="ttnp_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Discontinued operations &#8211; current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Discontinued operations &#8211; current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescription" xlink:label="ttnp_AssetSaleDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetSaleDescription" xlink:to="ttnp_AssetSaleDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ttnp_AssetSaleDescription_lbl" xml:lang="en-US">Asset sale description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Payment of legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromPromissoryNote" xlink:label="ttnp_ProceedsFromPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ProceedsFromPromissoryNote" xlink:to="ttnp_ProceedsFromPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ProceedsFromPromissoryNote_lbl" xml:lang="en-US">Proceeds from promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Interest accrued rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnrestrictedCommonStockVested" xlink:label="ttnp_UnrestrictedCommonStockVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnrestrictedCommonStockVested" xlink:to="ttnp_UnrestrictedCommonStockVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_UnrestrictedCommonStockVested_lbl" xml:lang="en-US">Unrestricted common stock vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashPayment" xlink:label="ttnp_CashPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashPayment" xlink:to="ttnp_CashPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CashPayment_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CommonStockIssuedForSettlementAgreement" xlink:label="ttnp_CommonStockIssuedForSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CommonStockIssuedForSettlementAgreement" xlink:to="ttnp_CommonStockIssuedForSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CommonStockIssuedForSettlementAgreement_lbl" xml:lang="en-US">Common stock issued for settlement agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetAdditions" xlink:to="ttnp_ContractWithCustomerAssetAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ContractWithCustomerAssetAdditions_doc" xml:lang="en-US">The amount of increase in contract assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetDeductions" xlink:to="ttnp_ContractWithCustomerAssetDeductions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ContractWithCustomerAssetDeductions_doc" xml:lang="en-US">The amount of decrease in contract assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:to="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_doc" xml:lang="en-US">Estimated forfeiture rates for options granted to management.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DavidLazarAndActivistInvestingLlcMember" xlink:to="ttnp_DavidLazarAndActivistInvestingLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_DavidLazarAndActivistInvestingLlcMember_doc" xml:lang="en-US">It represents the information pertaining to David Lazar and Activist Investing LLC .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_FutureMilestonePayments" xlink:to="ttnp_FutureMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_FutureMilestonePayments_doc" xml:lang="en-US">This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JtPharmaceuticalsMember" xlink:to="ttnp_JtPharmaceuticalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_JtPharmaceuticalsMember_doc" xml:lang="en-US">This member stands for JT Pharmaceuticals.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayments" xlink:to="ttnp_MilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_MilestonePayments_doc" xml:lang="en-US">This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLeasesRentExpenses" xlink:to="ttnp_OperatingLeasesRentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_OperatingLeasesRentExpenses_doc" xml:lang="en-US">Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_February2022OfferingsMember" xlink:to="ttnp_February2022OfferingsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_February2022OfferingsMember_doc" xml:lang="en-US">Represents the information pertaining to February 2022 Offerings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PreFundedWarrantsMember" xlink:to="ttnp_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_PreFundedWarrantsMember_doc" xml:lang="en-US">N/A.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredPrefundedWarrantsMember" xlink:to="ttnp_UnregisteredPrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to unregistered prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:to="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to unregistered five year and six month warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayment" xlink:to="ttnp_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_MilestonePayment_doc" xml:lang="en-US">Amount of milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:to="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_doc" xml:lang="en-US">Represents the information pertaining to restricted stock agreement with Maxim Group, LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Subordinated Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:to="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CashAndCashEquivalentsAndRestrictedCashEquivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetsHeldForSaleTextBlock" xlink:to="ttnp_AssetsHeldForSaleTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AssetsHeldForSaleTextBlock_2_lbl" xml:lang="en-US">AssetsHeldForSaleTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetGross_3_lbl" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetSaleDescription" xlink:to="ttnp_AssetSaleDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AssetSaleDescription_2_lbl" xml:lang="en-US">AssetSaleDescription</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ttnp-20230930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheets" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="ttnp-20230930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:href="ttnp-20230930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20230930.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShare" xlink:href="ttnp-20230930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20230930.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSale" xlink:href="ttnp-20230930.xsd#AssetSale" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20230930.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareTables" xlink:href="ttnp-20230930.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20230930.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20230930.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20230930.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/NetLossPerShareDetails" xlink:href="ttnp-20230930.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20230930.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20230930.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:href="ttnp-20230930.xsd#AssetSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:href="ttnp-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndNotesReceivableNet" xlink:label="loc_us-gaapAccountsAndNotesReceivableNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsAndNotesReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NotePayableToRelatedParty" xlink:label="loc_ttnpNotePayableToRelatedParty" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ttnpNotePayableToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DeferredGrantRevenue" xlink:label="loc_ttnpDeferredGrantRevenue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ttnpDeferredGrantRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaapGrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_IssuanceOfPreferredStockNet" xlink:label="loc_ttnpIssuanceOfPreferredStockNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpIssuanceOfPreferredStockNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CondensedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="loc_ttnpShareBasedPaymentArrangementMilestonePayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ttnpShareBasedPaymentArrangementMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="loc_ttnpProceedsFromEquityOfferings" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ttnpProceedsFromEquityOfferings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSubordinatedShortTermDebt" xlink:label="loc_us-gaapProceedsFromSubordinatedShortTermDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSubordinatedShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfSubordinatedShortTermDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfSubordinatedShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_InventoryTransferredWithSaleOfAssets" xlink:label="loc_ttnpInventoryTransferredWithSaleOfAssets" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpInventoryTransferredWithSaleOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets" xlink:label="loc_ttnpPropertyAndEquipmentNetTransferredWithSaleOfAssets" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpPropertyAndEquipmentNetTransferredWithSaleOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets" xlink:label="loc_ttnpNotesReceivableReceivedInConnectionWithSaleOfAssets" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpNotesReceivableReceivedInConnectionWithSaleOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AccountsPayableRelatedToSaleOfAssets" xlink:label="loc_ttnpAccountsPayableRelatedToSaleOfAssets" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpAccountsPayableRelatedToSaleOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets" xlink:label="loc_ttnpOtherAccruedLiabilitiesTransferredWithSaleOfAssets" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpOtherAccruedLiabilitiesTransferredWithSaleOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="loc_ttnpCashAndCashEquivalentsAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_ttnpCashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000008 - Disclosure - Stock Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShare" xlink:title="00000009 - Disclosure - Net Loss Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement">
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetPurchaseAgreementTextBlock" xlink:label="loc_ttnpAssetPurchaseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="loc_ttnpAssetPurchaseAgreementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000013 - Disclosure - Discontinued Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSale" xlink:title="00000014 - Disclosure - Asset Sale">
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureAssetSaleAbstract" xlink:label="loc_ttnpDisclosureAssetSaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetsHeldForSaleTextBlock" xlink:label="loc_ttnpAssetsHeldForSaleTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureAssetSaleAbstract" xlink:to="loc_ttnpAssetsHeldForSaleTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="loc_ttnpCompanyPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpCompanyPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_GoingConcernAssessmentPolicyTextBlock" xlink:label="loc_ttnpGoingConcernAssessmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpGoingConcernAssessmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000019 - Disclosure - Stock Plans (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareTables" xlink:title="00000020 - Disclosure - Net Loss Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000021 - Disclosure - Discontinued Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="loc_ttnpContractWithCustomerAssetAdditions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpContractWithCustomerAssetAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="loc_ttnpContractWithCustomerAssetDeductions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpContractWithCustomerAssetDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DavidLazarAndActivistInvestingLlcMember" xlink:label="loc_ttnpDavidLazarAndActivistInvestingLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ttnpDavidLazarAndActivistInvestingLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RubinMember" xlink:label="loc_ttnpRubinMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpRubinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProNeuraMember" xlink:label="loc_ttnpProNeuraMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpProNeuraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescriptions" xlink:label="loc_ttnpAssetSaleDescriptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpAssetSaleDescriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000026 - Disclosure - Stock Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AggregateIntrinsicValueOptionGranted" xlink:label="loc_ttnpAggregateIntrinsicValueOptionGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ttnpAggregateIntrinsicValueOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000027 - Disclosure - Stock Plans (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000028 - Disclosure - Stock Plans (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="loc_ttnpEstimatedForfeitureRatesForOptionsGrantedToManagement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ttnpEstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000029 - Disclosure - Stock Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_Plan2015Member" xlink:label="loc_ttnpPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchaseCommonStock" xlink:label="loc_ttnpPurchaseCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpPurchaseCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NumberOfCommonStockVested" xlink:label="loc_ttnpNumberOfCommonStockVested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpNumberOfCommonStockVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_NoncashStockCompensation" xlink:label="loc_ttnpNoncashStockCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpNoncashStockCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/NetLossPerShareDetails" xlink:title="00000030 - Disclosure - Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ConvertibleNotesMember" xlink:label="loc_ttnpConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ttnpConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FutureMilestonePayments" xlink:label="loc_ttnpFutureMilestonePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpFutureMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayments" xlink:label="loc_ttnpMilestonePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_OperatingLeasesRentExpenses" xlink:label="loc_ttnpOperatingLeasesRentExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_ttnpOperatingLeasesRentExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000033 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_N2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpN2015OmnibusEquityIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpN2015OmnibusEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_February2022OfferingsMember" xlink:label="loc_ttnpFebruary2022OfferingsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpFebruary2022OfferingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PreFundedWarrantsMember" xlink:label="loc_ttnpPreFundedWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="loc_ttnpUnregisteredPrefundedWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_PurchasePrice" xlink:label="loc_ttnpPurchasePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MilestonePayment" xlink:label="loc_ttnpMilestonePayment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000034 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="loc_ttnpU.s.CommercializationActivitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="loc_ttnpU.s.CommercializationActivitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/AssetSaleDetailsNarrative" xlink:title="00000035 - Disclosure - Asset Sale (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_DisclosureAssetSaleAbstract" xlink:label="loc_ttnpDisclosureAssetSaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureAssetSaleAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProNeuraMember" xlink:label="loc_ttnpProNeuraMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpProNeuraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_AssetSaleDescription" xlink:label="loc_ttnpAssetSaleDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ttnpAssetSaleDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_HauPromissoryNoteMember" xlink:label="loc_ttnpHauPromissoryNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpHauPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_LazarPromissoryNoteMember" xlink:label="loc_ttnpLazarPromissoryNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpLazarPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_ProceedsFromPromissoryNote" xlink:label="loc_ttnpProceedsFromPromissoryNote" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ttnpProceedsFromPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000037 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:label="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpFifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashNoteMember" xlink:label="loc_ttnpCashNoteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ttnpCashNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtCounterpartyNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_MDMWorldwideSolutionsMember" xlink:label="loc_ttnpMDMWorldwideSolutionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpMDMWorldwideSolutionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_UnrestrictedCommonStockVested" xlink:label="loc_ttnpUnrestrictedCommonStockVested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpUnrestrictedCommonStockVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CashPayment" xlink:label="loc_ttnpCashPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpCashPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20230930.xsd#ttnp_CommonStockIssuedForSettlementAgreement" xlink:label="loc_ttnpCommonStockIssuedForSettlementAgreement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ttnpCommonStockIssuedForSettlementAgreement" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713424638256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-13341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Titan Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3171940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Oyster Point Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">244-4990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
            Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TTNP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713424905520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,096<span></span>
</td>
<td class="nump">$ 2,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Notes receivable</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations - current assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,899<span></span>
</td>
<td class="nump">3,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,999<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_NotePayableToRelatedParty', window );">Note payable to related party</a></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DeferredGrantRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current liabilities</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, at amounts paid-in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at September&#160;30, 2023 and no shares issued and outstanding at December&#160;31, 2022.</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at September&#160;30, 2023 and December&#160;31, 2022.</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">397,977<span></span>
</td>
<td class="nump">387,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(389,860)<span></span>
</td>
<td class="num">(386,261)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 9,999<span></span>
</td>
<td class="nump">$ 4,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DeferredGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DeferredGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NotePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NotePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713424548496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,016,295<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,016,295<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423013104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">4,104<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">8,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(2,643)<span></span>
</td>
<td class="num">(5,346)<span></span>
</td>
<td class="num">(7,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense)</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on asset sale</a></td>
<td class="nump">1,732<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (338)<span></span>
</td>
<td class="num">$ (2,638)<span></span>
</td>
<td class="num">$ (3,599)<span></span>
</td>
<td class="num">$ (7,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per common share</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">14,629<span></span>
</td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">13,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per common share</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">14,629<span></span>
</td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">13,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420670992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 381,183<span></span>
</td>
<td class="num">$ (376,055)<span></span>
</td>
<td class="nump">$ 5,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,540)<span></span>
</td>
<td class="num">(2,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,029<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon exercises of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon exercises of warrants, shares</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Amortization of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,465<span></span>
</td>
<td class="num">(378,595)<span></span>
</td>
<td class="nump">7,882<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">12,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,462)<span></span>
</td>
<td class="num">(2,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon exercises of warrants</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon exercises of warrants, shares</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Amortization of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,709<span></span>
</td>
<td class="num">(381,057)<span></span>
</td>
<td class="nump">5,667<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">14,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Amortization of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">387,230<span></span>
</td>
<td class="num">(383,695)<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="nump">14,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">387,609<span></span>
</td>
<td class="num">(386,261)<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,675)<span></span>
</td>
<td class="num">(1,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">387,609<span></span>
</td>
<td class="num">(387,936)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,473<span></span>
</td>
<td class="num">(389,522)<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_IssuanceOfPreferredStockNet', window );">Issuance of preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,094<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 397,977<span></span>
</td>
<td class="num">$ (389,860)<span></span>
</td>
<td class="nump">$ 8,133<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_IssuanceOfPreferredStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_IssuanceOfPreferredStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423035552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (3,599)<span></span>
</td>
<td class="num">$ (7,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of assets</a></td>
<td class="num">(1,732)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ShareBasedPaymentArrangementMilestonePayment', window );">Stock-based milestone payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">122<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,846)<span></span>
</td>
<td class="num">(6,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of assets</a></td>
<td class="nump">228<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">228<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ProceedsFromEquityOfferings', window );">Net proceeds from equity offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from issuance of preferred stock</a></td>
<td class="nump">9,094<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSubordinatedShortTermDebt', window );">Proceeds from short-term loans</a></td>
<td class="nump">750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from the exercises of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSubordinatedShortTermDebt', window );">Payments on short-term loans</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,594<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,976<span></span>
</td>
<td class="num">(1,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">8,109<span></span>
</td>
<td class="nump">4,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_InventoryTransferredWithSaleOfAssets', window );">Inventory transferred with sale of assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets', window );">Property and equipment, net, transferred with sale of assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets', window );">Notes receivable received in connection with sale of assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AccountsPayableRelatedToSaleOfAssets', window );">Accounts payable related to sale of assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets', window );">Other accrued liabilities transferred with sale of assets</a></td>
<td class="nump">236<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">8,096<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows</a></td>
<td class="nump">$ 8,109<span></span>
</td>
<td class="nump">$ 4,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AccountsPayableRelatedToSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AccountsPayableRelatedToSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_InventoryTransferredWithSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_InventoryTransferredWithSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ProceedsFromEquityOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ProceedsFromEquityOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ShareBasedPaymentArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ShareBasedPaymentArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSubordinatedShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSubordinatedShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSubordinatedShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSubordinatedShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425298112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmozvx6vuxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_82C_zq2jLnIHhEzk">Organization and Summary of Significant Accounting Policies</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_846_ecustom--CompanyPolicyPolicyTextBlock_zLeoMA4DSHe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_z2qHsneFQdha">The Company</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a pharmaceutical company developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our first product based on the ProNeura technology was Probuphine<sup>&#174;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that had either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an
         approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DavidLazarAndActivistInvestingLlcMember_pdd" title="Ownership interest by Activist">25%</span> ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#8220;Board&#8221;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220801__20220815__srt--CounterpartyNameAxis__custom--RubinMember_zXKXT3GFaOZ4" title="Severance payments">0.4</span> million, of which,
         approximately $<span id="xdx_906_eus-gaap--SeveranceCosts1_pn3p0_c20230101__20230930_znHbsUs4svt5" title="Severance payments">247,000</span> have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, (the &#8220;Closing Date&#8221;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#8220;ProNeura Assets&#8221;). In July&#160;2023, <span id="xdx_900_ecustom--AssetSaleDescriptions_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember_zz06Sh1xbTUk" title="Asset sale description">we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;)
         with Fedson, Inc., a Delaware corporation (&#8220;Fedson&#8221;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6XMrSt2FfDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zHWyrJfCfZ7d">Basis of Presentation</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited condensed financial statements have been prepared in accordance
         with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial
         information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information
         and footnotes required by GAAP for complete financial statement presentation. In the
         opinion of management, all adjustments (consisting of normal recurring adjustments)
         considered necessary for a fair presentation have been included. Operating results
         for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending
         December&#160;31, 2023, or any future interim periods.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The balance sheet as of December&#160;31, 2022 is derived from the audited financial statements at that date but does not
         include all the information and footnotes required by GAAP for complete financial
         statements. These unaudited condensed financial statements should be read in conjunction
         with the audited financial statements and footnotes thereto included in the Titan
         Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been prepared assuming we will
         continue as a going concern.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30,
      2023, we had cash and cash equivalents of approximately $8.1
      million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zTuW97m8TUH4" style="display: none" title="Cash and cash equivalents">8,096</span>, which we believe, will be sufficient to fund our planned operations through December of 2024. We continue to explore
      several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_84C_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zbUao7Y1bYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zxqn8GlLGTCl">Discontinued Operations</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind
         down our commercialization activities, and to pursue a plan that will enable us to
         focus on our current, early-stage ProNeura-based product development programs.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been recast for all periods presented
         to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization
         activities as discontinued operations (see Note 7). The accompanying condensed financial
         statements are generally presented in conformity with our historical format. We believe
         this format provides comparability with the previously filed financial statements.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_840_ecustom--GoingConcernAssessmentPolicyTextBlock_z9YJr1ioPbGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zKHFBuOW8eZe">Going Concern Assessment</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We assess going concern uncertainty in our financial statements to determine if we
         have sufficient cash on hand and working capital, including available borrowings on
         loans, to operate for a period of at least one year from the date the financial statements
         are issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting
         Standard Update ASU No. 2014-15. As part of this assessment, based on conditions that
         are known and reasonably knowable to us, we will consider various scenarios, forecasts,
         projections, estimates and will make certain key assumptions, including the timing
         and nature of projected cash expenditures or programs, and our ability to delay or
         curtail expenditures or programs, if necessary, among other factors. Based on this
         assessment, as necessary or applicable, we make certain assumptions around implementing
         curtailments or delays in the nature and timing of programs and expenditures to the
         extent we deem probable those implementations can be achieved and we have the proper
         authority to execute them within the look-forward period in accordance with ASU No.
         2014-15.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based upon the above assessment, we concluded that, at the date of filing the condensed
         financial statements in this Quarterly Report on Form 10-Q for the nine months ended September&#160;30, 2023, we have sufficient cash to fund our operations for the next 12 months without additional
         funds. Additionally, we have suffered recurring losses from operations and have an accumulated
         deficit that raises substantial doubt about our ability to continue as a going concern beyond the next 12 months. We continue to explore several financing and strategic alternatives; however, there can be no assurance
         that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_84D_eus-gaap--UseOfEstimates_zgv8mh8HLin5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zyq8yLFBBmEl">Use of Estimates</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with accounting principles generally
         accepted in the U.S. requires management to make estimates and assumptions that affect
         the amounts reported in the financial statements and accompanying notes. Actual results
         could differ from those estimates.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zVBXZzICS3m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zqhwr1AVKcd5">Inventories</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Inventories are recorded at the lower of cost or net realizable value. Cost is based
         on the first in, first out method. We regularly review inventory quantities on hand
         and write down to its net realizable value any inventory that we believe to be impaired.
         The determination of net realizable value requires judgment including consideration
         of many factors, such as estimates of future product demand, product net selling prices,
         current and future market conditions and potential product obsolescence, among others.
         The components of inventories are as follows:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_z2bAMFYUdLl3" style="display: none">Schedule of components of inventories</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories">106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8A5_zTj1jCMRBNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Approximately $<span id="xdx_90C_eus-gaap--InventoryNet_iI_pn3p0_c20221231_zYeYqrXpeO8a" title="Raw materials and supplies and finished goods inventory">106,000</span> of raw materials and supplies and finished goods inventory
         at December&#160;31, 2022 were sold to Fedson under the Asset Purchase Agreement in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z91HH0nf1qB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zoO0xQFY0eZc">Revenue Recognition</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We generate revenue principally from collaborative research and development arrangements,
         sales or licenses of technology and government grants. Consideration received for
         revenue arrangements with multiple components is allocated among the separate performance
         obligations based upon their relative estimated standalone selling price.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In determining the appropriate amount of revenue to be recognized as we fulfill our
         obligations under our agreements, we perform the following steps for our revenue recognition:
         (i) identify contracts with customers; (ii) identify performance obligations; (iii)
         determine the transaction price; (iv) allocate the transaction price to the performance
         obligations; and (v) recognize of revenue when (or as) we satisfy each performance
         obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Grant Revenue</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department
         of Health and Human Services, or HHS, the Bill&amp; Melinda Gates Foundation, and other
         government-sponsored organizations for research and development related activities
         that provide for payments for reimbursed costs, which may include overhead and general
         and administrative costs. We recognize revenue from these contracts as we perform
         services under these arrangements when the funding is committed. Associated expenses
         are recognized when incurred as research and development expenses. Revenues and related
         expenses are presented gross in the condensed statements of operations.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Performance Obligations</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A performance obligation is a promise in a contract to transfer a distinct good or
         service to the customer. Our performance obligations include commercialization license
         rights, development services and services associated with the regulatory approval
         process.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have optional additional items in contracts, which are accounted for as separate
         contracts when the customer elects such options. Arrangements that include a promise
         for future commercial product supply and optional research and development services
         at the customer&#8217;s discretion are generally considered as options. We assess if these options provide
         a material right to the customer and, if so, such material rights are accounted for
         as separate performance obligations. If we are entitled to additional payments when
         the customer exercises these options, any additional payments are recorded in revenue
         when the customer obtains control of the goods or services.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Transaction Price</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have both fixed and variable considerations. Non-refundable upfront payments are
         considered fixed, while milestone payments are identified as variable consideration
         when determining the transaction price. Funding of research and development activities
         is considered variable until such costs are reimbursed at which point, they are considered
         fixed. We allocate the total transaction price to each performance obligation based
         on the relative estimated standalone selling prices of the promised goods or services
         for each performance obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At the inception of each arrangement that includes milestone payments, we evaluate
         whether the milestones are considered probable of being achieved and estimate the
         amount to be included in the transaction price using the most likely amount method.
         If it is probable that a significant revenue reversal would not occur, the value of
         the associated milestone is included in the transaction price. Milestone payments
         that are not within our control, such as approvals from regulators, are not considered
         probable of being achieved until those approvals are received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For arrangements that include sales-based royalties or earn-out payments, including
         milestone payments based on the level of sales, and the license or purchase agreement
         is deemed to be the predominant item to which the royalties or earn-out payments relate,
         we recognize revenue at the later of (a) when the related sales occur, or (b) when
         the performance obligation to which some or all of the royalty or earn-out payment
         has been allocated has been satisfied (or partially satisfied).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Allocation of Consideration</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As part of the accounting for these arrangements, we must develop assumptions that
         require judgment to determine the stand-alone selling price of each performance obligation
         identified in the contract. Estimated selling prices for license rights are calculated
         using the residual approach. For all other performance obligations, we use a cost-plus
         margin approach.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Timing of Recognition</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Significant management judgment is required to determine the level of effort required
         under an arrangement and the period over which we expect to complete our performance
         obligations under an arrangement. We estimate the performance period or measure of
         progress at the inception of the arrangement and re-evaluate it each reporting period.
         This re-evaluation may shorten or lengthen the period over which revenue is recognized.
         Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot
         reasonably estimate when our performance obligations either are completed or become
         inconsequential, then revenue recognition is deferred until we can reasonably make
         such estimates. Revenue is then recognized over the remaining estimated period of
         performance using the cumulative catch-up method. Revenue is recognized for licenses
         or sales of functional intellectual property at the point in time the customer can
         use and benefit from the license. For performance obligations that are services, revenue
         is recognized over time proportionate to the costs that we have incurred to perform
         the services using the cost-to-cost input method.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Contract Assets and Liabilities</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the activity related to our accounts receivable for the
         nine months ended September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8BA_zJunFJq2kcSf" style="display: none">Schedule of activity related to our accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,<br/>2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Balance at January&#160;1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance">36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Deductions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(194</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Balance at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">26</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8A3_z52B391iNeVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyCqZguNny61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zKu78sT64TXg">Research and Development Costs and Related Accrual</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Research and development expenses include internal and external costs. Internal costs
         include salaries and employment related expenses, facility costs, administrative expenses
         and allocations of corporate costs. External expenses consist of costs associated
         with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research
         studies, product registration, and investigator sponsored trials. Significant judgments
         and estimates must be made and used in determining the accrued balance in any accounting
         period. Actual results could differ from those estimates under different assumptions.
         Revisions are charged to expense in the period in which the facts that give rise to
         the revision become known.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zw10ww79lmq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_z99MMQQsVv4h">Leases</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We determine whether the arrangement is or contains a lease at inception. Operating
         lease right-of-use assets and lease liabilities are recognized at the present value
         of the future lease payments at commencement date. The interest rate implicit in lease
         contracts is typically not readily determinable, and therefore, we utilize our incremental
         borrowing rate, which is the rate incurred to borrow on a collateralized basis over
         a similar term an amount equal to the lease payments in a similar economic environment.
         Certain adjustments to the right-of-use asset may be required for items such as initial
         direct costs paid or incentives received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Lease expense is recognized over the expected term on a straight-line basis. Operating
         leases are recognized on our condensed balance sheets as right-of-use assets, operating
         lease liabilities current and operating lease liabilities non-current.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the minimum lease payments of our operating lease:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none">Schedule of minimum operating lease payments</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total minimum lease payments (base rent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8AB_zXRT6AQ0IWud" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFedDUfImZA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_z0bHIQxCJrj1">Recent Accounting Pronouncements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In June&#160;2016, the
      FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses, which requires
      an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience,
      current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking
      information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January&#160;1,
      2023. The adoption of Topic 326 did not have a material impact on our condensed financial statements and disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Accounting Standards Not Yet Adopted</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates
         certain models that require separate accounting for embedded conversion features,
         in certain cases. Additionally, among other changes, the guidance eliminates certain
         of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for
         all convertible instruments in the diluted earnings per share calculation and include
         the effect of share settlement for instruments that may be settled in cash or shares,
         except for certain liability-classified share-based payment awards. This guidance
         is effective beginning after December&#160;15, 2023 and must be applied using either a modified or full retrospective approach.
         Early adoption is permitted. We are currently evaluating the impact this guidance
         will have on our condensed financial statements and related disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcmC12GHullh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4UdCV7EIj1e">Fair Value Measurements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Financial instruments, including receivables, accounts payable and accrued liabilities
         are carried at cost, and their fair values are approximated due to the short-term
         nature of these instruments. Our investments in money market funds are classified
         within Level 1 of the fair value hierarchy.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At December&#160;31, 2022, the fair value of our investments in money market funds was approximately
         $<span id="xdx_90C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zj4aCXB5y65h" title="Fair value of investments">2.6</span> million which is included within our cash and cash equivalents in our condensed
         balance sheets. We had no investments in money market funds at September&#160;30, 2023.</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425544848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzed4J049NR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_82F_z7c9Vn5tng6k">Stock Plans</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes option activity:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z5nnMVw8iJNd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8B7_zYZvduR0ThPc" style="display: none">Schedule of our option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options<br/>(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br/>Exercise Price<br/> per share</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br/>Remaining Option<br/>Term (in years)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate
    Intrinsic<br/>Value<br/>(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at December&#160;31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930_z6Ie8JtpGro2" style="width: 9%; text-align: right" title="Outstanding at beginning">927</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zHUg2qVZL16" style="width: 9%; text-align: right" title="Weighted average exercise price, outstanding at beginning">7.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zdA3szvYYdP3" title="Weighted average remaining contractual term, outstanding (years)">8.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20230930_zdQX1r9aVlH8" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, option outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pn3n3_c20230101__20230930_zTSRuRX48Csl" style="text-align: right" title="Option granted">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zUOnt5Zelxo" style="text-align: right" title="Weighted average exercise price, granted">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AggregateIntrinsicValueOptionGranted_pn3n3_c20230101__20230930_z1iAYIBSGpp8" style="text-align: right" title="Aggregate Intrinsic Value, Option granted">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20230930_zzI37ciDhaPl" style="border-bottom: Black 1pt solid; text-align: right" title="Option forfeited or expired">(91</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zKwlQRNwRNoi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited or expired">23.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Outstanding at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930_zPCkxjJ3EP04" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending">2,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z0NTlHP4Ypn8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at outstanding at ending">2.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zKK5vz2MwD5k" title="Weighted average remaining contractual term, outstanding (years)">8.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20230930_zvC4ApkWn388" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, option outstanding at ending">213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Exercisable at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930_z6ssVuKi8KR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Option exercisable">2,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zkAGJxJf3Iw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable">2.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zBUFEZv4KYP4" title="Weighted average remaining contractual term, exercisable">8.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20230930_zNf2jzD0sHmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Option exercisable">213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8AD_zCCEZ8lu8xPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During August and September&#160;2022, our Board granted <span id="xdx_900_ecustom--PurchaseCommonStock_pid_c20220801__20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zvhRumcIyoy5" title="Purchase common stock">125,000</span> options to purchase common stock at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zGXjRaO8k0Hf" title="Purchase price, per value">1.52</span> per share
         and <span id="xdx_909_ecustom--PurchaseCommonStock_pid_c20220901__20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zqginXpCouv8" title="Purchase common stock">900,000</span> options to purchase common stock at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zGo7bdyUZ0tk" title="Purchase price, per value">1.31</span> per share which are subject
         to shareholder approval of an amendment to increase the number of shares reserved
         for issuance under our 2015 Plan. The options vest monthly over a 12-month period
         from the grant dates. The shares underlying these options were approved by our stockholders
         on June&#160;29, 2023 and have been included in the table above as of September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In July&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan, an aggregate of <span id="xdx_90A_ecustom--NumberOfCommonStockVested_pid_c20230701__20230731__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_z9ZDvy3uFPZf" title="NUmber of common stock vested">450,000</span> shares of fully vested unrestricted common
         stock to seven members of the Board of Directors and one member of the management team. As a result,
         we recognized non-cash stock compensation of approximately $<span id="xdx_90B_ecustom--NoncashStockCompensation_pn3n3_dm_c20230701__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zpXIcWTZlXx8" title="Non-cash stock compensation">0.2</span> million during the three months ending September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table summarizes the stock-based compensation expense recorded for awards
         under our stock option plans (in thousands):</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zr9U5dxd6CCi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B4_zud6aGf22ZHk" style="display: none">Schedule of the stock-based compensation expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">553</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">359</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">217</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">859</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">414</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">523</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">965</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8A7_zRYi7s2xUi71" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We use the Black-Scholes-Merton option-pricing model with the following assumptions
         to estimate the fair value of our stock options:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zscu0XQscKq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B7_zaoc03bvrYFc" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230701__20230930_zpa7NInYESP" title="Weighted-average risk-free interest rate">4.08</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220701__20220930_zUQ3j6gyW6m7" title="Weighted-average risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230930_zFe2O8PODCsa" title="Weighted-average risk-free interest rate">4.06</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20220930_zctL4QeGORuh" title="Weighted-average risk-free interest rate">1.91</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected dividend payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230701__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220701__20220930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230101__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pn3n3_c20220101__20220930_zPfLS6KjNQB" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected holding period (years)<sup>1</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_fMQ_____zoEf2M7s073c" title="Expected holding period (years)">4.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_fMQ_____zm48SGG4Nhi9" title="Expected holding period (years)">5.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_fMQ_____zZhsBAFFtto7" title="Expected holding period (years)">5.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average volatility factor<sup>2</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230701__20230930_fMg_____zpkQ7EmMkD1e" title="Weighted-average volatility factor">1.14</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220701__20220930_fMg_____zwsR6B0vI6Qj" title="Weighted-average volatility factor"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230101__20230930_fMg_____zS0oWeOz8tH7" title="Weighted-average volatility factor">1.10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20220930_fMg_____zWSFhnUKHTaj" title="Weighted-average volatility factor">1.16</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Estimated forfeiture rates for options granted<sup>3</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230701__20230930_fMw_____zmt8b1hERogc" title="Estimated forfeiture rates for options granted">7.5</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220701__20220930_fMw_____zCBW9FUa2Ni1" title="Estimated forfeiture rates for options granted"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230101__20230930_fMw_____zCO0v0ntbPbl" title="Estimated forfeiture rates for options granted">7.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20220930_fMw_____zTs9Swxouyke" title="Estimated forfeiture rates for options granted">5.6</span></td><td style="text-align: left">%</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>


      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F08_z5kvmQbmxKp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">(1)</td>
            <td id="xdx_F17_zN4SDFeVBgXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F01_zDZIppNRIJS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(2)</td>
            <td id="xdx_F1A_zHJEgIxAIpcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Weighted average volatility is based on the historical volatility of our common stock.</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F04_zHzkEMlpoTCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(3)</td>
            <td id="xdx_F10_zeMqbuVEBVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Estimated forfeiture rates are based on historical data.</td>
         </tr>
      </table>
      <p id="xdx_8A4_zGLiZvG85yR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30, 2023, there was <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_do_c20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zX2JBv3aVJCa" title="Total unrecognized compensation expense related to non-vested stock option">no</span> unrecognized compensation expense related to non-vested stock options.</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425800144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_z6JKFjf7Geml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_825_zEc1WsT7mNPf">Net Loss Per Share</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The table below presents common shares underlying stock options and warrants that
         are excluded from the calculation of the weighted average number of common shares
         outstanding used for the calculation of diluted net loss per common share. These are
         excluded from the calculation due to their anti-dilutive effect:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zr6dK2aGu7pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B8_zwGI0Egyn9Of" style="display: none">Schedule of antidilutive securities excluded from computation of net loss per common share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zT53y0SdXeVj" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares">3,767</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBQMbdURpx6h" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrS28VUi2jaf" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z3xFARqviuT2" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z8uVfaOtoRY6" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zRQKKL1gap42" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zesGqAUUrgt8" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zpD8zvIfSrud" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhr832iv8Qgd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfSlWR0bMLa" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5mc1mkceIO" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzsb9L2C0tVd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zhqIUwEB4Ey" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">9,818</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znoxPeF2W8ml" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">4,933</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpQUgLVuR4Va" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">7,678</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWgOtDosQEz8" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">5,586</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zY5pk2y1O8vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">15,950</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zGIVQrWCfKV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">5,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_zgGZudZuej71" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">10,358</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_zt5hwIGHU76c" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">6,561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713428889968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JT Pharmaceuticals Asset Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract', window );"><strong>Jt Pharmaceuticals Asset Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AssetPurchaseAgreementTextBlock', window );">JT Pharmaceuticals Asset Purchase Agreement</a></td>
<td class="text"><p id="xdx_80B_ecustom--AssetPurchaseAgreementTextBlock_zE64lpeKcwo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_825_z7Oe00vghNUl">JT Pharmaceuticals Asset Purchase Agreement</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals,
         Inc., or JT Pharma, to acquire JT Pharma&#8217;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with
         our ProNeura long-term, continuous drug delivery technology, for the treatment of
         chronic pruritus and other medical conditions. Under the terms of the JT Agreement,
         JT Pharma received a $<span id="xdx_901_ecustom--FutureMilestonePayments_pn3p0_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zfcPJZzbvD0b" title="Closing payment">15,000</span> closing payment and is entitled to receive future milestone
         payments, payable in cash or in stock, based on the achievement of certain developmental
         and regulatory milestones, and single-digit percentage earn-out payments on net sales
         of the product if successfully developed and approved for commercialization. In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $<span id="xdx_90C_ecustom--MilestonePayments_pn3p0_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zvtvmV3AKL3g" title="Milestone Payments">100,000</span> and issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zut7iQy2Xe28" title="Issuance of common stock, net (in shares)">51,021</span>
         shares of our common stock to JT Pharma. The related expense was included in research
         and development expenses in our condensed statements of operations.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713428889968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 6)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zo6G9s8X9cQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_82E_z0ONGqpE1A89">Commitments and Contingencies</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Lease Commitments</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We lease our office facility under an operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $<span id="xdx_907_ecustom--OperatingLeasesRentExpenses_c20230701__20230930_pn3p0" title="Rent expense">32,000</span> and $<span id="xdx_901_ecustom--OperatingLeasesRentExpenses_c20230101__20230930_pn3p0" title="Rent expense">96,000</span> for the three and nine months ended September&#160;30, 2023, respectively.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Proceedings</i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A legal proceeding has been initiated by a former employee alleging wrongful termination,
         retaliation, infliction of emotional distress, negligent supervision, hiring and retention
         and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted
         utilizing an outside investigator and concluded that such allegations were not substantiated.
         Fedson, as further consideration for the Asset Purchase Agreement, has agreed to assume
         all liabilities related to this pending employment claim (See Note 8. Asset Sale).</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713428893488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyiSJUdjzlYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_824_zDADuDoPjQZf">Stockholders&#8217; Equity</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our common stock outstanding as of September&#160;30, 2023 and December&#160;31, 2022 was <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_zSmejc0FF3Df" title="Common stock shares, outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zu98KW71MEO4" title="Common stock shares, outstanding">15,016,295</span></span> shares.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Annual Meeting of Stockholders</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In June&#160;2023, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan
         to increase the number of authorized shares to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--N2015OmnibusEquityIncentivePlanMember_zfDyL7C2eMpd" title="Number of shares agreed to issue">2,500,000</span> shares.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>September&#160;2023 Preferred Stock</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with
         The Sire Group Ltd. (&#8220;Sire Group&#8221; or the &#8220;Investor&#8221;), pursuant to which we agreed
         to issue <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20230930_zsJqRX54Xa9k" title="Preferred stock, shares issued">950,000</span> shares of Series AA Convertible Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930_zZje7QVEvyma" title="Preferred stock, par value (in dollars per share)">0.001</span>
         per share (the &#8220;Series AA Preferred Stock&#8221;) to the Investor at a price of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230930_zY1dfd7GBdXb" title="Share price">10.00</span> per
         share, for an aggregate purchase price of $<span id="xdx_904_ecustom--PurchasePrice_pn3n3_dm_c20230101__20230930_zseXorHTJzti" title="Purchase price">9.5</span> million (the &#8220;Private Placement&#8221;). The purchase price consisted of (i) $5.0 million in cash
         at closing and (ii) $4.5 million in the form of a promissory note from Sire Group
         which was paid off in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each share of Series AA Preferred Stock will be convertible, at the holder&#8217;s option at any time, into shares of our common stock at a conversion rate equal to the quotient of (i) the stated value of
         such share divided by (ii) the initial conversion price of $0.466, subject to specified
         adjustments as set forth in the Certificate of Designations. The Series AA Preferred
         Stock contains limitations that prevent the Investor from acquiring the lower of either
         (i) the maximum percentage of common stock permissible under the rules and regulations
         of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) without first obtaining shareholder approval or (ii) 19.99% of our outstanding common
         stock.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holder of the Series AA Preferred Stock is entitled to receive dividends on shares
         of the Series AA Preferred Stock equal (on an as-if-converted-to-common-stock basis)
         to and in the same form as dividends actually paid on shares of the common stock.
         No other dividends will be paid on shares of the Series AA Preferred Stock. Any shares
         of Series AA Preferred Stock may, at the option of the holder, be converted at any
         time into that number of shares of common stock at the conversion price set forth
         above. Without approval of holders of a majority of the outstanding Series AA Preferred
         Stock, we may not (a) alter or adversely change the powers, preferences or rights
         given to the Series AA Preferred Stock, (b) amend its certificate of incorporation
         or other charter documents in any manner that adversely affects any rights of the
         holders of the Series AA Preferred Stock, (c) increase the number of authorized shares
         of the Series AA Preferred Stock, (d) enter into or consummate any Fundamental Transaction
         (as defined in the Certificate of Designations), or (e) enter into any agreement with
         respect to any of the foregoing. In the event of any liquidation, dissolution or winding
         up, the holder of the Series AA Preferred Stock will be entitled to receive out of
         the assets, whether capital or surplus, the same amount that a holder of common stock
         would receive if the Series AA Preferred Stock were fully converted to common stock,
         which amounts shall be paid <i>pari passu</i> with all holders of common stock.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>February&#160;2022 Offerings</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In February&#160;2022, we completed a registered direct offering with an accredited investor pursuant
         to which we issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zHLC9jI8xC3f" title="Issuance of common stock, net (in shares)">1,100,000</span> shares of our common stock and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zcyIRoPxayWi" title="Number of warrants issued">2,274,242</span>
         pre-funded warrants to purchase shares of our common stock, with an exercise price
         of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zIfLyefPZ8rl" title="Exercise price of warrants (in dollars per share)">0.001</span> per share. In a concurrent private placement, we sold unregistered pre-funded
         warrants to purchase an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zpU7djWdqoH4" title="Number of warrants issued">1,289,796</span> shares of common stock with an exercise
         price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z4A56AkdgVZf" title="Exercise price of warrants (in dollars per share)">0.001</span> per share and issued unregistered five year and six month warrants
         to purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zPV8UXWjLDhf" title="Number of warrants issued">4,664,038</span> shares of common stock with an exercise price
         of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zbO5HGRD1uk8" title="Exercise price of warrants (in dollars per share)">1.14</span>. The net cash proceeds from these offerings were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zB0FEOBrdNe6" title="Proceeds from sale of common stock">5.0</span> million
         after deduction of underwriting fees and other offering expenses.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Warrant Exercises</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In March&#160;2022, we received approximately $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zIzA1MnKDUcj" title="Proceeds from warrant exercises">1,000</span> from the exercise of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9X29bKolA87" title="Number of warrants issued">974,242</span> pre-funded warrants
         issued in the February&#160;2022 registered direct offering.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>JT Pharma Milestone</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $<span id="xdx_906_ecustom--MilestonePayment_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zGTbrA1eDmP4" title="Milestone payment">100,000</span> and issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zG6NAJ567Hw7" title="Issuance of common stock, net (in shares)">51,021</span>
         shares of our common stock to JT Pharma.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Restricted Shares</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2021, we agreed to issue <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zBB2V1qVHb24" title="Number of shares agreed to issue">50,000</span> shares of our common stock pursuant to a restricted
         stock agreement with Maxim Partners, LLC in connection with the entry into an amendment
         to our existing advisory agreement. The shares vested monthly over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zrc4LFyglzYj" title="Vesting period">12</span> months. We recorded
         approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zz8DTeAwAhF3" title="Stock-based compensation">27,000</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zdfvPeCO6zV1" title="Stock-based compensation">54,000</span> of stock-based compensation expense during the three
         and nine months ended September&#160;30, 2022, respectively.</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713426593680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zykkeYiQ52s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_822_zBdiKt5KvhZi">Discontinued Operations</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents information related to assets and liabilities reported
         as discontinued operations in our condensed balance sheets:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zteT5bqhh3T9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;<span id="xdx_8BF_z1WwZLuzypm" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230930_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20221231_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pn3n3_maAODGIzGqL_z4M9TA2Moit" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzGqL_zEcaCDBqtcob" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzGqL_zY8IKu8PXB2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIzKdM_zNTLskm0GqLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzKdM_zCMMFjC6G4Pe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425356672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisclosureAssetSaleAbstract', window );"><strong>Asset Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AssetsHeldForSaleTextBlock', window );">Asset Sale</a></td>
<td class="text"><p id="xdx_800_ecustom--AssetsHeldForSaleTextBlock_zyJ19nGPjIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_826_zlpEru4H2yn4">Asset Sale</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, we closed on the sale of certain ProNeura Assets. In July&#160;2023, <span id="xdx_906_ecustom--AssetSaleDescription_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember" title="Asset sale description">we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisclosureAssetSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisclosureAssetSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425522416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zc5EW5TUCla9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_829_zeMJPa9Sc5Y4">Related Party Transactions</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the nine months ended September&#160;30, 2023, we made payments related to legal fees of approximately $<span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zNu5n9Yes3Ik" title="Payment of legal fees">100,000</span> to a law firm operated by one of our Board members.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2023, we received $<span id="xdx_90D_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zm3JGMJPDUF6" title="Proceeds from promissory note">500,000</span> in funding in exchange for the issuance of a convertible
         promissory note for that principal amount to Choong Choon Hau, a major stockholder
         (the &#8220;Hau Promissory Note&#8221;). Pursuant to the Hau Promissory Note, the principal amount
         will accrue interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember" title="Interest accrued rate">10% per annum</span> and will be payable monthly. All principal
         and accrued interest shall be due and payable on January&#160;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our common stock at a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zugrgQc4gGF4" title="Conversion price">0.5712</span> per share from time to time following the issuance date and ending on the maturity
         date. We incurred interest expense of approximately $<span id="xdx_90E_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zfnyBhUqCEM3" title="Interest expense">7,500</span> during the three months ended September&#160;30, 2023 on this promissory note. The Hau Promissory note is included in Notes Payable to Related Party in the condensed
         balance sheet at September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In July&#160;2023, we received $<span id="xdx_905_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zWojagLkkzB3" title="Proceeds from promissory note">250,000</span> in funding in exchange for the issuance of an unsecured
         promissory note for that principal amount to David E. Lazar, our Chief Executive Officer
         and chairman of our Board of Directors (the &#8220;Lazar Promissory Note&#8221;). Pursuant to
         the Lazar Promissory Note, the principal amount accrued interest at a rate of the
         <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember" title="Interest accrued rate">Prime Rate + 2.00% per annum</span>, and all principal and accrued interest would have been
         due and payable on the earlier of January&#160;1, 2024 or such time as we receive debt or equity financing or proceeds in excess of
         $500,000 from the aforementioned transaction with Fedson. The promissory note was paid off in September&#160;2023. We incurred interest expense of approximately $<span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zYtyjqRoWyS4" title="Interest expense">3,718</span> during the three months ended September&#160;30, 2023 on this promissory note.</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420842144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zsT4RXxL1O74" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_82D_z9UUaOOH2vJd">Subsequent Events</span></b></td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have evaluated events that have occurred after September&#160;30, 2023 and through the date that our condensed financial statements are issued.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan (the &#8220;2015 Plan&#8221;) an aggregate of <span id="xdx_90E_ecustom--UnrestrictedCommonStockVested_pid_c20230901__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zfxZD9ileSfl" title="Unrestricted common stock vested">113,750</span> shares of fully vested unrestricted common stock to six members
         of the Board of Directors and one member of the management team. The Board conditioned the grant on the filing of a Form S-8 registration statement
         to register the common shares authorized for issuance under the 2015 Plan, which occurred
         on October&#160;25, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2023, Fedson exercised the provision for a second extension of the maturity date of
         the Cash Note in exchange for a cash payment of $<span id="xdx_907_ecustom--CashPayment_pn3n3_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--CashNoteMember_z69qdWTGVslf" title="Cash payment">5,000</span>. The Cash Note is currently due and payable on December&#160;1, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2023, we agreed to issue <span id="xdx_90F_ecustom--CommonStockIssuedForSettlementAgreement_pid_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--MDMWorldwideSolutionsMember_zZKSuMqzoEX4" title="Common stock issued for settlement agreement">50,000</span> shares of our common stock pursuant to a settlement agreement with MDM Worldwide Solutions, Inc. The shares vested immediately. </p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425092960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CompanyPolicyPolicyTextBlock', window );">The Company</a></td>
<td class="text"><p id="xdx_846_ecustom--CompanyPolicyPolicyTextBlock_zLeoMA4DSHe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_z2qHsneFQdha">The Company</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a pharmaceutical company developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our first product based on the ProNeura technology was Probuphine<sup>&#174;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that had either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an
         approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DavidLazarAndActivistInvestingLlcMember_pdd" title="Ownership interest by Activist">25%</span> ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#8220;Board&#8221;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220801__20220815__srt--CounterpartyNameAxis__custom--RubinMember_zXKXT3GFaOZ4" title="Severance payments">0.4</span> million, of which,
         approximately $<span id="xdx_906_eus-gaap--SeveranceCosts1_pn3p0_c20230101__20230930_znHbsUs4svt5" title="Severance payments">247,000</span> have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In September&#160;2023, (the &#8220;Closing Date&#8221;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#8220;ProNeura Assets&#8221;). In July&#160;2023, <span id="xdx_900_ecustom--AssetSaleDescriptions_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember_zz06Sh1xbTUk" title="Asset sale description">we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;)
         with Fedson, Inc., a Delaware corporation (&#8220;Fedson&#8221;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.</span></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6XMrSt2FfDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zHWyrJfCfZ7d">Basis of Presentation</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited condensed financial statements have been prepared in accordance
         with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial
         information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information
         and footnotes required by GAAP for complete financial statement presentation. In the
         opinion of management, all adjustments (consisting of normal recurring adjustments)
         considered necessary for a fair presentation have been included. Operating results
         for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending
         December&#160;31, 2023, or any future interim periods.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The balance sheet as of December&#160;31, 2022 is derived from the audited financial statements at that date but does not
         include all the information and footnotes required by GAAP for complete financial
         statements. These unaudited condensed financial statements should be read in conjunction
         with the audited financial statements and footnotes thereto included in the Titan
         Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been prepared assuming we will
         continue as a going concern.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of September&#160;30,
      2023, we had cash and cash equivalents of approximately $8.1
      million <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zTuW97m8TUH4" style="display: none" title="Cash and cash equivalents">8,096</span>, which we believe, will be sufficient to fund our planned operations through December of 2024. We continue to explore
      several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zbUao7Y1bYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zxqn8GlLGTCl">Discontinued Operations</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October&#160;2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind
         down our commercialization activities, and to pursue a plan that will enable us to
         focus on our current, early-stage ProNeura-based product development programs.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying condensed financial statements have been recast for all periods presented
         to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization
         activities as discontinued operations (see Note 7). The accompanying condensed financial
         statements are generally presented in conformity with our historical format. We believe
         this format provides comparability with the previously filed financial statements.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_GoingConcernAssessmentPolicyTextBlock', window );">Going Concern Assessment</a></td>
<td class="text"><p id="xdx_840_ecustom--GoingConcernAssessmentPolicyTextBlock_z9YJr1ioPbGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zKHFBuOW8eZe">Going Concern Assessment</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We assess going concern uncertainty in our financial statements to determine if we
         have sufficient cash on hand and working capital, including available borrowings on
         loans, to operate for a period of at least one year from the date the financial statements
         are issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting
         Standard Update ASU No. 2014-15. As part of this assessment, based on conditions that
         are known and reasonably knowable to us, we will consider various scenarios, forecasts,
         projections, estimates and will make certain key assumptions, including the timing
         and nature of projected cash expenditures or programs, and our ability to delay or
         curtail expenditures or programs, if necessary, among other factors. Based on this
         assessment, as necessary or applicable, we make certain assumptions around implementing
         curtailments or delays in the nature and timing of programs and expenditures to the
         extent we deem probable those implementations can be achieved and we have the proper
         authority to execute them within the look-forward period in accordance with ASU No.
         2014-15.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based upon the above assessment, we concluded that, at the date of filing the condensed
         financial statements in this Quarterly Report on Form 10-Q for the nine months ended September&#160;30, 2023, we have sufficient cash to fund our operations for the next 12 months without additional
         funds. Additionally, we have suffered recurring losses from operations and have an accumulated
         deficit that raises substantial doubt about our ability to continue as a going concern beyond the next 12 months. We continue to explore several financing and strategic alternatives; however, there can be no assurance
         that our efforts will be successful.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zgv8mh8HLin5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zyq8yLFBBmEl">Use of Estimates</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with accounting principles generally
         accepted in the U.S. requires management to make estimates and assumptions that affect
         the amounts reported in the financial statements and accompanying notes. Actual results
         could differ from those estimates.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zVBXZzICS3m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zqhwr1AVKcd5">Inventories</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Inventories are recorded at the lower of cost or net realizable value. Cost is based
         on the first in, first out method. We regularly review inventory quantities on hand
         and write down to its net realizable value any inventory that we believe to be impaired.
         The determination of net realizable value requires judgment including consideration
         of many factors, such as estimates of future product demand, product net selling prices,
         current and future market conditions and potential product obsolescence, among others.
         The components of inventories are as follows:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_z2bAMFYUdLl3" style="display: none">Schedule of components of inventories</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories">106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8A5_zTj1jCMRBNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Approximately $<span id="xdx_90C_eus-gaap--InventoryNet_iI_pn3p0_c20221231_zYeYqrXpeO8a" title="Raw materials and supplies and finished goods inventory">106,000</span> of raw materials and supplies and finished goods inventory
         at December&#160;31, 2022 were sold to Fedson under the Asset Purchase Agreement in September&#160;2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z91HH0nf1qB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zoO0xQFY0eZc">Revenue Recognition</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We generate revenue principally from collaborative research and development arrangements,
         sales or licenses of technology and government grants. Consideration received for
         revenue arrangements with multiple components is allocated among the separate performance
         obligations based upon their relative estimated standalone selling price.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In determining the appropriate amount of revenue to be recognized as we fulfill our
         obligations under our agreements, we perform the following steps for our revenue recognition:
         (i) identify contracts with customers; (ii) identify performance obligations; (iii)
         determine the transaction price; (iv) allocate the transaction price to the performance
         obligations; and (v) recognize of revenue when (or as) we satisfy each performance
         obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Grant Revenue</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department
         of Health and Human Services, or HHS, the Bill&amp; Melinda Gates Foundation, and other
         government-sponsored organizations for research and development related activities
         that provide for payments for reimbursed costs, which may include overhead and general
         and administrative costs. We recognize revenue from these contracts as we perform
         services under these arrangements when the funding is committed. Associated expenses
         are recognized when incurred as research and development expenses. Revenues and related
         expenses are presented gross in the condensed statements of operations.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Performance Obligations</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A performance obligation is a promise in a contract to transfer a distinct good or
         service to the customer. Our performance obligations include commercialization license
         rights, development services and services associated with the regulatory approval
         process.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have optional additional items in contracts, which are accounted for as separate
         contracts when the customer elects such options. Arrangements that include a promise
         for future commercial product supply and optional research and development services
         at the customer&#8217;s discretion are generally considered as options. We assess if these options provide
         a material right to the customer and, if so, such material rights are accounted for
         as separate performance obligations. If we are entitled to additional payments when
         the customer exercises these options, any additional payments are recorded in revenue
         when the customer obtains control of the goods or services.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Transaction Price</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have both fixed and variable considerations. Non-refundable upfront payments are
         considered fixed, while milestone payments are identified as variable consideration
         when determining the transaction price. Funding of research and development activities
         is considered variable until such costs are reimbursed at which point, they are considered
         fixed. We allocate the total transaction price to each performance obligation based
         on the relative estimated standalone selling prices of the promised goods or services
         for each performance obligation.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At the inception of each arrangement that includes milestone payments, we evaluate
         whether the milestones are considered probable of being achieved and estimate the
         amount to be included in the transaction price using the most likely amount method.
         If it is probable that a significant revenue reversal would not occur, the value of
         the associated milestone is included in the transaction price. Milestone payments
         that are not within our control, such as approvals from regulators, are not considered
         probable of being achieved until those approvals are received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For arrangements that include sales-based royalties or earn-out payments, including
         milestone payments based on the level of sales, and the license or purchase agreement
         is deemed to be the predominant item to which the royalties or earn-out payments relate,
         we recognize revenue at the later of (a) when the related sales occur, or (b) when
         the performance obligation to which some or all of the royalty or earn-out payment
         has been allocated has been satisfied (or partially satisfied).</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Allocation of Consideration</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As part of the accounting for these arrangements, we must develop assumptions that
         require judgment to determine the stand-alone selling price of each performance obligation
         identified in the contract. Estimated selling prices for license rights are calculated
         using the residual approach. For all other performance obligations, we use a cost-plus
         margin approach.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Timing of Recognition</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Significant management judgment is required to determine the level of effort required
         under an arrangement and the period over which we expect to complete our performance
         obligations under an arrangement. We estimate the performance period or measure of
         progress at the inception of the arrangement and re-evaluate it each reporting period.
         This re-evaluation may shorten or lengthen the period over which revenue is recognized.
         Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot
         reasonably estimate when our performance obligations either are completed or become
         inconsequential, then revenue recognition is deferred until we can reasonably make
         such estimates. Revenue is then recognized over the remaining estimated period of
         performance using the cumulative catch-up method. Revenue is recognized for licenses
         or sales of functional intellectual property at the point in time the customer can
         use and benefit from the license. For performance obligations that are services, revenue
         is recognized over time proportionate to the costs that we have incurred to perform
         the services using the cost-to-cost input method.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Contract Assets and Liabilities</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the activity related to our accounts receivable for the
         nine months ended September&#160;30, 2023.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8BA_zJunFJq2kcSf" style="display: none">Schedule of activity related to our accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,<br/>2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Balance at January&#160;1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance">36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Deductions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(194</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Balance at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">26</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8A3_z52B391iNeVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Related Accrual</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyCqZguNny61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zKu78sT64TXg">Research and Development Costs and Related Accrual</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Research and development expenses include internal and external costs. Internal costs
         include salaries and employment related expenses, facility costs, administrative expenses
         and allocations of corporate costs. External expenses consist of costs associated
         with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research
         studies, product registration, and investigator sponsored trials. Significant judgments
         and estimates must be made and used in determining the accrued balance in any accounting
         period. Actual results could differ from those estimates under different assumptions.
         Revisions are charged to expense in the period in which the facts that give rise to
         the revision become known.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zw10ww79lmq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_z99MMQQsVv4h">Leases</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We determine whether the arrangement is or contains a lease at inception. Operating
         lease right-of-use assets and lease liabilities are recognized at the present value
         of the future lease payments at commencement date. The interest rate implicit in lease
         contracts is typically not readily determinable, and therefore, we utilize our incremental
         borrowing rate, which is the rate incurred to borrow on a collateralized basis over
         a similar term an amount equal to the lease payments in a similar economic environment.
         Certain adjustments to the right-of-use asset may be required for items such as initial
         direct costs paid or incentives received.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Lease expense is recognized over the expected term on a straight-line basis. Operating
         leases are recognized on our condensed balance sheets as right-of-use assets, operating
         lease liabilities current and operating lease liabilities non-current.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents the minimum lease payments of our operating lease:</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none">Schedule of minimum operating lease payments</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total minimum lease payments (base rent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <p id="xdx_8AB_zXRT6AQ0IWud" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFedDUfImZA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_z0bHIQxCJrj1">Recent Accounting Pronouncements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In June&#160;2016, the
      FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses, which requires
      an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience,
      current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking
      information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January&#160;1,
      2023. The adoption of Topic 326 did not have a material impact on our condensed financial statements and disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Accounting Standards Not Yet Adopted</i></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In August&#160;2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates
         certain models that require separate accounting for embedded conversion features,
         in certain cases. Additionally, among other changes, the guidance eliminates certain
         of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for
         all convertible instruments in the diluted earnings per share calculation and include
         the effect of share settlement for instruments that may be settled in cash or shares,
         except for certain liability-classified share-based payment awards. This guidance
         is effective beginning after December&#160;15, 2023 and must be applied using either a modified or full retrospective approach.
         Early adoption is permitted. We are currently evaluating the impact this guidance
         will have on our condensed financial statements and related disclosures.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcmC12GHullh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4UdCV7EIj1e">Fair Value Measurements</span></i></b></p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Financial instruments, including receivables, accounts payable and accrued liabilities
         are carried at cost, and their fair values are approximated due to the short-term
         nature of these instruments. Our investments in money market funds are classified
         within Level 1 of the fair value hierarchy.</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At December&#160;31, 2022, the fair value of our investments in money market funds was approximately
         $<span id="xdx_90C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zj4aCXB5y65h" title="Fair value of investments">2.6</span> million which is included within our cash and cash equivalents in our condensed
         balance sheets. We had no investments in money market funds at September&#160;30, 2023.</p>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_GoingConcernAssessmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_GoingConcernAssessmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423062096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of components of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_z2bAMFYUdLl3" style="display: none">Schedule of components of inventories</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories">106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of activity related to our accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8BA_zJunFJq2kcSf" style="display: none">Schedule of activity related to our accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,<br/>2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Balance at January&#160;1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance">36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Deductions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(194</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Balance at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">26</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum operating lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none">Schedule of minimum operating lease payments</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930" style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total minimum lease payments (base rent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713429021552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of our option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z5nnMVw8iJNd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8B7_zYZvduR0ThPc" style="display: none">Schedule of our option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options<br/>(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br/>Exercise Price<br/> per share</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted
    Average<br/>Remaining Option<br/>Term (in years)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate
    Intrinsic<br/>Value<br/>(in thousands)</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at December&#160;31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930_z6Ie8JtpGro2" style="width: 9%; text-align: right" title="Outstanding at beginning">927</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zHUg2qVZL16" style="width: 9%; text-align: right" title="Weighted average exercise price, outstanding at beginning">7.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zdA3szvYYdP3" title="Weighted average remaining contractual term, outstanding (years)">8.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20230930_zdQX1r9aVlH8" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, option outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pn3n3_c20230101__20230930_zTSRuRX48Csl" style="text-align: right" title="Option granted">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zUOnt5Zelxo" style="text-align: right" title="Weighted average exercise price, granted">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AggregateIntrinsicValueOptionGranted_pn3n3_c20230101__20230930_z1iAYIBSGpp8" style="text-align: right" title="Aggregate Intrinsic Value, Option granted">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20230930_zzI37ciDhaPl" style="border-bottom: Black 1pt solid; text-align: right" title="Option forfeited or expired">(91</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zKwlQRNwRNoi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited or expired">23.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Outstanding at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930_zPCkxjJ3EP04" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending">2,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z0NTlHP4Ypn8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at outstanding at ending">2.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zKK5vz2MwD5k" title="Weighted average remaining contractual term, outstanding (years)">8.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20230930_zvC4ApkWn388" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, option outstanding at ending">213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Exercisable at September&#160;30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930_z6ssVuKi8KR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Option exercisable">2,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zkAGJxJf3Iw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable">2.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zBUFEZv4KYP4" title="Weighted average remaining contractual term, exercisable">8.84</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20230930_zNf2jzD0sHmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Option exercisable">213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of the stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zr9U5dxd6CCi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span id="xdx_8B4_zud6aGf22ZHk" style="display: none">Schedule of the stock-based compensation expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">553</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">359</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">217</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">859</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">414</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">523</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">965</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions to estimate the fair value of options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zscu0XQscKq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B7_zaoc03bvrYFc" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230701__20230930_zpa7NInYESP" title="Weighted-average risk-free interest rate">4.08</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220701__20220930_zUQ3j6gyW6m7" title="Weighted-average risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230930_zFe2O8PODCsa" title="Weighted-average risk-free interest rate">4.06</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20220930_zctL4QeGORuh" title="Weighted-average risk-free interest rate">1.91</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected dividend payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230701__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220701__20220930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230101__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pn3n3_c20220101__20220930_zPfLS6KjNQB" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Expected holding period (years)<sup>1</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_fMQ_____zoEf2M7s073c" title="Expected holding period (years)">4.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_fMQ_____zm48SGG4Nhi9" title="Expected holding period (years)">5.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_fMQ_____zZhsBAFFtto7" title="Expected holding period (years)">5.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average volatility factor<sup>2</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230701__20230930_fMg_____zpkQ7EmMkD1e" title="Weighted-average volatility factor">1.14</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220701__20220930_fMg_____zwsR6B0vI6Qj" title="Weighted-average volatility factor"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230101__20230930_fMg_____zS0oWeOz8tH7" title="Weighted-average volatility factor">1.10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20220930_fMg_____zWSFhnUKHTaj" title="Weighted-average volatility factor">1.16</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Estimated forfeiture rates for options granted<sup>3</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230701__20230930_fMw_____zmt8b1hERogc" title="Estimated forfeiture rates for options granted">7.5</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220701__20220930_fMw_____zCBW9FUa2Ni1" title="Estimated forfeiture rates for options granted"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230101__20230930_fMw_____zCO0v0ntbPbl" title="Estimated forfeiture rates for options granted">7.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20220930_fMw_____zTs9Swxouyke" title="Estimated forfeiture rates for options granted">5.6</span></td><td style="text-align: left">%</td></tr>
  </table>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>


      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F08_z5kvmQbmxKp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">(1)</td>
            <td id="xdx_F17_zN4SDFeVBgXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F01_zDZIppNRIJS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(2)</td>
            <td id="xdx_F1A_zHJEgIxAIpcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Weighted average volatility is based on the historical volatility of our common stock.</td>
         </tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td id="xdx_F04_zHzkEMlpoTCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(3)</td>
            <td id="xdx_F10_zeMqbuVEBVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle">Estimated forfeiture rates are based on historical data.</td>
         </tr>
      </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425304224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per common share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zr6dK2aGu7pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B8_zwGI0Egyn9Of" style="display: none">Schedule of antidilutive securities excluded from computation of net loss per common share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">Nine Months Ended</td><td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(in thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zT53y0SdXeVj" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares">3,767</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBQMbdURpx6h" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrS28VUi2jaf" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z3xFARqviuT2" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z8uVfaOtoRY6" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zRQKKL1gap42" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zesGqAUUrgt8" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zpD8zvIfSrud" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Weighted-average anti-dilutive common shares resulting from options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhr832iv8Qgd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfSlWR0bMLa" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5mc1mkceIO" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">1,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzsb9L2C0tVd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares">975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zhqIUwEB4Ey" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">9,818</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znoxPeF2W8ml" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">4,933</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpQUgLVuR4Va" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">7,678</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWgOtDosQEz8" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares">5,586</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zY5pk2y1O8vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">15,950</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zGIVQrWCfKV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">5,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_zgGZudZuej71" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">10,358</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_zt5hwIGHU76c" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares">6,561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425590944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zteT5bqhh3T9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;<span id="xdx_8BF_z1WwZLuzypm" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230930_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20221231_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left">(In thousands)</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pn3n3_maAODGIzGqL_z4M9TA2Moit" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzGqL_zEcaCDBqtcob" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzGqL_zY8IKu8PXB2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIzKdM_zNTLskm0GqLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzKdM_zCMMFjC6G4Pe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Discontinued operations &#8211; current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420115280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713424526768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 1)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Beginning Balance</a></td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetDeductions', window );">Deductions</a></td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Ending Balance</a></td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423085296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 2)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments (base rent)</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420655296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,096<span></span>
</td>
<td class="nump">8,096<span></span>
</td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Raw materials and supplies and finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ttnp_RubinMember', window );">Rubin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance payments</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ttnp_ProNeuraMember', window );">Pro Neura [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AssetSaleDescriptions', window );">Asset sale description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">we entered into an asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;)
         with Fedson, Inc., a Delaware corporation (&#8220;Fedson&#8221;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#8220;Amendment&#8221;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ttnp_DavidLazarAndActivistInvestingLlcMember', window );">David Lazar and Activist Investing LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest by Activist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AssetSaleDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AssetSaleDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttnp_RubinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttnp_RubinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttnp_ProNeuraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttnp_ProNeuraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ttnp_DavidLazarAndActivistInvestingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ttnp_DavidLazarAndActivistInvestingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425154272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning | shares</a></td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at beginning | $ / shares</a></td>
<td class="nump">$ 7.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (years)</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, option outstanding at beginning | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted | shares</a></td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 0.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AggregateIntrinsicValueOptionGranted', window );">Aggregate Intrinsic Value, Option granted | $</a></td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Option forfeited or expired | shares</a></td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited or expired | $ / shares</a></td>
<td class="nump">$ 23.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending | shares</a></td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at outstanding at ending | $ / shares</a></td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, outstanding (years)</a></td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, option outstanding at ending | $</a></td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Option exercisable | shares</a></td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price per share, exercisable | $ / shares</a></td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Option exercisable | $</a></td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AggregateIntrinsicValueOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AggregateIntrinsicValueOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420136480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">$ 967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420066992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.08%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected holding period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility factor</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1.14%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement', window );">Estimated forfeiture rates for options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Weighted average volatility is based on the historical volatility of our common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Estimated forfeiture rates are based on historical data.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated forfeiture rates for options granted to management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420579616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense related to non-vested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_Plan2015Member', window );">Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_PurchaseCommonStock', window );">Purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember', window );">Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_NumberOfCommonStockVested', window );">NUmber of common stock vested</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_NoncashStockCompensation', window );">Non-cash stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NoncashStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NoncashStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NumberOfCommonStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NumberOfCommonStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_Plan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_Plan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420152992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of weighted-average anti-dilutive common shares</a></td>
<td class="nump">15,950<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
<td class="nump">10,358<span></span>
</td>
<td class="nump">6,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of weighted-average anti-dilutive common shares</a></td>
<td class="nump">3,767<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,269<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ttnp_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of weighted-average anti-dilutive common shares</a></td>
<td class="nump">504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of weighted-average anti-dilutive common shares</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of weighted-average anti-dilutive common shares</a></td>
<td class="nump">9,818<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
<td class="nump">5,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ttnp_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ttnp_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713428058656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JT Pharmaceuticals Asset Purchase Agreement (Details Narrative) - JT Pharmaceuticals [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_FutureMilestonePayments', window );">Closing payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_MilestonePayments', window );">Milestone Payments</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="nump">51,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713425364208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 6)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLeasesRentExpenses', window );">Rent expense</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OperatingLeasesRentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OperatingLeasesRentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713421988800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted stock agreement with Maxim Group, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember', window );">JT Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,274,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Unregistered prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Unregistered five year and six month warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,664,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_N2015OmnibusEquityIncentivePlanMember', window );">2015 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttnp_RestrictedStockAgreementWithMaximGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttnp_RestrictedStockAgreementWithMaximGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_N2015OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_N2015OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713420657408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current assets</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current liabilities</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member] | U.s. Commercialization Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Receivables</a></td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current liabilities</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ttnp_U.s.CommercializationActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ttnp_U.s.CommercializationActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423078464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ttnp_ProNeuraMember', window );">Pro Neura [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AssetSaleDescription', window );">Asset sale description</a></td>
<td class="text">we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#8220;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#8220;Escrow Note&#8221;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#8217;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AssetSaleDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AssetSaleDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttnp_ProNeuraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttnp_ProNeuraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713423051440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Payment of legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ttnp_HauPromissoryNoteMember', window );">Hau Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ProceedsFromPromissoryNote', window );">Proceeds from promissory note</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Interest accrued rate</a></td>
<td class="text">10% per annum<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.5712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ttnp_LazarPromissoryNoteMember', window );">Lazar Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ProceedsFromPromissoryNote', window );">Proceeds from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Interest accrued rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prime Rate + 2.00% per annum<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ProceedsFromPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ProceedsFromPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ttnp_HauPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ttnp_HauPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ttnp_LazarPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ttnp_LazarPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140713424912192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | M D M Worldwide Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CommonStockIssuedForSettlementAgreement', window );">Common stock issued for settlement agreement</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cash Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CashPayment', window );">Cash payment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember', window );">Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_UnrestrictedCommonStockVested', window );">Unrestricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CommonStockIssuedForSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CommonStockIssuedForSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_UnrestrictedCommonStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_UnrestrictedCommonStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttnp_MDMWorldwideSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttnp_MDMWorldwideSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ttnp_CashNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ttnp_CashNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>titanpharma_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:ttnp="http://titanpharm.com/20230930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ttnp-20230930.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2023-11-10</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_DavidLazarAndActivistInvestingLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ttnp:DavidLazarAndActivistInvestingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-15_custom_RubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_ProNeuraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:ProNeuraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttnp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_N2015OmnibusEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:N2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredFiveYearAndSixMonthWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="From2022-03-012022-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-31_custom_HauPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31_custom_HauPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_HauPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:HauPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:LazarPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_LazarPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:LazarPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_CashNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttnp:CashNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:MDMWorldwideSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-09-30">0000910267</dei:EntityCentralIndexKey>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:NotePayableToRelatedParty
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-07-012023-09-30_us-gaap_LicenseAndServiceMember"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0290"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0306"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:ShareBasedPaymentArrangementMilestonePayment
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:ProceedsFromEquityOfferings
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSubordinatedShortTermDebt
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfSubordinatedShortTermDebt
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:InventoryTransferredWithSaleOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:PropertyAndEquipmentNetTransferredWithSaleOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:NotesReceivableReceivedInConnectionWithSaleOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:AccountsPayableRelatedToSaleOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:OtherAccruedLiabilitiesTransferredWithSaleOfAssets
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0739"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0761"
      unitRef="Pure"
      xsi:nil="true"/>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0769"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0786"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0790"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_custom_ConvertibleNotesMember"
      id="xdx2ixbrl0794"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_custom_ConvertibleNotesMember"
      id="xdx2ixbrl0798"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      id="xdx2ixbrl0892"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-09-30">001-13341</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-09-30">Titan Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-09-30">94-3171940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-09-30">400 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-09-30">Suite 505</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-09-30">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-09-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-09-30">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-09-30">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30">244-4990</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-09-30">Common             Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-09-30">TTNP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-10" decimals="INF" unitRef="Shares">15016295</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2937000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">13000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">26000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">36000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsAndNotesReceivableNet contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">1500000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">106000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">244000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">314000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">20000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">14000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">9899000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3603000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">48000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">94000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">183000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">9999000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4058000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">407000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">695000</us-gaap:AccountsPayableCurrent>
    <ttnp:NotePayableToRelatedParty contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">500000</ttnp:NotePayableToRelatedParty>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">790000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1488000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">97000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ttnp:DeferredGrantRevenue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">12000</ttnp:DeferredGrantRevenue>
    <ttnp:DeferredGrantRevenue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</ttnp:DeferredGrantRevenue>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">60000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">129000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">1866000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2630000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">65000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">1866000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2695000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">950000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">950000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">397977000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">387609000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">-389860000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-386261000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1363000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">9999000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4058000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-07-012022-09-30_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-09-30_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-09-30_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      unitRef="USD">9000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-07-012023-09-30_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-07-012022-09-30_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">91000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-09-30_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-09-30_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">427000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">95000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">184000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">436000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">424000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1426000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">3315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">1806000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4104000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">4745000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">2065000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">2738000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">5530000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">8060000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-2061000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-2643000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-5346000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-7624000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-11000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">21000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">18000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">26000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1732000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1732000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-42000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1723000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1747000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-16000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-338000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-3599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-7640000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="Shares">14629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="Shares">14629000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="Shares">13031000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="Shares">13031000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">387609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-386261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1363000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-1675000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      unitRef="USD">-1675000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">387609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-387936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">-312000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-1586000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-1586000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">864000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">864000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">388473000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-389522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">-1034000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-338000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-338000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ttnp:IssuanceOfPreferredStockNet
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</ttnp:IssuanceOfPreferredStockNet>
    <ttnp:IssuanceOfPreferredStockNet
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">9093000</ttnp:IssuanceOfPreferredStockNet>
    <ttnp:IssuanceOfPreferredStockNet
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">9094000</ttnp:IssuanceOfPreferredStockNet>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">15016000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="Shares">950000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">397977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-389860000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8133000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">9914000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">381183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-376055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5138000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-2540000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31"
      decimals="-3"
      unitRef="USD">-2540000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">1151000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">5029000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31"
      decimals="-3"
      unitRef="USD">5030000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">974000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31"
      decimals="-3"
      unitRef="USD">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31"
      decimals="-3"
      unitRef="USD">226000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">12039000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">386465000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-378595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7882000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-2462000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-2462000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">2590000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">14629000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">386709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-381057000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">5667000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-2638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-2638000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">14629000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">387230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-383695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">3550000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">3599000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">7640000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1732000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">151000</us-gaap:DepreciationDepletionAndAmortization>
    <ttnp:ShareBasedPaymentArrangementMilestonePayment
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">50000</ttnp:ShareBasedPaymentArrangementMilestonePayment>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">965000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">1038000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-63000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">167000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-122000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">34000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-374000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-182000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-184000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-34000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-152000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">149000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-4846000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-6604000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">228000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">228000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ttnp:ProceedsFromEquityOfferings
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">4980000</ttnp:ProceedsFromEquityOfferings>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">9094000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromSubordinatedShortTermDebt
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">750000</us-gaap:ProceedsFromSubordinatedShortTermDebt>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">4000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfSubordinatedShortTermDebt
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">250000</us-gaap:RepaymentsOfSubordinatedShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">9594000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">4984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-1620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">4712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4000</us-gaap:InterestPaidNet>
    <ttnp:InventoryTransferredWithSaleOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">106000</ttnp:InventoryTransferredWithSaleOfAssets>
    <ttnp:PropertyAndEquipmentNetTransferredWithSaleOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">109000</ttnp:PropertyAndEquipmentNetTransferredWithSaleOfAssets>
    <ttnp:NotesReceivableReceivedInConnectionWithSaleOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1500000</ttnp:NotesReceivableReceivedInConnectionWithSaleOfAssets>
    <ttnp:AccountsPayableRelatedToSaleOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">17000</ttnp:AccountsPayableRelatedToSaleOfAssets>
    <ttnp:OtherAccruedLiabilitiesTransferredWithSaleOfAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">236000</ttnp:OtherAccruedLiabilitiesTransferredWithSaleOfAssets>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">4450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">13000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">262000</us-gaap:RestrictedCash>
    <ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8109000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
    <ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">4712000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zmozvx6vuxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82C_zq2jLnIHhEzk"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_846_ecustom--CompanyPolicyPolicyTextBlock_zLeoMA4DSHe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z2qHsneFQdha"&gt;The Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We are a pharmaceutical company developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura&lt;sup&gt;&#xae;&lt;/sup&gt;, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Our first product based on the ProNeura technology was Probuphine&lt;sup&gt;&#xae;&lt;/sup&gt; (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that had either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#x201c;Activist&#x201d;) acquired an
         approximately &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DavidLazarAndActivistInvestingLlcMember_pdd" title="Ownership interest by Activist"&gt;25%&lt;/span&gt; ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#x201c;Board&#x201d;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#x201c;Special Meeting&#x201d;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $&lt;span id="xdx_90D_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220801__20220815__srt--CounterpartyNameAxis__custom--RubinMember_zXKXT3GFaOZ4" title="Severance payments"&gt;0.4&lt;/span&gt; million, of which,
         approximately $&lt;span id="xdx_906_eus-gaap--SeveranceCosts1_pn3p0_c20230101__20230930_znHbsUs4svt5" title="Severance payments"&gt;247,000&lt;/span&gt; have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In September&#160;2023, (the &#x201c;Closing Date&#x201d;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#x201c;ProNeura Assets&#x201d;). In July&#160;2023, &lt;span id="xdx_900_ecustom--AssetSaleDescriptions_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember_zz06Sh1xbTUk" title="Asset sale description"&gt;we entered into an asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;)
         with Fedson, Inc., a Delaware corporation (&#x201c;Fedson&#x201d;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#x201c;Amendment&#x201d;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#x201c;Cash Note&#x201d;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#x201c;Escrow Note&#x201d;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#x2019;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6XMrSt2FfDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zHWyrJfCfZ7d"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance
         with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial
         information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information
         and footnotes required by GAAP for complete financial statement presentation. In the
         opinion of management, all adjustments (consisting of normal recurring adjustments)
         considered necessary for a fair presentation have been included. Operating results
         for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending
         December&#160;31, 2023, or any future interim periods.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The balance sheet as of December&#160;31, 2022 is derived from the audited financial statements at that date but does not
         include all the information and footnotes required by GAAP for complete financial
         statements. These unaudited condensed financial statements should be read in conjunction
         with the audited financial statements and footnotes thereto included in the Titan
         Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying condensed financial statements have been prepared assuming we will
         continue as a going concern.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;As of September&#160;30,
      2023, we had cash and cash equivalents of approximately $8.1
      million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zTuW97m8TUH4" style="display: none" title="Cash and cash equivalents"&gt;8,096&lt;/span&gt;, which we believe, will be sufficient to fund our planned operations through December of 2024. We continue to explore
      several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_84C_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zbUao7Y1bYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zxqn8GlLGTCl"&gt;Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In October&#160;2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind
         down our commercialization activities, and to pursue a plan that will enable us to
         focus on our current, early-stage ProNeura-based product development programs.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying condensed financial statements have been recast for all periods presented
         to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization
         activities as discontinued operations (see Note 7). The accompanying condensed financial
         statements are generally presented in conformity with our historical format. We believe
         this format provides comparability with the previously filed financial statements.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_840_ecustom--GoingConcernAssessmentPolicyTextBlock_z9YJr1ioPbGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zKHFBuOW8eZe"&gt;Going Concern Assessment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We assess going concern uncertainty in our financial statements to determine if we
         have sufficient cash on hand and working capital, including available borrowings on
         loans, to operate for a period of at least one year from the date the financial statements
         are issued, which is referred to as the &#x201c;look-forward period&#x201d; as defined by Accounting
         Standard Update ASU No. 2014-15. As part of this assessment, based on conditions that
         are known and reasonably knowable to us, we will consider various scenarios, forecasts,
         projections, estimates and will make certain key assumptions, including the timing
         and nature of projected cash expenditures or programs, and our ability to delay or
         curtail expenditures or programs, if necessary, among other factors. Based on this
         assessment, as necessary or applicable, we make certain assumptions around implementing
         curtailments or delays in the nature and timing of programs and expenditures to the
         extent we deem probable those implementations can be achieved and we have the proper
         authority to execute them within the look-forward period in accordance with ASU No.
         2014-15.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Based upon the above assessment, we concluded that, at the date of filing the condensed
         financial statements in this Quarterly Report on Form 10-Q for the nine months ended September&#160;30, 2023, we have sufficient cash to fund our operations for the next 12 months without additional
         funds. Additionally, we have suffered recurring losses from operations and have an accumulated
         deficit that raises substantial doubt about our ability to continue as a going concern beyond the next 12 months. We continue to explore several financing and strategic alternatives; however, there can be no assurance
         that our efforts will be successful.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zgv8mh8HLin5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zyq8yLFBBmEl"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of financial statements in conformity with accounting principles generally
         accepted in the U.S. requires management to make estimates and assumptions that affect
         the amounts reported in the financial statements and accompanying notes. Actual results
         could differ from those estimates.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zVBXZzICS3m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zqhwr1AVKcd5"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is based
         on the first in, first out method. We regularly review inventory quantities on hand
         and write down to its net realizable value any inventory that we believe to be impaired.
         The determination of net realizable value requires judgment including consideration
         of many factors, such as estimates of future product demand, product net selling prices,
         current and future market conditions and potential product obsolescence, among others.
         The components of inventories are as follows:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B1_z2bAMFYUdLl3" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8A5_zTj1jCMRBNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Approximately $&lt;span id="xdx_90C_eus-gaap--InventoryNet_iI_pn3p0_c20221231_zYeYqrXpeO8a" title="Raw materials and supplies and finished goods inventory"&gt;106,000&lt;/span&gt; of raw materials and supplies and finished goods inventory
         at December&#160;31, 2022 were sold to Fedson under the Asset Purchase Agreement in September&#160;2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z91HH0nf1qB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zoO0xQFY0eZc"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We generate revenue principally from collaborative research and development arrangements,
         sales or licenses of technology and government grants. Consideration received for
         revenue arrangements with multiple components is allocated among the separate performance
         obligations based upon their relative estimated standalone selling price.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our
         obligations under our agreements, we perform the following steps for our revenue recognition:
         (i) identify contracts with customers; (ii) identify performance obligations; (iii)
         determine the transaction price; (iv) allocate the transaction price to the performance
         obligations; and (v) recognize of revenue when (or as) we satisfy each performance
         obligation.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department
         of Health and Human Services, or HHS, the Bill&amp;amp; Melinda Gates Foundation, and other
         government-sponsored organizations for research and development related activities
         that provide for payments for reimbursed costs, which may include overhead and general
         and administrative costs. We recognize revenue from these contracts as we perform
         services under these arrangements when the funding is committed. Associated expenses
         are recognized when incurred as research and development expenses. Revenues and related
         expenses are presented gross in the condensed statements of operations.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;A performance obligation is a promise in a contract to transfer a distinct good or
         service to the customer. Our performance obligations include commercialization license
         rights, development services and services associated with the regulatory approval
         process.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have optional additional items in contracts, which are accounted for as separate
         contracts when the customer elects such options. Arrangements that include a promise
         for future commercial product supply and optional research and development services
         at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide
         a material right to the customer and, if so, such material rights are accounted for
         as separate performance obligations. If we are entitled to additional payments when
         the customer exercises these options, any additional payments are recorded in revenue
         when the customer obtains control of the goods or services.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have both fixed and variable considerations. Non-refundable upfront payments are
         considered fixed, while milestone payments are identified as variable consideration
         when determining the transaction price. Funding of research and development activities
         is considered variable until such costs are reimbursed at which point, they are considered
         fixed. We allocate the total transaction price to each performance obligation based
         on the relative estimated standalone selling prices of the promised goods or services
         for each performance obligation.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;At the inception of each arrangement that includes milestone payments, we evaluate
         whether the milestones are considered probable of being achieved and estimate the
         amount to be included in the transaction price using the most likely amount method.
         If it is probable that a significant revenue reversal would not occur, the value of
         the associated milestone is included in the transaction price. Milestone payments
         that are not within our control, such as approvals from regulators, are not considered
         probable of being achieved until those approvals are received.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;For arrangements that include sales-based royalties or earn-out payments, including
         milestone payments based on the level of sales, and the license or purchase agreement
         is deemed to be the predominant item to which the royalties or earn-out payments relate,
         we recognize revenue at the later of (a) when the related sales occur, or (b) when
         the performance obligation to which some or all of the royalty or earn-out payment
         has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;As part of the accounting for these arrangements, we must develop assumptions that
         require judgment to determine the stand-alone selling price of each performance obligation
         identified in the contract. Estimated selling prices for license rights are calculated
         using the residual approach. For all other performance obligations, we use a cost-plus
         margin approach.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Significant management judgment is required to determine the level of effort required
         under an arrangement and the period over which we expect to complete our performance
         obligations under an arrangement. We estimate the performance period or measure of
         progress at the inception of the arrangement and re-evaluate it each reporting period.
         This re-evaluation may shorten or lengthen the period over which revenue is recognized.
         Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot
         reasonably estimate when our performance obligations either are completed or become
         inconsequential, then revenue recognition is deferred until we can reasonably make
         such estimates. Revenue is then recognized over the remaining estimated period of
         performance using the cumulative catch-up method. Revenue is recognized for licenses
         or sales of functional intellectual property at the point in time the customer can
         use and benefit from the license. For performance obligations that are services, revenue
         is recognized over time proportionate to the costs that we have incurred to perform
         the services using the cost-to-cost input method.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Contract Assets and Liabilities&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table presents the activity related to our accounts receivable for the
         nine months ended September&#160;30, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BA_zJunFJq2kcSf" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(In thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Deductions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Balance at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8A3_z52B391iNeVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyCqZguNny61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zKu78sT64TXg"&gt;Research and Development Costs and Related Accrual&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Research and development expenses include internal and external costs. Internal costs
         include salaries and employment related expenses, facility costs, administrative expenses
         and allocations of corporate costs. External expenses consist of costs associated
         with outsourced contract research organization (&#x201c;CRO&#x201d;) activities, sponsored research
         studies, product registration, and investigator sponsored trials. Significant judgments
         and estimates must be made and used in determining the accrued balance in any accounting
         period. Actual results could differ from those estimates under different assumptions.
         Revisions are charged to expense in the period in which the facts that give rise to
         the revision become known.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zw10ww79lmq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z99MMQQsVv4h"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We determine whether the arrangement is or contains a lease at inception. Operating
         lease right-of-use assets and lease liabilities are recognized at the present value
         of the future lease payments at commencement date. The interest rate implicit in lease
         contracts is typically not readily determinable, and therefore, we utilize our incremental
         borrowing rate, which is the rate incurred to borrow on a collateralized basis over
         a similar term an amount equal to the lease payments in a similar economic environment.
         Certain adjustments to the right-of-use asset may be required for items such as initial
         direct costs paid or incentives received.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating
         leases are recognized on our condensed balance sheets as right-of-use assets, operating
         lease liabilities current and operating lease liabilities non-current.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table presents the minimum lease payments of our operating lease:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Total minimum lease payments (base rent)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8AB_zXRT6AQ0IWud" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFedDUfImZA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z0bHIQxCJrj1"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In June&#160;2016, the
      FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses, which requires
      an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience,
      current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking
      information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January&#160;1,
      2023. The adoption of Topic 326 did not have a material impact on our condensed financial statements and disclosures.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Accounting Standards Not Yet Adopted&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In August&#160;2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates
         certain models that require separate accounting for embedded conversion features,
         in certain cases. Additionally, among other changes, the guidance eliminates certain
         of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if converted method for
         all convertible instruments in the diluted earnings per share calculation and include
         the effect of share settlement for instruments that may be settled in cash or shares,
         except for certain liability-classified share-based payment awards. This guidance
         is effective beginning after December&#160;15, 2023 and must be applied using either a modified or full retrospective approach.
         Early adoption is permitted. We are currently evaluating the impact this guidance
         will have on our condensed financial statements and related disclosures.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcmC12GHullh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z4UdCV7EIj1e"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities
         are carried at cost, and their fair values are approximated due to the short-term
         nature of these instruments. Our investments in money market funds are classified
         within Level 1 of the fair value hierarchy.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;At December&#160;31, 2022, the fair value of our investments in money market funds was approximately
         $&lt;span id="xdx_90C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zj4aCXB5y65h" title="Fair value of investments"&gt;2.6&lt;/span&gt; million which is included within our cash and cash equivalents in our condensed
         balance sheets. We had no investments in money market funds at September&#160;30, 2023.&lt;/p&gt;
      </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <ttnp:CompanyPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_846_ecustom--CompanyPolicyPolicyTextBlock_zLeoMA4DSHe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z2qHsneFQdha"&gt;The Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We are a pharmaceutical company developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura&lt;sup&gt;&#xae;&lt;/sup&gt;, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Our first product based on the ProNeura technology was Probuphine&lt;sup&gt;&#xae;&lt;/sup&gt; (buprenorphine implant), which is approved in the United States, Canada and the European
         Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable
         patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues
         to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that had either licensed or acquired the rights from Titan, we discontinued commercialization
         of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our
         commercial operations has allowed us to focus our limited resources on important product
         development programs and transition back to a product development company.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In December&#160;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, other business combination, sales of assets, licensing or other transaction.
         In June&#160;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&#160;2022, David Lazar and Activist Investing LLC (collectively, &#x201c;Activist&#x201d;) acquired an
         approximately &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DavidLazarAndActivistInvestingLlcMember_pdd" title="Ownership interest by Activist"&gt;25%&lt;/span&gt; ownership interest in Titan, filed a proxy statement and nominated
         six additional directors, each of whom was elected to our board of directors (the
         &#x201c;Board&#x201d;) at a special meeting of stockholders held on August&#160;15, 2022 (the &#x201c;Special Meeting&#x201d;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. Following the
         election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced
         as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer.
         In connection with the termination of his employment as Executive Chairman, Dr. Rubin
         will receive aggregate severance payments of approximately $&lt;span id="xdx_90D_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220801__20220815__srt--CounterpartyNameAxis__custom--RubinMember_zXKXT3GFaOZ4" title="Severance payments"&gt;0.4&lt;/span&gt; million, of which,
         approximately $&lt;span id="xdx_906_eus-gaap--SeveranceCosts1_pn3p0_c20230101__20230930_znHbsUs4svt5" title="Severance payments"&gt;247,000&lt;/span&gt; have been paid as of September&#160;30, 2023. In December&#160;2022, we implemented additional cost reduction measures including a reduction in our
         workforce.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In September&#160;2023, (the &#x201c;Closing Date&#x201d;), we closed on the sale of certain ProNeura assets including our portfolio of drug addiction products,
         in addition to other early development programs based on the ProNeura drug delivery
         technology (the &#x201c;ProNeura Assets&#x201d;). In July&#160;2023, &lt;span id="xdx_900_ecustom--AssetSaleDescriptions_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember_zz06Sh1xbTUk" title="Asset sale description"&gt;we entered into an asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;)
         with Fedson, Inc., a Delaware corporation (&#x201c;Fedson&#x201d;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#x201c;Amendment&#x201d;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#x201c;Cash Note&#x201d;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#x201c;Escrow Note&#x201d;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#x2019;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      </ttnp:CompanyPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-07-31_custom_DavidLazarAndActivistInvestingLlcMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-08-012022-08-15_custom_RubinMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">247000</us-gaap:SeveranceCosts1>
    <ttnp:AssetSaleDescriptions contextRef="From2023-09-012023-09-30_custom_ProNeuraMember">we entered into an asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;)
         with Fedson, Inc., a Delaware corporation (&#x201c;Fedson&#x201d;) for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine
         and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment and Extension Agreement (the &#x201c;Amendment&#x201d;) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#x201c;Cash Note&#x201d;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#x201c;Escrow Note&#x201d;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#x2019;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and payable on December&#160;1, 2023. The Cash Note and Escrow Note are included in Notes Receivable in the condensed balance sheet at September&#160;30, 2023.</ttnp:AssetSaleDescriptions>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6XMrSt2FfDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zHWyrJfCfZ7d"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance
         with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial
         information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information
         and footnotes required by GAAP for complete financial statement presentation. In the
         opinion of management, all adjustments (consisting of normal recurring adjustments)
         considered necessary for a fair presentation have been included. Operating results
         for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending
         December&#160;31, 2023, or any future interim periods.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The balance sheet as of December&#160;31, 2022 is derived from the audited financial statements at that date but does not
         include all the information and footnotes required by GAAP for complete financial
         statements. These unaudited condensed financial statements should be read in conjunction
         with the audited financial statements and footnotes thereto included in the Titan
         Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying condensed financial statements have been prepared assuming we will
         continue as a going concern.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;As of September&#160;30,
      2023, we had cash and cash equivalents of approximately $8.1
      million &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230930_zTuW97m8TUH4" style="display: none" title="Cash and cash equivalents"&gt;8,096&lt;/span&gt;, which we believe, will be sufficient to fund our planned operations through December of 2024. We continue to explore
      several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">8096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84C_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zbUao7Y1bYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zxqn8GlLGTCl"&gt;Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In October&#160;2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind
         down our commercialization activities, and to pursue a plan that will enable us to
         focus on our current, early-stage ProNeura-based product development programs.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying condensed financial statements have been recast for all periods presented
         to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization
         activities as discontinued operations (see Note 7). The accompanying condensed financial
         statements are generally presented in conformity with our historical format. We believe
         this format provides comparability with the previously filed financial statements.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <ttnp:GoingConcernAssessmentPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_840_ecustom--GoingConcernAssessmentPolicyTextBlock_z9YJr1ioPbGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zKHFBuOW8eZe"&gt;Going Concern Assessment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We assess going concern uncertainty in our financial statements to determine if we
         have sufficient cash on hand and working capital, including available borrowings on
         loans, to operate for a period of at least one year from the date the financial statements
         are issued, which is referred to as the &#x201c;look-forward period&#x201d; as defined by Accounting
         Standard Update ASU No. 2014-15. As part of this assessment, based on conditions that
         are known and reasonably knowable to us, we will consider various scenarios, forecasts,
         projections, estimates and will make certain key assumptions, including the timing
         and nature of projected cash expenditures or programs, and our ability to delay or
         curtail expenditures or programs, if necessary, among other factors. Based on this
         assessment, as necessary or applicable, we make certain assumptions around implementing
         curtailments or delays in the nature and timing of programs and expenditures to the
         extent we deem probable those implementations can be achieved and we have the proper
         authority to execute them within the look-forward period in accordance with ASU No.
         2014-15.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Based upon the above assessment, we concluded that, at the date of filing the condensed
         financial statements in this Quarterly Report on Form 10-Q for the nine months ended September&#160;30, 2023, we have sufficient cash to fund our operations for the next 12 months without additional
         funds. Additionally, we have suffered recurring losses from operations and have an accumulated
         deficit that raises substantial doubt about our ability to continue as a going concern beyond the next 12 months. We continue to explore several financing and strategic alternatives; however, there can be no assurance
         that our efforts will be successful.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </ttnp:GoingConcernAssessmentPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zgv8mh8HLin5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zyq8yLFBBmEl"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of financial statements in conformity with accounting principles generally
         accepted in the U.S. requires management to make estimates and assumptions that affect
         the amounts reported in the financial statements and accompanying notes. Actual results
         could differ from those estimates.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      </us-gaap:UseOfEstimates>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zVBXZzICS3m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zqhwr1AVKcd5"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is based
         on the first in, first out method. We regularly review inventory quantities on hand
         and write down to its net realizable value any inventory that we believe to be impaired.
         The determination of net realizable value requires judgment including consideration
         of many factors, such as estimates of future product demand, product net selling prices,
         current and future market conditions and potential product obsolescence, among others.
         The components of inventories are as follows:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B1_z2bAMFYUdLl3" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8A5_zTj1jCMRBNX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Approximately $&lt;span id="xdx_90C_eus-gaap--InventoryNet_iI_pn3p0_c20221231_zYeYqrXpeO8a" title="Raw materials and supplies and finished goods inventory"&gt;106,000&lt;/span&gt; of raw materials and supplies and finished goods inventory
         at December&#160;31, 2022 were sold to Fedson under the Asset Purchase Agreement in September&#160;2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_z2qhqe93ri14" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B1_z2bAMFYUdLl3" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_c20221231_pn3n3" style="width: 9%; text-align: right" title="Raw materials and supplies"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--InventoryFinishedGoodsNetOfReserves_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Finished goods"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InventoryNet_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total inventories"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">60000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">106000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">106000</us-gaap:InventoryNet>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z91HH0nf1qB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zoO0xQFY0eZc"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We generate revenue principally from collaborative research and development arrangements,
         sales or licenses of technology and government grants. Consideration received for
         revenue arrangements with multiple components is allocated among the separate performance
         obligations based upon their relative estimated standalone selling price.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our
         obligations under our agreements, we perform the following steps for our revenue recognition:
         (i) identify contracts with customers; (ii) identify performance obligations; (iii)
         determine the transaction price; (iv) allocate the transaction price to the performance
         obligations; and (v) recognize of revenue when (or as) we satisfy each performance
         obligation.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department
         of Health and Human Services, or HHS, the Bill&amp;amp; Melinda Gates Foundation, and other
         government-sponsored organizations for research and development related activities
         that provide for payments for reimbursed costs, which may include overhead and general
         and administrative costs. We recognize revenue from these contracts as we perform
         services under these arrangements when the funding is committed. Associated expenses
         are recognized when incurred as research and development expenses. Revenues and related
         expenses are presented gross in the condensed statements of operations.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;A performance obligation is a promise in a contract to transfer a distinct good or
         service to the customer. Our performance obligations include commercialization license
         rights, development services and services associated with the regulatory approval
         process.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have optional additional items in contracts, which are accounted for as separate
         contracts when the customer elects such options. Arrangements that include a promise
         for future commercial product supply and optional research and development services
         at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide
         a material right to the customer and, if so, such material rights are accounted for
         as separate performance obligations. If we are entitled to additional payments when
         the customer exercises these options, any additional payments are recorded in revenue
         when the customer obtains control of the goods or services.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have both fixed and variable considerations. Non-refundable upfront payments are
         considered fixed, while milestone payments are identified as variable consideration
         when determining the transaction price. Funding of research and development activities
         is considered variable until such costs are reimbursed at which point, they are considered
         fixed. We allocate the total transaction price to each performance obligation based
         on the relative estimated standalone selling prices of the promised goods or services
         for each performance obligation.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;At the inception of each arrangement that includes milestone payments, we evaluate
         whether the milestones are considered probable of being achieved and estimate the
         amount to be included in the transaction price using the most likely amount method.
         If it is probable that a significant revenue reversal would not occur, the value of
         the associated milestone is included in the transaction price. Milestone payments
         that are not within our control, such as approvals from regulators, are not considered
         probable of being achieved until those approvals are received.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;For arrangements that include sales-based royalties or earn-out payments, including
         milestone payments based on the level of sales, and the license or purchase agreement
         is deemed to be the predominant item to which the royalties or earn-out payments relate,
         we recognize revenue at the later of (a) when the related sales occur, or (b) when
         the performance obligation to which some or all of the royalty or earn-out payment
         has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;As part of the accounting for these arrangements, we must develop assumptions that
         require judgment to determine the stand-alone selling price of each performance obligation
         identified in the contract. Estimated selling prices for license rights are calculated
         using the residual approach. For all other performance obligations, we use a cost-plus
         margin approach.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Significant management judgment is required to determine the level of effort required
         under an arrangement and the period over which we expect to complete our performance
         obligations under an arrangement. We estimate the performance period or measure of
         progress at the inception of the arrangement and re-evaluate it each reporting period.
         This re-evaluation may shorten or lengthen the period over which revenue is recognized.
         Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot
         reasonably estimate when our performance obligations either are completed or become
         inconsequential, then revenue recognition is deferred until we can reasonably make
         such estimates. Revenue is then recognized over the remaining estimated period of
         performance using the cumulative catch-up method. Revenue is recognized for licenses
         or sales of functional intellectual property at the point in time the customer can
         use and benefit from the license. For performance obligations that are services, revenue
         is recognized over time proportionate to the costs that we have incurred to perform
         the services using the cost-to-cost input method.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Contract Assets and Liabilities&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table presents the activity related to our accounts receivable for the
         nine months ended September&#160;30, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BA_zJunFJq2kcSf" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(In thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Deductions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Balance at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8A3_z52B391iNeVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zEMftcbIGdEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8BA_zJunFJq2kcSf" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(In thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20230101__20230930_zKRWNLSUbWMf" style="width: 9%; text-align: right" title="Beginning Balance"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerAssetAdditions_c20230101__20230930_pn3n3" style="text-align: right" title="Additions"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Deductions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContractWithCustomerAssetDeductions_c20230101__20230930_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Balance at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20230101__20230930_zgaqH2Gj7r0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">36000</us-gaap:ContractWithCustomerAssetGross>
    <ttnp:ContractWithCustomerAssetAdditions
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">184000</ttnp:ContractWithCustomerAssetAdditions>
    <ttnp:ContractWithCustomerAssetDeductions
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-194000</ttnp:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">26000</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyCqZguNny61" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zKu78sT64TXg"&gt;Research and Development Costs and Related Accrual&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Research and development expenses include internal and external costs. Internal costs
         include salaries and employment related expenses, facility costs, administrative expenses
         and allocations of corporate costs. External expenses consist of costs associated
         with outsourced contract research organization (&#x201c;CRO&#x201d;) activities, sponsored research
         studies, product registration, and investigator sponsored trials. Significant judgments
         and estimates must be made and used in determining the accrued balance in any accounting
         period. Actual results could differ from those estimates under different assumptions.
         Revisions are charged to expense in the period in which the facts that give rise to
         the revision become known.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_zw10ww79lmq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z99MMQQsVv4h"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We determine whether the arrangement is or contains a lease at inception. Operating
         lease right-of-use assets and lease liabilities are recognized at the present value
         of the future lease payments at commencement date. The interest rate implicit in lease
         contracts is typically not readily determinable, and therefore, we utilize our incremental
         borrowing rate, which is the rate incurred to borrow on a collateralized basis over
         a similar term an amount equal to the lease payments in a similar economic environment.
         Certain adjustments to the right-of-use asset may be required for items such as initial
         direct costs paid or incentives received.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating
         leases are recognized on our condensed balance sheets as right-of-use assets, operating
         lease liabilities current and operating lease liabilities non-current.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table presents the minimum lease payments of our operating lease:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Total minimum lease payments (base rent)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8AB_zXRT6AQ0IWud" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zHBcSLQ52Wgb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BF_zMDMzYjcc9Kc" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz0EG_zb2d4edkwdm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz0EG_zIdYRzTDyeZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz0EG_zsPfLZY3fGL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Total minimum lease payments (base rent)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXvG8aEatbYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">33000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">99000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">97000</us-gaap:OperatingLeaseLiability>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFedDUfImZA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z0bHIQxCJrj1"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In June&#160;2016, the
      FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses, which requires
      an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience,
      current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking
      information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January&#160;1,
      2023. The adoption of Topic 326 did not have a material impact on our condensed financial statements and disclosures.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Accounting Standards Not Yet Adopted&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In August&#160;2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates
         certain models that require separate accounting for embedded conversion features,
         in certain cases. Additionally, among other changes, the guidance eliminates certain
         of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if converted method for
         all convertible instruments in the diluted earnings per share calculation and include
         the effect of share settlement for instruments that may be settled in cash or shares,
         except for certain liability-classified share-based payment awards. This guidance
         is effective beginning after December&#160;15, 2023 and must be applied using either a modified or full retrospective approach.
         Early adoption is permitted. We are currently evaluating the impact this guidance
         will have on our condensed financial statements and related disclosures.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zcmC12GHullh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z4UdCV7EIj1e"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities
         are carried at cost, and their fair values are approximated due to the short-term
         nature of these instruments. Our investments in money market funds are classified
         within Level 1 of the fair value hierarchy.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;At December&#160;31, 2022, the fair value of our investments in money market funds was approximately
         $&lt;span id="xdx_90C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zj4aCXB5y65h" title="Fair value of investments"&gt;2.6&lt;/span&gt; million which is included within our cash and cash equivalents in our condensed
         balance sheets. We had no investments in money market funds at September&#160;30, 2023.&lt;/p&gt;
      </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">2600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzed4J049NR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82F_z7c9Vn5tng6k"&gt;Stock Plans&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table summarizes option activity:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z5nnMVw8iJNd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B7_zYZvduR0ThPc" style="display: none"&gt;Schedule of our option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted
    Average&lt;br/&gt;Exercise Price&lt;br/&gt; per share&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted
    Average&lt;br/&gt;Remaining Option&lt;br/&gt;Term (in years)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Aggregate
    Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Outstanding at December&#160;31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930_z6Ie8JtpGro2" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;927&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zHUg2qVZL16" style="width: 9%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;7.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zdA3szvYYdP3" title="Weighted average remaining contractual term, outstanding (years)"&gt;8.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20230930_zdQX1r9aVlH8" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, option outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pn3n3_c20230101__20230930_zTSRuRX48Csl" style="text-align: right" title="Option granted"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zUOnt5Zelxo" style="text-align: right" title="Weighted average exercise price, granted"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AggregateIntrinsicValueOptionGranted_pn3n3_c20230101__20230930_z1iAYIBSGpp8" style="text-align: right" title="Aggregate Intrinsic Value, Option granted"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20230930_zzI37ciDhaPl" style="border-bottom: Black 1pt solid; text-align: right" title="Option forfeited or expired"&gt;(91&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zKwlQRNwRNoi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited or expired"&gt;23.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930_zPCkxjJ3EP04" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;2,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z0NTlHP4Ypn8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at outstanding at ending"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zKK5vz2MwD5k" title="Weighted average remaining contractual term, outstanding (years)"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20230930_zvC4ApkWn388" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, option outstanding at ending"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Exercisable at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930_z6ssVuKi8KR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Option exercisable"&gt;2,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zkAGJxJf3Iw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zBUFEZv4KYP4" title="Weighted average remaining contractual term, exercisable"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20230930_zNf2jzD0sHmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Option exercisable"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8AD_zCCEZ8lu8xPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;During August and September&#160;2022, our Board granted &lt;span id="xdx_900_ecustom--PurchaseCommonStock_pid_c20220801__20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zvhRumcIyoy5" title="Purchase common stock"&gt;125,000&lt;/span&gt; options to purchase common stock at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220831__us-gaap--PlanNameAxis__custom--Plan2015Member_zGXjRaO8k0Hf" title="Purchase price, per value"&gt;1.52&lt;/span&gt; per share
         and &lt;span id="xdx_909_ecustom--PurchaseCommonStock_pid_c20220901__20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zqginXpCouv8" title="Purchase common stock"&gt;900,000&lt;/span&gt; options to purchase common stock at $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--Plan2015Member_zGo7bdyUZ0tk" title="Purchase price, per value"&gt;1.31&lt;/span&gt; per share which are subject
         to shareholder approval of an amendment to increase the number of shares reserved
         for issuance under our 2015 Plan. The options vest monthly over a 12-month period
         from the grant dates. The shares underlying these options were approved by our stockholders
         on June&#160;29, 2023 and have been included in the table above as of September&#160;30, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In July&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan, an aggregate of &lt;span id="xdx_90A_ecustom--NumberOfCommonStockVested_pid_c20230701__20230731__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_z9ZDvy3uFPZf" title="NUmber of common stock vested"&gt;450,000&lt;/span&gt; shares of fully vested unrestricted common
         stock to seven members of the Board of Directors and one member of the management team. As a result,
         we recognized non-cash stock compensation of approximately $&lt;span id="xdx_90B_ecustom--NoncashStockCompensation_pn3n3_dm_c20230701__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zpXIcWTZlXx8" title="Non-cash stock compensation"&gt;0.2&lt;/span&gt; million during the three months ending September&#160;30, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table summarizes the stock-based compensation expense recorded for awards
         under our stock option plans (in thousands):&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zr9U5dxd6CCi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B4_zud6aGf22ZHk" style="display: none"&gt;Schedule of the stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;106&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;553&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;217&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;859&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;523&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p id="xdx_8A7_zRYi7s2xUi71" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We use the Black-Scholes-Merton option-pricing model with the following assumptions
         to estimate the fair value of our stock options:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zscu0XQscKq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B7_zaoc03bvrYFc" style="display: none"&gt;Schedule of assumptions to estimate the fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Weighted-average risk-free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230701__20230930_zpa7NInYESP" title="Weighted-average risk-free interest rate"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220701__20220930_zUQ3j6gyW6m7" title="Weighted-average risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230930_zFe2O8PODCsa" title="Weighted-average risk-free interest rate"&gt;4.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20220930_zctL4QeGORuh" title="Weighted-average risk-free interest rate"&gt;1.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected dividend payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230701__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220701__20220930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230101__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pn3n3_c20220101__20220930_zPfLS6KjNQB" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected holding period (years)&lt;sup&gt;1&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_fMQ_____zoEf2M7s073c" title="Expected holding period (years)"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_fMQ_____zm48SGG4Nhi9" title="Expected holding period (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_fMQ_____zZhsBAFFtto7" title="Expected holding period (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average volatility factor&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230701__20230930_fMg_____zpkQ7EmMkD1e" title="Weighted-average volatility factor"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220701__20220930_fMg_____zwsR6B0vI6Qj" title="Weighted-average volatility factor"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0761"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230101__20230930_fMg_____zS0oWeOz8tH7" title="Weighted-average volatility factor"&gt;1.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20220930_fMg_____zWSFhnUKHTaj" title="Weighted-average volatility factor"&gt;1.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Estimated forfeiture rates for options granted&lt;sup&gt;3&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230701__20230930_fMw_____zmt8b1hERogc" title="Estimated forfeiture rates for options granted"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220701__20220930_fMw_____zCBW9FUa2Ni1" title="Estimated forfeiture rates for options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230101__20230930_fMw_____zCO0v0ntbPbl" title="Estimated forfeiture rates for options granted"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20220930_fMw_____zTs9Swxouyke" title="Estimated forfeiture rates for options granted"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


      &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F08_z5kvmQbmxKp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;(1)&lt;/td&gt;
            &lt;td id="xdx_F17_zN4SDFeVBgXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F01_zDZIppNRIJS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;(2)&lt;/td&gt;
            &lt;td id="xdx_F1A_zHJEgIxAIpcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F04_zHzkEMlpoTCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;(3)&lt;/td&gt;
            &lt;td id="xdx_F10_zeMqbuVEBVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Estimated forfeiture rates are based on historical data.&lt;/td&gt;
         &lt;/tr&gt;
      &lt;/table&gt;
      &lt;p id="xdx_8A4_zGLiZvG85yR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;As of September&#160;30, 2023, there was &lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_do_c20230930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zX2JBv3aVJCa" title="Total unrecognized compensation expense related to non-vested stock option"&gt;no&lt;/span&gt; unrecognized compensation expense related to non-vested stock options.&lt;/p&gt;
      </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z5nnMVw8iJNd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B7_zYZvduR0ThPc" style="display: none"&gt;Schedule of our option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options&lt;br/&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted
    Average&lt;br/&gt;Exercise Price&lt;br/&gt; per share&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted
    Average&lt;br/&gt;Remaining Option&lt;br/&gt;Term (in years)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Aggregate
    Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Outstanding at December&#160;31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230930_z6Ie8JtpGro2" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;927&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230930_zHUg2qVZL16" style="width: 9%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;7.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zdA3szvYYdP3" title="Weighted average remaining contractual term, outstanding (years)"&gt;8.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20230930_zdQX1r9aVlH8" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, option outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pn3n3_c20230101__20230930_zTSRuRX48Csl" style="text-align: right" title="Option granted"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zUOnt5Zelxo" style="text-align: right" title="Weighted average exercise price, granted"&gt;0.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AggregateIntrinsicValueOptionGranted_pn3n3_c20230101__20230930_z1iAYIBSGpp8" style="text-align: right" title="Aggregate Intrinsic Value, Option granted"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20230930_zzI37ciDhaPl" style="border-bottom: Black 1pt solid; text-align: right" title="Option forfeited or expired"&gt;(91&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230930_zKwlQRNwRNoi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited or expired"&gt;23.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Outstanding at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230930_zPCkxjJ3EP04" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;2,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230930_z0NTlHP4Ypn8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at outstanding at ending"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zKK5vz2MwD5k" title="Weighted average remaining contractual term, outstanding (years)"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20230930_zvC4ApkWn388" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, option outstanding at ending"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Exercisable at September&#160;30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20230930_z6ssVuKi8KR9" style="border-bottom: Black 2.5pt double; text-align: right" title="Option exercisable"&gt;2,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230930_zkAGJxJf3Iw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zBUFEZv4KYP4" title="Weighted average remaining contractual term, exercisable"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20230930_zNf2jzD0sHmd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Option exercisable"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">927000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-09-30">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="Shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ttnp:AggregateIntrinsicValueOptionGranted
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">235000</ttnp:AggregateIntrinsicValueOptionGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="Shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">23.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-09-30" decimals="-3" unitRef="Shares">2311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-09-30">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-09-30" decimals="-3" unitRef="Shares">2311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-09-30">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">213000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ttnp:PurchaseCommonStock
      contextRef="From2022-08-012022-08-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">125000</ttnp:PurchaseCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.52</us-gaap:SharesIssuedPricePerShare>
    <ttnp:PurchaseCommonStock
      contextRef="From2022-09-012022-09-30_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">900000</ttnp:PurchaseCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-30_custom_Plan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.31</us-gaap:SharesIssuedPricePerShare>
    <ttnp:NumberOfCommonStockVested
      contextRef="From2023-07-012023-07-31_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">450000</ttnp:NumberOfCommonStockVested>
    <ttnp:NoncashStockCompensation
      contextRef="From2023-07-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember"
      decimals="-3"
      unitRef="USD">200000</ttnp:NoncashStockCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zr9U5dxd6CCi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B4_zud6aGf22ZHk" style="display: none"&gt;Schedule of the stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;106&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;553&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;217&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;859&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;523&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">52000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">859000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">414000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">411000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">523000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">967000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zscu0XQscKq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B7_zaoc03bvrYFc" style="display: none"&gt;Schedule of assumptions to estimate the fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Weighted-average risk-free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230701__20230930_zpa7NInYESP" title="Weighted-average risk-free interest rate"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220701__20220930_zUQ3j6gyW6m7" title="Weighted-average risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20230930_zFe2O8PODCsa" title="Weighted-average risk-free interest rate"&gt;4.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20220930_zctL4QeGORuh" title="Weighted-average risk-free interest rate"&gt;1.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected dividend payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230701__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220701__20220930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230101__20230930_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0749"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pn3n3_c20220101__20220930_zPfLS6KjNQB" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Expected holding period (years)&lt;sup&gt;1&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930_fMQ_____zoEf2M7s073c" title="Expected holding period (years)"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930_fMQ_____zm48SGG4Nhi9" title="Expected holding period (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930_fMQ_____zZhsBAFFtto7" title="Expected holding period (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average volatility factor&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230701__20230930_fMg_____zpkQ7EmMkD1e" title="Weighted-average volatility factor"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220701__20220930_fMg_____zwsR6B0vI6Qj" title="Weighted-average volatility factor"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0761"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20230101__20230930_fMg_____zS0oWeOz8tH7" title="Weighted-average volatility factor"&gt;1.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20220930_fMg_____zWSFhnUKHTaj" title="Weighted-average volatility factor"&gt;1.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Estimated forfeiture rates for options granted&lt;sup&gt;3&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230701__20230930_fMw_____zmt8b1hERogc" title="Estimated forfeiture rates for options granted"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220701__20220930_fMw_____zCBW9FUa2Ni1" title="Estimated forfeiture rates for options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20230101__20230930_fMw_____zCO0v0ntbPbl" title="Estimated forfeiture rates for options granted"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20220930_fMw_____zTs9Swxouyke" title="Estimated forfeiture rates for options granted"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


      &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F08_z5kvmQbmxKp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"&gt;(1)&lt;/td&gt;
            &lt;td id="xdx_F17_zN4SDFeVBgXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F01_zDZIppNRIJS9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;(2)&lt;/td&gt;
            &lt;td id="xdx_F1A_zHJEgIxAIpcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
            &lt;td id="xdx_F04_zHzkEMlpoTCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;(3)&lt;/td&gt;
            &lt;td id="xdx_F10_zeMqbuVEBVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: justify; vertical-align: middle"&gt;Estimated forfeiture rates are based on historical data.&lt;/td&gt;
         &lt;/tr&gt;
      &lt;/table&gt;
      </us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Pure">0.0408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Pure">0.0191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-07-012023-09-30" id="Fact000753">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-09-30" id="Fact000755">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30" id="Fact000757">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000759"
      unitRef="Pure">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      id="Fact000763"
      unitRef="Pure">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      id="Fact000765"
      unitRef="Pure">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000767"
      unitRef="Pure">0.075</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      id="Fact000771"
      unitRef="Pure">0.070</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      id="Fact000773"
      unitRef="Pure">0.056</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_z6JKFjf7Geml" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_825_zEc1WsT7mNPf"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The table below presents common shares underlying stock options and warrants that
         are excluded from the calculation of the weighted average number of common shares
         outstanding used for the calculation of diluted net loss per common share. These are
         excluded from the calculation due to their anti-dilutive effect:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zr6dK2aGu7pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B8_zwGI0Egyn9Of" style="display: none"&gt;Schedule of antidilutive securities excluded from computation of net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zT53y0SdXeVj" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;3,767&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBQMbdURpx6h" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrS28VUi2jaf" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z3xFARqviuT2" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z8uVfaOtoRY6" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zRQKKL1gap42" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zesGqAUUrgt8" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zpD8zvIfSrud" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhr832iv8Qgd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfSlWR0bMLa" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5mc1mkceIO" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzsb9L2C0tVd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zhqIUwEB4Ey" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;9,818&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znoxPeF2W8ml" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;4,933&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpQUgLVuR4Va" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;7,678&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWgOtDosQEz8" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;5,586&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zY5pk2y1O8vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;15,950&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zGIVQrWCfKV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;5,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_zgGZudZuej71" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;10,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_zt5hwIGHU76c" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;6,561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zr6dK2aGu7pg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&lt;span id="xdx_8B8_zwGI0Egyn9Of" style="display: none"&gt;Schedule of antidilutive securities excluded from computation of net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(in thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zT53y0SdXeVj" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;3,767&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zBQMbdURpx6h" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zrS28VUi2jaf" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z3xFARqviuT2" style="width: 9%; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z8uVfaOtoRY6" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zRQKKL1gap42" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zesGqAUUrgt8" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zpD8zvIfSrud" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhr832iv8Qgd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfSlWR0bMLa" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5mc1mkceIO" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;1,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzsb9L2C0tVd" style="text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zhqIUwEB4Ey" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;9,818&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znoxPeF2W8ml" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;4,933&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpQUgLVuR4Va" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;7,678&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWgOtDosQEz8" style="border-bottom: Black 1pt solid; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;5,586&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zY5pk2y1O8vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;15,950&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zGIVQrWCfKV5" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;5,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_zgGZudZuej71" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;10,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_zt5hwIGHU76c" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount of weighted-average anti-dilutive common shares"&gt;6,561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">3767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1269</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_ConvertibleNotesMember"
      decimals="INF"
      unitRef="Shares">504</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_ConvertibleNotesMember"
      decimals="INF"
      unitRef="Shares">170</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">9818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4933</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">7678</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">5586</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">15950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">5865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">10358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">6561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ttnp:AssetPurchaseAgreementTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80B_ecustom--AssetPurchaseAgreementTextBlock_zE64lpeKcwo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_825_z7Oe00vghNUl"&gt;JT Pharmaceuticals Asset Purchase Agreement&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In October&#160;2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals,
         Inc., or JT Pharma, to acquire JT Pharma&#x2019;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with
         our ProNeura long-term, continuous drug delivery technology, for the treatment of
         chronic pruritus and other medical conditions. Under the terms of the JT Agreement,
         JT Pharma received a $&lt;span id="xdx_901_ecustom--FutureMilestonePayments_pn3p0_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zfcPJZzbvD0b" title="Closing payment"&gt;15,000&lt;/span&gt; closing payment and is entitled to receive future milestone
         payments, payable in cash or in stock, based on the achievement of certain developmental
         and regulatory milestones, and single-digit percentage earn-out payments on net sales
         of the product if successfully developed and approved for commercialization. In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $&lt;span id="xdx_90C_ecustom--MilestonePayments_pn3p0_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zvtvmV3AKL3g" title="Milestone Payments"&gt;100,000&lt;/span&gt; and issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zut7iQy2Xe28" title="Issuance of common stock, net (in shares)"&gt;51,021&lt;/span&gt;
         shares of our common stock to JT Pharma. The related expense was included in research
         and development expenses in our condensed statements of operations.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</ttnp:AssetPurchaseAgreementTextBlock>
    <ttnp:FutureMilestonePayments
      contextRef="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">15000</ttnp:FutureMilestonePayments>
    <ttnp:MilestonePayments
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">100000</ttnp:MilestonePayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="INF"
      unitRef="Shares">51021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zo6G9s8X9cQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82E_z0ONGqpE1A89"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Lease Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We lease our office facility under an operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $&lt;span id="xdx_907_ecustom--OperatingLeasesRentExpenses_c20230701__20230930_pn3p0" title="Rent expense"&gt;32,000&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--OperatingLeasesRentExpenses_c20230101__20230930_pn3p0" title="Rent expense"&gt;96,000&lt;/span&gt; for the three and nine months ended September&#160;30, 2023, respectively.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;A legal proceeding has been initiated by a former employee alleging wrongful termination,
         retaliation, infliction of emotional distress, negligent supervision, hiring and retention
         and slander. An independent investigation into this individual&#x2019;s allegations of whistleblower retaliation, while still an employee, was conducted
         utilizing an outside investigator and concluded that such allegations were not substantiated.
         Fedson, as further consideration for the Asset Purchase Agreement, has agreed to assume
         all liabilities related to this pending employment claim (See Note 8. Asset Sale).&lt;/p&gt;
      </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ttnp:OperatingLeasesRentExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">32000</ttnp:OperatingLeasesRentExpenses>
    <ttnp:OperatingLeasesRentExpenses
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">96000</ttnp:OperatingLeasesRentExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyiSJUdjzlYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_824_zDADuDoPjQZf"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Our common stock outstanding as of September&#160;30, 2023 and December&#160;31, 2022 was &lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_zSmejc0FF3Df" title="Common stock shares, outstanding"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zu98KW71MEO4" title="Common stock shares, outstanding"&gt;15,016,295&lt;/span&gt;&lt;/span&gt; shares.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Annual Meeting of Stockholders&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In June&#160;2023, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan
         to increase the number of authorized shares to &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230930__us-gaap--PlanNameAxis__custom--N2015OmnibusEquityIncentivePlanMember_zfDyL7C2eMpd" title="Number of shares agreed to issue"&gt;2,500,000&lt;/span&gt; shares.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;September&#160;2023 Preferred Stock&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In September&#160;2023, we entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with
         The Sire Group Ltd. (&#x201c;Sire Group&#x201d; or the &#x201c;Investor&#x201d;), pursuant to which we agreed
         to issue &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20230930_zsJqRX54Xa9k" title="Preferred stock, shares issued"&gt;950,000&lt;/span&gt; shares of Series AA Convertible Preferred Stock, par value $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930_zZje7QVEvyma" title="Preferred stock, par value (in dollars per share)"&gt;0.001&lt;/span&gt;
         per share (the &#x201c;Series AA Preferred Stock&#x201d;) to the Investor at a price of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230930_zY1dfd7GBdXb" title="Share price"&gt;10.00&lt;/span&gt; per
         share, for an aggregate purchase price of $&lt;span id="xdx_904_ecustom--PurchasePrice_pn3n3_dm_c20230101__20230930_zseXorHTJzti" title="Purchase price"&gt;9.5&lt;/span&gt; million (the &#x201c;Private Placement&#x201d;). The purchase price consisted of (i) $5.0 million in cash
         at closing and (ii) $4.5 million in the form of a promissory note from Sire Group
         which was paid off in September&#160;2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Each share of Series AA Preferred Stock will be convertible, at the holder&#x2019;s option at any time, into shares of our common stock at a conversion rate equal to the quotient of (i) the stated value of
         such share divided by (ii) the initial conversion price of $0.466, subject to specified
         adjustments as set forth in the Certificate of Designations. The Series AA Preferred
         Stock contains limitations that prevent the Investor from acquiring the lower of either
         (i) the maximum percentage of common stock permissible under the rules and regulations
         of The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) without first obtaining shareholder approval or (ii) 19.99% of our outstanding common
         stock.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The holder of the Series AA Preferred Stock is entitled to receive dividends on shares
         of the Series AA Preferred Stock equal (on an as-if-converted-to-common-stock basis)
         to and in the same form as dividends actually paid on shares of the common stock.
         No other dividends will be paid on shares of the Series AA Preferred Stock. Any shares
         of Series AA Preferred Stock may, at the option of the holder, be converted at any
         time into that number of shares of common stock at the conversion price set forth
         above. Without approval of holders of a majority of the outstanding Series AA Preferred
         Stock, we may not (a) alter or adversely change the powers, preferences or rights
         given to the Series AA Preferred Stock, (b) amend its certificate of incorporation
         or other charter documents in any manner that adversely affects any rights of the
         holders of the Series AA Preferred Stock, (c) increase the number of authorized shares
         of the Series AA Preferred Stock, (d) enter into or consummate any Fundamental Transaction
         (as defined in the Certificate of Designations), or (e) enter into any agreement with
         respect to any of the foregoing. In the event of any liquidation, dissolution or winding
         up, the holder of the Series AA Preferred Stock will be entitled to receive out of
         the assets, whether capital or surplus, the same amount that a holder of common stock
         would receive if the Series AA Preferred Stock were fully converted to common stock,
         which amounts shall be paid &lt;i&gt;pari passu&lt;/i&gt; with all holders of common stock.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;February&#160;2022 Offerings&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In February&#160;2022, we completed a registered direct offering with an accredited investor pursuant
         to which we issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zHLC9jI8xC3f" title="Issuance of common stock, net (in shares)"&gt;1,100,000&lt;/span&gt; shares of our common stock and &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zcyIRoPxayWi" title="Number of warrants issued"&gt;2,274,242&lt;/span&gt;
         pre-funded warrants to purchase shares of our common stock, with an exercise price
         of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zIfLyefPZ8rl" title="Exercise price of warrants (in dollars per share)"&gt;0.001&lt;/span&gt; per share. In a concurrent private placement, we sold unregistered pre-funded
         warrants to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zpU7djWdqoH4" title="Number of warrants issued"&gt;1,289,796&lt;/span&gt; shares of common stock with an exercise
         price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z4A56AkdgVZf" title="Exercise price of warrants (in dollars per share)"&gt;0.001&lt;/span&gt; per share and issued unregistered five year and six month warrants
         to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zPV8UXWjLDhf" title="Number of warrants issued"&gt;4,664,038&lt;/span&gt; shares of common stock with an exercise price
         of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zbO5HGRD1uk8" title="Exercise price of warrants (in dollars per share)"&gt;1.14&lt;/span&gt;. The net cash proceeds from these offerings were approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zB0FEOBrdNe6" title="Proceeds from sale of common stock"&gt;5.0&lt;/span&gt; million
         after deduction of underwriting fees and other offering expenses.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Warrant Exercises&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In March&#160;2022, we received approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zIzA1MnKDUcj" title="Proceeds from warrant exercises"&gt;1,000&lt;/span&gt; from the exercise of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z9X29bKolA87" title="Number of warrants issued"&gt;974,242&lt;/span&gt; pre-funded warrants
         issued in the February&#160;2022 registered direct offering.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;JT Pharma Milestone&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In January&#160;2022, we entered into an agreement with JT Pharma to clarify certain provisions of
         the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided
         for in the JT Agreement was achieved and made a payment of $&lt;span id="xdx_906_ecustom--MilestonePayment_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zGTbrA1eDmP4" title="Milestone payment"&gt;100,000&lt;/span&gt; and issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zG6NAJ567Hw7" title="Issuance of common stock, net (in shares)"&gt;51,021&lt;/span&gt;
         shares of our common stock to JT Pharma.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Restricted Shares&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In August&#160;2021, we agreed to issue &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zBB2V1qVHb24" title="Number of shares agreed to issue"&gt;50,000&lt;/span&gt; shares of our common stock pursuant to a restricted
         stock agreement with Maxim Partners, LLC in connection with the entry into an amendment
         to our existing advisory agreement. The shares vested monthly over &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zrc4LFyglzYj" title="Vesting period"&gt;12&lt;/span&gt; months. We recorded
         approximately $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zz8DTeAwAhF3" title="Stock-based compensation"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zdfvPeCO6zV1" title="Stock-based compensation"&gt;54,000&lt;/span&gt; of stock-based compensation expense during the three
         and nine months ended September&#160;30, 2022, respectively.&lt;/p&gt;
      </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-09-30_custom_N2015OmnibusEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">950000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <ttnp:PurchasePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">9500000</ttnp:PurchasePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">2274242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">1289796</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">4664038</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember"
      decimals="-3"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-03-012022-03-31_custom_PreFundedWarrantsMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-06-30_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">974242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ttnp:MilestonePayment
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">100000000</ttnp:MilestonePayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="INF"
      unitRef="Shares">51021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember"
      decimals="-3"
      unitRef="USD">27000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember"
      decimals="-3"
      unitRef="USD">54000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80E_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zykkeYiQ52s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_822_zBdiKt5KvhZi"&gt;Discontinued Operations&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The following table presents information related to assets and liabilities reported
         as discontinued operations in our condensed balance sheets:&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zteT5bqhh3T9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;span id="xdx_8BF_z1WwZLuzypm" style="display: none"&gt;Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230930_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20221231_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(In thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pn3n3_maAODGIzGqL_z4M9TA2Moit" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzGqL_zEcaCDBqtcob" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzGqL_zY8IKu8PXB2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Discontinued operations &#x2013; current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIzKdM_zNTLskm0GqLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzKdM_zCMMFjC6G4Pe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Discontinued operations &#x2013; current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

      </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2023-01-01to2023-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zteT5bqhh3T9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;span id="xdx_8BF_z1WwZLuzypm" style="display: none"&gt;Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20230930_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20221231_us-gaap--DisposalGroupClassificationAxis_us-gaap--SegmentDiscontinuedOperationsMember_us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_custom--U.s.CommercializationActivitiesMember" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-style: italic; text-align: left"&gt;(In thousands)&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pn3n3_maAODGIzGqL_z4M9TA2Moit" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzGqL_zEcaCDBqtcob" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzGqL_zY8IKu8PXB2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Discontinued operations &#x2013; current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIzKdM_zNTLskm0GqLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIzKdM_zCMMFjC6G4Pe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Discontinued operations &#x2013; current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">14000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">14000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">129000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">129000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ttnp:AssetsHeldForSaleTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_800_ecustom--AssetsHeldForSaleTextBlock_zyJ19nGPjIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_826_zlpEru4H2yn4"&gt;Asset Sale&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In September&#160;2023, we closed on the sale of certain ProNeura Assets. In July&#160;2023, &lt;span id="xdx_906_ecustom--AssetSaleDescription_c20230901__20230930__srt--CounterpartyNameAxis__custom--ProNeuraMember" title="Asset sale description"&gt;we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#x201c;Cash Note&#x201d;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#x201c;Escrow Note&#x201d;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#x2019;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</ttnp:AssetsHeldForSaleTextBlock>
    <ttnp:AssetSaleDescription contextRef="From2023-09-012023-09-30_custom_ProNeuraMember">we entered into an Asset Purchase Agreement with Fedson for the sale of the ProNeura Assets. The ProNeura Assets constituted only a portion of our assets. In August&#160;2023, we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million,
         consisting of (i) $500,000 in readily available funds, paid in full on the Closing
         Date, (ii) $500,000 in the form of a promissory note due and payable on October&#160;1, 2023 (the &#x201c;Cash Note&#x201d;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&#160;1, 2024 (the &#x201c;Escrow Note&#x201d;). We will also be eligible to receive potential milestone payments of up to $50 million
         on future net sales of the products and certain royalties on future net sales of the
         products. As further consideration, Fedson assumed all liabilities related to a pending
         employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson
         of all of Fedson&#x2019;s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions,
         which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November&#160;1, 2023 and again to December&#160;1, 2023 upon payment of $5,000 for each extension. The Cash Note is currently due and
         payable on December&#160;1, 2023.</ttnp:AssetSaleDescription>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zc5EW5TUCla9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_829_zeMJPa9Sc5Y4"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;During the nine months ended September&#160;30, 2023, we made payments related to legal fees of approximately $&lt;span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zNu5n9Yes3Ik" title="Payment of legal fees"&gt;100,000&lt;/span&gt; to a law firm operated by one of our Board members.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In August&#160;2023, we received $&lt;span id="xdx_90D_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zm3JGMJPDUF6" title="Proceeds from promissory note"&gt;500,000&lt;/span&gt; in funding in exchange for the issuance of a convertible
         promissory note for that principal amount to Choong Choon Hau, a major stockholder
         (the &#x201c;Hau Promissory Note&#x201d;). Pursuant to the Hau Promissory Note, the principal amount
         will accrue interest at a rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230801__20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember" title="Interest accrued rate"&gt;10% per annum&lt;/span&gt; and will be payable monthly. All principal
         and accrued interest shall be due and payable on January&#160;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our common stock at a conversion price of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230831__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zugrgQc4gGF4" title="Conversion price"&gt;0.5712&lt;/span&gt; per share from time to time following the issuance date and ending on the maturity
         date. We incurred interest expense of approximately $&lt;span id="xdx_90E_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--HauPromissoryNoteMember_zfnyBhUqCEM3" title="Interest expense"&gt;7,500&lt;/span&gt; during the three months ended September&#160;30, 2023 on this promissory note. The Hau Promissory note is included in Notes Payable to Related Party in the condensed
         balance sheet at September&#160;30, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In July&#160;2023, we received $&lt;span id="xdx_905_ecustom--ProceedsFromPromissoryNote_pn3n3_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zWojagLkkzB3" title="Proceeds from promissory note"&gt;250,000&lt;/span&gt; in funding in exchange for the issuance of an unsecured
         promissory note for that principal amount to David E. Lazar, our Chief Executive Officer
         and chairman of our Board of Directors (the &#x201c;Lazar Promissory Note&#x201d;). Pursuant to
         the Lazar Promissory Note, the principal amount accrued interest at a rate of the
         &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20230701__20230731__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember" title="Interest accrued rate"&gt;Prime Rate + 2.00% per annum&lt;/span&gt;, and all principal and accrued interest would have been
         due and payable on the earlier of January&#160;1, 2024 or such time as we receive debt or equity financing or proceeds in excess of
         $500,000 from the aforementioned transaction with Fedson. The promissory note was paid off in September&#160;2023. We incurred interest expense of approximately $&lt;span id="xdx_90A_eus-gaap--InterestExpense_pn3n3_c20230701__20230930__us-gaap--LongtermDebtTypeAxis__custom--LazarPromissoryNoteMember_zYtyjqRoWyS4" title="Interest expense"&gt;3,718&lt;/span&gt; during the three months ended September&#160;30, 2023 on this promissory note.&lt;/p&gt;
      </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">100000000</us-gaap:LegalFees>
    <ttnp:ProceedsFromPromissoryNote
      contextRef="From2023-08-012023-08-31_custom_HauPromissoryNoteMember"
      decimals="-3"
      unitRef="USD">500000000</ttnp:ProceedsFromPromissoryNote>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="From2023-08-012023-08-31_custom_HauPromissoryNoteMember">10% per annum</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-08-31_custom_HauPromissoryNoteMember"
      decimals="INF"
      unitRef="USDPShares">0.5712</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30_custom_HauPromissoryNoteMember"
      decimals="-3"
      unitRef="USD">7500000</us-gaap:InterestExpense>
    <ttnp:ProceedsFromPromissoryNote
      contextRef="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember"
      decimals="-3"
      unitRef="USD">250000000</ttnp:ProceedsFromPromissoryNote>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="From2023-07-012023-07-31_custom_LazarPromissoryNoteMember">Prime Rate + 2.00% per annum</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30_custom_LazarPromissoryNoteMember"
      decimals="-3"
      unitRef="USD">3718000</us-gaap:InterestExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zsT4RXxL1O74" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82D_z9UUaOOH2vJd"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;We have evaluated events that have occurred after September&#160;30, 2023 and through the date that our condensed financial statements are issued.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In September&#160;2023, our Board granted, pursuant to our Fifth Amended and Restated 2015 Omnibus Equity
         Incentive Plan (the &#x201c;2015 Plan&#x201d;) an aggregate of &lt;span id="xdx_90E_ecustom--UnrestrictedCommonStockVested_pid_c20230901__20230930__us-gaap--PlanNameAxis__custom--FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember_zfxZD9ileSfl" title="Unrestricted common stock vested"&gt;113,750&lt;/span&gt; shares of fully vested unrestricted common stock to six members
         of the Board of Directors and one member of the management team. The Board conditioned the grant on the filing of a Form S-8 registration statement
         to register the common shares authorized for issuance under the 2015 Plan, which occurred
         on October&#160;25, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In October&#160;2023, Fedson exercised the provision for a second extension of the maturity date of
         the Cash Note in exchange for a cash payment of $&lt;span id="xdx_907_ecustom--CashPayment_pn3n3_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--CashNoteMember_z69qdWTGVslf" title="Cash payment"&gt;5,000&lt;/span&gt;. The Cash Note is currently due and payable on December&#160;1, 2023.&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;In October&#160;2023, we agreed to issue &lt;span id="xdx_90F_ecustom--CommonStockIssuedForSettlementAgreement_pid_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--MDMWorldwideSolutionsMember_zZKSuMqzoEX4" title="Common stock issued for settlement agreement"&gt;50,000&lt;/span&gt; shares of our common stock pursuant to a settlement agreement with MDM Worldwide Solutions, Inc. The shares vested immediately. &lt;/p&gt;
      </us-gaap:SubsequentEventsTextBlock>
    <ttnp:UnrestrictedCommonStockVested
      contextRef="From2023-09-012023-09-30_custom_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">113750</ttnp:UnrestrictedCommonStockVested>
    <ttnp:CashPayment
      contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_CashNoteMember"
      decimals="-3"
      unitRef="USD">5000000</ttnp:CashPayment>
    <ttnp:CommonStockIssuedForSettlementAgreement
      contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember"
      decimals="INF"
      unitRef="Shares">50000</ttnp:CommonStockIssuedForSettlementAgreement>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000753"
          xlink:label="Fact000753"
          xlink:type="locator"/>
        <link:footnote id="Footnote000774" xlink:label="Footnote000774" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected holding period is based on historical experience of similar awards, giving
               consideration to the contractual terms of the stock-based awards, vesting schedules
               and the expectations of future employee behavior.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000753"
          xlink:to="Footnote000774"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000755"
          xlink:label="Fact000755"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000755"
          xlink:to="Footnote000774"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000757"
          xlink:label="Fact000757"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000757"
          xlink:to="Footnote000774"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000759"
          xlink:label="Fact000759"
          xlink:type="locator"/>
        <link:footnote id="Footnote000775" xlink:label="Footnote000775" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Weighted average volatility is based on the historical volatility of our common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000759"
          xlink:to="Footnote000775"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0761"
          xlink:label="xdx2ixbrl0761"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0761"
          xlink:to="Footnote000775"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000763"
          xlink:label="Fact000763"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000763"
          xlink:to="Footnote000775"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000765"
          xlink:label="Fact000765"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000765"
          xlink:to="Footnote000775"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000767"
          xlink:label="Fact000767"
          xlink:type="locator"/>
        <link:footnote id="Footnote000776" xlink:label="Footnote000776" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Estimated forfeiture rates are based on historical data.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000767"
          xlink:to="Footnote000776"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0769"
          xlink:label="xdx2ixbrl0769"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0769"
          xlink:to="Footnote000776"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000771"
          xlink:label="Fact000771"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000771"
          xlink:to="Footnote000776"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000773"
          xlink:label="Fact000773"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000773"
          xlink:to="Footnote000776"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M]];_*)U7SMQC018L_8<F<G,U" <@(6M<I/(K>_Q$:H<FVE[,4E'^!X^UK#<
M<2$DRVIEA2"C>?6+?]6!:"G <8\"JA70<Q7\6L$O':V0E6XML<3S&6>/@&MI
M94U?E+$IM94W--?3N))<O:5*3\X77VZ7-[>KFR7X>/WG]>WB!JP^W=Q\6X'W
MWW-<)%22Y ,X ]]72_#^[0?P%M <?-NP0N \$;.15!"TH5%<#_>Q&@[U#+<B
MVW/@>T. /.1;U!=N]26)E3HLU=&Q^D@Y?O >';Q'I3V_S_N"<Y)+@(4@4ES8
M_*D,C.T&]"*[$%L<DZN!6D6"\!T9S-^]@8%W:?/NE8P=^>H??/5=UN<++#9
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M=\_[+%+0#WKV;W[3P?CN#L;@GS*'7^@ -$Y)+7L\BY1ECS=JG?/KCRQ_8?Y
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M ZX#U/,%8_*YH^\(U9W0_PM02P,$%     @ \8%N5\U?UW;;!0   "   !@
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM66MSFS@4_2L:;V>GG6D"$@_;
M6<<SB:'=SC2/B=/MAYW]H!C%9LK#1;*3_?<K'@$C+EHGY4L"^-PCG7LOT@%F
M3VGV@V\8$^@YCA)^/MH(L3TS#+[:L)CRTW3+$OG+8YK%5,C3;&WP;<9H4 3%
MD4%,TS5B&B:C^:RX=IO-9^E.1&'";C/$=W%,LW\O690^G8_PZ.7"7;C>B/R"
M,9]MZ9HMF?BVO<WDF5&S!&',$AZF"<K8X_GH I_YQ,D#"L1?(7OB!\<HE_*0
MIC_RDR_!^<C,9\0BMA(Y!97_]FS!HBAGDO/X69&.ZC'SP,/C%_9/A7@IYH%R
MMDBC[V$@-N>CR0@%[)'N(G&7/OW)*D'%!%=IQ(N_Z*G"FB.TVG&1QE6PG$$<
M)N5_^EPEXB! \L !I H@:H#=$V!5 =:Q(]A5@'WL"$X54$@W2NU%XCPJZ'R6
MI4\HR]&2+3\HLE]$RWR%2=XH2Y')7T,9)^:+FVO/OU[Z'EK>7]S[5_[U_1+=
M?$(WM_[=Q?V7F^LE>O\MH;L@%"SX@$[0MZ6'WK_[@/B&9HRC,$'WFW3':1+P
MC^A=ZWQF"#G#?!QC5<WFLIP-Z9F-A:[21&PX\I. !4"\IX^?:N(-F9DZ/>0E
M/9=$2[ADVU-DF1\1,8D%S&=Q?#B!Y/S:Z/Z;1V\EPZI[Q2KXK!Z^.[9GR8[Q
M,ZBP9:@-A^;+W1G?TA4['\GUC+-LST;SWW_#KOD'E-4AR;PAR?R!R%KYM^O\
MVSKV^7TJ:"17Y[(*4!'*>+>(S[>(_=R>&?O#S'814Z<-\;H0/%%H?& @RZTQ
M+75.K<[1=M?-EF54A,D:L6>Y#?*>/G.&[+,AR;PAR?R!R%J5<.M*N-H^NY.,
M-%MMD%S$Y::[EVYB*[V!@,I1,CF'C4#4GNMBIA91FJZ+P39QE:[K@BP+.W#;
MC6NQ8ZW8SRR1?1<56FD@=]B0B[P/]PR2.^Y.T[6QHA< 34Q%B]<%V=A4;S,
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MT_4#.-GM.G&LT_Z@Q7G+VJ&?MN\E6U">(/;#;%Q6KCUA-HN' BJ;.WL4UQG
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M ^#WJ8#B6IV8&VR^W!G_#U!+ P04    " #Q@6Y7 !(G_9T9   ?1@  &
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M>(>]/7CR#B/H&F]QNEMY*#%G*EVY>F=\C:VN=O/EA-#0$Y@YQS5TUR2)X:X
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MIT<A+!MZA=&R -U7AD@/&S9P>M>7_P!02P,$%     @ \8%N5Y)7.$.5!P
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MLS>BC'=S?[=@&ZS/9VF6GZ3%?,:NE.IXS3Y D@1&2 ,>[+UB?W1*>, 4QYI
MH'_,V];H.U'A+,:1_17^.^8T<VO:D\_8QT;)16=[2]ZK$BN0VJRMN4JP4JH2
M]<D*OT5UGBQ8\,ZMM9'_!;9=<P2/4(MTEF5IEF4#<[VIUZ@.PA@L]NR)]OZ*
ME&T$P\F"UD@%+(X596>DD\"^[DRY)A)7*R.$-^* ^% <BNSESX_]@_SE(0J
M6R>?L?1&&L%^-[IKV3]<-68'<>_N?MS#M&$#[/?J3L"GID=,6=L9V_'@Q\U:
MEFOBSNGDRCO,VDZP^2PX(AMG6<YR^F#S\8R]Y5CO/1948<B\JZN?/+21=<T6
M K+"^<;)12U2QIUG%J(;-0AUM:$D.T3YGCE4^32X, 8&Y^@?!4J+(W;H"-S!
M_[<DM:B.VT[#]; 2VP_DH;\'33LPO.-U1_03VVV-J>2=1)UBBWNLCLNE0O2
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MFHU/9Z-0COL+IUO_.K_0SNG&?UT+N,#0 CQ?:NWZ"SI@^_O.Y?\ 4$L#!!0
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MK0<;K0>[Z/]W'KL1HV0(?Y?\@%")%0*N1.V%PYQ&P>$JX3J7SC)O#'E$X=
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M^Z7ZU(F5/;C@JCQ?V/DPMSR+)!4;+7+8HF3A,HZ<6RRE,&:#]Q=RY.O&);4
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MZ'W*$1,15^C(*RA?>P[M/+S@N['E9FA$Y+)U'[_&1Q+'P#2?,12W_J)%?/Z
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M-GWZY)[8]/"A;;;\DT^+IJ4HG?]$1X&Q>(&^QX6[\ $3Q!\!>_E_4$L#!!0
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MXHML@BNB]&*F1]EAL%I0K$V1%U;O@ LPA6PT$[D^=/EC/]'SJ'?G*A;S(_:
MBAJ0TW#4B=CFHZG_:*ISRITG(8*"#*=" 3J0)2I%%*E:LWN(_6$ZA"/H^U$Z
MAJ-_MH^0AAR2<&"QA^$;D65M;T$3RU':AW$<6;X#&@V3-^&NF5+DKF'LC_HC
M&/CC.(:AGPY'D/C)*.WU$W^<A&2,T@3ZH1\G(TC]A$CLJIE@J[55J%:N@6NB
MT C3=KENMGLC3MO6^.S>/C"73*TX*2YQ2:'A\3#Q0+5-NS6,K%VC7$A#;=<-
M"WKG4%D'6E]*NH&-83?H7L[9'U!+ P04    " #Q@6Y7IL9UT;8"  "3!@
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M[8"R"W ^D](\=6QEZW]D\6]02P,$%     @ \8%N5YL#@/U] @  (@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA57?;],P$/Y7K#"A38(E3=MT
M&VFD=F6"AXEJ9?" >'"32V+-L8/MM(._'O](0V%I>&E\]MWW?7?V7>,]%T^R
M!%#HN:),SKU2J?K&]V5:0H7E):^!Z9.<BPHK;8K"E[4 G-F@BOIA$$1^A0GS
MDMCNK442\T91PF MD&RJ"HN?2Z!\/_=&WF'C@12E,AM^$M>X@ VHQWHMM.5W
M*!FI@$G"&1*0S[W%Z&8Y,_[6X0N!O3Q:(Y/)EO,G8WS,YEY@! &%5!D$K#\[
MN 5*#9"6\:/%]#I*$WB\/J#?V=QU+ELLX9;3KR13Y=R[\E &.6ZH>N#[#]#F
M,S5X*:?2_J)]ZQMX*&VDXE4;K!54A+DO?F[K<!00AB<"PC8@M+H=D56YP@HG
ML>![)(RW1C,+FZJ-UN((,Y>R44*?$AVGDD^BP(S\PJY$+$,;=SN(YVA#"D9R
MDF*FT")-><,4805:<TI2 A*=KT!A0B4:7: S1!CZ7/)&:A 9^TIK,PQ^VNI8
M.AWA"1W7Z)XS54KTGF60_1WOZYRZQ,)#8LMP$' #]24:!V]0&(1C]+A9H?.S
MBP'<<5>PL<4=G\#M*\2WQ58JH1_8][[$'=ZD'\\TW8VL<0IS3W>5!+$#+WG]
M:A0%[P;43CJUDR'T9 D%8<R(76**60I] AU$9"%,$^^2<13[NQ[::4<[':1=
M9!DQ+ZKW(;C0Z1'=Z&K2SQ=U?-$@WPJR)CU)&+T@?#NZ/L$XZQAG@XSZF?ZG
MJK,750W_K:I_U+<5B,).)XGL W,MW.UV W#A^OZ/NYN>]UCHFY:(0JY#@\N9
M3E>XB>0,Q6L[!;9<Z9EBEZ4>XB",@S[/.5<'PQ!T?PO);U!+ P04    " #Q
M@6Y7OVUY?H<"   N!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R-
M56UOTS 0_BM6F- FP9*E;<I*&VEC0B"!J-8-/B ^N,FEL>;8P;ZT&[^>LY-%
MA66%+XW?GI>S[Z[SG39WM@1 =E])91=!B5C/PM!F)53<GNH:%.T4VE0<:6HV
MH:T-\-R#*AG&492$%1<J2.=^;6G2N6Y0"@5+PVQ35=P\7(+4NT5P%CPN7(M-
MB6XA3.<UW\ *\+9>&IJ%/4LN*E!6:,4,%(O@XFQV.77G_8&O G9V;\Q<)&NM
M[]SD8[X((F<()&3H&#A]MO .I'1$9.-GQQGTD@ZX/WYD?^]CIUC6W,([+;^)
M',M%\"9@.12\D7BM=Q^@BV?B^#(MK?]EN^YL%+"LL:BK#DP.*J':+[_O[F$/
M$,?/ .(.$'O?K9!W><61IW.C=\RXT\3F!CY4CR9S0KE'6:&A74$X3+^8#5?B
M%V^O2.5LU;X.TP5;B8T2A<BX0G:19;I1*-2&+;44F0#+CJ\ N9"6Q2?LB G%
M;DK=6"*Q\Q#)FU,(L\['9>LC?L;'"NI3-HI>L3B*1^QV=<6.CT[^I DIM#Z^
MN(\O]KRC9WB'?'^_6%LTE \_AGRV?.-A/E<C,UOS#!8!%8$%LX4@??GB+(G>
M'G [ZMV.#K&G+O@A3RTJ\2A79MMT1.>V TKC7FG\+Z7QD%*+FNPI)<FPTJ17
MFAQ4NM'(I4M=4345DT EQ&K^0(6-E$*NHJBX%9X,N9D\<7-^/NPFZ=TD!]U\
M FMG3%1U@Y!3SB+0*^*0=O)$^W4\K#WMM:?_<1/43PWW"=G>A11\+:1 RLPA
M&],G3W\^_<M&N%?^KI-^YF8CE"7^@D#1Z92",&UW:B>H:]\1UAJIO_AA20T=
MC#M ^X76^#AQ3:;_BTA_ U!+ P04    " #Q@6Y7ZE(@#]('  #S(P  &0
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M"[Q%*8@<U-TKI!>(.KJ&J%5_P5<V&!M1:W@;(=I-_01!_:H3^6_M1*^"W>2
MW]"-SFCIUH:A!$24C7Q21VO'5#X7E:?E6#G/AZGJ\WPF_42$_M<C40P;+>IU
MAIJ+(A_S\HWB:39:K;G2@UJVW.K1&(3Y0+_?<*Z.&V.@'+9G_P%02P,$%
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MB8'B/>.D:,#B"8JLK#_Q0W,0)P#!,PQP&H#3!WC/ -P&X+XT@]< O)=F\!N
M*MVL:U<'%V*.@RDE1T1EM&"3%^KT%5J<5U;*1EES*NYF L>#-2?Q/5KEN&3H
M30@<9SE#]EMTB3ZO0_3FU5OT"F4E^I22/<-EPJ8F%UDEUHR;#(LZ@_-,!A?=
MDI*G#$5E LD /CR/GYS!FZ+:MF3GL>2%<Y9P#=45<JT+Y%B.._ \RY?#G:%R
M?BU[]+^S=P[#;?5W%9_['%^**5PNQ%<M02O\75@ 1W-*<;D#>7V!H@?A2?*N
M4!\M<95QG&?_0G*!Y@79B^BO'P4E^L"A8-^&NJ/.[PWGESYXPRH<P\P01L>
M'L (7O]ACZQW0]+H) MUDD6:R#HB>JV(WCGVX!,1HB FO\J7&R5E3 HI&Y9F
M/"1*S3=2?/*WY!!XMCTU#Z=G_33&EQU[&A,^C9F,_&Y,-!0S;F,Z!?MMP?[9
M@N_$$6(:IZHI0SB(W[M*M6[3K>CK+10;H(,->9;Z9QM2)UFHDRS21-;19]3J
M,_K-KC+2*:).LE G6:2)K"/BN!5QK-E5:CZ_XQ@]4WD:XEJCGJD\C;'[,=%
M*M\=-I7KMM[KL_7^"2504;%LR7DBWK4RQBF6[[$OLI6SY#_;D3K)0IUDD2:R
MCD*35J');[:5B4X1=9*%.LDB360=$6WKQ\AA:3:6AO#T'<+U)SUK&0AR[''/
M6P:"KOM,T4"09WL]=S%/AJX"Z$Y-NTR4(OJL?O]N=]N)>J[FR-[^PKY9V@/[
MH9S U9#W@[X>WV\QW65B8,MA*U)95V/A@[2>B.L%)Y4:^3:$BP%27:: $Z R
M0-S?$L(?%S)!^W^)X#]02P,$%     @ \8%N5^;A]+99!   1A   !D   !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&ULK5C=;^(X$'^_OV*4.YVZTI9\\%'@
M *DMH+N'E:JM=O>AN@>7#,1J$N=L ^6_O[$3LH!,MMV%!W <SV]F?F//>!AM
MA7Q1":*&URS-U=A+M"Z&OJ\6"69,M42!.;U9"IDQ38]RY:M"(HNM4);Z41#T
M_(SQW)N,[-R#G(S$6J<\QP<):IUE3.[N,!7;L1=Z^XG/?)5H,^%/1@5;X2/J
M+\6#I">_1HEYAKGB(@>)R[%W&P[G86 $[(JO'+?J8 S&E6<A7LS#/_'8"XQ%
MF.)"&PA&/QN\QS0U2&3'?Q6H5^LT@H?C/?K<.D_./#.%]R+]QF.=C+V^!S$N
MV3K5G\7V;ZP<ZAJ\A4B5_89MM3;P8+%66F25,%F0\;S\9:\5$0<"8?N,0%0)
M1"<"4?>,0+L2:)]JZ)P1Z%0"G;=JZ%8"W;<*]"J!GN6^),LR/66:3492;$&:
MU81F!C9<5IH(YKG968]:TEM.<GKRJ,7B!1Y2EBNXFJ)F/%40?8!K^/(XA:L_
M/HQ\36K,8G]10=Z7D-$9R#9\$KE.%,SR&&.'_*Q9?M @[Y-[M8_1WL?[J!'P
M$8L6M(./$ 51VV'/].WBD<N=7],^_VGM1V2TZX"W+5[['%[")%[?T6&,X8'M
M*$EHN)62Y2NTXZ?;9Z4E'?A_79$OL3MN;),%AZI@"QQ[E.84R@UZDS]_#WO!
M7R[:+PDVNR38_$)@1P'JU 'J-*%/OMEDB/$UVZ"DY Z2JY?KI40$GFLDA1HD
MT^@*3XE,>=Y FZ*RF02MH!/T1_[FD/E&"]S^@8OT<_IZQ_KF[G7A(*S7'5'5
MK:GJ-E(U>RVH0-%&COF&QYC'4)0[6KG(:<1ZN]/3"^',+H0S_W6<(_)[-?F]
MMY&?B#3F^0H*E%S$<+5#)I6K;MPU SZ%SI33+-0!JPX&D)5%(^Q#S':N#3!M
M1'IOOFDVJUN9U?ZQ6?-+(!U%\*:.X,W[,LU&I$SSE.L=+*D"".D*8C/F4^0,
MXHT[ 82=D\34"/Z.LW5.WTE>.K>LY\Y+_9K8?O/14)K3I9?.!EW]E\CU6J+-
MV<I,@"C,I5K!BJJN=MZ0[IKQG]I.DOM.;VZZ)QPW8K^#XQ)G<*(M./J<$NXV
ML7N&[X%W,A$&WZ^UP8^2R;D$Q97M16*@QB;A=,.6?,%2P%?S'O,%@EB"XAE/
MF02V93)6'V%%%29?_0;'GP6%D0H/A=9T25J 3M!,V@O4FD"I7F?*X)D7RMRU
MKTO=>]P-E7-CFVD9XW6*ZE0%HZIFA-%ZP\J=0X#+M=U5F!6IV-'=X!D3MN%"
MMN@$[@\V. [VH?<&]X"!@U6D0*PEN9)1UBD-;]&N:]C8=*MTTAI35])R)2O_
MH&G)4*YL>ZE(Y3K7Y16@GJU;V#O;N)W,WX?#:>B8GYF6US%_.QC.!J[Y,!C.
MRA[9_VY0V6%_8G+%B?@4EV1<T+JAHBO+IK5\T**P3=:ST-2RV6%"C3Y*LX#>
M+X70^P>CH/[K8/(_4$L#!!0    ( /&!;E<<'9#*0@0  &86   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;,6874_C.!2&_XJ5':UF)"!?+5_;5BHD
MHV$U, B&W8O17KB)VT0D=L9V6MA?/\=.""D$BTJ6A@N:.#Z/G?>MCWL\V3!^
M+S)")'HH"RJF3B9E=>JZ(LE(B<4!JPB%)TO&2RSAEJ]<47&"4QU4%F[@>8=N
MB7/JS":Z[9K/)JR614[)-4>B+DO,'\](P393QW>>&F[R5295@SN;5'A%;HF\
MJZXYW+D=)<U+0D7.*.)D.77F_FGLARI ]_@G)QO1NT;J51:,W:N;BW3J>&I&
MI"")5 @,'VMR3HI"D6 >/UNHTXVI OO73_3/^N7A9198D'-6_)NG,ILZQPY*
MR1+7A;QAFR^D?:&QXB6L$/H_VC1]CTX<E-1"LK(-AAF4.6T^\4,K1"\ .,,!
M01L0O P8O1$0M@'A>P-&;<#HO5,:MP'ZU=WFW;5P$99X-N%L@[CJ#31UH=77
MT:!73M47Y59R>)I#G)S=2I;<H^L"4X$^1D3BO!#H"G..E8&?T#ZZNXW0QP^?
MT ?D(I%A3@3**;JCN11[T C7WS-6"TQ3,7$E3$F!W:0=_JP9/GAC>!]=,BHS
M@6*:DG0@/C;'AX9X%Z3H] B>]#@+C,"_Z^( A?X>"KP@')C/N3G\EE00[NGP
M8" \,H?/ZU4W^E!X_/[10X,88??E"#5O] 8O_EGG\A%]J_2:_G%)R@7A_PVY
M;.2H9'<J*IR0J0/93!"^)L[LSS_\0^^O(8EMPB*;L-@2;,N,46?&2-/#M\Q5
M:V__#))BBLY9"3N%P-J7.2Q6NB*0O25:/*)^OVO\J)OG&\Q3].,K(-&%)*48
M-'%DTT2;L,@F++8$VS)QW)DX-JZH[TSB M64DX2M:/X_>)3TO20/ZIK %EQ@
M"0\E0Y31_341ZD[H9,WT<APRT#CVK@;:A$4V87$#.]0P]4-H/?,F[GK E</.
ME4.C*VK[@YSICXTYSLC855V;L,@F++8$VS+BJ#/BZ#?GN".;)MJ$139AL278
MEHG'G8G'YM54\R0#:U1F*\$[G;6&O#!B=O6B@8U[2>'$4W]=9FA4?MW-#\:O
MNL66IK:EWTFGW\G[]*MXGI ]5!&.UKBHR9"&1M2N&C:PX[XX!Z'_0L&A3N/@
MA7Z6IK6EG^\]US2>4<'/^5)F: YI 8H"!)4)NH$-5&^H.LM_*VF^J*%H:'[?
M7M $$@B4.[H.,NX!YH%WU=LJ+;)*BVW1MBWLE:7^;]X)V@G8LM(F+;)*BVW1
MMJT,GJT,C*OQZDXM)\266QL":G[3#CH3O$K2H_'K7'YN'G=GS6W28ENT;<V?
M"W??7+E?0=&08)&U6O=KC$'%K=;O5FF155K<TOK%0^"]+!_<WGE:2?A*'V0*
M4+&FLCE*ZEJ[P]*Y/B)\T7[FGT;-D><SICF!O<1\E5.!"K($I'=P!-]VWAQJ
M-C>25?K4;L&D9*6^S A."5<=X/F2,?ETHP;HCI9GOP!02P,$%     @ \8%N
M5Q+#6&]3!   =1H  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULS5EM
MC]HX$/XK5DXZW4G=S1L)L =(+,GI*G5[J*CMA^H^F&2 :..8LPUL__W9)AM(
MR$;+U:KV"R3.S#.>>>P')AX=*'OD&P"!GDA>\+&U$6)[9]L\V0#!_)9NH9!/
M5I01+.0M6]M\RP"GVHGDMN<XH4UP5EB3D1Z;L\F([D2>%3!GB.\(P>S[/>3T
M,+9<ZWG@4[;>"#5@3T9;O(8%B,_;.9-W=H629@0*GM$",5B-K:E[%[NA<M 6
M7S(X\+-KI%)94OJH;MZG8\M1,X(<$J$@L/S:PPSR7"')>?Q;@EI53.5X?OV,
M_J=.7B:SQ!QF-/^:I6(SM@862F&%=[GX1 ]_09E0H/ 2FG/]B0ZEK6.A9,<%
M):6SG ')BN,W?BH+<>8@<=H=O-+!:SKT7G#P2P?_M1%ZI4/OM1&"TD&G;A]S
MUX6+L,"3$:,'Q)2U1%,7NOK:6]8K*]1"60@FGV;23TP^RK7X@7*.YL#08H,9
MH-\B$#C+^>_H!G$UPD>VD*&4@YV4L/='6.\%6!\]T$)L.(J+%-(6_ZC;?]CA
M;\L4JSR]YSSOO4[ !6QOD>^\0Y[C^2WSF;W>W6M+Y\>BQ_\[>JT8?D6ZK_'\
M%_"FA<C2+-^I/8H6D.Q8)C*0Q7Y*\IVL-UHQ2M",DNU.8+V?Z0K%F!59L3Y?
M*=\^2&#T7@#A_[2MD>,L>NVS4!)XQ[<X@;$E-8X#VX,U^?47-W3^:"/()%AD
M$BPV!%:CLE=1V>M"GTP)W15"\7/0F@CI#=X#DQJ/L&3YIJ(YH81((E_>T,<X
M@8ZC?E[V$S<8!L[(WI^S<&D5#,*@;A2U0#E^,*A;Q9=681"ZE5&M'$%5CJ"S
M'#-:R.Q%MLP!S>5/#C FE_-"T.01?7L L@36NE([4:]=J2;!(I-@L2&P&C5A
M14WX)D0G-$FE2;#()%AL"*Q&9;^BLO^31*=_H0%^/^PW-*=S,NVIHK;Z7P9S
MO7#84*4?#U8KZ: JZ>#5PO61"KDONN2J$^O:-6X2+#()%AL"JQ$RK @9O@FY
M&IJDTB189!(L-@16H])U3DV.\Y,$JPQ4^P/D]!J"U3V;*Q2K)9K;;_PEBPU$
MJY?UK'=T.\NJ5_C-O>S34S3'WPG(&D\9P\4:U/4[]/=6[XPN*>L.<>T&,(H6
M&46+3:'5R?).9'EO0M#*:9@BU"1:9!0M-H56)_34Q+N=C:5)4?,O969PUHJ5
M5%Q:#7VOT?JU07D]MRE9+5#]H+WU<T^ML-O="W_%2GM$M]QT0ER].DVB14;1
M8E-H=3).C;@;O VY,=JZ&T6+C*+%IM#JA)[:=[>SI30I-^'E[A^X@Z;<7%KU
MAK[?U)M+*]E -E\UM5@%P2!L"(Y]]AJ= %OK\PLN\Y%Y'U^N5J/5&<E4GPPT
MQN_=NYG;,AZI,Q7]VOX$?SR0><!LG14<Y;"2H9S;OIPJ.YYQ'&\$W>J7^$LJ
M!"7Z<@,X!:8,Y/,5E4UC>:,"5"=-D_\ 4$L#!!0    ( /&!;E<FAFRIS@(
M *D'   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*U5:V_3,!3]*U:8
MT":-Y=$':+21V@[$)@K5'O!AV@<WN6VLQ7:PG7;[]UP[:>A&%FF(+XD?]QR?
M<_VXHZU4]SH#,.2!YT*/O<R8XM3W=9(!I_I$%B!P9B45IP:[:NWK0@%-'8CG
M?A0$0Y]3)KQXY,86*A[)TN1,P$(177).U>,4<KD=>Z&W&[ADZ\S8 3\>%70-
M5V!NBH7"GM^PI(R#T$P*HF U]B;AZ6QHXUW #P9;O=<FULE2RGO;.4_'7F %
M00Z)L0P4?QN809Y;(I3QJ^;TFB4M<+^]8__LO*.7)=4PD_E/EIIL['WP2 HK
M6N;F4FZ_0.UG8/D2F6OW)=LZ-O!(4FHC>0U&!9R)ZD\?ZCSL 9"G'1#5@.@Y
MH/\"H%<#>LYHI<S9.J.&QB,EMT39:&2S#9<;AT8W3-A=O#(*9QGB3'QQ3189
MQ7PD4!J6T%R3B=9X>A:E2C+,#YFL%0#NFR&'9V HPXAO5"EJTW]$WI$6AMLY
M\"6H.YR]N3HCAP='Y( P0:XS66HJ4CWR#6JW"ORDUCFM=$8OZ S)7 J3:?))
MI) ^Q?OHN3$>[8Q/HT[""RI.2"\\)E$012UZ9MWP[XEIX$&'G%ZS#SW'UWN!
MKTKZ)/E5,LW< ;_]BB'DW #7=VWYJOCZ[7SV\I_J O=D[.'MUJ VX,5OWX3#
MX&.;V?]$]L1ZO['>[V*/9[G43*Q)01_M,6OSVDGP6J\5V="1V4=N$X>#D;]I
M<3!H' PZ'<Q9#GA3<;L6E8?6 S[X>]T@:!:NM'6N\X_[,&Q<##M=G&M=4I$
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M+LF)-=#D(4J-WB"G2]F4^^#P5<,O3,Z\Q\[?*\/T_I*#TL;3C7).2;(.1OV
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M)7&T1^(S2AP-LDNC1]\9)8D4*>,M35$81L^U(&(;':<L/5S!HPQ:&=D>QD&
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M$P-\GUF(;!<28'.#GOP'4$L#!!0    ( /&!;E>D/I&R. 0    9   9
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M6A0ML!M=?$M3VT#BM-@ FS:(F_:AZ ,MC2TB$JF0E-T ^_$[I!3%=AVA"63
M$DEQSLPY'(JC\4:J6YTB&OB59T)/O-28XL3W=9QBSO21+%#0DZ54.3/452M?
M%PI9XHSRS(^"8.CGC MO.G9C5VHZEJ7)N, K!;K,<Z;NSS"3FXD7>@\#UWR5
M&CO@3\<%6^$<S4UQI:CG-R@)SU%H+@4H7$Z\T_!D%CH#-^,;QXW>:H.ELI#R
MUG8NDHD7V(@PP]A8"$:W-<XPRRP2Q7%7@WJ-3VNXW7Y _^3($YD%TSB3V7>>
MF'3B'7N0X)*5F;F6FW^P)C2P>+',M+O"IIH[(H]QJ8W,:V/JYUQ4=_:K%F++
M@' .&T2U0;1OT'_"H%<;]!S1*C)'ZYP9-ATKN0%E9Q.:;3AMG#6QX<(NX]PH
M>LK)SDSGY4+C78G"P,<U736\/4?#>*;A,U.*69'?P=]P,S^'MZ_?P6O@ KZF
MLM1,)'KL&XK!(OEQ[>^L\A<]X2^$2RE,JN&C2##9M?<I]H9 ]$#@+&H%_!*;
M(^B%?T$41+T#\<S:S>=8D'EPR'PGG%ZC9\_A]?]03_AQB?D"U4_X#R[AG/[?
MI<H26F2$N<Q*F\NZF71(SU9_=I>?Z(+%./%H&VM4:_2F;UZ%P^##(3$Z MN1
MIM](TW?HO3^6YE^: 1<&<WV0>;]+YAV![3 ?-,P'K4DQDWE.KRS:S/$M<*U+
M3(#>P*#1F QSJP5;*72M0T)4Z .';M_+Z^D@H-_87V\S;(WAA0R'#</AB]-^
MQG0*GZ7!UC1OQ7_N8G<$MB/%J)%BU&V:C[IDWA'8#O/CAOEQ>YK;A2[8_5-I
M7%D/]])X+XM;7;R0P/N&P/M6 I_XTJ1P2O'3V01TP,$U:L,,=:(@',"77/!%
M26?77<G-/5R(F)C2 0E7&1.MV=WJ][EKW!'8CD1A\%@P!-WF=XW7$?FNT';9
M;Y5+86N*W A"-8K'-BGB[??ZFL;W*YI:@%;(9PL0_G8:A&%O-'C<2!4U?ZLH
MS%&M7*VL*>92F*J\:D:;>OS45:%[XV>V3G?%YB-,5>1?,K7B5+YDN"3(X&A$
M0:FJ;JXZ1A:N]%Q(0X6L:Z;TK8'*3J#G2TG'0MVQ#IJOE^G_4$L#!!0    (
M /&!;E>[&J/I-@,  $X3   -    >&PO<W1Y;&5S+GAM;-U874_;,!3]*Y$9
M$T@3:9L1FM%6VBHA3=HF)'C8&W(;)[7DV)GCLI9?CV^<IA_X5AT/&UTJ&OL>
MGW./[1MB&%1F*=C=C#$3+ HAJR&9&5-^"L-J.F,%K2Y4R:1%,J4+:FQ7YV%5
M:D;3"DB%"'N=3AP6E$LR&LAY<5.8*IBJN31#$K>AP-V^ID/2C3^2P,F-5<J&
MY.'L_:^Y,M?O G<_^7!RTGDXO]Z-G]7 .0F]HI<'B%YT.K@P@)AX?)CX/FU,
M^FI;NAY^:H4<\12C]3TTFV7-A Y&3@Y<J_V+Y:84-GL^&F1*KK<^(BY@\]."
M!8]4#,F8"C[1'%@9+;A8NG / E,EE Z,K3EKJ N1ZLG!7=>#<FQT"BZ5KG.[
M#.Y[T@S? 58],,B%: WVB N,!B4UAFEY8SOUX#KX @J:]OVRM YS39?=WB59
M$^J;33)1.F6Z3=,EJ]!H(%@&=C3/9W WJ@P!-$85MI%RFBM):P\K1M.PLE,F
MQ!T\JS^S+>U%MK&S'=A7V3:MH:;I9%P']#?5G/:F;.]5ND')'Y7Y,K?3D74?
MRH7=:I;Q1=U?9*T!3+V+J].R%,O/@N>R8&[R!R<<#>B*%\R4YD\V&Y3*U :8
M)L$CTX9/-R._-2WOV<*LRFF1X9Y[1^CY[ZYSSB335&R:MK7_EE?YU8ZCJW]E
MN?ZMLFO8Z[%Y ;]UDY?'8#(^!I-'49/]8S"9O$F38?,"WS@E;)T1VF@ 9[$A
M^0%G/[%.&DSF7!@NF]Z,IRF3+XX*5M[0B?UC84O?CD]91N?"W+?@D*S;WUG*
MYT72CKJ%A6A&K=O?8'K=N#T(VEQ<IFS!TG'3U?FD;@:V8;,V%Q!VD9OZ\B,8
MQV%^!# L#^8 XS@6EN=_FD\?G8_#,&]]+])'.7V4XU@^9%Q_L#Q^3F(O_TR3
M)(KB&%O1\=CK8(RM6QS#CU\-\P8,+ ]D^K.UQG<;KY#]=8#MZ;X*P6:*5R(V
M4WRM ?&O&S"2Q+_;6!Y@8+N U0[D]^>!FO)SH@AV%?.&/<$XDB08 K7HK]$X
M1E8GAH]_?["G)(J2Q(\ YG<011@"3R..8 [  X9$4?T>W'D?A:OW5+C^#]KH
M&5!+ P04    " #Q@6Y7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( /&!;E<J?6A1? ,   ,9   /    >&PO=V]R
M:V)O;VLN>&ULQ9G1<]H@&,#_%2Y/W<MB$K5KK_;.:;IV<\9KLK[V,$'#E8 %
M8M?^]2/)><75?ML+]4D#'/GQ"?SX\.))R(>E$ _H=\6X&GFEUIMSWU=Y22JL
M/HL-X:9F)62%M7F4:U]M),&%*@G1%?/#7F_H5YAR[_)BU]="^O:#T"375'!3
MV!3<4?*D7NN;1[2EBBXIH_IYY+7?&?%013FMZ LI1E[/0ZH43]="TA?!-69I
M+@5C(R_H*NZ(U#1_4YPVD!E>JK9$X^4M-B C;]@S':ZH5+IMT?:/#>.6F,;=
M4ZW%%66:R"G6Y)L4]8;R==.-&85O#:.-P^ZS"^*Y_)\PBM6*YF0J\KHB7'=Q
ME(0U@%R5=*,\Q'%%1MY$;(ELQF-><%-T8],&RHJ4/*>F0MX4+9Y#E&0^C>=I
M/$5?Q[/Q?!*C]#J.LQ2=_.*X+BS($( ,CPAY'UJ0$0 9?11DFHVS^&<\-X#)
M%4H6\>TXN[$@^P!D_SB0:99,?EPG%N0 @!P<!W(R3J_1U<R"' *00[>0B5QC
M3E_:"H1Y@=*ZJK!\1F*%4KJV($\!R%.WD*D6^0-:,,R5!?0% /KB%FAN^IT)
MI=""2)266!*+ZPS@.G/+]3U#"T-3X9S4K784&BME7K:H95YB>Z_N09MUS_'*
M$%5%==-(M7-N8LQI)$9X3HG]"P>@41PKI9UTI6 %D>H>Q8^U.0/8;)!( L<F
MF5*5MS&K28&2#9%=$QL/4DC@V"'=G$LQLY=% /DB<"R,VZ;0Q&J!I7Y&F30[
M"<[?Q R21>#8%FF]5.2Q-HU0O&U6A@T&"2(XIB'V3BT!I(C L2-@S,C&A,01
M.#:'I3)T8L[TC*A/-ALDC\"Q/=Y:[1!B")DC=&R.=S:^':>-";DC=.P.>#+V
M;4PP'W&L$1AS8&-".@D=ZP3&'-J8D&-"QXZ!,4]M3$@TH6O1V#O0E&A,V?[Z
MAF03.I;-(3@4[.%!D@D_+A%YQ0OW\""YA!\IEQW>',MFE]R2/4S(,^$1/'-@
M(D:0:"+'H@$SJ?V[&D@TD>M[+RB30B<V)B2:R+%H#N52U@RU,<&K+\>B>?=T
MT9':F)!H(L>B>4VO_K'*(\@SD6//O)]RM=0V)F2<R+5Q_LZ[]F-J8T+FB5KS
M^+M+]X*L*"?%W+Q"F7*S?^0+B9J/[NZ@/VA.^JN:L8DI2_A,X&)WA[_[_^'R
M#U!+ P04    " #Q@6Y7F3ZBA'P!  "6%@  &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSS=A-;L(P$(;AJT0^ ,[,\%L!JV[85EP@"H8@\J?85>'V
MC<(B?%$7W2#/*K*CC-_5H\C;+U=FX=K4OKBV/KE79>UWI@BA_;#6YX6K,C]K
M6E?W;\Y-5V6A7W87VV;Y+;LXRVFZM-WK#+/?OLY,CH_6_6=B<SY?<_?9Y-^5
MJ\,?@^U/T]U\X5PPR3'K+B[LC+V7X[:WPX-F_623'$X[TQU.9&SL((8@CA\D
M$"3Q@^80-(\?M("@1?R@)00MXP>M(&@5/V@-0>OX01L(VL0/HA1E3!4D3;!6
MH#4AUZ3 :T*P28'8A&23 K,)T28%:A.R30K<)H2;%,A-2#<IL)L0;U*@-Z/>
MK$!O1KU9@=X\^=E6H#>CWJQ ;T:]68'>C'JS KT9]68%>C/JS0KT9M2;%>C-
MJ#<KT%M0;U&@MZ#>HD!O0;U%@=XRN2Q1H+>@WJ) ;T&]18'>@GJ+ KT%]99W
MZNW#HW1^['FN\?QW4AWZ;]UX_+!\;D[8&7"V< V]_P502P,$%     @ \8%N
M5ZIG%&&8 0  "Q<  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9C-;L(P$(1?
M)<H5$6.[I3\"+FVO+8>^@)ML2$026[:A\/9UPH_4BD8@*G4NL1+OSHR]TG?(
MY'UKR$6;NFK<-"Z\-X^,N;2@6KE$&VK"3JYMK7QXM0MF5+I4"V)B-!JS5#>>
M&C_TK48\FSQ3KE:5CUXVX;,K=3.-+54NCIYVA:W7-%;&5&6J?-AGZR;[X3+<
M.R2ALZMQ16G<(!3$[*1#N_.[P;[O;4W6EAE%<V7]JZI#%=M4S/EM12[IESB1
M4>=YF5*FTU4=6A)G+*G,%42^KI*=Z*#?V8<;IMV37^W?R?09ALJYU<:%B5FZ
MW.XPDK9[:((065_V'_'H&*2O/A^UT\XH.],[7.^GMLMN'HYUR_5W_'W&1_T+
M<PB0'!(DQPU(CEN0'&.0''<@.>Y!<CR Y. CE" H1.4H2.4H3.4H4.4H5.4H
M6.4H7.4H8.4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9)4H9)4H
M9)4H9)4H9)4H9)4H9)4H9)7_2=8/K9=__7NV79-:E<W!GW7_P&=?4$L! A0#
M%     @ \8%N5P=!36*!    L0   !               ( !     &1O8U!R
M;W!S+V%P<"YX;6Q02P$"% ,4    " #Q@6Y766F0,.X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #Q@6Y7
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( /&!;E<D>#55[ 4  ,L?   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #Q@6Y7
MGWFM:@(&  !)&@  &               @($O#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ \8%N5PFJW*<" P  'PH  !@
M     ("!9Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M /&!;E?-7]=VVP4    @   8              " @9\7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #Q@6Y75 H9;"@(   H/@  &
M            @(&P'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ \8%N5["HG]A3!P  Q2,  !@              ("!#B8  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /&!;E< $B?]G1D  !]&
M   8              " @9<M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #Q@6Y76*VO(5\%  !?#   &               @(%J1P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ \8%N5T'\TI=B
M P  1 @  !@              ("!_TP  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( /&!;E<M38_D] (  -(&   9              "
M@9=0  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ \8%N
M5UN!I3VH P  XP<  !D              ("!PE,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #Q@6Y7DE<X0Y4'  #K$0  &0
M        @(&A5P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( /&!;E<C/X&DV0(  .8&   9              " @6U?  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ \8%N5TM0F,9V!   3@H
M !D              ("!?6(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #Q@6Y75DD\%H,"  "_!0  &0              @($J9P
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /&!;E<X#C7K
M#P,  )L&   9              " @>1I  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ \8%N5YYM5U)Z&@  $$P  !D
M ("!*FT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Q
M@6Y7$,)1ET8#  !'"   &0              @(';AP  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /&!;E=C0=C!IP0  +,+   9
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M970R,RYX;6Q02P$"% ,4    " #Q@6Y7OVUY?H<"   N!@  &0
M    @(&SFP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M /&!;E?J4B /T@<  /,C   9              " @7&>  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ \8%N5XZ*Y_WW P  > \  !D
M             ("!>J8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #Q@6Y7T0_E!8\#  "C$   &0              @(&HJ@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /&!;E?FX?2V600
M $80   9              " @6ZN  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ \8%N5QP=D,I"!   9A8  !D              ("!
M_K(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #Q@6Y7
M$L-8;U,$  !U&@  &0              @(%WMP  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( /&!;E<FAFRIS@(  *D'   9
M      " @0&\  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ \8%N5ZPUA>). @  VP4  !D              ("!!K\  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #Q@6Y7PV)O'6<+  "!F
M&0              @(&+P0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( /&!;E>#?YN?3P,  #L,   9              " @2G-  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ \8%N5ZLK"\B\
M!   30L  !D              ("!K]   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #Q@6Y7I#Z1LC@$    &0  &0
M@(&BU0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /&!
M;E>K#E9O6 ,  ,D,   9              " @1':  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ \8%N5[L:H^DV P  3A,   T
M         ( !H-T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #Q@6Y7EXJ[
M',     3 @  "P              @ $!X0  7W)E;',O+G)E;'-02P$"% ,4
M    " #Q@6Y7*GUH47P#   #&0  #P              @ 'JX0  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ \8%N5YD^HH1\ 0  EA8  !H
M     ( !D^4  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ \8%N5ZIG%&&8 0  "Q<  !,              ( !1^<  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     "T +0 R#   $.D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>139</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement</Role>
      <ShortName>JT Pharmaceuticals Asset Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Asset Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/AssetSale</Role>
      <ShortName>Asset Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlans</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DiscontinuedOperations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Stock Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails</Role>
      <ShortName>Stock Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Stock Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails1</Role>
      <ShortName>Stock Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Stock Plans (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails2</Role>
      <ShortName>Stock Plans (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Stock Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetailsNarrative</Role>
      <ShortName>Stock Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/NetLossPerShareTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative</Role>
      <ShortName>JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Asset Sale (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/AssetSaleDetailsNarrative</Role>
      <ShortName>Asset Sale (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/AssetSale</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="titanpharma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="titanpharma_10q.htm">titanpharma_10q.htm</File>
    <File>ttnp-20230930.xsd</File>
    <File>ttnp-20230930_cal.xml</File>
    <File>ttnp-20230930_def.xml</File>
    <File>ttnp-20230930_lab.xml</File>
    <File>ttnp-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="447">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "titanpharma_10q.htm": {
   "nsprefix": "ttnp",
   "nsuri": "http://titanpharm.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "titanpharma_10q.htm"
     ]
    },
    "schema": {
     "local": [
      "ttnp-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ttnp-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ttnp-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ttnp-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ttnp-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 176,
   "keyCustom": 33,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 18,
   "hidden": {
    "total": 86,
    "http://titanpharm.com/20230930": 9,
    "http://fasb.org/us-gaap/2023": 72,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 139,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 356,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 447,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://titanpharm.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://titanpharm.com/role/CondensedBalanceSheets",
     "longName": "00000002 - Statement - CONDENSED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://titanpharm.com/role/CondensedStatementsOfOperations",
     "longName": "00000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
     "longName": "00000005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://titanpharm.com/role/CondensedStatementsOfCashFlows",
     "longName": "00000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS  (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "00000007 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://titanpharm.com/role/StockPlans",
     "longName": "00000008 - Disclosure - Stock Plans",
     "shortName": "Stock Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://titanpharm.com/role/NetLossPerShare",
     "longName": "00000009 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement",
     "longName": "00000010 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement",
     "shortName": "JT Pharmaceuticals Asset Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://titanpharm.com/role/CommitmentsAndContingencies",
     "longName": "00000011 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://titanpharm.com/role/StockholdersEquity",
     "longName": "00000012 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://titanpharm.com/role/DiscontinuedOperations",
     "longName": "00000013 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://titanpharm.com/role/AssetSale",
     "longName": "00000014 - Disclosure - Asset Sale",
     "shortName": "Asset Sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:AssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:AssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://titanpharm.com/role/RelatedPartyTransactions",
     "longName": "00000015 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://titanpharm.com/role/SubsequentEvents",
     "longName": "00000016 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:CompanyPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "ttnp:CompanyPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://titanpharm.com/role/StockPlansTables",
     "longName": "00000019 - Disclosure - Stock Plans (Tables)",
     "shortName": "Stock Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://titanpharm.com/role/NetLossPerShareTables",
     "longName": "00000020 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://titanpharm.com/role/DiscontinuedOperationsTables",
     "longName": "00000021 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
     "longName": "00000023 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ContractWithCustomerAssetGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ContractWithCustomerAssetGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
     "longName": "00000024 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ttnp:CompanyPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ttnp:CompanyPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://titanpharm.com/role/StockPlansDetails",
     "longName": "00000026 - Disclosure - Stock Plans (Details)",
     "shortName": "Stock Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://titanpharm.com/role/StockPlansDetails1",
     "longName": "00000027 - Disclosure - Stock Plans (Details 1)",
     "shortName": "Stock Plans (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://titanpharm.com/role/StockPlansDetails2",
     "longName": "00000028 - Disclosure - Stock Plans (Details 2)",
     "shortName": "Stock Plans (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://titanpharm.com/role/StockPlansDetailsNarrative",
     "longName": "00000029 - Disclosure - Stock Plans (Details Narrative)",
     "shortName": "Stock Plans (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://titanpharm.com/role/NetLossPerShareDetails",
     "longName": "00000030 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
     "longName": "00000031 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)",
     "shortName": "JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2020-10-012020-10-31_custom_JtPharmaceuticalsMember",
      "name": "ttnp:FutureMilestonePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ttnp:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2020-10-012020-10-31_custom_JtPharmaceuticalsMember",
      "name": "ttnp:FutureMilestonePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ttnp:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000032 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "ttnp:OperatingLeasesRentExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "ttnp:OperatingLeasesRentExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://titanpharm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000033 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://titanpharm.com/role/DiscontinuedOperationsDetails",
     "longName": "00000034 - Disclosure - Discontinued Operations (Details)",
     "shortName": "Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://titanpharm.com/role/AssetSaleDetailsNarrative",
     "longName": "00000035 - Disclosure - Asset Sale (Details Narrative)",
     "shortName": "Asset Sale (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-09-012023-09-30_custom_ProNeuraMember",
      "name": "ttnp:AssetSaleDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ttnp:AssetsHeldForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-09-012023-09-30_custom_ProNeuraMember",
      "name": "ttnp:AssetSaleDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ttnp:AssetsHeldForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000036 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://titanpharm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000037 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember",
      "name": "ttnp:CommonStockIssuedForSettlementAgreement",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-10-31_us-gaap_SubsequentEventMember_custom_MDMWorldwideSolutionsMember",
      "name": "ttnp:CommonStockIssuedForSettlementAgreement",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "titanpharma_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r349",
      "r459"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r383"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r383",
      "r401",
      "r556",
      "r557"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_NoncashStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "NoncashStockCompensation",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash stock compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments (base rent)",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "ttnp_CashNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "CashNoteMember",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454"
     ]
    },
    "ttnp_MDMWorldwideSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "MDMWorldwideSolutionsMember",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M D M Worldwide Solutions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r370",
      "r371",
      "r372",
      "r406",
      "r407",
      "r408",
      "r428",
      "r430"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r289"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, at amounts paid-in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at September\u00a030, 2023 and no shares issued and outstanding at December\u00a031, 2022.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r348",
      "r459"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r11",
      "r12",
      "r45",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r57",
      "r87"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Discontinued Operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ttnp_DeferredGrantRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "DeferredGrantRevenue",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r82",
      "r385",
      "r401",
      "r425",
      "r426",
      "r459",
      "r471",
      "r500",
      "r504",
      "r544",
      "r556"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r291",
      "r548"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r100",
      "r125",
      "r170",
      "r326",
      "r409",
      "r469",
      "r555"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r54",
      "r85",
      "r86"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from the exercises of common stock warrants",
        "verboseLabel": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ttnp_ShareBasedPaymentArrangementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ShareBasedPaymentArrangementMilestonePayment",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_ProNeuraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ProNeuraMember",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Neura [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "EstimatedForfeitureRatesForOptionsGrantedToManagement",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated forfeiture rates for options granted",
        "documentation": "Estimated forfeiture rates for options granted to management."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of restricted stock",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r113",
      "r117",
      "r191",
      "r192",
      "r193",
      "r342",
      "r443"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_CommonStockIssuedForSettlementAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "CommonStockIssuedForSettlementAgreement",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for settlement agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r76",
      "r133"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance payments",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r112",
      "r135",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r297",
      "r300",
      "r301",
      "r318",
      "r459",
      "r508",
      "r546",
      "r547"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials and supplies",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r494"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r54",
      "r85",
      "r86"
     ]
    },
    "ttnp_IssuanceOfPreferredStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "IssuanceOfPreferredStockNet",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock, net"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_Plan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "Plan2015Member",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations",
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r343",
      "r367",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r464"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r439"
     ]
    },
    "ttnp_OtherAccruedLiabilitiesTransferredWithSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "OtherAccruedLiabilitiesTransferredWithSaleOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued liabilities transferred with sale of assets"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "FifthAmendedAndRestated2015OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_JtPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "JtPharmaceuticalsMember",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JT Pharmaceuticals [Member]",
        "documentation": "This member stands for JT Pharmaceuticals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_N2015OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "N2015OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_February2022OfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "February2022OfferingsMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 Offerings [Member]",
        "documentation": "Represents the information pertaining to February 2022 Offerings."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_DisclosureAssetSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "DisclosureAssetSaleAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_NotesReceivableReceivedInConnectionWithSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "NotesReceivableReceivedInConnectionWithSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes receivable received in connection with sale of assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "N/A."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "ttnp_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments",
        "documentation": "This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_AccountsPayableRelatedToSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AccountsPayableRelatedToSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable related to sale of assets"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_OperatingLeasesRentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "OperatingLeasesRentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment",
        "documentation": "Amount of milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "CashAndCashEquivalentsAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows",
        "label": "CashAndCashEquivalentsAndRestrictedCashEquivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "PurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "ttnp_InventoryTransferredWithSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "InventoryTransferredWithSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory transferred with sale of assets"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_AssetSaleDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AssetSaleDescription",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Asset sale description",
        "label": "AssetSaleDescription"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_ProceedsFromPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ProceedsFromPromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_UnrestrictedCommonStockVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "UnrestrictedCommonStockVested",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted common stock vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      },
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued operations - current assets",
        "totalLabel": "Discontinued operations \u2013 current assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r54",
      "r85",
      "r86",
      "r109",
      "r110"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r172",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r248",
      "r249",
      "r343"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r317"
     ]
    },
    "us-gaap_RepaymentsOfSubordinatedShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfSubordinatedShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on short-term loans",
        "label": "Repayments of Subordinated Short-Term Debt",
        "documentation": "The cash outflow for an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ttnp_AssetSaleDescriptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AssetSaleDescriptions",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset sale description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r374",
      "r501",
      "r502",
      "r503",
      "r543",
      "r556"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnSalesOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows",
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on asset sale",
        "negatedLabel": "Gain on sale of assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations."
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_ContractWithCustomerAssetDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ContractWithCustomerAssetDeductions",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deductions",
        "documentation": "The amount of decrease in contract assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest accrued rate",
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r39"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net, shares",
        "verboseLabel": "Issuance of common stock, net (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r93",
      "r368",
      "r424",
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndNotesReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes receivable",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r551"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of minimum operating lease payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r135",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r297",
      "r300",
      "r301",
      "r318",
      "r382",
      "r445",
      "r471",
      "r508",
      "r546",
      "r547"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued operations \u2013 current liabilities",
        "totalLabel": "Discontinued operations \u2013 current liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r54",
      "r85",
      "r86",
      "r109",
      "r110"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r340"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r108",
      "r122",
      "r123",
      "r124",
      "r139",
      "r140",
      "r141",
      "r143",
      "r149",
      "r151",
      "r166",
      "r188",
      "r189",
      "r239",
      "r286",
      "r287",
      "r288",
      "r292",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r362",
      "r363",
      "r364",
      "r374",
      "r424"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r139",
      "r140",
      "r141",
      "r143",
      "r149",
      "r151",
      "r188",
      "r189",
      "r286",
      "r287",
      "r288",
      "r292",
      "r293",
      "r302",
      "r304",
      "r305",
      "r307",
      "r309",
      "r362",
      "r364",
      "r374",
      "r556"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r340"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r340"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r229",
      "r465",
      "r466",
      "r467",
      "r468"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r98",
      "r351",
      "r459",
      "r500",
      "r504",
      "r544"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r340"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r108",
      "r122",
      "r123",
      "r124",
      "r139",
      "r140",
      "r141",
      "r143",
      "r149",
      "r151",
      "r166",
      "r188",
      "r189",
      "r239",
      "r286",
      "r287",
      "r288",
      "r292",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r362",
      "r363",
      "r364",
      "r374",
      "r424"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r93",
      "r374",
      "r424",
      "r431",
      "r470"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r93",
      "r350",
      "r365",
      "r366",
      "r369",
      "r384",
      "r459"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares agreed to issue",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "ttnp_NumberOfCommonStockVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "NumberOfCommonStockVested",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NUmber of common stock vested"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ttnp_GoingConcernAssessmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "GoingConcernAssessmentPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern Assessment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r210",
      "r227",
      "r337",
      "r440",
      "r442"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 6)",
        "verboseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://titanpharm.com/role/StockPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r254",
      "r282",
      "r283",
      "r285",
      "r455"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted net loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r310",
      "r311",
      "r344",
      "r355",
      "r444"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Option exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ttnp_ContractWithCustomerAssetAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ContractWithCustomerAssetAdditions",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions",
        "documentation": "The amount of increase in contract assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r116",
      "r135",
      "r167",
      "r174",
      "r178",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r296",
      "r300",
      "r318",
      "r347",
      "r395",
      "r459",
      "r471",
      "r508",
      "r509",
      "r546"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173",
      "r177",
      "r179",
      "r446"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r84"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "verboseLabel": "Total inventories",
        "terseLabel": "Raw materials and supplies and finished goods inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r438",
      "r459"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercises of warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercises of warrants, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total unrecognized compensation expense related to non-vested stock option",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r501",
      "r502",
      "r543",
      "r553",
      "r556"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivables",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Option forfeited or expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited or expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r67"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "auth_ref": [
      "r180",
      "r343",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r436",
      "r452",
      "r460",
      "r492",
      "r506",
      "r507",
      "r513",
      "r552"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ttnp_CompanyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "CompanyPolicyPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r343",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r436",
      "r452",
      "r460",
      "r492",
      "r506",
      "r507",
      "r513",
      "r552"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r310",
      "r311",
      "r344",
      "r355",
      "r444"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares used in computing basic net loss per common share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r161"
     ]
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of activity related to our accounts receivable",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r99",
      "r110",
      "r120",
      "r121",
      "r124",
      "r135",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r157",
      "r167",
      "r173",
      "r177",
      "r179",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r311",
      "r318",
      "r354",
      "r403",
      "r422",
      "r423",
      "r446",
      "r469",
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r144",
      "r145",
      "r146",
      "r147",
      "r153",
      "r154",
      "r158",
      "r161",
      "r167",
      "r173",
      "r177",
      "r179",
      "r446"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r190",
      "r510",
      "r511"
     ]
    },
    "ttnp_AssetsHeldForSaleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AssetsHeldForSaleTextBlock",
     "presentation": [
      "http://titanpharm.com/role/AssetSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Asset Sale",
        "label": "AssetsHeldForSaleTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "ttnp_PurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "PurchaseCommonStock",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred grant revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations",
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r343",
      "r367",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r464"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r46",
      "r47",
      "r48"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r120",
      "r121",
      "r129",
      "r135",
      "r142",
      "r150",
      "r151",
      "r167",
      "r173",
      "r177",
      "r179",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r295",
      "r298",
      "r299",
      "r311",
      "r318",
      "r345",
      "r353",
      "r373",
      "r403",
      "r422",
      "r423",
      "r446",
      "r457",
      "r458",
      "r470",
      "r496",
      "r508"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r162",
      "r163",
      "r164"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ttnp_FutureMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "FutureMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing payment",
        "documentation": "This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership interest by Activist",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r252"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r114",
      "r437"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r119",
      "r135",
      "r187",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r296",
      "r300",
      "r318",
      "r459",
      "r508",
      "r509",
      "r546"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets",
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "periodEndLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r498",
      "r549",
      "r550"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r459"
     ]
    },
    "ttnp_NotePayableToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "NotePayableToRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable to related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of assets",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r327",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r499"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price, per value",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ttnp_HauPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "HauPromissoryNoteMember",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hau Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r30",
      "r31",
      "r38",
      "r39",
      "r41",
      "r42",
      "r91",
      "r92",
      "r138",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r327",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r499"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receivables",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r54",
      "r86"
     ]
    },
    "ttnp_AssetPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AssetPurchaseAgreementTextBlock",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JT Pharmaceuticals Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_RestrictedStockAgreementWithMaximGroupLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "RestrictedStockAgreementWithMaximGroupLlcMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock agreement with Maxim Group, LLC [Member]",
        "documentation": "Represents the information pertaining to restricted stock agreement with Maxim Group, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ttnp_LazarPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "LazarPromissoryNoteMember",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lazar Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs and Related Accrual",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r134",
      "r224",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r308",
      "r427",
      "r429",
      "r432"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r96"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ttnp_ProceedsFromEquityOfferings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "ProceedsFromEquityOfferings",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from equity offering"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "UnregisteredFiveYearAndSixMonthWarrantsMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unregistered five year and six month warrants [Member]",
        "documentation": "Represents the information pertaining to unregistered five year and six month warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r553",
      "r556"
     ]
    },
    "ttnp_PropertyAndEquipmentNetTransferredWithSaleOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "PropertyAndEquipmentNetTransferredWithSaleOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net, transferred with sale of assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of weighted-average anti-dilutive common shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ttnp_UnregisteredPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "UnregisteredPrefundedWarrantsMember",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unregistered prefunded warrants [Member]",
        "documentation": "Represents the information pertaining to unregistered prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ttnp_U.s.CommercializationActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "U.s.CommercializationActivitiesMember",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.s. Commercialization Activities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r29"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r346",
      "r352",
      "r459"
     ]
    },
    "ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Jt Pharmaceuticals Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r11",
      "r12",
      "r45",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r57",
      "r87"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income (expense)",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://titanpharm.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of antidilutive securities excluded from computation of net loss per common share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares used in computing diluted net loss per common share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r161"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ]
    },
    "ttnp_DavidLazarAndActivistInvestingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "DavidLazarAndActivistInvestingLlcMember",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Lazar and Activist Investing LLC [Member]",
        "documentation": "It represents the information pertaining to David Lazar and Activist Investing LLC ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSubordinatedShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSubordinatedShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from short-term loans",
        "documentation": "The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ttnp_RubinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "RubinMember",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rubin [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding at beginning",
        "periodEndLabel": "Weighted average exercise price, outstanding at outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, option outstanding at beginning",
        "periodEndLabel": "Aggregate Intrinsic Value, option outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r209"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend payments",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://titanpharm.com/role/AssetSaleDetailsNarrative",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": [
      "r136",
      "r137",
      "r210",
      "r227",
      "r337",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r405"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r184",
      "r185",
      "r186"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average volatility factor",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://titanpharm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r196",
      "r197",
      "r433",
      "r505"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r225"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r408"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions to estimate the fair value of options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r408"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, outstanding (years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r383"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r340"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r383",
      "r401",
      "r556",
      "r557"
     ]
    },
    "ttnp_AggregateIntrinsicValueOptionGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://titanpharm.com/20230930",
     "localname": "AggregateIntrinsicValueOptionGranted",
     "crdr": "debit",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Option granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected holding period (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of our option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r34"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheetsParenthetical",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollar per share)",
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r225"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r171"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://titanpharm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://titanpharm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r459",
      "r554"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001829126-23-007422-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-23-007422-xbrl.zip
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MH_WN3>SN">3IR*,\=IZH8'?-6>6CSSAZK]8?>@_AQWHL>"=+G@\A1;JW)?<
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M4J3*3*,^P+#@^E.:P8\I;:S@O3.[<D$?<_HJ',_<\HKQ<LV7+7C^GA=F<[)
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M-ED@JPRS!OQBBLJ2:3J^Z&8CX<-V/4,)8%(J!1QFEK>[O8'%F?FU.!,K'RO
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MNFZ\[?&!4\,$&<+&,AQ9=7_#CD7>NCD::SP%6#P9SB:R<^>B"F$%'IB3;B%
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MA@:?B3(6C*E!VH8,XI\BVF%7<F=-Z_1D;*1539RU#=S8OC,T>;)CZ)H.: *
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M%\4<O3TC/&-N?]29[_?-0DCW>[XU([PU"WS#J?QX*06<"[:<LE)N[I(]6B9
M(%G>WU_'0U;@]:=Q:8?444BIW55-=]C4;L 5M6N19ECA9<A8])NGC:8@N5*F
MHY0@C_RK]'+%7?T4KO/#(/*O^SM> -8V7S5LK@X!*K92B>RZ\H-):5P2H0?
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M9<+)&?.##-5%JCC\2$TX=23"//1BDNE%( ,N"\!OD')Q.%N1(?-4P\E%;XR
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M^V^99>F/]L/D5P94XUS7+5D,8G)>1' SX&5JV9>N+/7T-V\#N0&/!_>SP@O
M9.P\@X.@C<7I+2@G'"V/4)_'RZ=+.:;?UU0]F^WR8Z )+B)U'V/]4X1P!JWZ
M(FK]OAUI$&P09)#(VX1NCHEKB;\ADMJ?"L()I8LZ5A#SU1$9)>=OP4+8+V_;
M_O,-L5=BO)0%')CK[_M<OL\\>JO=G"?2LZPCDWX++AUN2[R61__+"GXH91TG
MP,V6P1N"C19,Y?XR6VQJ$?:3E8G9;-GI:8)OBO,0> I@<P$8C-<5%10%XL"G
M 2%['H,YQ:X1"0%,SQ5KQH'"J<2)G+]#?0!UXAC;8N1+_.""BW4LQE-$=.H$
M(=WJC>70CV 5D40\M:HQ,K $8)%B"AEL:EDRBSUVUQKHQAS(GL7TRTTUO4@)
M(*QWY]9YJFB:B-7"5BT.'(>G)' 0@[WP)QPEL?#$RFI.J:;S:\?P!)76.O"+
M,IB]!1H!12ZC@3I13ZD;3N6I.P,4/*&)BD #\TL4Y4SGH?$"(3Y>/U4;<Z)*
M3"I&PI).TC1C8CM/BEG.7AM#I.%XNX.5)%)7--WJ 2P22$#$8MD=/- 8_&$$
MQD*9F0RHN2X)PT3 <8S_+$J2?=R+XD8C%8UP4*EALT=LZ73>.WVXHO_^;U4!
M.O.%77N F@)1(].?RCDYUQ<FEKXKTZ#OS)^8@J7Y:CA9A-0I.'NS=8U&%FYI
MK=<?7W_T<I^;7.=7?JZ^NFM+WJ:R5M;HU4RP/&\F6,["8BT5Y5C/[MMYQ=7M
M//K4[<R_J8,@NI3,2&5H1C\93Y.T1I+B9I),:4*/',U8],C1E1S=?Y6O!MJ]
MEM>>]$+(^ WD. 2]5AZ2+V5HUS-X)DK'''#[ "&9=)@@8CP$[W>J._S7'$UT
M8.Z4<G-M71RTA6;G 5Z':S5!G :61G,ZGLN>UW+T@KUB0 &/CB<T6,$MQFMF
MR;C4)(4XRG5@9-NR$!3S\,4BE6 ?!+*]T7EJP72Y'1C&>AE';V U1(683IQ-
MPD0RL6Y%9)I3F' ZQZ(BL;S$8T><*LW<PSWW+,=2'M#I'"^R'T[(Y^^9AX86
M9G75R06,K8JW\V E?AN?/G+LNFB6=%>6I-N/MK4792O<5[K8'3,O@][]XUPA
MD!E-B@B+.>=*87.NO6(J54OD;:6Z/.U2QMT5OI.+9YQ?(RD][*$I)*(CZX*P
M@A_C[L8<V#33+W-BW5S\K?U0U7[(1O^2B02CVT2"AG5P2^9/P;B#0I"X9YQ*
MYA5U:CL^'ZS!S8?G;IB=6K*9=XE;3*J?4CB'YN#..>=:B5<D.-ZTDD).,P#>
M1IN3)FB(%MFR.:.:+MK*E&1D(*5!QI:!QSDR[2*A8@D5X42G=VCRH@OFJX!!
M8>X"-U[T_\_>ES:GS2U_OI^J^0Z:S+U33@WV9;4ASYU4X35.O,5+G.2-2Z #
MR!82D9!M^/33W6?1D9!8;+ -\7^YUP%Q=)8^O?>OT?I%U3+]".33:J-$<5'6
MV>2XK8@K0]\!.0+Y5O-#)G59G3LN(+ED/ DS>J0']$DG\J_B1E[)V9BM3)LO
MU.8U^Z/QKTH^CZ(%>87/3,O&?;LW;8>LWE;H6L L2:C  ZT0E"O!'@2#TP;?
M)>?WFIT8E3N^_"[WK\,1=NT@0'@8UT-O?\B=T+*\&$8_!4U6<=8"%UIQWHH)
M=I@3$QD&, *\&-]<P/=._>X$R6FS^&JZH>D/]%F48[/8@VOK/<3FL6%<,ZZ!
M@D0G9R9PS389"N3GX%IIY!B $P(+S'/C6FG8PZ=A"^4)ZGY&/ 2*/[B"5P4)
MWZ/PGPAYXGL#,$=L[O[+^*7NX!5C; "!P>.^\*8"T5C"ZYA3%"KT?Q-6J]>Z
M:O7AL.-P(^)$HFGU3<>TNT#I,$]0+T+D&3'2$@0EWB<$$!FH#[[=ASTTVG!"
M<'L&:&7A\8*TM'N\CH__*A'=<;2O\,P*6__ )C3@C(1'%<@=O6&>L$H4H?'[
M'QTX9T#1U\HQ1:$HY!%!+GZAT?23K<^L''?;XAK%U^08[#/AW!?4($\V>@\\
M=N+=:XJ'O![DX<*=Q$?BRIU\).PA'XY&_E>%;@FR$#+7F61O(XL#UAKZ/OP,
M]8;1^YKZNN0@B0VDJ*7:-9@V3W&+(#!&DVQC%9QHYV;IMU)+%@);9?HL1O<4
MV7#P2D:X[NSSN,RXK<S,.*D$%4O5F^%.^_S6KYP\EFH3"MQ6-6>N,EO.7+1Y
MI9OAE[.O7_<>NOG@D$6;MQS9=$2ZDHY&Z*JGK1.,VN.KTZN'KC/\Z=S.*\<H
M\7YQ69+W:?Y98"+I*I%2-2$117?/3#? S7#SY[%_T2_NMW:=%\M)*0))7@_\
MKZV=UN\MZ\-GFBMR8#W';"6S4U $F$T1H$%IIU(+-;X>1<FT,@K-H>$SL.E$
M;@*,Y5LH!9+F#$5:VV K^!01@P=1.%CT"Y&R)=0#U'ND77-0KY_%K!IRBH-2
MHN84,Z85OBM),^6[1/7%Y[X/"A+MH\)9R*]_YW$;3(\#>5;%$S]G[=#A0URL
M_]R@C#+L8MC&V V,!?+50]U4BD926?@[U,L3*FO+\_JNP+L2,1[0AG!EM"+<
M?(>!P$W99MQ;18!D%<6U0<P;$M834 2P*&ZTX)Q,"T^>G]5:W*H0(@6T75 :
MR#<4/?LQ:8M8I-&Y(/:# +./N$'3,FT_-CF-'J32 -JBBMSQ)!H]<"=-5!=S
M#;I Y9T \U8PGR)=:R"%!'=>SL6FP"K8K^3(EZJ8>!,/1W;- >GXCST>W) O
M'3#3-T8TW[B:5!)Z$N5K8*:64,XE!?)\FF!%/&;("!+Z&W' U#TI\EPGGP#;
M5-]@R3A2V05%/> _+/3U-T*LBH$UP''&[F_FE7K:1=(C86HJI/>"*3XUIPLZ
M7NA82$=H?@N NMO0;2;NNF(WXS<BMA TWQAP)%W1QB$HWJ>-?19+'@RX5\BH
MNV !.\"ST(N"BKYD;-]&*!V&3C_*'!XTCRNJ!5P@9^#&(G>K\"Y(F*>)YKGN
M>+K8VU&V]>K<A)A(G%T0DN6-/WW@SH8X3Z7@(NZZ:;0]\8(F\]T5V;]Z1FA#
M3D3Y\C#IJYD%&9$2_*MN%.08PNTRXIW>G!UYXU $"IM1+.HRO*YM=:N75U^B
M6%\FMH524BT[Z#GF "TVERTSX 2IN=(Y\H"T[=CLGN6XWPS8H)9:@QEMH<OS
MK- #C+FO6OY;O^-[8;NC6(](J"N3&TY=A2CG2IXO#P8[>B-<U\K(TOG'Z'@/
M^'R.<U,X(1=GZ7IT#WD D60/3I*U8-^ O**U-%&;:(7.@J_?XDVT72T5\E2=
MP7@+36_:/M7O;X:-*]/;^E5H_++*+VF@/?YQJP?.T<'ECO/ALSY5(YKK2IIH
MAPE_.R:DIF0YXIT/1!A12XK%W'Z'ZF&BS%X]]Y7;2;$T> LKZ''(D71:K1TU
M3S?AT8\@9"I9$.\9W2T]*R^F]E/^JW@!=UKF>,1S/<!D+15!6>>QSK0\5A5E
M6HT3?KK& 2:<&?2Y309[+DP2:9C%$H<HO-&B.@_2457"J H,Y"CUU!7N8Y7L
MJ84+\,R(:L8E6D<T@CI.+#];DPQK@:B:-K9$/M>D'4A5YLDHC+P*:N%"2T<9
M:?<'4<)O!ZQ@SZ<"'"X_21()"1>KHK #\40$A$CS\_E^#2)M&5YZ;WMAX R$
M'IUV:$LK72@4?H!ZZ@Y74S&P&02XJ/&B1<L4F.KG-\/:KZ]^P?;.&@?-%Y,L
MNS?#;U_VM\/3ZRK[#6H;3=40<S6BR:ZD:+GF?" (XH:(@5*%HI/]@<@52F=$
M*&H83PP$J=("H:1=(>)2FJI(BC,YBC 2AF+'\ZE&1220Y_1D)17?;GB^3W$X
M%!K:Z(YG8@0/F1(Q%28C[<0"R7KH&PY#[HC16S*#E:>"G! 4>4Y9E<[*T-T3
M8*ZX5@4$7)3C!&/\E->Z"5O8\;R[=9C& V:2\HD(VY@X(8.W<9=%Y 377G8!
M%K^%O[SJT?SJ%U? (#= 7RZ4UPL5"OAB[@QW=&$YDB+.7)07A(S3ELIWK# ,
M%W/GHFSGN#EFX*&('M"'IHB AT%.&JW*_6?<FS[R-S D0*C#GP'5+I'HB24S
M :.\Y6FCF& ,A(>66R!4#!BP:]XQ%?>^8P-N)_?$#Z+3IW13NQO?'DIQ-F5A
MGWB51/TA807KIIPWSU<* M=2*+%$<&TB60?+H&+5.R%.RADS#E"W\H'F$&L6
M7:D4?&^9E->[86Q'N5EVC(JT<P(ZB%RI2+"]'C!!W'W:]]@.:;L#AX?P3%'V
M7WQOQ/1%?H+/5QA(/4_L&NEKM*MB Z,"HMBR>4J,GA" 8><^%5LQUL5?-CBY
M=+Q 2T@4@EU87V:S@R)5W'3&N8&L9&7ZWILA#.2+LV&41$Q/=G68X)2K%0\W
M<'$L[HPVNKP]J\&P.8E1G@ I<0WOGL7HZX',:N%+1 :0D_GFQ%/@X$%%D7=,
M*5FZ?I[&YVU.T\9W7A8'/&/4Y?A]=H]^3A%&4DSH;@5-:51O@+TQ"D7Y$CQZ
M+^QK^;#Z@C!!"IBG^@X#.?I[*;X1Q4(<+Z#29Y05VJN1C.DG5,#5#+NADZBU
M0/[>M(6;VS=M'$64$E,J$<) ]?'(PGZ2(XUQ"L)=&G@BZ22^["P?RMR=)S&U
M>/7=*%<!5D))Z34FHAU_\&;8OJ]V.]4O1[9;>3'UM7PS'/RI#H[VM[>[>\Z'
MSU<!77(UJY546R^YT86VF,P=S6);21LP/=JL#,B8&2L"U+JW1,2= BW:RHL.
M06S'%1Y=>-.M,8'3-).%^A*S7B'CRXS(K,A1S$BF$!*&J/LAA7.3(=8FQ:TL
M&WF<5'Y19*N9+NJNSI9Q59TBXVK[9NCL7[>'I7RG,ZS]G1E7FT_-N-J\&9;]
M^^)VP_Q5.3%7-^,*;/G[AXO6[HGU>%SN+'O&E6J#.=[-4HTUY$W_R<WPQ_;/
MW\/#G8M2]^60?NHWPS^=![]0__&M:56BMJ/VBHHE;7UD;&/7%)]JX?O"AGG@
M$3 JU@)5%M.\X0ZB#Q7M*<(-V#"P= W]#&32QQ/+N6CPJ20X)_Y"=;)+-="D
M$/J4OX0J.GHE&3:]ELU>_V =@RU3S3L)[!LTT\ *8]S]CRD)_2!UAI0+$XW*
M/?[*ARH@0L J-#%!0S?%4&Q+=Y$2W*EO4&+V-K3:)&0CYT LUSV>/=ZE+!U3
M5#CSIC"!)I=13^ Y/%%0 7YCY=2_*?%>!$RH5"/FWQ#A"I["P0<"0KEC?=WK
M0JG7JGY #NPU0"(Q=* T6<Q]$"1W".6[Y\H0N)V@*<S5H*KC8,&-:N;/SR*8
M <6F=OB&7N+1Z_QM.A0]Q6EJL2[W4[Y&A/V'Q3^=/ZQ6\NT"AC,YK!R-^XE
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M!9[(ZXD_'XR>3:S^)M50TN_9AG'8HI)JGR!FT2O%Z[LBNE"2%P\UD<8;':_
MCPSB2\Y1SE3:8+$\,0)X)8FDH\J,T)#7P/(@WJ? ]QP)?,3]1MA139SJV\CN
MK4V'ISAD/WX<'^Q[YM^*I[CUU.S>PLTP[(8_BS\V;\].2JN;W5N_&99WBNSA
MY$_KMK&UV.S>%U2J+C7S^0S-Y]51IZ28);3>EOTHJ@&QG)0G^.F.,N#!)YZ[
M[C.T!3AT1 _,#41[T)AE7,Q*P4-CDYB&GZ5 -E,=+_>%V%Q.I<\AR7:3[J(1
M5\>&L2\L%_);9/D7TTP[.]!7H.:#J8,.EW%DB D)H0P]3+8E;:3GV5CP1Y"$
M'!5>#A:KYGMD/"\X[K*A^%^JXR;I7-&UX(R,Y!D\B3H4-JHUUJC42F@Z8^:S
M(LIHO2_ [K#>2&1%TZHU4SFF%08I),[!\7D'I(3VP)O =;2+$20()BKIA5<W
M&%4,ZN6[\EP3=<'"82H2OA, =J/$%0;R&G4QP]VQ[S"8* 81&>S:Z*"0V90'
MK]4;\^Y26K)MY"O%GGE TP]4\H0HD5ZS&?*J1I%4'FM6*R!0I!44;:@=3%[*
MAG$\<@!)IXT$JQ1>*@ZG0_I:E)DN[2Q1;:HL,-07Q<]3;_68X^+L@Y=Y1<,+
M+9/B$"MR:_;1_,JTFRAR(P"$-(!]:JWBKF/)1'1Q5&F!ML,I,B36><5![DY]
MS?!%.=7S51CE!!TPT@TDSORQEEXU"A8P,A:U<,/ +!BA4<<)WL!KW"J$\TH/
M7CVD^>]D)8HIFINNF1\C T-Z(D78B]\?>-M:XV.:T9,A)-2L S!6# %,)+%9
M:1&#M"5H@R,0/Z$;12$O]1&/ : 07R-OJ"\:;*K/5P6%$C3#.E^^$ FQJ.+J
MZ(@Q4!.FU^>*8O^$SYC#9,"04L,:J;2-!5FICB@J(XH!UE $%165]11-14GA
M=#+7[W*D6$8^87( ;:@Z;"NI!K6BJ++NPFB:3G,$6" 2G*!AVA;6^A)KA]EA
M#T)QPTC,9[@W:-,P>&*24KG><T)=8/&#BP9=#<I"VTK!G<32(5;E[NAE1UI!
M>E0TIP$ECU"^$F$<RD$]J1,>Q6T0\$+31*6HDT!+H'A%4*$<:)M#6@@P9B_N
MW1X;,8^_BNP67?>,D;=\OR^;W<45/,*WH:;G*>HU<9K$FGRV+O5G5#SI[O.R
M?+JV]+9XK1YM[[K6=A3C;D$'"_E=WG/=;?>E<!W=+BF3:1@9QM+?L$.@RQ*0
M)X@A#.AN0X_B$1R1A )X9K_960][J++8RK791+C(.'-4"%!JDTD7\,;$(T23
M=FX_\!.F,VC 9+KZX<)^8X-H]&*AB"9%W#52<ANX+B0@M;CZRF>K3Q !%O10
M"BK0$8J!C./A4.(U*BQ(&\YY)[:&IB[2BBDKL#"=<+251YPW;7MEU>UYVD'J
M'%[GM6CIRLY.+8$A3KFX?49=HD/NRX=9@)XD:)=,?1(NP#/BON!F#"6<6+R+
M4.4N:P$1*\ S,1$N+K+.5MDM@0J0C[JCXXODNXNSPCGS5FYF/XIQD0=#5@B3
M+TA%:!$Z="1DS).:9-@XVGT46GUOG0JG;;<7E3RO!B,'427S"V7?.#S&HPB;
M<W6$UF4L]8E7^HK8>B!40/*6#9+ HT(U#(0ER[O?<1U1HZ"IP:<63#KSSVI-
MRT E8JF[EJ24P;-+J?=U!/79WRBKJO>.6_UFX_# VNLLO*K:**QB7?4,I2JC
M%=3UF^'7T-W_^J=XU[QH35-!/<.M2]14OVS=]*)*I!=<Z'LXKM!WFO+LURH
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MVMKQNIB-2T:6*-BB"JX+M&BVT:"10=\,*1X+[#]S9.Q/8I6_YLNUD_.YM9[
M9+&I<BZ?^#JA/V+0*JD_XF>QW,4Q>8LC 2ZED> "DOE&L,*,3"090$M!KVK
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M29HK/&#.<U:*V:2L-R62;T3)DRD6DK&&O .UPV+^G]&OZ8O"/Q^3>3\8MKO
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MA%HX6HHD71&U:,^$Y7(N$Y,"">8"\MUQC ;34?9SALC'X[:+<BQSL%-B.^X
MB+S+<ES5&)/T0SR*CXT^<,-'ZF%_T"P4[.Q/Z(&*PO/RD$;P,\K=L80\B"46
MDC.9+XL<W]RS3Y2"/^3^?D=_8W35\QOES<T<>IUO69-T#HSMV"T[IFV8%FZL
M"&\'!CIX@=[Z'4E\.[A++;N)"X%1=UD IR%2B[AZ-+K7VO!\U_&"F[8;&([=
MM?O"+T[>\I[/[LDRU#D]D37/],;+@=]Q=S[&'VSTCVMOD)O8-1_M;MC5,T\3
MZ6KX%5X?4@E"E4;MAPX+].16G%T\+177>6(&EOE'+.C8].\P]4WP"?Y=3(G$
MA->6[0=PT U<.RZ$#I)3F3"0X>Q@O72>A=I&K?9O256Z'X^O0:<*G,.*7-Q+
M=?%D_F_VY<W(BN8WP[4HL9A?SM&LXNQ1^?5<PZL._Q>LVY20B]R!6>M];YUO
M_SHGH88)+/YC7%NGS$Y^6P*0<9Q?PUV*Y@6B!M[A# 0S=C46@K_2B52/"YUX
MH@X@&DGRK_2!,A>) ;9!ZMYD[TO7'"C6*'BA> T_KYS&1]'10WQ2WQD@#AFZ
M@R_=I/LB>3O%JT9XF6)).M=J>/=LP[@6%RVZ3"U#>J!(8';-6\]']Y*8N7ZM
MIF!<9&;"/E#X;LW\:)A.']< U]?"26(&!V@ ;IN[IGK(I# #G\;#O+T GZ4R
M0'W;VT"UKA0(F0>0,]8:'[GSS+"!.S?CG-AVFY[?\WB$4#]37Q -3,S'V5I>
M,^3\W79)E,'5=8GWX9&I=9BM%HB)@)[@,Q:;IHVM[>VDJ3<_3NVVF^&RPL#6
M1V[X<]+R>*@T[&(^#<U]'SB[R6L7C$O?= .NY^D2 ^\F:]DNLZ:0<A^I"FF-
MQ5Z++XH7#L2BYY1$88CGQ)HP ;/M >%1;0)^PB4?[@@\Y=@@[BP1J;90R<.2
M4+QS/HQ/%*M'IGLY[29.YG&2;:2Q3[Q (]4,)H9Z XR9,TY,9@_;6>-L@M#O
M.6&0BQB>R:MJ.4%I<]*OMZZ;>J%CJ=?;$^>.\7-> A)Q&RS.T#/11U1?/J<
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M7X/W:["<UP"HN,]= F0L(>-'(]GMZZT\T!YU''@L-#$)$^L^03"@Z>%CD6W
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MZQNL<!1(N6QJS:FBR#YHXGV9]Q@P$IO-CN^Y=A/4J8"9V+D0'^:9JJ CF=:
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M,.!6B.,U";(2!$T'[,[F=&&NB<$M6GE\-W0UF[@_(^4Y.C%G$$,7$SG,W.4
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MKF^(,=;GET@R. ?84_=[G[75F< CK$G-/Z'8CVKR;03;NIC44[1,)1$S(*%
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M@2;N)T[61?RUZT] [:X1):BQ$5AS199!@(A.2CN7MVZCCA1VHH.=BYGXL+H
MF-\]KJ58%J'BT9Y\XOK)%!55]2<^M4]HZM]DXD/C-R].EJ<X./S]!B]+/#67
M/(,=W&R*.\>E17Q5C:P.\>L R%0<1*D&.Q1RP2?4 2@4:Z$+V6#]$[ETE"[)
MJ9!. M)1_4G6OUMBLH? ,SRBEAUQJ7TGZ"G)C[8$DD)@)X?31-I[N2 ;1 09
M^2GYK'Z3B/3@B.F7NRQXJ 0C14&Y R>;" =<)I01L:$/XXKXA6-P# C[;[R1
MBA @2<IMH\4[8O"R7Q@\ 8.7S7QA\-Y/[ 3 BXBQ+8O&=KO:Z4F-QB<4IO%E
M93=\"/E NL#NC&WJL0,T_!,N=!MDF[6>G :+0TNQK^L6Z]GL43M-0=L'>E"R
M+I9@:.A#3.-P;&LX\$T)HBV&1=,)!4'KZ!Z9"\LRA):U1H"2UR>V1UM=:M"(
MDYAN4/=J2&8.8&[7)\893;M+22/#X2!L\D%(M-P(P+JF AKH@'C*$BP4LA3A
M.RQ@.61VF86W" 8H1W(T#8TXU4'2("XJ+$:R((]YIMXG)A7V<!860OY$#%7R
M64B\"IM[IC"&170+Y )$="@QZ$QC3== =)('N9?"U&R'F8@1&YUV>A8FQ10\
M_*7O>A!!@1T2NZO2H"A6L4C,] R"!=O3EX$%PDQEFA$JTGI[:BC2E66';N2$
M?D+C,B(<<IO"H7J $2GI1%')#NZ08(#4)$W#O@/\UHT7J@M=G$B(*N)RKFP?
M0K"^"5?KC@X)YJNH[84,21.Y*>W0"_%==I75AK2_1HHG92=2FZ5G<R,7XUL0
M#N.I(BJ.OV$1XL-]WS4LE#>!Y1>='UL[.2LLO9KV*6?5!FB;\K!Y>'P*07=J
M))P563Q]=X @<9Y*1IAJ=0!F,[&&X>1"I%J#1!=[D7JR+WHPA:BU'B4;_B@3
M2B51[ZF(H%1E/ !V<?(,HN%U(7MX;-D+Y!V?]3$GX@QR \/T8B)NX.]](@8G
M06-SS+"?*"MA.J+HT2!M4W]V+X4=)#-.VXYPL\@W<C<.*A%%O%R201,)M>"6
MECJ BCFQH<0BH=R*1HAI!27J%[$J2OS,T-?$M$)0<$%#=ZX[P*9V=9T5D\#S
M@9I9@>R[4#69B-8@'(TA?"RZ@5I#W%+" <'G0>](0QOK#=G 919(U!W9J9^Q
M35CL+5%D$8I[M) 4'05-N"F1QUC("74X=<+I,8QNZR;=#^!V0=PE=KO@/GV]
M@+FUF:S,HV6O<_J#'$&!,@GUI@0H00IR!,L1W$$474+8=$KCE>:*1T*U\!KN
M2>1$?&B!'&14<0ZE@TIT#OEP4M$YH/IP=7&%6-85#;RY3F<U(&*?;2.9;2K(
MT8]%+W#KR/&!!U.8-4NE(XO1PA415C^#"]J1;1)]ZS)#%Z%PK)9<K, 7%P0X
MNJ:K)H2">$QTJA .!3; 0B*A^M--5U]  "JJA:)1Z*="VO\P.13S-R&;5O4B
M\@1*9\%IVTKN<-\#P@M+>$K:T6"UK?IXW2SDC29FB-)@^0ANS^,%">C.2' +
MH3.("6$4>\IK=T3J U%42EC.!6P15@*"/$KG)FKD<-EXX*E/!%X87K.G>*$"
M7AJ"+6[HV MBU+'!>99RK!:((,VQKF,?"],(]>N0>(:C?8>A5D&=#" J7CT(
MRR0+&CK*Q!7]&!!TX'Y!I0<R$[8,U##N2U3,AF(1OAT5=;NA7L G&:"%I5AH
MB0F'  !,[F"%>]U27$V9!24DV;TZ?QHP-A3< _35%$>+WX%0-X!]!2])4ILU
M%JCI#9<]NHDPB"!]&_\P4J!VDVBZQ50-.43(+$'-@<V2"[&MIJ:'$MJKO&!A
ME&OAXV902Y/=Y+ K>,Z9XC@'N^/2X44J71JM$1@I]F,R?)#U!)/L,;>"_C6L
MCM6+%)O:8" @,^<7>N5$S1"%>SYD/<29 /'QA*X"!4"DF0XJZ,^L4"LP4KR+
M/@N7%9$B8@IYVC(F_D3J&QKC*B)#'IG"8)=_*I]?4+,+BEMFQ)(=O;B6<Q-R
M^Q=A;0*%%0D+5HBU40Q\%LM6(/^QN:D;M=?H3(5924PE\5>>()CPUH'4I<XX
MZ"S%,*EL)!-9;4YB<_N(WC4-%582-=NQY >Q"$/6H;N<( _ H1.D 44]T:</
MI 8>[XAQ([QJN((0,3PF6APHMJ'S8DC),B(H\6J"JA'E&.B3L*!N4!:/%0X2
M:?J.ET"YKTL@\1)(_KH$^K":Q9*JY!2:= H%P9D+*J8I$!V"<RJ<?/S58 7"
MQG=#$$F-*H4@)O^4_^*&P(Z7H^0B5<^W.+)<U041/:Y.4I)&- A&X 6C:M-\
M$F4VO1BGBQ:DT 5[E&HK)%VAD-GK?]N3OP633=3$W)IB@[A<GS+IJKZ<@J"B
M0JV:8G7ML#15/*:JA[1^6DW_*:=RQ1S6ZP01G*+A!1IVP^_$*<C62->&Q:^2
M:4)=R"T%IL$%I* A6GA,4+10"8@#?_(%25-6 8A'8YX/QBF '0&=LW&UA([2
MF6_I3W*XJ7M0!RI ]/+]16 K_[!+Y@\.$7?O-KAB\U PWQ@C.ECUFU4^"VU=
MN9SY3E;%.!LA$L0E)'H^4G,U&\#';$0!)5@C;">>XLP=<9<(@S>ACOJV$H\O
MWDYB)PT&L).]\+2B?2WL*3^UMA.82(G;S.$[IFT-\:[E*7-11-4%1JTH=D"$
M; JFIRS\@Q@#"$/$6$'YMI?]%LJ?B.!AV1F!R9MD?"?8UL)@/33:D/ST)B10
M#I$O;!A\"[R[!@ <_3@7HCD\'J)=':@ ((G "#([VZQ2G" 1^(0P?FC#E86N
M(>@N&FU+)+,P<IS@#:Q_2"RY<(\33E]9SNRIW_9R1/VP'0IR%GS6I8#( )1L
MPNF/!=OD%P@ T1-(YJK^"F*#&"I-<%@B^Q-JENA6L_K6?!RL28IW@ASVR,,"
MN* =$3B7&^75Y5RR'M%T 4G!V4[T<H\B#US@ X&[R^65L"E=%%%P0R!> 5!&
M]A@GL-,K\L(6+4"//H:..1@A*(=--Y;LHPW(0,J1_+ E,=V!=$UKP J&7P0Z
M0JQ\E^N[Z52G1: QKARA4BH2->)5E6-F4%14\ B5Z[M35GZ67=>2']E7 CZT
M-VOC!X>)QA?0S,P6OK>ZQ^&W <RLA0>K&_0AH86G.4H2HC+$F8X',[K'M=#J
M%,-GY"3:<SW96 Z'0$;@XHCB9J R)T.!D/_%%1:72;MQW@0$ ^4.>@H ]$,!
MV.Q.(^DPX1F)EO%_4B.">-;@6*0X;]*"E.J*;(@SIZ6-HR8; I; $@05TE=<
M@V:9T5 '&8CQE8L0H)2XUPQ8$;D5UP [)1F>2W-<$X2Z$!F3J#M,F/945VBM
MT[9BZ6:$^? WG/W$@-< @C#T++HA70,&C!S+'6&E6YTMF&QD&/O<7"XMCD]I
M.8W5\A;R*&*P&?U%1E>9*%#6[@5SE!7J>%+IY0IM+=RHD,'[*\,4Q*(HJ3A4
M"]MJ\!UG"Z,) ]A@B"]J1/D%0WV1VO1909--X;(,G11>A?4)>R.HR;]A=,34
M #<_^)H$?B:N'WR*7;-R@C]IQ42J^(M35H(),[,.'%=ZJTKUADNF[V&Q=\4Q
M5ZQZ[&6<'B4Q4X?2CGMN0!2FU[98Z#PPK1$Q;U&!C;=5/V"I19-*6>'U'3F5
MC00'0 @6BY&FA(@TU:0\<6!$7&NP'B)%HZ%K##NA<*OYG?R#B%8?(H#LRHC'
MKF.?!K,(N! ^R!V!^!>$@2;,.W1UTQ0P80FW:1,0VYH!R3^^23985Q4?.',"
M$%%'FM&4VB@JBYQZ5C8[LF3RM3[40J8G"FJ,I\2>1V[D"D]9Z1R&H-,_B+?D
M$*]QR8:AJV2%0+( CX"F/8W7NBG65(,L]%\8L9I@X7<6A(^#@\CDV>7<S+<]
M)6QD&)5T?['[ $T(ZR]B,B'VAJ@^XU*<9\<QNF&)<ZX7B<0$%8QWD!Q"QVPS
MN/+A%UQ]QQ[#W0@S2:.XB)B8!JVAC1C3X!9#72(+,=#L@G5J$_.PCW4J((K&
M^DTH?-GB[1O<=:"H9\8P [0$K$R-<R(3@B=BUY\B69-&"/$&EKY@U5>(1;-R
M/9J!J+ && *T\2]F)//FP9IX<XO72%%KAAM) I'@@Q1B(/P]3-;G38$0P,!!
M-@Q9&KE9HO8S$!'>H<!N%)VLP@04!B$TF$+3))=_%N0K-<?&_&&VPFVW5A19
M X,)4 60)X0>AO/LY34V:(I=O,?GK@256 S6ZHJ^&_10"#IS(!A+7^@1T(5X
MRJ80U_6ML-B!_YX77_FOBR_QXBO[=?'U84V0390\T!OA12EPE5YJH- 6&AXU
M&2+:^TG[@]J7['Z>)]4(3IR@K+BN0H7"9$F IA8E#35[!5C,T_?K02M[%H )
MFB:JMHO-2$2\&W15]49VT$R%1EF?#XM@3!/SK3$U1;.G'K9"'4)R-=@$HCF/
MRI@H3VC?@#!SR&9-5."<)M0Y9Q=83.>LJ!F XT4H$8,1T. 5>1UZ@X@M-A/Q
M)?I2GR"0UTTT':/ DN<9Y1GVB'8!C1@)6V>]Q5#NZT'2!O620BK&\3\L;(5>
MI/ 8XSQN("G,1/JN@5^-I1Q84$)D(E1SPD=BV0:(15N [J2$#2]KF-U$:,\:
MS$%8DB%:L"A K-Z*I-FJ'U.+R  LSNY&$E\HV%"85^AKTS0)CI<5EL\\AM@M
M1X0(TL0';0T9$&Q8>KE,?FM#[AV:M+Q9$+=)L$B08!XGX%=%FY5=5PMES9C(
MB,Z$+P<;"A+V<'$S-E%Z?*>H=\ :A^&-!MB( BC='85]LQAW4L@KI %"3SJ<
M9!P<*XV(NN#4Y'0(L_7H,/02)1+KV^2[4"!$,&A)7!<UUB/\)]DJH;^;2J 8
M[MU$&</'\+P38X(W-(SX%W$.B\\7"D<0X6'0#A/4F@ON\_!AEK+GL*@N;3\9
M^4M(HJ"K*M-/PCI1!(7@KJ@-C4MTV4%"_!8OEQIC F[&0KB<.CV,(C10!2(_
M47' )P5ED^C[<5,V_!1YU.".68I=<VU\7KA!=06Q%7'Y1 'VR>(A\;S$_$9>
M8A;N581&7%W>%I1%S4*-FX*V*?"7-B](!GO30&1?D!N:_.H.06-;> T6U*O!
MJQO?L0QW]/G+8A4VN*-P(%TBB+L1JK0=VLSD[M-A[\YLX=6].PDY?;R=CDJ1
M>./A <]SW.C/"9U:%:+0I>,#Z4)9*PXUM+;4M8H[_B/%(-L41/@/;6+$(!(*
M&RJ">!1O;O#[\3Z9(5A;:#(:D^2)+VYI.,KZ@ HQ!K'%*$:]'2BOU('?[!.!
ME!&[CK++K==T%\6@:D)G41@*0O$&[>:6V-X9RTD1$P,+/M',':XUH?@D_)T9
M_V% "7I0<I%(V8,6!!.3P'@7V,#J5,"8F-#B!"!)Q![R85-SZO68-H#2>)MZ
M&Z\F$UO5[\RI_/D]=7DC5\^(@M-?=3!K(YL8"_0_V&)6/$Q/=NQ-/%0XR9=W
M[J4L[VXY2)N]>@WW%6UZPZ^"._GKV_)&$Q:3&_1RDW!GV_*^(.)9^(IXBA'/
MW%?$\]W%>-R,+&Z8D44H6#$R^H;W"^J>A.T6Q?:*\?:+KQY4Z*GX1._%/_X6
M1(70$N6EXT3>ER+M,EX^U:<:B/&F*=LJ).[UO]$M"CIV_/RI;!L[RB/1"02]
M-M@/K-_&%Q.]CHE>TICPQW:6-_EA2ZPD=D4CF]RRWY*_8K-([LVVT93F70F5
MV4:I(RR:@'< SYZ('V.4U_0A>ULQ0!>=/Y!_O>!Y"3>\B<!3I)&C#_[SQ\CS
MINZ_TNG%8G'@ZNK!T)ZGJXXZ@FH0:5T;*DZ:&)U*NB)GLL52FC@^<CE;D;/%
M;"Z3*<I%.0W%\:TII,HK_]67^>_RP<B;_/%W#>:"20DZS88"Z T-_:>(&0YM
M&1!H@X9O!QHCL<(;B!VL5J$N+G>9V/,8(J214->?_KTG$VT!__AW6OE5#!KI
M&?8KN%+.?+'E:]FR4"ID8VPI9SA?5B?$RPH@FL?@/*(C%]05)/Z@MX <MAY\
M06KC)U3=QR60134L]0#?Y14,X1<I=,TTEOH7B2#P3!W*L]E?S[/O*52A"-(7
M^_YCJ1JR+Z*B44X&8(2DTI@B-VY-Y^FO>$,H%I'@R'WX+2(>X/ZQ3IAI*EUX
MVN\E=7-?;/LSV#8;9=N.F-O#M/[.LNT["][\;\C!&_R79]9HQ)B,QH!?JN_C
M ?C_W64)F)-_2[LSRC\Y>=.;$:!([> NXSC2"25LXL$N2B-95F&RE)S;4[Y]
ME_/D_X-F+:%:CS22@3N62B[_*UGN/:57+OO%?<M<]@VX3RY+UP?=@]J!).<*
M&5KSA.%4Q<>Z.EX'4XI4,L6 /Q6GKUBZ^_UR:>HKSIK93":[T])0SL@'C5;W
M]V')N\/.173 A@6X5%67CA@"]3<00[#MW=KI[[SM/65I6_9D)41*NNI(GRB_
MF@_>Y<S7JA=?FQ_9?/(EE64S2!>&-89*O[^;2#@Z/OGBB@A7'$'RBO&N3/$N
M\N&B>OC%"1%.N%#ZNOG;2H9VY_B+'R+\T*8E*]Y78;R#;/B-@F\U2.N+CH@@
M,NQPJM FO$>*IQ#/U-2E/8KE9W'>A@6-&R1@)=Y7S%-X*P<&R2'3A>#M^T!R
MHHA(B-U\YP@Y$=3'\!39PO_\\7<"(!)1>8DPCN^NL08\I8C. V0>^W\1F1<9
MG*(U^?[N*&#HYW-K#(KV![T7>%LX4.(TDA\&_+EJ.U/;X0T- Z!$B-[G=RB6
M%Z3/U5BR9:R<</G[.;M2B5^FE/FE],\7P+]T/_^@-^J[OX$BI(!WHWEZ]WZR
M4 S$82AL1.$2%SX_.-23^.6(1"(S"GGSY>P""]!B4CL)EDKU^/\BA84W$K]Y
M@N43H3(.9,^P3<&]"/?@UP+UBU] ?1&HG_\"ZK\?4#^Y,7-)Q.EW&_56M7?=
M.>[N3GIG/-4JWK+E!;=]K*5FH"T$20_U/C0?6F JV!M.:&'&$H,!;DF[G4"Y
MS;X^4LP!Z"/X)!;Z9P] AJWN6Y$L2_RRXGLCVX$B%&^<VO=EO<853Z+]\XR#
M1Q8$Q^D_?V1_@%8OG  YJKU&K]J2VJ?53K-:.[[N-6K5BVY*:K1J!V^$$W\C
M"C/V* !WQ!<[,33-U'^V1[U]#N\_A?SKY_!QMS:1=X_ C/Y7K/ZIG*>6]-O1
M-W$NAZM__:H$D!?.*.VF6>8_9M=_\KU^ZT.3."BU.G_QH)"I(V[;9Y+ 'V?K
M>H9GZL\<R;?8NBUU-;ZV\0<I^LLW<"\)A,5V,3&5=4N$1O3@(O[AIG?XZEA
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M$GZ!>>E-[*MWL,3^J!O@2GKJ;7_8'\&3'X#*)_V+"5$29OH^P)/2F_B+@2.
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M],"8@!V"11AKS=C/-%VV9NJOKIC@J%LRP<5N 9VU*))Y@KXU-B+='<_1&N_
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M"Y:)''YH"MMXXN@V(<?@QY@T32#%JE IZ,:@..;DM$'?P2R1V!W0L)!(%@D
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M&;P"#&40K]>-QRAT(G96VKMEKZI>]:I%_P[7KJTV<J"JA?';7!)VT4PW8&8
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MQ8**']LBOFHHCE^+60!1@LGGU/)WSKTTEJ:U(8R,@.,@"@]4CZ@!\UAL*C+
MR85RL Y!;D24.:078FP@ZA32#'](F?/779H8"^$DWH?Q'XV.DT@G(>[U:-SB
MC3Y4H\MC'7"SO&-,3I>U2@0Y0SW@R \@FX@_0B/['EU!6M-,+8I+>@/G/#>$
MZ@B8N'E*NOC> >+>W9&S M0LK@/;M:_1O7Q'I:+);>#N?',3CG0-%7]-5,\L
MJ[)2>)TZF$(SU*-"M8BOJ'=DDB;BZM!93@:J_7-ZD.J&\BER>(1QDBCC-Q1,
M(<N>1R]BCLLY]A@#;L:U;"+S)AWBQ"V[V;XX>8\_=U_):I[\_7;KUT_ZINO7
MO7(*1*@P,05&T$IAL*6U> 4ZE7A_YP9V.9E7,=&(J9,ZN-$=-Y7>$5;"=6%4
MO2.JZ BR2HL1UA \J60ZLSE>N/H*">D*Y"M?=609TOJOB<H=BU&AF8OQ]DB[
M*7G"?MUY]D >?LJRY*X8R[?[&(L38_EV'V-Y]+K/EZ+Y'!U\QVW?,SA"N4']
MK4(9W=53;V>UE"X<F1)F-D,(BB\_)PF+:38HY[NU3%]ZGCQ (;O\P]3!@^3B
MC9Q-8TKW)\W-@F\B6#**EII:)+BLE9""&,:V[]!\G:><T"LXV$:]H$R]=0JR
M7W78)-2?N##AB/J(F7E3230@&3++5I+QO,32,Q3"\MW"&9:@H3$B$^:VPH3S
M/8JNZ2,C$(K:>!'*<596$ZTE];WIHRJ5/Q%"#DI8TMHDO=$A.!,V,<7$#3NW
MXQ6C-2SJZ,6+RFX1PJ6#X(CPJ5TK0M>(: [?,@+4YBS98APS=9[B3?U8N9/B
MY<H+0@W4J_WL;E<8V! ]ZVXU#Y^0<,2"%I70ZS3A%$W9VY1R^F?=7/?LRI=T
M;/ %:(#;J<[8Z\4HXC>@$F7YKEF_/#SJA 9/W D@]KCPX>B'Y\\IY0ND#6*#
M>CFL_N.FK85;UB].@WB9W8#0;&PR36UU O'Y<>9[8GNQ_R8>8^ZL5])5XP1V
M0]R;T'@N=Y\L#0_,ZK-11VU#4A>QVJF=$!AE"0FOL55V%+IXQ"4";2'W</"0
M<9*!X.0[;M!=<$A"M'9K)]7HK==2+\D-U$Q?.L:VO0>[S?+&<1RZDGOMGD.Y
MK(?'76&>6%F8HR4G&+/#*(U:^&V8LPT8DS.-.&[)T64Q@8R#D(I&EGS6;1_U
M5T]9P6[4X=0A>V ^4X?Y_:;^^ECW>!_V!Y-W_5&[!?^JP7A\V1N>]%5O>*K&
MO;.^.G^C\(-Q_^1R-)@,^F,UZE\@K.9PTC]5QQ_@T\%8G?1'D\&;P4EOTE?#
M\U'U*X/AY%S]\FYP\@X_&7N?]49]U?^O_NAD,.X=G_7;K7>]G_OJN-\?PIO>
M#L:3_@A>=#D\[=>&[9U,<'[,3GOP^_L^/'8:*)A![^+B#.8#(P*]<%K.]\YZ
MOXP/JH.][WV J4_@S3#F&WQIN_4&!D(J !W/SV#<R:@W',-G."-\QW@\>#N$
MGSN#+JR11NP= VE.B&[82*$W5'T8[60R@$7Q>D:]R>!\R+.""4_4FSK!FI;;
M;NU:;^>87G9^,1CBZ/#8R?GE<-P_4QTFO/YU_*YW=H:KA%]@7GH3^^H=++$_
MZ@:XDIYZVQ_V1_#D!Z#R2?]B0I2$F;X/\*3T)OYBX @@[4;]_[P<V.T:]P:G
MO$DPOP'0Z')XUA^/B9CJXG*$9VVBX&B,+F%PE 3PH/ZYUS#(.9Y49VO;+3@Y
M[R]P"@<X@5_@* -=AZ>#X5M:$TRX__8<?@N:MAN(<''6/WT+$X8UGYP/A[A1
ML!P<!VAP?#[LJ3>#TSX\/7J+9#E!*CI3.3M'FL/E>3,8PKW!U_9&<$C>\L[2
M^RR%[>L/U#MX+\T2CU2/7HOWY.?SLY]E\N-MQQ,F>GI).R?TI,F_!Z+@U6VW
M:/;UJV*]&\?[MIN/Q%L^0>U&2UJCW%6:W)"T=J @[M$TG<OTO4 OAM(H*9FP
M.ZOEN3P'PC:H^>)W6'BL+)HTZ$:K+O@UYAL9!=HLW&Z^!4WF6Z@[S!0A8UR9
MF6OX#$_!$_45FR\ZK2JL4N6VH #=5Z<+U(Q4!V>#,0,:\L(=A-;Z[# D3LO@
MW@!D:CLE;<9.^C5PIFRVL?*\X=1UH]J3\HN3\0L#>-5;=<UVRRJ;W!/HSS 1
M3+CY84V$"EA)K6N=!:3DK6:+K<&C81)9?=HV52^YI]0Q$K<Y$S@"Y.Y(("%>
M6+5+UY%IEJ+&)HI@PPI):0":J;]%Q @>J>IKG)93+M3R9J)MZN<'S]R(TY,.
MT]['O?[=WKWNN->_V[O7'Z&R]!L6\X2<^=^3,[_/>@4ZA4"9PKQB8HO%'E7U
M$6G9&E75;N;[.+_"RL83D'C(4EE^JGXYXT!-KR&_SD.!1GTI8'5KP]A0!&!&
M.08Z79$=UYX#K=VBOTJ!+-4&5U,H D>?78=NS:Q?8>ZHP?0:6#M[+TWN@:,G
MVW0[[*>(V@H(^)>'?]<OO\DHNVREAZ^6W?#24"^=!P9IQJ?=DDAJ%3F3K@*J
M^]1IL^H.C<GMY;6DJV5.32DWKF]H)(_/2E=[!#A+:S,E6#7<H'5^D]P87)DX
MP7&YX4"U.6P(NFQ-V:GX_4T1.KHY7$7()K96S+(&["3?1C,P'$C(]7(I6C59
M9HP=9X'V*1)"7GYGUS'YF?,98\S0T\/K%>CTV!T+T58&5L&"T"WCBJ/91DZ^
M[4R[!O-+/(N\#_4.A[2/P 82T'S76!T^R_)5)CHJ9ZK#BQ9)* 4>,Z[6"DA-
ME\9IZ%(NLEFB%=N2ZKK,X:+4X0UWXKP*T^1?]-R>(3\6ABS8H[T(!R<3\I1]
M&'<QYL$\\*"JA0<XE0,.\(T+@(&_&X1GM_*@=( #O%8I\(JES*;"ZF+=03BS
M+7OR6'K*R%G$O[AG,W#0(A!^"$Q1LBTY=D*]Q_'29J95Z18@M,;N-U/=03!B
M1LH2:DE2*:3LWCC?UO$E3*6,?Q%BZD F/PG8J,:YJ'5O]=Q#>@R^EI)_;'!X
M"-% G!VNQ&P6D8H2!W:*2!?)K0$E .S]12A6./:7+&TJ<H,,"M@)X#!FUW.B
MJT%*VU+'I$":M&T-$++;!6/X_30L$H%YTW]J[*UB@0P8TH.1-Q);B[LKU.LX
M-&CN94;.O^TEM^PAXM[3/LJ>;(*1=*;0@+HEV7BQ+>AP:)*D=<%U'4;*!6B)
M]4PDRY*ZYK@K,!>W.E2[U7%<=F$>Z2;B;L=+?U.J^,0"\B>U5,5:=U!WXIE>
M"%Y?..,OU'X<XXH2A!H>E<L:"E^'K(2.Q85)[EV#"V_>*.AZ'5.E%1A_V,+I
MX&Z_P4A^H>6MQF_H]YK23>8K[C,^4+O]BK$@8M4NQS1V/'C8T06;F(;8J!1^
MTFB1.6[>S")&+@SN2+V!EQP^YQ52R60G)SJ4GJ#64B:>HFEQ&T.V HS[6PZE
M5R16R1LA[4<PC##S(RFE= 9!>0JJ\L%#W#EZV>7L;#ZPIF$XDXRKXMLMG;%-
MUQ?O>+@P8'%Z W0[9*0)'L0;J>J8BY@B3==%279Z2;OZI&(\,U3\&V59N_5K
MA-D66::T(QE9.^];1QI'"/-(I+%/!00+470LZ]!%,@[R&C5;F':%C+H8QN8V
MX4&9Z>[2HAQVI);%9?9=G-<:E16G1HI;BRT)Y(ZL/@>(2E]4_RSPX>(P38TW
M"$D6&]M(5R:*_- C?Z'-)O@!"8?Q#/$"LRBF#3'ZQKZ7U:-1<&?;%-Q3=-=+
MR_KF4G8^15$,:ACC39D>AI'S73R9U&Y2[ADF^+'<098Q8[!V> !9,#Y!B8Y.
MDW6_'65!:B)&*B@/2 H?P!:$@U<P#O8M5P" )K'.6;F2'HI>H*?CU!+3C'E,
M.LS>]+=61KC<3TIFE<W.:EXG?]AU9U5H=3DD]3(!52+?8&;L07P0X!]7<"2R
M^;R+1?@&'L"9H<[,VZT?6GU <S!1])IZBAJ=TM9..-4[R,3G5!'#<%[$X5QJ
MN#R26+H[W<!5NDAU-E67$A1RE#AI<VDU-PW@['LHFJ)4]THMK%8:HL+GU/?R
M.W$T7AJI^QY4<M7J21T!RC33Q<<.N#^3^?XDVW/3Q\)-H^W<=+&FR/1 P*CO
MZR4(\WB+IZ "M2,E]&0"+Q8%P^O=G6G\+<Q9:^[H/S7^1KIS\F8<%"/BI/4V
MGWS2Y$U@E@_Y2O196$)'@.8B!.+4-\"! ,*"][3@^2-,$(,=TZ\4K4<5"/D,
M%F(ANR@$+C"[9>0$W[HFU1-7V[5M EAEJID6B4X;L 5DS.CH%AKH\ [Q.Z*-
M_EM7W<$,7'9=V7W#LVE6J6=#&E.A]JV@V3K247$'Y-3GJUK7]G9&5#:=$D.=
M(/P#E6I.5)G&DV9'=\7-O]_'S9VX^??[N/E>?#YLDF'=8[Q;)FW3\ZJQ0=9T
M81JI)RROP(PM"X$GRNF70!1WDJ <605]GM FC,T0+U>+;!/'6GWG^"NZ<XLN
M=30BIP-\GT$J+'>//R$"'O6+#UC9F[([A[,*<X$_(G.F@D+8U)>CA@N"D#UB
MA9-@Q5%]J20RZ<3YILWB,D56'>+]=9*0$B(TJ4_5XDTW#T_J#+LSV;3(8Z<D
MRZ"?G?,+S&1T0NF*Y)VC5N#JV%*H*/D5/9_<EDQY*]SE+?BTWTRH)F%91FM-
MP1I:'GH#/VK-+!WJI'>9F?-Y/5!OL%'*.N="]TRW7@)A3,>+^AX9B2]4J8QA
M%U^!;?BLU>NH*.E^;*%P$B!9Q#@7G69;9J4!I@D4]Q8+;$IMEFL <L9TK&@3
M85%10;1=9!O4RV44[R)YJ)R)!G"[UEPUAC;G<KUT&FHYX/ &38>06^P+[90K
M-J1MM-=$J^9I!-46#EN.>Z4F:]=&!)^QM*HV)PMJ<C([_$!)!)%@'&A'$]UH
M9\OTV7<\!6MVZ4,05;@,-];5%;?+\!.M@0_,=M"M9G35NS8 \P2*->&C4/C%
M]UTT+X3WWKC[N]@Z#PM]2\*7<P(0<B2VJM@42S'3%! Z>X*;LK;OYC_2Z80-
ME"U;=_<1DX:&6U[RI'7VIZ0#]<PE7VR""K;>'Z,1D?O P;"C$^?"#^_4;QPN
M$=3E=E5RW2&VJ^XYE#'F2OQZL5U_\G.D-LG]AQ+=GTT PQ)$<+=;#R"YU6\5
MW!@3XHPPS:VW,>+/%.+J5\CPG8Q49*#Z0T0@1MIWR\!&K_1N.7 'B5W9YL36
M3=#_P67;]IGNFN5>'CT.>:2[3UUH0V]$AN#OY;ZVT2@^,=;4)6O<1M2,X2F9
M0-92]=,RV&(VK2M=@(O*DES\? 7\)M3,1:(Y$JJ1Q-<-9Y]5;_(=03A]U]QP
MC\0&@UJ2E=-J6.119<:B'U@.6OE<9^@Y :V9S822]T;(4]U', :&?3:;TVUJ
M$5D:Q<.=D%2V;0 4GYT(90$X)1'*4S@DL*!=]P0.Q^L.]<[!F\OP8VQ%%]F9
M04V"&9Y5I2,BV5*2AI?(HH<-;-R Z_C$**^?G3KU3&=31X0WS/+.*>[YZ6/A
MI]+>Q.+^V6!AX33MH_R>V8P://)SA 7C)LM1V\][),\5=!-TUFZIBT6!D^U,
M)?,9-#%ZS..02)T&80%FN5R5"TZ.7Y>B3.V8)N<WQRL\^OBSX&T9_<04AKM%
MX45<,JHPY4/>YQ7%-0-#)ZE J-+@V)>W8$;K\$972ZJ.!329PC6+FEI/.RQ;
MIVCI;BNN5*Q4Y<B"#5,W"Z8F]<ZJVRU_V08L;?O2'3C8^CEP-%X;]:2$-8.V
MVL#N*\Y%OQVC5<CA*SL;7PM+=N; 2;E3IRI_5UKRDV9P=P4=?]@''9V@XP_[
MH..C%\A?BC@^.OB!Q/'8-. 9V[0L1QP7ZZEIP+VUD?9T Y]H-J^=+\)(J<\G
M]PG+X^FFYLLS=06([(>B88NZS>S:A8_VVZ<4+.^M\>&XD*ALKJGU+$]F1DV"
MB,'K/K.<=AVO."B3<HU&O9[$$5K<:WM76DR8&IU?=W:I]H3U4S7#&Q#?;&&
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MY(7%AW),E.-&/$ IH'<:IH2-@@1*RK7)ZI;^Y0OR[A5\,'+;GY$ZU**6,\M
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M*S$8-NJ+J,]L1G^FSX_ 0&Z$(DB%E<!CH7IL)%P?([0#B+R':+=<&J!S.L9
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M8+44\2*YX[U1?7C:L&JV%N*8^2SR,VP#-R=FZYEG9LJMKQ&@3QG[&4^A'@;
M^_<\,_>TA(TX"[X])]A6 'N:V#O"R9F/A[W>23KN"TB";ZUKB#(ZGV'G">HX
M6&'L=6/LV4HM3^WH^D4XMN?R'J#Y['[2B)U,<H#\_L8R,/2/H/@J<A4O?W^K
M5G%\0<9U=H%YW3YV\BT#%5$8^^Q\X,N_=7+F"_A:,*M6BQ%OMO^>5SGY8XY/
M_MHM87<D>73%=@I9AV-_:S 4%7/DPA,9O@SXJ'&:'9)&#>/Q ^.#FQF8&HU,
MB)N^-4O?E@U?GZ5OV?X+4$L#!!0    ( /&!;E>%F9=QB@0  -@<   6
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MV(3Z#BCQW:<.GW!FUXBBWI0I-%"YH!9[E%]DYU0(%Z8#S,FP!,L6"P[VOBR
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MY3P[R*#9;"3$XS?^Y(GS6$O]++<R OT:TWO8Q!#B3:*'[=!87:MD!D1$'X"
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M%,![TK)29TK+(.K5Q=5GUW/L.VZSH>MH!BF[+R8I@Q(XJ@/Z@'*,W/C[HV7
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M;5+5,.!)$29/4LVD1^DIXK51113Q99/<)P2MH.<.'E<\_6+F,@X7B&@F+EK
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M3TC1%$_'?N2F,B?8TW< <JJF>$MM9X@"Y=BH-&R*@VL<L'G68[XX?KZA;!)
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MQ=B+^-6#? I#(>=>_O+9(FI3D&X6JIKB0 A^M '!S.KFMB@[&BZAVES<Q)*
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MFF /SD15PMZI9HM06"$S*9(MVJWW/B>Q,WJ75PP8^_+V<L&V_,J+\&9Q=SY
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M52MK8;8M+A5"T?HZ9,*3R[4L&0H[IL5-EL1A7,;I\B/;?.9Q("N53,@5(=0
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MAMTQ*3F/4V$L@!"G0JF!;>5FA58:5\ [MQC8G#+*G]#Z?WN;BN9\U+"'G9*
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M>F>2)4#98+@>S-Z4Z['YNU;T/@CVRZ2ZG\V6*/4/E'WDOU@L=:8DYFL%.KW
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MBP $@EGXGQE.@QQ\U<#-E!?$,.:KQ5TRU@2Z3T65+!J.&0 *;]HVXH3)$ZZ
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M\P?K"?77S36KHN]Z1IU-9>R+.*]NZ@I"T%J>X"D=TWT@>4GGU3M4]9SGU5O
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M=DV)N6\\HB94R]*&YC2\R^ZGRV*Y.XT#_H 1GYGY]V?+.+S-T_(9AK.8/[;
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M5(:EX</NROEG+V?+R668I@E]XO$!RB6TM#3VD:':6NKK-8W"EE;1Y]Y?'C4
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M5_V&_^N6C73L)_\#4$L! A0#%     @ \8%N5V4I&7[R_   /I\) !,
M         ( !     '1I=&%N<&AA<FUA7S$P<2YH=&U02P$"% ,4    " #Q
M@6Y7]Y>#;1)F  "K0 ( %@              @ $C_0  =&ET86YP:&%R;6%?
M97@Q,"TT+FAT;5!+ 0(4 Q0    ( /&!;E?$L>Y#R0<  &P[   6
M      "  6EC 0!T:71A;G!H87)M85]E>#,Q+3$N:'1M4$L! A0#%     @
M\8%N5X69EW&*!   V!P  !8              ( !9FL! '1I=&%N<&AA<FUA
M7V5X,S(M,2YH=&U02P$"% ,4    " #Q@6Y7AL23H^<+  ".>0  $0
M        @ $D< $ ='1N<"TR,#(S,#DS,"YX<V102P$"% ,4    " #Q@6Y7
M9^1AWW0-  #LJP  %0              @ $Z? $ ='1N<"TR,#(S,#DS,%]C
M86PN>&UL4$L! A0#%     @ \8%N5U@;+M2U&@  \*(! !4
M ( !X8D! '1T;G M,C R,S Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( /&!;E<1
MRL3\AD8  -[K P 5              "  <FD 0!T=&YP+3(P,C,P.3,P7VQA
M8BYX;6Q02P$"% ,4    " #Q@6Y7B6+W?E<P   R$P, %0
M@ &"ZP$ ='1N<"TR,#(S,#DS,%]P<F4N>&UL4$L%!@     )  D 6 (   P<
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
